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Abstract
This thesis addresses several questions focused on the activation of receptors expressed within
the area postrema (AP) and the nucleus tractus solitarius (NTS), regions known to influence
nausea and emesis. Prevention of such effects were achieved via corrination, covalent
attachment to vitamin B12 (B12) or other corrin constructs, of GLP glucagon-like peptide-one
(GLP-1) receptor (GLP-1R) agonists or via the use of GRASP a growth differentiation factor 15
(GDF15) glial derived neurotropic family receptor α-like (GFRAL) complex antagonist.

Q1: (Chapter 2) Can a B12 bound Ex4 (B12-Ex4) reduce central nervous system penetrance
while maintaining peripheral glucoregulation in Goto-Kakizaki (GK) rats and the musk shrew?
Goal: Perform in vivo analysis of glucose levels, feeding behavior, and presence of
emesis following administration of B12-Ex4.
Q2: (Chapter 3) Can covalent attachment of Ex4 to B12 biosynthetic precursor
dicyanocobinamide (Cbi) (Cbi-Ex4) mitigate nausea and emesis in the musk shrew?
Goal: Perform in vivo analysis of glucose levels, feeding behavior, and presence of emesis
following administration of Cbi-Ex4.
Q3: (Chapter 3) Can a Cbi-Ex4 conjugate prevent brain penetrance while maintaining
equipotent agonism and binding to the GLP-1R and retained pharmacodynamic profile on
pancreatic GLP-1R populations?
Goal: Design and synthesis a library of Cbi-Ex4 conjugates with the goal of designing a
construct with equipotent binding and agonism of the GLP-1R.

Q4: (Chapter 4) Can antagonism of the growth differentiation factor 15 (GDF15) glial derived
neurotropic family receptor α-like (GFRAL) complex mitigate nausea?
Goal: Design peptide antagonists for the antagonism of the GDF15:GFRAL complex for
the mitigation of nausea and emesis.
Q5: (Chapter 5) Can functional fluorescent probes be utilized in the identification of new
receptor populations and elucidation of their function?
Goal: Design functional fluorescent probes of leptin, Ex4, and oxytocin to investigate
receptor location and function in vivo.
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delivered centrally. Ex4 (0.24 nmol, i.e., 1 μg), equimolar B12-Ex4 or vehicle was
infused into the lateral ventricle. The percentage of shrews showing emesis was
similar between Ex4 and B12-Ex.4. The number of single emetic episodes or bouts
following Ex4, B12-Ex4 or saline was recorded for 120 minutes. Both Ex4 and B12-Ex4
induced comparable emetic responses, while none of the animals experienced emesis
following vehicle delivery (data not shown). Latency to the first emetic episode in Ex4and B12-Ex4–treated animals that exhibited emesis did not differ. Evidence of emesis
was analyzed with Fisher's exact test. Emetic episodes and bouts were analyzed with
Student t-test (n=8, within subject design). Values are expressed as mean ± SEM.
Figure 10. B12-Ex4 enhances glucose clearance during an oral glucose tolerance test
(OGTT) without inducing anorexia and body weight loss in the Goto-Kakizaki lean
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diabetic rat model. In an OGTT, liraglutide (100 μg/kg, i.e., 26.6 nmol/kg) and 5
nmol/kg B12-Ex4 suppressed blood glucose levels after intraperitoneal (IP) glucose
administration (1 g/kg, per os (PO)) compared with 5 nmol/kg Ex4 (i.e.; ≈20 μg/kg)
and saline. * saline versus others; #: Ex4 versus others; $: liraglutide versus others. *,
#, $: P < .05; **, ##, $$: P < .01; ***, ###, $$$: P < .001.Liraglutide and Ex4 induced a
strong anorectic effect, which was not observed after B12-Ex4 treatment.
Hypophagia was accompanied by body weight loss in liraglutide- and Ex4-treated
animals, while no significant body weight change was observed following B12-Ex4.
Data were analyzed with repeated measure two-way ANOVA or one-way ANOVA
followed by Tukey post hoc test; n = 21, within subject design. All data are expressed
as mean ± SEM. Means with different letters are significantly different from each
other (P < .05).
Chapter 3: Corrination of a GLP-1 Receptor Agonist for Glycemic Control without
Emesis
Figure 1. Synthetic scheme for Cbi. Cbi was formed via microwave from B12.
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Figure 2. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse
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XDB-C18 5μm, 4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 70%
CH3OH/H2O + 0.1% TFA in 15 min)) showing the α- and β-isomer products at 5.2 and
6.7 minutes. Purity 98%.
Figure 3. ESI-MS (Shimadzu LCMS-8040) of Cbi, expected m/z = 1042, observed m/z =
1016 [M-CN]+1.
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Figure 4. Synthetic scheme for Cbi-AB synthesis, 1-amino-3-butyne was coupled to
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Cbi through secondary alcohol to create carbamate linkage utilizing 1,1’-carbonyl-di(1,2,4-triazole) (CDT), priming the Cbi for conjugation to Ex4.
Figure 5. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse
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XDB-C18 5μm, 4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 70%
CH3OH/H2O + 0.1% TFA in 15 min)) showing the α- and β- isomers of the Cbi-AB
Product at 7.4 and 7.9 minutes. Purity 97%.
Figure 6. ESI-MS (Shimadzu LCMS-8040) of Cbi-Alkyne, expected m/z = 1129,
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observed m/z = 1111 [M+-H2O]+.
Figure 7. Synthetic scheme for Cbi-Ex4, Cbi-AB was clicked onto an azido Exendin-4
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utilized CuAAC.
Figure 8. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse
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XDB-C18 5μm, 4.6 x 150 mm) (RP-HPLC, from 1% CH3CN/H2O + 0.1% TFA to 70%
CH3CN/H2O + 0.1% TFA in 15 min)) showing the Cbi-Ex4 Product at 11.7 min. Purity
98%.
Figure 9. ESI-MS (Shimadzu LCMS-8040) of Cbi-Ex4, expected m/z = 5354, observed
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m/z = 1339 [M++3H+]+4, 1071 [M++4H+]+5.
Figure 10. Dose-dependent Cbi-Ex4 agonism at the human GLP-1 receptor, as
monitored in FRET assays using the cAMP biosensor H18869 expressed in HEK293
cells.70 EC50 value for Cbi-Ex4 was determined to be 200 ± 0.09 pM (mean ± SEM).
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Table 1. B12 and its binding proteins, transcobalamin (TC) and haptocorrin (HC) as
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measured in shrew serum, and their inhibition by increasing concentration of Cbi-Ex4.
The sum of Apo TC + Apo HC ~equals B12 binding capacity. * Conducted by Dr. Ebba
Nexo at University of Aarhus, Denmark.
Figure 11. Binding affinity plots of Cbi ((CN)2Cbi) and Cbi-Ex4 by the B12 binding
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proteins transcobalamin (TC) and haptocorrin (HC). Figure 11 shows the binding
affinity (Ka) of B12 binding proteins transcobalamin and haptocorrin to endogenously
occurring Cbi and the Cbi conjugated Ex4 (Cbi-Ex4). HC is known to be the only
physiologically relevant binder of Cbi and this is reflected in the binding constant of
HC with Cbi (Ka 0.036 nM). HC also binds Cbi-Ex4 (Ka 0.456), albeit with ~ 10-fold lower
affinity. Consistent with the known binding profile of TC, only weak binding occurs for
TC with Cbi or Cbi-Ex4 (Ka > 2 µM). * Conducted by Dr. Ebba Nexo at University of
Aarhus, Denmark.
Figure 12. Ex4 (1.25, 5, and 50 nmol/kg, i.p.; i.e., ≈5, 20, and 200 mg/kg; respectively)
dose-dependently suppressed blood glucose (BG) levels following glucose
administration (2 g/kg, i.p.). Saline versus 5 nmol/kg Ex4: **p < 0.01, ***p < 0.001;
saline versus 50 nmol/kg Ex4: ###p < 0.001; saline versus 1.25 nmol/kg Ex4: §§p <
0.01; 1.25 nmol/kg Ex4 versus 50 nmol/kg Ex4: @@@p < 0.001; 1.25 nmol/kg Ex4
versus 5 nmol/kg Ex4: Φp < 0.05, ΦΦp < 0.01, ΦΦΦp < 0.001. Area under the curve
(AUC) from 0 (i.e., post-glucose bolus) to 120 min after Ex4. In an IPGTT Cbi-Ex4 dosedependently reduced BG levels comparably to equimolar doses of Ex4. Saline versus
5-nmol/kg Cbi-Ex4: **p < 0.01, ***p < 0.001; saline versus 50 nmol/kg Cbi-Ex4: ###p
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< 0.001; saline versus 1.25 nmol/kg Cbi-Ex4: §p < 0.05; 1.25 nmol/kg Cbi-Ex4 versus
50 nmol/kg Cbi-Ex4: @@@ p < 0.001. AUC from 0 to 120 min following Cbi-Ex4. All
data expressed as mean ± SEM. Data in IPGTT was analyzed with repeatedmeasurements two-way ANOVA followed by Tukey’s post hoc test. AUC data in was
analyzed with repeated-measurements one-way ANOVA followed by Tukey’s post
hoc test. Means with different letters are significantly different (p < 0.05).
Figure 13. In an IPGTT, Ex4 (5 nmol/kg, i.e. 20 μg/kg) and equimolar doses of Cbi-Ex4
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suppressed blood glucose (BG) levels after IP glucose administration (2 g/kg, IP)
compared to saline; vehicle vs Cbi-Ex4: *** P < 0.001; vehicle vs Ex4: ### P < 0.001;
Ex4 vs Cbi-Ex4: §§ P < 0.01). Area under the curve (AUC) analyses from 0 (i.e., postglucose bolus) to 60 and 0 to 120 min; respectively. Cbi-Ex4 and Ex4 similarly reduced
AUCs compared to vehicle. All data expressed as mean ± SEM. IPGTT data in was
analyzed with repeated measurements two-way ANOVA followed by Tukey's posthoc test. All other data was analyzed with repeated measurements one-way ANOVA
followed by Tukey’s post hoc test. Means with different letters are significantly
different (P < 0.05).
Figure 14. In a delayed glucose load IPGTT, Ex4, Cbi-Ex4 (5 nmol/kg) or vehicle were
injected 6 h before glucose load. While Ex4-treatment was no longer effective in
reducing BG levels, Cbi-Ex4 retained its BG lowering properties; saline versus CbiEx4: **p < 0.01, ***p < 0.001; Ex4 versus Cbi-Ex4: §§p < 0.01), §§§p < 0.001. AUC
analyses from 0 to 60 min and 0 to 120 min, respectively. Cbi-Ex4-treated animals
had lower AUC 0-120 compared to Ex4-treated animals and a lower AUC 0–60
xxvii
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compared to Ex4-treated animals and controls. All data expressed as mean ± SEM.
Data in IPGTT was analyzed with repeated-measurements two-way ANOVA followed
by Tukey’s post hoc test. AUC data in was analyzed with repeated-measurements
one-way ANOVA followed by Tukey’s post hoc test. Means with different letters are
significantly different (p < 0.05).
Figure 15. Ex4 dose-dependently induced anorexia leading to weight loss. (J and K)
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Equimolar doses of Cbi-Ex4 had no effect on food intake or body weight. All data
expressed as mean ± SEM. Data was analyzed with repeated-measurements twoway ANOVA followed by Tukey’s post hoc test.
Figure 16. Ex4 (5 nmol/kg) induced anorexia at 3h, 6h, 12h and 24h post injection,

124

whereas Cbi-Ex4 had no effect on food intake. Latency to eat was increased only in
Ex4-treated animals. All data expressed as mean ± SEM. Food intake was analyzed
with repeated measurements two-way ANOVA followed by Tukey's post-hoc test.
All other data were analyzed with repeated measurements one-way ANOVA
followed by Tukey’s post hoc test. Means with different letters are significantly
different (P < 0.05).
Figure 17. Pharmacokinetic profile of two equimolar doses (25 nmol/kg and 50
nmol/kg) of Ex4 and Cbi-Ex4. Data expressed as mean ± SEM. Full PK parameters are
given in Table 2.
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Table 2. Pharmacokinetic parameters measured for Ex4 and Cbi-Ex4 in S. murinus.
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AUC indicates area under the curve between 0 and 360 or 0-1440 minutes; CMax is the
maximum measured concentration; T1/2 is the elimination half-life; Vd is volume of
distribution, Cl is clearance and Ke is elimination rate constant.
Figure 18. Ex4 (1.25, 5, and 50 nmol/kg) induced emesis during 120 min after injection
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in a dose-related fashion. The number of animals exhibiting emesis, expressed as a
fraction of the total number of animals tested, is indicated above each treatment
group. Latency to the first emetic episode of shrews that exhibited emesis after Ex4
treatment. Number of shrews experiencing emesis following Cbi-Ex4 (1.25, 5, and 50
nmol/kg) during 120 min after injection. The ratio of animals exhibiting emesis is
indicated above each treatment group. Latency to the first emetic episode of shrews
that experienced emesis after Cbi-Ex4 treatment. Heatmaps showing latency,
number, and intensity of emesis following Ex4 and Cbi-Ex4 dosing for each individual
animal across time. All data expressed as mean ± SEM. Means with different letters
are significantly different (p < 0.05). Emetic episode data was analyzed with repeatedmeasurements one-way ANOVA followed by Tukey’s post hoc test.
Figure 19. Cbi-Ex4 vs. Ex4 direct comparison on emesis. The number of single emetic
episodes following, Ex4 (5 nmol/kg, i.e. 20 μg/kg), Cbi-Ex4 or saline administration
was recorded for 120 min. Ex4 induced robust emetic responses that were not
observed after Cbi-Ex4 or saline injections. The number of emetic bouts was also
lower in Cbi-Ex4-treated animals compared to Ex4 and it did not differ from controls.
Graphical representation of latency to the first emetic episode between Ex4 and Cbixxix
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Ex4-treated animals that exhibited emesis. The percentage of shrews experiencing
emesis was significantly different between Ex4 and Cbi-Ex4. Heatmap showing
latency, number and intensity of emesis for each animal across time. All data
expressed as mean ± SEM. Means with different letters are significantly different (P <
0.05). Emetic episode and bout data was analyzed with repeated measurements oneway ANOVA followed by Tukey’s post hoc test. Frequency of emesis in animals was
analyzed with Fisher’s exact test.
Figure 20. Quantification of c-Fos positive neurons in the rostral, medial, and caudal
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NTS and medial AP. Peripheral Ex4 administration significantly increased the number
of c-Fos immunoreactive cells in the AP/NTS of shrews 3 h after injection. The number
of c-Fos positive cells in the AP/NTS was significantly lower in Cbi-Ex4 treated animals.
All data expressed as mean ± SEM. Data was analyzed with one-way ANOVA followed
by Tukey’s post hoc test. Scale bar, 100 mm.
Figure 21. Dose response and regression plot for HC-Cbi-Ex4 agonism at the GLP-1R.
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Figure 22. (Left) Structure of the Cbi ((CN)2Cbi) starting material, a purple solid

135

prepared via microwave chemistry from B12, with the hydroxyl group boxed used as
a site of conjugation to linker series. (Right) Library of linkers used in the conjugation
of Cbi to Ex4 peptides. The library of linkers chosen in this study included short
hydrophobic alkane chains, amphiphilic PEG, and rigid substituted ethynyl phenyl
methanamines, which were coupled to the Cbi hydroxyl group via CDT-mediated
amide formation, resulting in Cbi compounds (4−11) with an available alkyne group
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for subsequent reaction with azido-modified Ex4 peptides via copper-mediated
alkyne-azide click chemistry (Figure 23).
Figure 23. Synthetic Scheme of Cbi Linkers (4−11) and Cbi-Peptide Conjugates
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(12−27).
Figure 24. Effect of Cbi conjugation on the secondary structure of Ex4 or Ex40. CD
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spectra were collected with a sample concentration of 40 μM at pH 7 between 200
and 250 nm. % helicity was measured at 222 nm.
Figure 25. Conjugation of Cbi to Ex4 or Ex40 peptides maintains agonism at the GLP-
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1R. Nonlinear regression analysis was performed with GraphPad Prism 8. All
compounds were assayed at least as triplicate independent runs. Data are shown as
mean ± SEM.
Figure 26. In vitro dose escalation competition binding studies of 12-27 compared
with Ex4 and Ex40 controls against fluorescent GLP-1red. * Conducted by
EuroscreenFast.
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Table 3. EC50 and IC50 Values with Hill Slopes and % Helicity of Cbi Conjugates 12−27.
aData
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represents EC50 obtained using nonlinear regression analysis of data from

highest FRET values obtained for each data point. Experiments were performed as
three independent runs. bData represents the Hill slope obtained using nonlinear
regression analysis of data from highest FRET values obtained for each data point.
Experiments were performed as three independent runs. cData represents mean
residue ellipticity [θ]222 determined from the CD spectra of a 40 μM solution of
peptide in H2O at RT pH 7.0. Average [θ]222 values utilized to calculate percent
helicity were obtained by performing the experiment in triplicate. Percent helicity
was calculated using 100 × ([θ]222/max[θ]222). max[θ]222 = −40,000 [1 −(2.5/n)], where n
is the residue number. Experiments were performed as three independent runs.
dData

represents IC50 values obtained from competitive binding assays against red

fluorescent GLP-1 using nonlinear regression analysis from highest values obtained
for each data point. Experiments were performed as two independent runs. eHill
slopes were obtained using nonlinear regression analysis from highest values
obtained for each data point. Results are expressed as mean ± SEM.
Figure 27. 22 increases glucose-stimulated insulin secretion in rat islets relative to
glucose controls. Insulin secretion rate from static cultures of Sprague−Dawley rat
islets incubated in media containing glucose (10 mM) and Ex4 (10 or 50 nM) or 22 (10
or 50 nM).104 Data was calculated from three independent experiments and analyzed
with repeated-measurements two-way ANOVA followed by Tukey’s post hoc test.
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Results are expressed as mean ± SEM, **** p <0.0001. * Conducted by Varun Kamat
under the guidance of Dr. Ian R. Sweet at University of Washington.
Figure 28. Cbi-Ex4 enhances glucose clearance without inducing emesis or body
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weight loss. (A) In an IPGTT, Ex4, 1, and 22 (50 nmol/kg, IP) showed similar potency
in suppressing BG levels after glucose administration (2 g/kg, IP) compared to saline;
vehicle vs 1: *** P < 0.001; vehicle vs 22: ### P < 0.001; vehicle vs Ex4: §§§ P < 0.001;
1 vs 22: ΦΦ P < 0.01 (n = 12 shrews). Area under the curve (AUC) analysis from 0 (i.e.,
post-glucose bolus) to 60 min following 1, 22, and Ex4. AUC analysis from 0 to 120
min; 22 and Ex4 similarly reduced AUCs compared to vehicle (P < 0.05). All data
expressed as mean ± SEM (n = 10). IPGTT data was analyzed with repeatedmeasurements two-way ANOVA followed by Tukey’s posthoc test. AUC data was
analyzed with repeated measurements one-way ANOVA followed by Tukey’s posthoc
test. Means with different letters are significantly different (P < 0.05).
Figure 29. Ex4 and 22 (5 nmol/kg, IP) induced anorexia at 6, 24, and 48 h (and at 72 h
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for Ex4 only), whereas 1 had no effect on food intake (n = 10). Ex4-induced anorexia
was accompanied by significant body weight loss at 24 h. No significant changes in
body weight occurred after 1 and 22 administration compared to controls. All data
expressed as mean ± SEM (n = 10). Data was analyzed with repeated-measurements
two-way ANOVA followed by Tukey’s post hoc test. Means with different letters are
significantly different (P < 0.05).
Figure 30. The number of single emetic episodes following Ex4, 1, 22, or saline
systemic administration was recorded for 120 min. The number of animals
xxxiii
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exhibiting emesis, expressed as a fraction of the total number of animals tested, is
indicated above each treatment group. Ex4 induced robust emetic responses that
were not observed after 1 or saline injections. 22 induced emesis in two of the
animals tested; however, the number of emetic episodes was significantly lower
than that of Ex4 and did not differ from animals treated with vehicle or 1 (n = 10).
Heatmaps showing latency, number, and intensity of emesis following Ex4, 1, and 22
dosing for each individual animal across time. All data expressed as mean ± SEM (n =
10). Emetic episode data was analyzed with repeated measurements one-way
ANOVA followed by Tukey’s post hoc test. Means with different letters are
significantly different (P < 0.05).
Chapter 4: Peptide Ligands of the GDNF Family Receptor α-like (GFRAL)
Table 1. Designed GFRAL antagonists. Sequences were designed using amino acids of
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native ligand, GDF15, known to interact with GFRAL receptor. Note: Sequences are
confidential (Office of Technology Transfer, Syracuse University).
Figure 1. The AP lies at the caudal end of the fourth ventricle adjacent to the NTS.
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Direct injection via the fourth ventricle allows for activation of neurons found in the
AP and NTS.
Figure 2. GRASP-05 reduces GDF15-induced kaolin intake. 4th ICV GRASP-05 (300
pmol) significantly reduces 4th ICV GDF15 (30 pmol)-induced kaolin intake in the rat
(n=9/group, within-subject design) Data expressed as mean ± SEM. Means with
different letters are significantly different (P < 0.05).
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Figure 3. Synthetic scheme for GRASP-555. DBCO AF-546 was successfully “clicked”
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to GRASP-05 utilizing SPAAC.
Figure 4. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse
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XDB-C18 5μm, 4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 90%
CH3OH/H2O + 0.1% TFA in 25 min)) showing GRASP-555 product at 10.9 min. Purity
99%.
Figure 5. ESI-MS (Shimadzu LCMS-8040) of GRASP-555, expected m/z = 4386,
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observed m/z = [M+2H++Na+]+3: 1487, [M+3H]+3: 1463, [M+4H++H2O]+4: 1116,
[M+4H]+4: 1097, [M+5H]+5: 878.
Figure 6. GRASP-555 electronic absorption spectra were obtained on a Varian Cary
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50 Bio spectrophotometer in a 2mL quartz cuvette between 400 nm – 700 nm in
aqueous acetonitrile.
Figure 7. GRASP-555 10 mg/kg; IP shows co-localization with GFRAL-expressing
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neurons in the AP and NTS of rats.
Figure 8. Solution state structure of GRASP solved by NMR revealing secondary
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‘Hairpin-like’ structure with GDF15 like ‘loop’. Structure solved by Dr. Deborah
Kerwood, Syracuse University.
Figure 9. GDF15 (green) binding to GFRAL (blue/purple) (PDB 5VZ4) with bound
GRASP (Red) simulated using HADDOCK 2.2. A close-up rendering shows GRASP
‘blocking’ the region of GDF15 (W32) known to be vital for RET recruitment.
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Figure 10. Microsomal stability assay in rats. The half-life was calculated to be: 104.43
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min. Reaction velocity (V) was calculated to be 511 µL/mg. Intrinsic clearance (Clint)
was determined to be 339 µL/min/mg protein.
Figure 11. Synthetic scheme for Lip-GRASP-05. DBCO AF-546 was successfully
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“clicked” to GRASP-05 utilizing SPAAC.
Figure 12. ESI-MS (Shimadzu LCMS-8040) of Lip-GRASP-05, expected m/z = 4258,
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observed m/z = [M+3H+]+3: 1420, [M+4H+]+4: 1065, [M+5H+]+5: 852.
Figure 13. ELISA assay of GDF15 binding to human recombinant GFRAL (0.1 μg/mL).
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Figure 14. GenScript Generated Primary Antibody.
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Chapter 5: Fluorescent Probes of Neuroendocrine Hormones for the Identification
of Receptor Distribution and Function
Figure 1. Structure of leptin. PDB code 1AX8. Image generated by the author using

187

PyMol.
Figure 2. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse
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XDB-C18 5μm, 4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 90%
CH3OH/H2O + 0.1% TFA in 25 min)) showing Cy5-Leptin product at 9.9 min. Purity 98%.
Figure 3. Cy5-Leptin mass was found to be between 15-20 kDa and confirmed utilizing

189

12.5% SDS-PAGE.
Figure 4. Cy5-Leptin electronic absorption spectra were obtained on a Varian Cary 50
Bio spectrophotometer in a 2mL quartz cuvette between 500 nm – 800 nm in aqueous
acetonitrile.
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Figure 5. Immunohistochemical visualization of Cy5-Lep colocalized to DVC
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astrocytes. Used with permission of publisher under the Creative Commons license.
Figure 6. Synthetic scheme for REX.
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Figure 7. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse
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XDB-C18 5μm, 4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 90%
CH3OH/H2O + 0.1% TFA in 25 min)) showing REX product at 14.1 min. Purity 97%.
Figure 8. ESI-MS (Shimadzu LCMS-8040) of REX, expected m/z = 5319, observed m/z
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= [M+3H+]+3: 1773, [M+4H+]+4: 1331.
Figure 9. REX electronic absorption spectra were obtained on a Varian Cary 50 Bio
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spectrophotometer in a 2mL quartz cuvette between 400 nm – 700 nm in aqueous
acetonitrile.
Figure 10. In vitro dose escalation study of REX showing increase in cAMP levels in
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GLP-1R stably transfected HEK-293-H188 c20 cells.
Figure 11. Synthetic scheme for ROxy. B12-DBCO was successfully “clicked” to OTaz
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utilizing SPAAC.
Figure 12. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse
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XDB-C18 5μm, 4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 90%
CH3OH/H2O + 0.1% TFA in 25 min) showing ROxy product at 12.0 min. Purity 99%.
Figure 13. ESI-MS (Shimadzu LCMS-8040) of B12-Oxy, expected m/z = 2154,
observed m/z = [M+H2O+2H+]+2: 1097, [M+2H+]+2: 1078.
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Figure 14. ROxy electronic absorption spectra was obtained on a Varian Cary 50 Bio
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spectrophotometer in a 2mL quartz cuvette between 400 nm – 700 nm in aqueous
acetonitrile.
Chapter 6: Experimental
Figure 1. RP-HPLC trace showing the α- and β-isomer products of 2 at 5.2 and 6.7
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min.
Figure 2. ESI-MS of 2, expected m/z = 1042, observed m/z = [M-CN]+1 1016.
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Figure 3. Electronic absorption spectroscopy of 2.
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Figure 4. H NMR of 2 (400 MHz, 298K, D2O).
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Figure 5. 13C NMR of 2 (400 MHz, 298K, D2O).
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Figure 6. RP-HPLC trace showing the α- and β-isomer products of 4 at 8.8 and 9.5

211

min.
Figure 7. ESI-MS of 4, expected m/z = 1115, observed m/z = [M+-H2O]+1: 1096, [M+-
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H2O+H+]+2: 549.
Figure 8. Electronic absorption spectroscopy of 4.
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Figure 9. 1H NMR of 4 (400 MHz, 298K, D2O).
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Figure 10. 1H NMR of 4 (400 MHz, 298K, D2O) (Aromatic). Characteristic signals
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(H19) of β- (6.50) and α- (6.42) aquo-isomers of 4 are observed.
Figure 11. RP-HPLC trace showing the α- and β-isomer products of 5 at 7.4 and 7.9
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min.
Figure 12. ESI-MS of 5, expected m/z = 1129, observed m/z = [M+-H2O]+1: 1111, [M+H2O+H+]+2: 556.
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Figure 13. Electronic absorption spectroscopy of 5.
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Figure 14. 1H NMR of 5 (400 MHz, 298K, D2O).
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Figure 15. 1H NMR of 5 (400 MHz, 298K, D2O) (Aromatic). Characteristic signals
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(H19) of β-(6.49) and α- (6.42) aquo-isomers of 5 are observed.
Figure 16. RP-HPLC trace showing the α- and β-isomer products of 6 at 10.4 and 11.0

219

min.
Figure 17. ESI-MS of 6, expected m/z = 1143, observed m/z = [M+-H2O]+1: 1124, [M+-
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H2O+H+]+2: 563.
Figure 18. Electronic absorption spectra of 6.
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Figure 19. 1H NMR of 6 (400 MHz, 298K, D2O).
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Figure 20. 1H NMR of 6 (400 MHz, 298K, D2O) (Aromatic). Characteristic signals

222

(H19) of β- (6.50) and α- (6.43) aquo-isomers of 6 are observed.
Figure 21. RP-HPLC trace showing the α- and β-isomer products of 7 11.3 and 11.8
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min.
Figure 22. ESI-MS of 7, expected m/z = 1157, observed m/z = [M+-H2O]+1: 1139, [M+-

224

H2O+H+]+2: 570.
Figure 23. Electronic absorption spectra of 7.
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Figure 24. 1H NMR of 7 (400 MHz, 298K, D2O).
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Figure 25. 1H NMR of 7 (400 MHz, 298K, D2O) (Aromatic). Characteristic signals
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(H19) of β- (6.49) and α- (6.42) aquo-isomers of 7 are observed.
Figure 26. RP-HPLC trace showing the α- and β-isomer products of 8 at 18.4 and 19.3
min.
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Figure 27. ESI-MS of 8, expected m/z = 1204, observed m/z = [M+-H2O]+1: 1185, [M+-
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H2O+H+]+2: 593.
Figure 28. Electronic absorption spectra of 8.
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Figure 29. 1H NMR of 8 (400 MHz, 298K, D2O).
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Figure 30. 1H NMR of 8 (400 MHz, 298K, D2O) (Aromatic). Characteristic signals
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(H19) of β- (6.50) and α- (6.43) aquo-isomers of 8 are observed.
Figure 31. RP-HPLC trace showing the α- and β-isomer products of 9 at 20.0 and 21.8
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min.
Figure 32. ESI-MS of 9, expected m/z = 1292, observed m/z = [M+-H2O]+1: 1273, [M+-
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H2O+H+]+2: 637.
Figure 33. Electronic absorption spectra of 9.
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Figure 34. 1H NMR of 9 (400 MHz, 298K, D2O).
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Figure 35. 1H NMR of 9 (400 MHz, 298K, D2O) (Aromatic). Characteristic signals
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(H19) of β- (6.50) and α- (6.43) aquo-isomers of 9 are observed.
Figure 36. RP-HPLC trace showing the α- and β- isomer products of 10 at 12.4 and
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12.8 min.
Figure 37. ESI-MS of 10, expected m/z = 1191, observed m/z = [M+-H2O]+1: 1173.
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Figure 38. Electronic absorption spectra of 10.
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Figure 39. 1H NMR of 10 (400 MHz, 298K, D2O).
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Figure 40. 1H NMR of 10 (400 MHz, 298K, D2O) (Aromatic). Characteristic Signals
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(H19) of and β- (6.49) and α- (6.43) aquo-isomers of 10 are observed. Additional
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peak groupings between 7.56-7.51 and 7.35-7.28 are indicative of the phenyl ring
linker.
Figure 41. RP-HPLC trace showing the α- and β- isomer products of 11 at 12.6 and
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13.0 min.
Figure 42. ESI-MS of 11, expected m/z = 1191, observed m/z = [M+-H2O]+1: 1172, [M+-
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H2O+H+]+2: 587.
Figure 43. Electronic absorption spectra of 11.
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Figure 44. 1H NMR of 11. (400 MHz, 298K, D2O).
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Figure 45. 1H NMR of 11. (400 MHz, 298K, D2O) (Aromatic). Characteristic signals

242

(H19) of β- (6.49) and α- (6.42) aquo-isomers of 11 are observed. Additional peak
groupings between 7.48-7.37 are indicative of the phenyl ring linker.
Figure 46. RP-HPLC trace showing product 12 at 11.7 min.
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Figure 47. ESI-MS of 12, expected m/z = 5327, observed m/z = [M+-H2O+2H+]+3: 1771,
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[M+-H2O+3H+]+4: 1328.
Figure 48. In vitro dose escalation study of 12 showing increase in cAMP levels in GLP-
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1R stably transfected HEK-293-H188 c20 cells.
Figure 49. RP-HPLC trace showing product 13 at 12.0 min.
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Figure 50. ESI-MS of 13, expected m/z = 5341, observed m/z = [M+-H2O+2H+]+3: 1775,
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[M+-H2O+3H++CH3OH]+4: 1364, [M+-H2O+3H+]+4: 1332.
Figure 51. In vitro dose escalation study of 13 showing increase in cAMP levels in
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GLP-1R stably transfected HEK-293-H188 c20 cells.
Figure 52. RP-HPLC trace showing product 14 at 12.0 min.
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Figure 53. ESI-MS of 14, expected m/z = 5355, observed m/z = [M+-H2O+2H+]+3: 1780,
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[M+-H2O+3H+]+4: 1335.
Figure 54. In vitro dose escalation study of 14 showing increase in cAMP levels in
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GLP-1R stably transfected HEK-293-H188 c20 cells.
Figure 55. RP-HPLC trace showing product 15 at 12.0 min.
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Figure 56. ESI-MS of 15, expected m/z = 5369, observed m/z = [M+-H2O+2H+]+3: 1784,
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[M+-H2O+3H+]+4: 1339.
Figure 57. In vitro dose escalation study of 15 showing increase in cAMP levels in
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GLP-1R stably transfected HEK-293-H188 c20 cells.
Figure 58. RP-HPLC trace showing product 16 at 11.7 min.
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Figure 59. ESI-MS of 16, expected m/z = 5416, observed m/z = [M+-H2O+2H+]+3: 1800,
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[M+-H2O+3H+]+4: 1350.
Figure 60. In vitro dose escalation study of 16 showing increase in cAMP levels in GLP-
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1R stably transfected HEK-293-H188 c20 cells.
Figure 61. RP-HPLC trace showing product 17 at 12.3 min.
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Figure 62. ESI-MS of 17, expected m/z = 5504, observed m/z = [M+-
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H2O+2H++CH3CN]+3: 1870, [M+-H2O+3H++CH3OH]+4: 1404, [M+-H2O+4H+]+5: 1098.
Figure 63. In vitro dose escalation study of 17 showing increase in cAMP levels in GLP-
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1R stably transfected HEK-293-H188 c20 cells.
Figure 64. RP-HPLC trace showing product 18 at 12.2 min.
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Figure 65. ESI-MS of 18, expected m/z = 5403, observed m/z = [M+-H2O+2H+]+3: 1796,
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[M+-H2O+CH3OH+3H+]+4 : 1379, [M+-H2O+3H+]+4: 1347.
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Figure 66. In vitro dose escalation study of 18 showing increase in cAMP levels in GLP-
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1R stably transfected HEK-293-H188 c20 cells.
Figure 67. RP-HPLC trace showing product 19 at 12.6 min.
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Figure 68. ESI-MS of 19, expected m/z = 5403, observed m/z = [M+-H2O+2H+]+3: 1796,

257

[M+-H2O+CH3OH+3H+]+4: 1379, [M+-H2O+3H+]+4: 1347.
Figure 69. In vitro dose escalation study of 19 showing increase in cAMP levels in GLP-
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1R stably transfected HEK-293-H188 c20 cells.
Figure 70. RP-HPLC trace showing product 20 at 11.8 min.
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Figure 71. ESI-MS of 20, expected m/z = 5456, observed m/z = [M+-H2O+2H+]+3: 1813,

259

[M+-H2O+3H+]+4: 1360, [M+-H2O+4H+]+5: 1088, [M+-H2O+5H+]+6: 907, [M+-H2O+6H+]+7:
777.
Figure 72. In vitro dose escalation study of 20 showing increase in cAMP levels in
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GLP-1R stably transfected HEK-293-H188 c20 cells.
Figure 73. RP-HPLC trace showing product 21 at 11.8 min.
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Figure 74. ESI-MS of 21, expected m/z = 5469, observed m/z = [M+-

261

H2O+2H++CH3CN]+3: 1859, [M+-H2O+2H+]+3: 1819, [M+-H2O+3H++CH3OH]+4: 1395, [M+H2O+3H+]+4: 1364 [M+-H2O+4H+]+5: 1091.
Figure 75. In vitro dose escalation study of 21 showing increase in cAMP levels in
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GLP-1R stably transfected HEK-293-H188 c20 cells.
Figure 76. RP-HPLC trace showing product 22 at 11.8 min.
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Figure 77. ESI-MS of 22, expected m/z = 5483, observed m/z = [M+-H2O+2H+]+3: 1822,
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[M+-H2O+3H+]+4: 1367, [M+-H2O+5H+]+6: 912, [M+-H2O+6H+]+7: 781.
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Figure 78. In vitro dose escalation study of 22 showing increase in cAMP levels in
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GLP-1R stably transfected HEK-293-H188 c20 cells.
Figure 79. RP-HPLC trace showing product 23 at 11.8 min.

265

Figure 80. ESI-MS of 23, expected m/z = 5497, observed m/z = [M+-H2O+2H+]+3: 1827,
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[M+-H2O+3H+]+4: 1371, [M+-H2O+5H+]+6: 914, [M+-H2O+6H+]+7: 784, [M+-H2O+7H+]+8:
685.
Figure 81. In vitro dose escalation study of 23 showing increase in cAMP levels in GLP-
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1R stably transfected HEK-293-H188 c20 cells.
Figure 82. RP-HPLC trace showing product 24 at 11.6 min.
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Figure 83. ESI-MS of 24, expected m/z = 5544, observed m/z = [M+-
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H2O+2H++CH3CN]+3: 1884, [M+-H2O+3H++CH3OH]+4: 1414, [M+-H2O+3H+]+4: 1382.
Figure 84. In vitro dose escalation study of 24 showing increase in cAMP levels in GLP-
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1R stably transfected HEK-293-H188 c20 cells.
Figure 85. RP-HPLC trace showing product 25 at 12.0 min.
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Figure 86. ESI-MS of 25, expected m/z = 5632, observed m/z = [M+-

269

H2O+2H++CH3CN]+3: 1914, [M+-H2O+3H++CH3OH]+4: 1436.
Figure 87. In vitro dose escalation study of 25 showing increase in cAMP levels in GLP-
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1R stably transfected HEK-293-H188 c20 cells.
Figure 88. RP-HPLC trace showing product 26 at 11.9 min.

271

Figure 89. ESI-MS of 26, expected m/z = 5531, observed m/z = [M+-

271

H2O+CH3OH+3H+]+4: 1411, [M+-H2O+3H+]+4: 1379, , [M-H2O+4H+-CN]+4: 1353, [M+H2O+4H+]+5: 1104.
xliv

Figure 90. In vitro dose escalation study of 26 showing increase in cAMP levels in GLP-
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1R stably transfected HEK-293-H188 c20 cells.
Figure 91. RP-HPLC trace showing product 27 at 11.9 min.
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Figure 92. ESI-MS of 27, expected m/z = 5531, observed m/z = [M+-

273

H2O+CH3CN+2H+]+3: 1880, [M+-H2O+2H+]+3: 1838, [M+-H2O+CH3OH+3H+]+4: 1410,
[M+-H2O+3H+]+4: 1379, [M+-H2O+4H+]+5: 1103.
Figure 93. In vitro dose escalation study of 27 showing increase in cAMP levels in GLP-

274

1R stably transfected HEK-293-H188 c20 cells.
Chapter 7. Ongoing and Future Work
Figure 1. Synthetic scheme for B12-DBCO. B12 was functionalized with a DBCO linker
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through CDT activation of the 5’-alcohol of the f-sidechain.
Figure 2. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse
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XDB-C18 5μm, 4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 90%
CH3OH/H2O + 0.1% TFA in 25 min)) showing B12-DBCO linker product at 10.5 min.
Purity 92%.
Figure 3. ESI-MS (Shimadzu LCMS-8040) of B12-DBCO, expected m/z = 1808, observed
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m/z = [M+2H]2+: 905.
Figure 4. Synthetic scheme for B12-Oxy. B12-DBCO was successfully “clicked” to OTaz
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utilizing SPAAC.
Figure 5. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse
XDB-C18 5μm, 4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 90%
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CH3OH/H2O + 0.1% TFA in 25 min)) showing B12-Oxy product at 11.2 min. Purity
99%.
Figure 6. ESI-MS (Shimadzu LCMS-8040) of B12-Oxy, expected m/z = 2856, observed
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m/z = [M+2H+]+2: 1429, [M+3H+]+3: 953.
Figure 7. Peripherally administered, IP, oxytocin reduces food intake in male and
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female rats.
Figure 8. CNS penetrance is not required for the hypophagic effect of oxy. All rats
receiving B12-Oxy reduced food intake compared to their intake on vehicle (saline).
Equimolar dose of oxy also reduced food intake, with preliminary indication of a more
potent and longer-lasting feeding behavior impact of B12-OT.
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Chapter 1: Introduction
1.1 Glucose Homeostasis
Carbohydrates are one of the four major classes of biological macromolecules and
performs various functions including energy supply, energy storage, and structural support in
humans, animals, and plants.1 One of the simplest, most common, and critically important sugars
is glucose. This six-carbon monosaccharide is the most preferred source of energy in mammalian
cells.2 The high demand for glucose by most tissues and organs, including the brain, requires a
constant available supply. Despite the high requirements for glucose, its concentration must be
finely regulated within a narrow window.3,4 In humans, an accepted value of fasting blood glucose
(BG) levels ranges between 70 mg/dL and 100 mg/dL.5 Deviations from this concentration can
have profound effects ranging from disease to death. In cases of high BG levels (hyperglycemia;
defined BG levels >125 mg/dL when fasting or greater than 200mg/dL two hours following a
meal), individuals may suffer from blindness, renal failure, or vascular disease. Individuals with
low BG levels (hypoglycemia; defined as BG levels ≤70 mg/dL), could lose consciousness,
experience seizures, or death.5
Glucose homeostasis is controlled through the hormones glucagon and insulin produced
by the α- and β-cells of the pancreatic islets of Langerhans.3,4,6–8 Following energy consumption
glucose levels increase resulting in increased secretion of insulin. Secretion of insulin results in a
decrease in blood glucose concentrations by promoting cellular uptake of glucose while also
stimulating glycogen formation (Figure 1).9–12 In fasted states, blood glucose concentration
decreases promoting the release of glucagon. The secretion of glucagon promotes the
breakdown of glycogen and increases glucose release from the liver (Figure 1).6,10–12
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Figure 1. Glucose homeostasis is controlled through the hormones, glucagon and insulin.

1.1.1 Type I and II Diabetes mellitus Effect on Glucoregulation
One of the largest global public health concerns and leading causes of morality and
reduced life expectancy is diabetes mellitus (DM).13–16 Diabetes, meaning “siphon” and mellitus
meaning “honey”, was first described by the ancient Greek physician Aretaeus, due to the sweet
taste of urine from affected individuals.17 Characterized by chronic hyperglycemia, DM is a
metabolic disease resulting in diminished glucoregulation due to defects in insulin secretion,
insulin action, or both.17,18 There are two predominant forms of the disease, type 1 (T1DM) and
type 2 (T2DM), but additional forms exist.18 Typically identified before the age of 30, T1DM is an
autoimmune disease defined by the destruction of the β-islets of the pancreas and comprises
approximately 5-10% of all diabetic cases but is the most prevalent form (80-90%) in children and
adolescents.18 The absence of β-islets results in an inability to produce insulin with concomitant
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elevated blood glucose concentrations. Treatment for T1DM necessitates the use of insulin
injections.18
T2DM is the most prevalent form of the disease making up 90-95% of all cases across the
entire population. T2DM is defined by insulin resistance. Individuals suffering from T2DM are
capable of producing insulin, but the body is incapable of utilizing it to perform its proper
function.18 The increased demand for insulin due to diminished function can result in damage to
the pancreatic β-islets resulting in similar outcomes as observed in individuals with T1DM. 18
1.1.1.1 Impact of T2DM and Comorbid Obesity
There is currently a major increase in co-morbid obesity and T2DM.14–16 Worldwide, there
are 1.9 billion people who are overweight of which 600 million are obese. In addition, 387 million
people have been diagnosed with diabetes, 95% of which are T2DM.14,19–21 In 2017, the World
Health Organization (WHO) estimated there were 476 million cases of T2DM and project cases
to reach 571 million by 2025.13 Similar estimates and values have been proposed by the
International Diabetes Federation (IDF). The IDF estimates 451 million current cases and
increasing to 693 million cases by 2045.13 The estimations of current cases can be difficult as
many cases go undiagnosed. Individuals suffering from diabetes are at higher risk for mortality
as it is currently a top-10 cause of death.13 These co-morbidities are costly, and their dramatic
rise in prevalence has caused a substantial increase in health cost.14,19–21 In 2007, the direct
medical cost of diabetes was estimated at $116 billion, but that value has dramatically risen to
$237 billion in 2017.22,23 These values account for 1 in every 4 health care dollars spent in the
United States.22,23 The financial burden of treating/managing diabetes is largely due to the
lifelong need for pharmaceutical intervention.24,25
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1.1.1.1.1 Treatment of T2DM
Given individuals suffering from T2DM can produce insulin their treatment does not
require insulin injections, as observed in individuals suffering from T1DM. The first attempts to
maintain a blood sugar levels should be through a change in diet and implementation of an
exercise program.18,26 If an individual is unable to maintain glucose levels via exercise and diet, a
clinician may prescribe one of various medications. One of the most widely and generally first
prescribed drugs for the treatment of T2DM is metformin.26–29 The primary function of metformin
is to increase an individual’s sensitivity to insulin and thus allowing the insulin produced to be
used more efficiently.27,28 In addition to influencing insulin function, metformin also lowers
glucose production in the liver. The use of metformin as a therapeutic is limited by the fact that
it is only effective for a few years, Kahn et al. identified that metformin fails in 21% of prescribed
patients within five years,30 and is coupled with side effects including nausea, abdominal pain,
and diarrhea.26–29 As the efficacy of metformin declines sulfonylureas are often added to the
treatment regimen.26,29,31–33 Sulfonylureas act directly by stimulating insulin secretion. While
potent and effective in stimulating insulin secretion, the use of this pharmacotherapy can
facilitate hypoglycemia.31–33 An alternative to sulfonylureas is the use of glinides.26,29 Much like
sulfonylureas, glinides stimulate the pancreas to secrete more insulin. While faster acting than
sulfonylureas, glinides function is much shorter. Side effects caused using glinides include
hypoglycemia and weight gain.26,29 Additional therapeutic options that do not aim to increase
insulin secretion including thiazolidinediones and dipeptidyl peptidase IV (DPP-IV) inhibitors.26,29
Thiazolidinediones, like metformin, increase body tissues sensitivity to insulin.34–36 DPP-IV
inhibitors prevent the degradation of endogenous peptide hormones capable of increasing
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insulin levels (e.g. glucagon-like peptide-one (GLP-1)).37,38 Metformin, sulfonylureas, glinides,
thiazolidinediones, and DPP-IV inhibitors are all oral medications and are considered first and
second line therapeutics. Third- and fourth-line medications are injectable medications, many of
which target the GLP-1 receptor (GLP-1R), e.g. Exenatide.39–43 Table 1 provides a list of current
approved therapeutics for the treatment of glucoregulation. These medications regulate gastric
emptying and food intake while increasing insulin secretion and decreasing glucagon
secretion.26,29 A final treatment option, if none of the previously described options are effective,
is direct use of insulin itself. Administration of insulin injections must be precisely monitored as
too frequent injections may lead to excessive drop in blood sugar.44
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Table 1. Properties of Some Glucose-Lowering Agents Used in the Treatment of Type 2 Diabetes Mellitus.26,29
Class

Compounds

Biguanides

•

Metformin

Sulfonylureas

•
•
•
•
•
•

Glyburide
Glipizide
Glimepiride
Repaglinide
Nateglinide
Pioglitazone

•
•
•
•
•
•

Sitagliptin
Saxagliptin
Linafliptin
Exenatide
Liraglutide
Semaglutide

Glinides
Thiazolidinediones
DPP-IV Inhibitors

GLP-1R Agonists

Route of
Administration
Oral

Physiological
Function

Cost

Increase insulin sensitivity
Decrease glucose production
Increase insulin secretion

Low

Oral

•
•
•

Oral

•

Increase insulin secretion

Oral

•

Oral

Injection and Oral

Advantages

Disadvantages

•
•
•
•

Experience
No weight gain
Experience
No weight gain

•
•
•
•

GIT side effects
Vitamin B12 deficiency
Hypoglycemia
Weight gain

High

•

Dosing flexibility

Increase insulin sensitivity

Low

•

Inhibits DPP-IV activity

High

•
•
•

No hypoglycemia
Durability
Well tolerated

•
•
•
•
•

Hypoglycemia
Weight gain
Weight gain
Bone fractures
Pancreatitis

•
•

Increase insulin secretion
Satiety

High

•
•

No hypoglycemia
Weight reduction

•
•

GIT side effects
Patient compliance

Low
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1.1.1.1.2 Glucagon-like peptide-one (GLP-1) and its Receptor (GLP-1R)
Produced by the α-cells of the pancreas and the intestinal L-cells, proglucagon is a protein
and precursor to glicentin, glicentin-related pancreatic polypeptide, glucagon, oxyntomodulin,
major proglucagon fragment, glucagon-like peptide-1 (GLP-1) and -2 (GLP-2).45 Each of these
smaller proglucagon fragments play roles in metabolic functions including food intake and
satiety, fluid homeostasis, thermogenesis, and gastrointestinal motility.45 Three forms of GLP-1
may be processed from proglucagon including a single full form, GLP-1 (1-37), and two truncated
forms: amidated GLP-1 (7-36amide) and glycine extended GLP-1 (7-37).45 The primary function
of GLP-1 is to control insulin levels in response to a rise in blood glucose concentrations, typically
post prandially. Nearly all GLP-1 found in humans is in one of the truncated forms, 80% of which
is 7-36amide and 20% 7-37. While both the truncated forms are equally potent in stimulating
insulin secretion the full form has a much lower effect.45 The ability for GLP-1 stimulate insulin
secretion is dependent on its intact form. DPP-IV quickly degrades GLP-1 (t1/2 = 1-2 min) resulting
in the production of GLP-1 (9-36amide) or GLP-1 (9-37), which are rapidly cleared by the
kidneys.37,45 Fasting levels of GLP-1 in humans are found to be 5-10 pM and increase upon
addition of glucose.46 GLP-1 function is dependent upon binding and activation of its receptor
GLP-1R.
1.1.1.1.2.1 Exendin-4 (Ex4)
The glucagon superfamily consists of various biologically active peptides, many of which
contain a characteristic n-terminal histidine residue and a phenylalanine residue in their sixth
position.47 Investigations in Heloderma lizards, specifically Heloderma horridum and Heloderma
suspectum, have identified numerous peptides all fitting this characteristic and capable of acting
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at the GLP-1R.48 The venom of these lizards was shown to have a secretory effect on pancreatic
acini of guinea pigs.49,50 Initial investigations in to these lizards found two biologically active
peptides: helospectin (exendin-1 (Ex1))51 and helodermin (exendin-2(Ex2)).52 Further
investigations into Heloderma horridum by Eng et al. identified a third Exendin, Exendin-3 (Ex3).47
A fourth exendin, exendin-4 (Ex4) (Figure 2), was found exclusively in the saliva of Heloderma
suspectum.53 While structurally similar to Ex3, Ex4 contains amino acid substitutions at the
second (S2G) and third (D3E) residues.53 Ex4 and GLP-1 only share 53% sequence similarity, but
Ex4 is able to fully agonize the GLP-1R (EC50 33 pM) resulting in dose-dependent glucose-induced
insulin secretion.54 Structural differences observed in Ex4 include various amino acid
substitutions and a c-terminal extension to the sequence. One key amino acid substitution is
observed in the second position (A2G) resulting in resistance to DPP-IV leading to a half-life of
2.4 hours. The protection from DPP-IV provided by this substitution does not translate to other
proteases and as such must be administered subcutaneously.54 A synthetic variant of Ex4, Byetta
(Exenatide), was approved by the FDA for the treatment of T2DM in 2005.54

Figure 2. Structure of Ex4. PDB code 1JRJ.55 Image generated by the author using PyMol.
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1.1.2 Distribution and Activation of the GLP-1R
The actions of GLP-1 are mediated through its receptor GLP-1R. The GLP-1R is a class B Gprotein coupled receptor (GPCR) and a member of the glucagon receptor superfamily.45
Activation of this receptor occurs via endocrine hormones and stimulates the GS pathway
resulting in an increase in cyclic adenosine monophosphate (cAMP).45 The human GLP-1R is
distributed in both the central nervous system (CNS) and the peripheral nervous system
(PNS).45,56–61 Within the CNS the receptor may be found in regions of the hindbrain,
hypothalamus (HYP), and subfornical organ (SFO); specifically: paraventricular nucleus (PVN),
dorsal medial nucleus, arcuate nucleus (ARC), area postrema (AP), and nucleus of the solitary
tract (NTS).61 Activation of the GLP-1R in the CNS is not limited to glucoregulation but is also
largely attributed to the anorectic effects observed following administration of a GLP-1R
agonist.62 The GLP-1R is distributed throughout the PNS including: the vagus nerve, pancreatic βcells, stomach, and adipose tissue.56–59 Distinct activation of the GLP-1R in the PNS has been
shown to maintain glucoregulation without anorectic effects observed when activation
populations in the CNS.46,63–66
1.1.2.1 Unwarranted Side Effects Associated with GLP-1R Activation in the CNS
Activation of the GLP-1R population in AP and NTS is the cause of many negative side
effects, hypophagia and nausea/malaise, of current GLP-1R agonists as this the vomiting control
center of the CNS.67–69 The hypophagic effects of all known GLP-1R agonists are accompanied by
nausea, vomiting, and malaise. In fact, ~20-50% of T2DM patients prescribed GLP-1R agonists
experience nausea and/or vomiting, leading to discontinuation of drug treatment in ~6-10% and
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reduced dose tolerance in another ~15%.70–77 Thus, ~1 in 4 T2DM patients (~7 million US citizens)
are not able to fully benefit from current FDA-approved GLP-1-based drugs.
1.2 Vitamin B12 (B12)
Vitamin B12 (B12) is a naturally occurring water soluble organometallic compound that is
essential for normal physiological functioning.78,79 As only bacteria are capable of producing this
essential vitamin, humans must obtain it through their diet.78,80 High concentrations of B12
(μg/100 g) can be consumed via red meats including: liver (26-58), beef and lamb (1-3); other
sources are found in assorted dairy foods (0.3-2.4).79 The average human consumes 5-30 μg of
B1280 despite the recommended daily requirement being 2.4 μg.78,81,82 B12, unlike other
essential vitamins, can be stored for prolonged periods of time in the liver (2-3 mg).80 While a
lack of B12 intake can lead to pernicious anemia as well as other diseases and disorders,
identification can take years due to such large storage in the liver. There are no reported effects
from an overconsumption or intake of B12.78,79 The cellular uptake of B12 is highly dependent on
the binding and transport of B12 through the gastrointestinal tract (GIT) utilizing a system of
proteins and receptors.80–85
1.2.1 History of B12
The discovery, isolation, and characterization of the largest and most complex vitamin86
and “nature’s most beautiful cofactor”87 took more than 100 years and warranted the receipt of
two Nobel Prizes.88 Published in 1824, The first documented description of pernicious anemia, a
B12 deficiency disease, took place in 1824 when James Scarth Combe described the symptoms
of a 47 year old patient with previously excellent health whom died within one year.89 Published
under the title “History of a Case of Anemia”, Combe’s description lacked evidence and detail
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leading scientists to be unconvinced this was the condition the patient suffered from. Despite
evidence for the first description of pernicious anemia Combe is not credited with its original
description.88 In 1855, Thomas Addison describes what is accepted at the first description of
pernicious anemia in his work titled “On the Constitutional and Local effects of Disease of the
Suprarenal Capsuels”. In this work, Addison described an idiopathic anemia that occurred in both
sexes and resulted in failed appetite and waxy appearance and was ultimately fatal.90 In a 1872
article entitled “Progressive Pernicious Anemia”, Anton Biermer provided a detailed account of
15 cases of fatal anemia in which he later designated pernicious anemia.90 Identifying the cause
of pernicious anemia and the symptoms associated with the disease were investigated for years
to come with little progress in identifying the cause of the condition. In 1860, Austin Flint
hypothesized that the disease was degenerative to the glandular tubuli of the stomach. Building
on this hypothesis, Samuel Fenwick analyzed stomach tissue postmortem from patients suffering
from pernicious anemia. In 1877 Fenwick reported the presence of atrophy and glandular lesions
in this tissue.88 Additional postmortem investigations performed by James Russell and coworkers
identified degeneration of the spinal cord in patients that suffered from pernicious anemia.91
After nearly two decades no progress had been made for the clinical treatment of pernicious
anemia until work by George Whipple identified that diet could influence blood formation in dogs
made anemic by repeated phlebotomy. Whipple also found raw liver and extracts were more
effective at stimulating blood cell production than cooked liver.88 In 1926, Minot and Murphy
showed patients suffering from pernicious anemia could be treated utilizing a specific diet. Their
diet suggested the consumption of 120-240 gm of cooked calf, beef liver, or lamb kidney and ≥
120 gm of mutton muscle meat. The diet was completed with high amounts of fruits and
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vegetables due to high iron content and limited amounts of fat due to the belief it contained
blood destroying properties.92 Minot and Murphy’s study encompassed 45 patients and all
showed rapid improvement with the exception of one patient whom discontinued the diet.92 The
investigative worked on pernicious anemia by Whipple, Minot, and Murphy awarded them the
Nobel Prize in 1934.88
In related investigations William Castle was investigating achlorhydria, an absence of
hydrochloric acid in gastric juices, a condition nearly always found in patients suffering from
pernicious anemia. Castle believed pernicious anemia was caused by malnourishment or a lack
of dietary consumption, but was caused by a missing component in dietary uptake leading to a
decrease in uptake.88 Through experimentation Castle was able to identify that the lack of
hydrochloric acid did not affect the patient, but that the patients lacked an ability to respond to
specific component found in beef muscle. This component was believed to prevent pernicious
anemia from occurring. Castle identified this component as “extrinsic factor” and the stomach
component responsible for activity “intrinsic factor”.93,94
The identification of an “extrinsic factor” by Castle led to increased research to identify
this factor. The successful isolation of this factor occurred in 1948 simultaneously by a research
group led by Folkers of Merck Sharpe and Dohme and a group led by Smith and Parker of Glaxo
Laboratories. Both groups were able to successful isolate small red needle B12 crystals.95–100
Given the isolation of B12 crystals the composition and structure was able to be determined.
Both groups were able to identify that the compound contained cobalt. Utilizing elemental
analysis Brink et al. and several other groups were able to identify the composition of B12.101,102
Once the composition of the compound had been solved, Dorothy Hodgkin utilized X-ray
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crystallography to solve its structure.103,104 Hodgkin’s work utilizing X-ray crystallography
awarded her the Nobel Prize in 1964.88 The total synthesis of B12 took more than a decade
following the identification of its structure. Woodward and his team of over 100 scientists
reported the first total synthesis in 1971.105
1.2.2 Structure of B12 and Corrinoids
The determination of B12 composition to be C61-64H86-92N14O13PCo and the presence of
cyanide paved the way for determining the structure of B12.101,102 Initial crystallographic
investigations identified the planar groups of the molecule before ultimately determining the
final structure.103 At the core of the vitamin is a macrocyclic, corrin, ring composed of four
reduced pyrrole rings coordinated around a cobalt atom (Co3+) (Figure 3).106 While similar to the
porphyrin ring, the corrin contains key structural differences to distinguish the two structures.
Porphyrins are completely saturated and composed of 20 carbons, whereas corrins, due to the
loss of a methylene spacer, have a lower degree of saturation resulting an asymmetric 19 carbon
construct (Figure 3).107 Methylene spacers are found between pyrroles A-B, B-C, and C-D while a
direct bond is formed between pyrroles A and D. The corrin ring contains seven amide side chains
composed of three acetamides (side chains a, c, and g) and four propionamides (side chains b, d,
e, and f) (Figure 3).103,108 Given the electronic configuration of Co3+ (d6, low spin) there is a
preferred 6-coordinate octahedral geometry.82 While the corrin occupies the four planar
coordination sites, the two additional axial coordination sites, on the α- and β-faces of the corrin,
remain available.103,106,107 In “base-on” forms, predominant at physiological pH, of B12 the α-axial
ligand is occupied by a 5,6-dimethylbenzamidazole (DMB) base and coordinated to the cobalt
through a nitrogen atom. DMB is linked to the corrin ring through the D pyrrole via a ribose ring,
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a phosphate, and propanolamine and propionic acid residues (Figure 3).103 Protonation of the
DMB ligand results in a “base-off” variant of B12 with altered properties.108,109 The ligands of the
β-axial position may be occupied by various anions including: CN-, CH3-, Ado-, NO2-, SCN-, SeCN-,
SO3-, and thiourea.83 Despite the extensive library of ligands that may occupy the β-axial site, only
two are biologically active: methylcobalamin (MeCbl) and adenosylcobalamin (AdoCbl).82,110–112
Additional constructs, including B12 biosynthetic precursors, containing the corrin moiety are
deemed corrinoids.106

Figure 3. Chemical Structure of B12 as cyanocobalamin, with corrin ring highlighted in red.
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1.2.2.1 Biosynthetic Precursors and Structural Derivatives of B12
The biosynthesis of B12 requires microbial fermentation and is limited to few bacteria
and archaea.113 There are two primary routes of synthesis; an aerobic pathway carried out by
bacteria and an anerobic pathway performed by archaea (Figure 4). A third alternative pathway
capable of being utilized by some strains of bacteria and archaea is a salvage pathway (Figure
4).113 The two primary routes of synthesis are differentiated from one another based upon the
timing of insertion of the cobalt ion and the oxygen requirements.113 The aerobic pathway utilizes
precorrin-2 as its precursor while the anaerobic pathway utilized sirohydrochlorin (Figure 4).113
Both precorrin-2 and sirohydrochlorin are derived from uroporphyrinogen III, a porphyrin
precursor derived from δ-aminolevulinate (ALA). The synthetic pathways reconverge at
coby(II)rinic acid a, c-diamide (Figure 4).113 In bacteria and archaea capable of utilizing the salvage
pathway, exogenous corrinoids are shipped into the cell through an ATP-binding cassette
transport system.113 One such corrinoid utilized in this pathway is cobinamide, the penultimate
biosynthetic precursor of B12 (Figure 5). Other potential corrinoids include, but are not limited
to, cobyric acid and cobinamide phosphate (Figure 5).114

16

Figure 4. Biosynthetic pathways of adenosylcobalamin. Used with permission of publisher under
the Creative Commons license (http://creativecommons.org/licenses/by/4.0/.).113
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1.2.2.1.1 Dicyanocobinamide (Cbi)
Of particular interest for this research program is the B12 precursor dicyanocobinamide
(Cbi).109,115–119 Cbi is a “base-off” precursor and lacks the pseudo-nucleotide moiety observed in
B12 (Figure 5).109,120 Both the α- and β-axial ligands are occupied by CN- ion in Cbi (Figure 5), but
in acidic aqueous environments one or both ions may be replaced by water.109 If only one of the
axial ligands are replaced, isomers may form as substitution could occur at either the α- or β-axial
position.109 If both are replaced by water the resulting construct is deemed diaquocobinamide.121
At elevated pH levels the axial ligands may be replaced by hydroxide ions resulting in the
formation of dihydroxocobinamide.122 At neutral pH cobinamide may also for isomers of
aquohydroxocobinamide.122 To date there is limited synthetic cobinamide chemistry in the
literature, mostly focusing on the novel cobinamides to treat hydrogen sulfide123,124 or cyanide
poisoning115,118,125–130. Cbi is of particular interest in this program since it has no known biological
function in humans and has no effect on B12 physiology, is highly water soluble, and its uptake
into the CNS would be limited.116,131 This compound also contains a readily modifiable primary
alcohol in its structure allowing for chemical transformation.

Figure 5. Chemical structures of cobinamide phosphate, cobinamide, and cobyric acid. All
structures are truncated form of B12.
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1.2.3 Metabolism of B12
The ability of B12 to act as a coenzyme in the body is highly dependent on the β- face axial
ligand and the oxidation state of the central cobalt atom. While only the alkyl cobalamins methyl
cobalamin and adenosylcobalamin are biologically functional, both cyanocobalamin and
hydroxocobalamin can be readily converted in vivo to the biological active forms.132,133 The
central cobalt atom is capable of existing as Co(I), Co(II), and Co(III) at physiological conditions.
The oxidation state of the cobalt atom influences the coordination number. Co(I) prefers four
coordinate square planar geometry while Co(II) and Co(III) prefer five coordinate square
pyramidal and six coordinate octahedral geometry, respectively.82,86 The carbon cobalt bonds
observed in alkyl cobalamins, specifically in MeCbl and AdoCbl, is characteristically weak and is
essential in the ability for B12 to act as a cofactor.82 Both MeCbl and AdoCbl work as coenzymes
in the cytoplasm and mitochondria, respectively.82,85 Upon binding to their respective enzymes,
both MeCbl and AdoCbl exist in the “base-off” conformation with the α-axial ligand occupied by
histidine found in the enzyme.82 In the cytoplasm, methionine synthase – a methyltransferase –
utilizes MeCbl for the formation of methionine from homocysteine (Figure 6).82 The formation of
methionine and reformation of MeCbl occurs over a two-step process. First, the carbon cobalt
bond in MeCbl is heterolytically cleaved and transferred to homocysteine resulting in the
formation of methionine and cob(I)alamin. Secondly, the reformation of the cofactor occurs via
the removal a methyl group from 5-methyltetrahydrofolate (5-methyl-THF) to produce MeCbl
and tetrahydrofolate (THF).82,85,134,135 In the mitochondria, methylmalonly-CoA-mutase (MCM) –
an isomerase – utilizes AdoCbl for the formation of succinyl-CoA from methylmalonyl-CoA (Figure
6). During the catalytic formation of succinyl-CoA AdoCbl is homolytically cleaved resulting in the
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formation of cob(II)alamin and the initiation of the 5’-deoxyadenosyl radical. Propagation of the
5’-deoxyadenosyl radical initiates the rearrangement of methylmalonyl-CoA to succinyl-CoA.
Termination of the radical species occurs at the end of each catalytic cycle when cob(II)alamin
and the 5’-deoxyadenosyl radical recombine.82,85,136,137

Figure 6. B12 functions as a co-factor for the enzymes methionine synthase and methylmalonylCoA Mutase within the cytosol and mitochondria, respectively.

1.2.4 Dietary Uptake of B12 in Humans
The entrance of B12 into the cell is reliant upon its uptake and transportation through the
GIT utilizing three transport proteins: haptocorrin (HC), intrinsic factor (IF), and transcobalamin
(TC) as well as two receptors: CD320 and the cubilin (CUB) and amnionless (AMN) complex
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CUBAM (Figure 7).82,85,138,139 Following the consumption of food, B12 is released through the
action of peptic enzymes and the acidic environment of the GIT.82,83,116,138 The now free vitamin
is bound by HC, forming a new HC:B12 complex that travels from the stomach to the duodenum
where increased pH levels lead to the degradation of the HC:B12 complex (Figure 7).82,83,116,138
Following the dissociation from HC, B12 freely binds to IF. The IF:B12 complex allows for the
transport of B12 across the intestinal enterocyte site via receptor mediated endocytosis at the
CUBAM receptor (Figure 7).82,83,116,138 Within the enterocyte IF is broken down in the lysosome
leading to the release of B12 into the bloodstream. Within the bloodstream B12 is capable of
binding to TC and HC. Following the binding of B12 to TC, TC:B12, it is transported across cellular
membranes through the TC:B12 CD320 receptor (Figure 7).82,83,116,138 Once internalized the
vitamin is released and via the breakdown of TC in the lysosome where B12 undergoes further
chemical modification in order to perform its function as a cofactor in the previously stated
enzymes (Figure 7).82,85,138,140
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Figure 7. Human Dietary Uptake Pathway of B12. Abbreviations used: HC: Haptocorrin; Cbl:
cobalamin/B12; P: Protein; IF: Intrinsic Factor; TC: Transcobalamin.
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1.2.4.1 Transport Proteins of B12
The successful uptake and delivery of B12 to the cell is vastly dependent on the three
transport proteins HC, IF, and TC. Despite their low sequence similarity, approximately 25%,
these proteins have evolved from a single common ancestor. TC is the oldest transport protein
followed by IF and lastly HC.82,141 The age of these various transport proteins is reflected in their
distribution of species other than homo sapiens. The structural scaffold of each of these proteins
is highly conserved and allows each protein to bind and transport a single molecule of B12.85 Each
of these carrier proteins have a high affinity for B12 and provide protection form the highly acidic
environment of the GIT. Protection of B12 by the transport proteins begins immediately upon
consumption. B12 is highly susceptible to degradation142,143 and hydrolysis108,144,145 and must be
protected to ensure proper delivery and function in the cell.
1.2.4.1.1 Haptocorrin (HC)
The first protein found in the human B12 uptake pathway is HC (Figure 8). Found in both
the saliva as well as the bloodstream,82 HC is a heavily glycosylated 65 kDa protein with high
affinity (Kd = 0.01 pM) for B12 under acidic conditions (pH ≤ 3).85,138,146,147 Given HC’s stability
under highly acidic conditions it is able to protect B12 from degradation via acid
hydrolysis.108,144,145 HC’s binding affinity for B12 decreases as it enters the duodenum due to
increased pH and the presence of pancreatic enzymes. This high stability to acidic conditions is
highlighted by its 9-10 day half-life.148 The binding specificity of HC to B12 is lower than both TC
and IF as it can bind not only B12, but also incomplete B12 and other corrinoids.116,139 While the
specific function of HC in the B12 pathway is understood its function in plasma has yet to be
identified. Its ability to bind other corrin rings suggests a roll as a scavenger preventing inactive
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corrinoids from entering the cell.82,149,150 Upon the binding of an inactive corrin it could be
recycled through the hepatobiliary pathway.82

Figure 8. B12 bound to haptocorrin. PDB code 4KKI.147 Image generated by the author using
PyMol.

1.2.4.1.2 Intrinsic Factor (IF)
IF, the second transport protein, like HC, is a glycoprotein with a molecular weight 50 kDa
(Figure 9).82,85,151 IF has both a high binding affinity (Kd = 1.0 pM) and binding specificity for
B12.82,83,85 IF is produced by gastric mucosa and is resistant to proteolytic degradation.138 The
primary function of intrinsic factor Is to facilitate the transport of B12 across the intestinal
enterocyte via the CUBAM receptor.82,85 IF is broken down in the ileal enterocyte via lysosomal
enzymes.152 IF is only capable of binding intact B12.139
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Figure 9. B12 bound to intrinsic factor. PDB code 2PMV.151 Image generated by the author using
PyMol.

1.2.4.1.3 Transcobalamin (TC)
The final transport protein TC is a non-glycosylated protein with a molecular weight of
45.5 kDa (Figure 10).82,85,153–155 TC has both a high binding affinity (Kd = 0.005 pM) and binding
specificity for B12.82,83,85,139 Produced by endothelial cells, the primary function of TC is to bind
and transport newly absorbed B12 in the bloodstream to cells.82,83,85 Internalization of the TC:B12
complex occurs via the CD320 receptor.82,83,85,156 Once internalized TC is degraded by the
lysosome.82,83 Like intrinsic factor, TC will only bind intact B12.139
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Figure 10. B12 bound to transcobalamin. PDB code 2BB5.153 Image generated by the author using
PyMol.

1.2.5 Distribution of B12 Transport Proteins and Investigations of B12 Conjugates in Various
Lab Animal Models
Given the evolution and specialization of the B12 uptake pathway the distribution of
binding proteins varies in animal species. To date, the transition, of a corrinated conjugate, from
benchtop to in vivo investigation has frequently culminated with in vitro experiments. Despite
the lack of progression to in vivo investigation, several corrin conjugates have been investigated
in vivo. Nearly all corrin conjugates tested in vivo to date consist of peptide B12conjugates.
1.2.5.1. Zebrafish
Zebrafish are an ideal animal model due to their ability to rapidly breed and their low cost
of housing.141,157 Dating back to 1930, zebrafish were used as a developmental and embryological
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model.158 By 1990, the successful use of zebrafish mutants made it a mainstream model in
developmental biology.158 The successful use of this animal as a developmental model have
increased its use in the study of human disease.158 The integration of zebrafish into small
molecule screening has helped in the identification of new therapeutic compounds.159,160 Despite
the positive benefits of working with a small animal model like zebrafish there are limitations in
their use as a model for investigating a corrinated conjugate. Although this animal model may be
used for preliminary investigations it would not readily translate to that of a human due to the
large differences in their uptake pathways. Investigations by Greibe et al.141 have identified that
zebrafish do not contain the three transport proteins found in humans but contain one transport
protein resembling structure and function to that of the three proteins found in humans.141
The single protein isolated from the zebrafish experiment was termed HIT,141 given its
likeness to specific portions of the B12 binding proteins HC,147 IF,151 and TC.153 This protein had
properties similar to that of IF, resistance towards degradation by enzymes,138 while also being
similar to TC, in that no carbohydrates were observed.141 The HIT protein was found to be similar
in size to TC (~46 kDa), but the cobalamin binding site contained the highest sequence similarity
with that of IF.141 Despite similar structure and function to the transport proteins found in
humans the binding affinities of HIT for cobalamin and its analogues differed compared to
humans. Specifically, HIT showed decreased binding of Cbi compared to that of human HC, but
also showed improved binding of AdoCbl compared to that of human TC. HIT was capable of
binding B12 with equal potency to that of human HC, IF, and TC while also having the capacity to
bind additional corrinoids.141 The available amount of HIT protein to be targeted with a
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therapeutic requires further investigation as a large portion of the protein is secreted into water
much like the secretion of HC to extracellular fluids in mammals.141,161
Given the differences found in B12 transport between the zebrafish and the human it
would not be an ideal animal model for studying a corrinated conjugate. Given the presence of
only a single protein performing all known functions of transport proteins found in humans, the
ability to specifically target a single transport protein is lost. Although, it could provide some
preliminary insight and be coupled with other investigations a higher order species such as a
mammalian vertebrate should be used if translation to human studies is to occur.
Despite the potential limitations associated with studying corrinated conjugates in
zebrafish, work by Wang et al.162 utilized this model to access the cytotoxic effects of a B12
conjugated chitosan derivative used in the delivery of scutellarin (Scu) for the treatment of type
2 diabetes mellitus (T2DM) induced retinopathy.162 The B12-conjugate was assessed for both
acute toxic effects and the presence of developmental defects in zebrafish embryos. 72 hours
post incubation no embryonic developmental defects were observed at concentrations up to 250
μg/mL.162
1.2.5.2 Mammalian Vertebrates
Rats and mice have long been used as animal models due to their similarity to humans in
regard to anatomy, physiology, and genome.163 Depending on the diseased state being studied
either of these two species could be utilized and are often the chosen species for pre-clinical
trials.164 Depending on the diseased state being investigated a preference for mice over rats or
vice versa may occur.164 In application and investigation of corrinated conjugates both mice and
rats have slightly different uptake pathways than humans much like that of the zebrafish. While
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human transport of B12 consists of three transport proteins82,85,116 rats and mice utilize two
transport proteins.165,166 Like that of the zebrafish both mice and rats lack HC that is found in
humans.82,85,116 Unlike that of the zebrafish both rats and mice contain IF and TC. Despite the lack
of HC in these rodents the TC found in serum acts similarly to that of human HC and TC.165,166 This
TC, like a zebrafish,141 lacks the presence of carbohydrates and is similar to human TC in both
sequence and size.165,166 In addition to its structural similarity to that of human TC its function is
also similar to that of human HC based on its ability to bind additional corrin rings, specifically
Cbi.165
Due to the presence of only two transport proteins in the rat and the mouse there are
limitations to its application in studying a corrinated conjugate. Specifically, the ability to
specifically target HC and TC is lost due to the presence of a single protein capable of performing
both functions in this species.165 If a designed conjugate aimed to target IF specifically, this model
could still be utilized. While both rats and mice are an ideal animal for studying a human
disease,163,164 limitations exist in their ability to properly investigate a corrinated conjugate.
Although both rats and mice lack the same B12 uptake pathway observed in humans they
both are a standard for preliminary in vivo screening. Building on the results obtained in zebrafish
Wang et al.162 also investigated the pharmacokinetic enhancement of Scu, a compound limited
by poor oral bioavailability and water solubility, through their B12 chitosan derivative conjugate
for the delivery of sculletarin in male Sprague-Dawley rats. Rats were administered (40mg/kg)
doses of Scu, Scu loaded chitosan derivative (Chit-DC-Scu), and Scu loaded B12-conjugated
chitosan derivative (Chit-DC-VB12-Scu).162 Both Chit-DC-Scu and Chit-DC-VB12-Scu showed
improved bioavailability compared to that of free SCU. Additional experiments in rats
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investigating retinal damage and blood flow performed by Wang et al. found scutellarin to be
effective in attenuating retinal damage in diabetic Sprague-Dawley rats, but Chi-DC-Scu and ChiDC-VB12-Scu were more effective than the compound alone.162 Wang et al., concluded that ChiDC-VB12-Scu shows promising preliminary in vivo results and has therapeutic application in the
treatment of retinopathy induced by diabetes.162
The improvement of the pharmacodynamic properties of bioavailability and water
solubility is a hallmark of corrination.167,168 Given the poor oral bioavailability of luteinizing
hormone releasing hormone (LHRH) antagonists’ patients require frequent injection or nasal
inhalation of the therapeutic.169 To circumvent such drawbacks and the limitations associated
with peptide delivery, Russell-Jones et al.169 exploited the B12 uptake pathway for the delivery
of LHRH antagonists. Specifically, Russel-Jones and coworkers used covalently linked ANTIDE, one
of the most potent antagonists described to date, and its derivatives to B12 with the aim to
improve oral bioavailability of LHRH antagonists.169 Direct conjugation of B12 to ANTIDE and
derivatives resulted in decreased potency in vitro and in vivo in castrated Sprague-Dawley rats.169
It was presumed the presence of B12 resulted in a steric effect limiting binding of the antagonists
to its receptor. In attempts to restore the in vivo function of the B12-ANTIDE conjugate, RussellJones and coworkers utilized a biodegradable disulfide linkage.169 The employment of such a link
caused a slight decrease in in vitro potency but improved the ability to inhibit the release of
luteinizing hormone castrated Sprague-Dawley rats. All conjugates synthesized regardless of
function showed improved solubility compared to that of the free ANTIDE.169
Another investigation utilizing B12 to improve bioavailability of a protein was performed
by Petrus et al.170 The delivery of insulin for glycemic control has been limited by a variety of
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factors including poor bioavailability, possibility of contaminant pathogen uptake, compromised
function of lungs as a result of prolonged usage, trouble dispensing exact dose.171 Glycemic
control is often regulated using oral delivery for long or intermediate acting insulin while short
acting insulin is utilized through injection. The use of frequent injection commonly leads to a
decrease in patient compliance.170,171 In order to develop a non-invasive delivery system of insulin
Petrus et al. utilized a vitamin B12 conjugated for the delivery of insulin.170 To determine the
efficacy of the newly designed conjugate, Petrus et al. utilized a STZ-induced diabetic rat model.
Results of this investigation showed a 4.7-fold increase in area under the blood glucose curve. An
additional study delivered the B12-insulin conjugate in the presence of excess free B12. The area
under the blood glucose curve showed no effect at maintaining blood glucose confirming the
hypothesis that the construct was mediated by the B12 uptake pathway. In addition to its ability
to maintain glucoregulation the B12-insulin construct showed prolonged hypoglycemic activity
compared to that of free insulin.170
The most commonly corrinated peptides are those of neuroendocrine hormones,
including both PYY3-36 (PYY)172 and Exendin-4 (Ex4).138,167,168,173 Limitations of PYY as a
therapeutic include short half-life and initiation of nausea upon administration.172,174 To
potentially increase peptide activity through protection, B12 has been utilized as a potential
bioconjugate by Henry et al. In investigations using Sprague Dawley rats as an in vivo model B12PYY and PYY were delivered as subcutaneous pulses and resulted in B12-PYY having a stronger
reduction in daily food intake and weight gain compared to that of a free PYY.172
Another neuroendocrine hormone used in the treatment of T2DM is Ex4, but like PYY, is
commonly accompanied by nausea and malaise.138,167,168,173 Mietlicki-Baase et al. utilized a B12-
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Ex4 conjugate to improve glucose tolerance without producing anorexia and malaise.168 MietlickiBaase and coworkers investigated the effects of this construct in male rats and mice. Using male
Sprague Dawley rats B12-Ex4 did not suppress food intake, reduce body weight, nor induce
conditioned taste avoidance (CTA) as observed in matching studies utilizing Ex4.168 To further
investigate the potential beneficial effects of conjugating Ex4 to B12, glycemic control was
measured using C57BL/6J mice. In an IPGTT the administration of B12-Ex4 had a hypoglycemic
response similar to that of free Ex4.168
Corrin-conjugates have also been utilized outside of drug delivery and the improvement
of bioavailability. Investigations by Ikotun et al. utilized a copper64 labeled B12-NOTA construct
to explore the nutritional demand or proliferating cells in preclinical tumor models.175 This
construct was the first B12 conjugate utilized for positron emission tomography (PET) imaging.
The effectiveness of this B12-en-Bn-NOTA-64Cu was investigated in various murine tumor models.
This conjugate was effective and resulted in high tracer accumulation in various animal models.175
Given the limitations observed in the use of both rats and mice, lower ordered mammals,
additional higher ordered mammals provide opportunities for investigations of cobalamin
conjugates and ultimately translation into human studies. The musk shrew (Suncus murinus) is a
well-established model of emesis and feeding behavior and is suitable for examination of the
GLP-1 system as this species exhibits glucoregulatory, hypophagic and emetic responsivity
following administration of current Food and Drug Administration-approved GLP-1R
agonists.176,177
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1.2.6 B12/ Corrin Binding Capacity
The ability to design effective cobalamin conjugates for the treatment of a variety of
diseases has been hindered by the inability to translate successful in vitro screening to an
appropriate in vivo model. The ability to identify and select an animal model for in vivo
investigation has been hindered by the lack of readily useable data regarding the uptake
pathways of various laboratory animal models. A compilation of the available data regarding the
cobalamin uptake pathway in various laboratory models including the presence of transport
proteins and their saturated binding capacities was compiled by the author and is detailed in
Table 2.141,167,178–184
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Table 2. Unsaturated Binding Capacity (UBC) of Serum and Gastric Juice in Various Lab Animal
Models.
Species

Total
Serum
UCBC
(nmol/L)

Haptocorrin
UCBC
(nmol/L)

Transcobalamin
UCBC
(nmol/L)

Total
Gastric
UCBC
(nmol/L)

Homosapien

0.735-1.710178-183

0.075-0.350182,183

0.300-1.165182,183

30-51178,179

Rhesus Monkey

1.5-30178,181

NF

NF

NF

Porcine (Hog)

1.1-7.1178-181

NF

NF

NF

Dog

1.7-2.3178,181

NF

NF

180178

Cat

12-23178,180,181

NF

NF

NF

Shrew

12.38167

4.63167

8.04167

NF

Rabbit

13-18178-181

NF

NF

NF

Hamster

30178

NF

NF

NF

Guinea Pig

2.0-6.8178,178,181

NF

NF

NF

Rat

1.7-2.9178-181

NA

2.3178

7.5178

Mouse

28-32178,181

NA

28178

NF

Rainbow Trout

2500184

NA

NA

NF

Zebrafish

8.2141

NA

NA

NF

1.2.7 Chemical Modifications of B12 and Cbi
While bound to each protein in its uptake pathway B12 maintains a solvent exposed
surface. The solvent exposed surface of B12 while bound to HC is 3.2% (≈39 Å2) (Figure 8),147 this
value is doubled when bound to TC, 6.6% ( ≈80 Å2) (Figure 9) ,153 and doubles again to 13.2%
(≈163 Å2) when bound to IF (Figure 10).151 Given the complex structure of the compound there
are multiple functional groups that can be readily modified. These modifiable functional groups
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are ideal locations for conjugation to small molecules or peptides.83 While multiple sites can be
easily chemically modified few locations can be chosen while maintaining recognition by all three
transport proteins. The ability to modify at multiple locations allows for specific targeting of one
of the three transport proteins.
The B12 structure contains five different regions which may be chemically modified while
maintaining recognition by all transport proteins: 1) the peripheral corrin ring ɛ-propionamide,
2) the peripheral corrin ring b-propionamide, 3) the 5’-hydroxyl group found in the ribose unit of
the α-tail, 4) the 2’-hydroxyl group found in the ribose unit of the α-tail, 5) the phosphate moiety
of the α-tail, 6) the cobalt cation (Figure 3).83,117,185 The B12 molecule contains multiple other
functional groups that are capable of being modified, but modifications at these locations can
affect the binding of the conjugate to individual or all transport proteins. While this may be of
interest depending on the conjugate being designed those modifications are not discussed herein
and the reader is directed to Wierzba et al.117 and o’Proinsias et al.185 for further discussion.
1.2.8 Developing a GLP-1R Agonist Devoid of Nausea, Emesis, and Weight loss
The dramatic rise of type 2 diabetes (T2D) and obesity as comorbidities has driven a
concomitant rise in new pharmaceutical interventions to treat such disorders, either together or
individually.24,25,186–190 One extremely successful family of pharmaceuticals in this field has been
that of glucagon-like peptide-1 receptor agonists (GLP-1RAs),46,64,65,191–193 such as exenatide (i.e.,
Exendin-4; Ex4),54,138 liraglutide,194–197 and semaglutide.196–198 Exenatide and liraglutide confer
glucoregulation in tandem with a body weight reduction of 5−6% over ∼1 year,196,197 while
semaglutide can produce a weight loss of 10− 12% over the same time period.196,197 The
hypophagic effects of all GLP-1RAs are however accompanied by nausea and vomiting (emesis)
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in upward of 25% of patients,70–76 the result of penetrance and direct action of the GLP-1RA in
the CNS, particularly in the nucleus tractus solitarius and area postrema of the hind-brain.62,199–
201

Thus, the development of a GLP-1RA that does not access the CNS would be expected then to

mitigate the side effects of nausea and emesis and reduce the hypophagic effects. The reasons
for removing the side effects are obvious, but less clear is the fact that there is a current unmet
clinical need to broaden pharmacopoeia for certain subpopulations of T2D patients, including
lean individuals, those in a state of cachexia (wasting of body tissues/chronic weight loss), or
those who must avoid weight loss from other life-threatening diseases such as chronic
obstructive pulmonary disease, cystic fibrosis, cancer, and HIV, among others.202–206 Indeed, the
prevalence of T2DM in COPD patients is ≈20% with an incidence for COPD of ≈10% in the overall
diabetic population.207–209 Further, depending on the tumor type, between 8% and 18% of the
cancer patients at the time of diagnosis also suffer from T2DM,204,210 and 30%–40% of
hospitalized heart failure patients are diabetic.211 This subgroup of T2DM patients is already at
increased risk for cachexia, nausea/malaise, and unintended weight loss.212,213 In these T2DM
patients, as well as overweight/obese T2DM patients that cannot effectively tolerate the
nausea/emesis of existing GLP-1-based therapeutics. the data provided here support the
hypothesis that the a corrinated Ex4 construct can improve glycemic control without producing
anorexia and drug-treatment-induced malaise.
Reduced caloric intake and body weight may be viewed as positive therapeutic outcomes
in many T2DM patients prescribed existing GLP-1-based therapeutics (i.e., in those patients with
accompanying obesity); however, there is a substantial number of T2DM patients that require
glycemic control without weight loss. Thus, we set out to create GLP-1RAs with reduced brain
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penetrance but with retained, comparable pharmacodynamic profiles on pancreatic GLP-1R
populations.138,167,168,172,173 Recently, we have taken the approach of utilizing components of the
vitamin B12 (B12) dietary uptake pathway including that of the corrin ring containing
B12138,168,172,173,214 itself as well as B12 precursors such as Cbi (Figure 11)167 in a process we have
coined “corrination”. The benefits of corrination over other conjugation modes lie in the ability
to specifically target select corrin binding proteins such as intrinsic factor, transcobalamin, or
haptocorrin for use in targeting or to affect pharmacokinetics, modify solubility, and alter drug
localization, all without having to reverse the process to allow for maintained drug function
pending suitable design.

Figure 11. Corrination of Ex4 (Cbi-Ex4) does not prevent GLP-1R agonism in the pancreas but does
mitigate agonism in the CNS as tracked by emesis and anorexia. Ex4 alone agonizes GLP-1R
populations in both the pancreas and CNS.
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1.3 Glial cell-derived neurotrophic factor (GDNF) Family and the GDNF Family Ligands (GFLs)
The transforming growth factor-β (TGF-β) superfamily is a constantly expanding family of
peptides and proteins involved in the proliferation, growth, and differentiation of cells. The
superfamily consists of bone morphogenetic proteins, growth and differentiation factors,
activins, inhibins, and glial-derived neurotrophic factors (GDNFs). Additional proteins and
peptides are also part of this superfamily, but are not further separated into their own
subfamily.215–219

Due to their various roles in cell signaling they are heavily involved in

development and disease. The dysregulation of the TGF-β superfamily signaling has been
identified in cancer, cardiovascular, fibrotic, and skeletal diseases.217 Some of the most distant
members of the TGF-β superfamily are the members of the GDNF family.220 There are four
members of the GDNF family including: GDNF, artemin (ARTN), persephin (PSPN) and neurturin
(NRTN).221–227 The ligands of this family are considered distant members of the TGF-β superfamily
due to their conserved pattern of cysteine residues in their primary sequence and structural
similarity observed with other members of the family.228 Monomers of the GFL are composed of
an α-helical heel region, a cysteine-knot motif, and a finger region composed of two fingers
formed by anti-parallel β-strands connected by loops (Figure 12). In circulation the GFLs are found
as homodimers in which the monomers are coupled in a head-to-tail conformation (Figure 13).228
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Figure 12. Monomer of GDF15 a Member of the GFL. PDB code 5VZ4.229 Image generated by the
author using PyMol.

Figure 13. Dimer of GDF15 a Member of the GFL. PDB code 5VT2.222 Image generated by the
author using PyMol.
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1.3.1 Growth/Differentiation Factor 15 (GDF15)
Growth differentiation factor 15 (GDF15), previously known as macrophage inhibitory
cytokine 1 (MIC-1), NAG1, PLAB, and PDF, here on referred to as GDF15, is a stress response
cytokine and a distant member of the TGF-β superfamily.220,230–232 Unlike the other GFLs, GDF15,
has high specificity for its receptor and is in capable of binding to other receptors found in the
GNDF family.220 GDF15 is found in all individuals and circulates as a mature dimer with a
molecular weight of approximately 25 KDa.220 Serum concentrations vary with individuals with
basal levels ranging from 200-1,200 pg/mL.233 Concentrations of GDF15 increase in states of
inflammation including exercise, smoking, obesity, pregnancy, and cancer.220–222,234–237 In cases
of pregnancy In advanced cancers GDF15 influences anorexia/cachexia syndrome and has been
shown to induce weight loss and appetite supression.220,230,238 Tumor bearing mice engineered
to increase GDF15 expression resulted in increased weight loss due to a loss in both fat and lean
mass due to decreased energy intake. Loss of mass was able to be mitigated through antibody
treatment targeting GDF15.238 The overexpression of GDF15 in transgenic mice lead to lean
phenotypes, decreased energy consumption, and resistance to obesity.238 The overexpression of
GDF15 improved glucose tolerance in both normal and high fat diets.239 In an inverse study, it
was shown that mice with a deletion of GDF15 resulted in an obese phenotype which could be
corrected with injections of GDF15.240
1.3.2 The receptors of GFL, GDNF Receptor-α (GFRα)
The binding receptors of the GFLs are of the GDNF family receptors, GFRα. Each of the
GFLs have unique binding affinities to their own GFRα.241 GDNF specifically binds to GFRα1, NRTN
binds to GFRα2, ARTN to GFRα3, and PSPN GFRα4.225–228,241 While each ligand of the GFL contains
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their own receptor, there is some promiscuity in binding and GFLs have been shown to activate
other GFRα receptors.225,229,242 These receptors are anchored to the cell surface via a
glycophosphatidylinositol (GPI).225,226,228,230,241,243 Given that the GFRαs are GPI anchored they are
commonly localized in lipid rafts.241 In addition to GPI anchored receptors, the GFRα receptors
are capable of existing in soluble forms.223,244 Transmembrane forms of the GFRα1 exist but are
unable to transport RET to the lipid rafts despite activating RET phosphorylation.244
1.3.2.1 GDNF Family Receptor-α Like (GFRAL)
The receptor for GDF15 remained unclear until 2017 when four independent laboratories
identified its receptor, GFRAL.20,224,229,245,246 Highly expressed in the CNS, specifically in the AP
and NTS, GFRAL is a distant member of the GFRα family.20,220,224,229,245,246 While the individual
isoforms found in the GFRα family are capable of binding more than one ligand, GFRAL is highly
specific in its binding only for GDF15.220 While the members of the GFRα family are GPI anchored,
GFRAL is a transmembrane protein.220,230 An additional isoform of GFRAL exists in which exon 6
has been removed. The resulting receptor maintains binding sites for GDF15, but eliminates the
transmembrane sequence and thus producing a soluble receptor.220,247 To date the expression
and function of this receptor is still being investigated.220 Deletion of the GFRAL receptor in mice
resulted in no response following GDF15 injection, but predisposed the mice to obesity when fed
a high fat diet.20,229 In experiments performed by Tsai et al., it was found that the AP and NTS
had to be intact in order for effects of GDF15 to be observed and that animals were unresponsive
to treatments following lesion of the AP and NTS.248
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1.3.2.2 GFL Signaling Receptor RET
Rearranged during transformation (RET),225,228 is a single-pass transmembrane receptor
tyrosine kinase (RTK).228 The extra cellular region of RET is composed of four cadherin like
domains (CLD1-4) and a cysteine-rich domain proximal to the cellular membrane.228 Given the
presence of the repeating CLD and calcium binding site RET is defined as a distant member of the
cadherin superfamily.225,228 Between CLD2 and CLD3 is a calcium binding site. The binding of
calcium is required for proper folding and function of RET.228 The intracellular region of RET is
composed of a juxtamembrane domain, a tyrosine kinase domain, and a C-terminal tail.228 All
members of the GFLs including GDF15 share a common signaling receptor, RET.220,228,230,241,249,250
While RET is the signaling receptor for the GFLs they are not able to stimulate signaling via the
receptor alone.228 The GFRα/GFRAL:RET complex is unique as it is the only known RTK requiring
separate ligand binding components.228,243 While the GFRα receptors are found in lipid rafts, RET
is not and must be recruited in order for signaling to occur.241
1.3.2.3 Signaling Through the GFRα/GFRAL:RET Complex
Following the binding of a GFL to its unique GPI anchored binding receptor, GFRα, the
GFL-GFRα complex then recruits RET to the lipid raft containing GFRα. This new ternary complex
leads to dimerization, autophosphorylation, and intracellular signaling.241 The final signaling
assembly is composed of a 2:2:2 stoichiometry containing two GFL: two GFRα: and two
RET.228,249,250 The proper function and ability to signal requires intact lipid rafts as cholesterol
depletion has been shown to decrease GDNF stimulated intracellular effects.244 Various models
have been proposed for how the complex formation takes place. The first proposed model
suggests a circulating homodimer of the GFL symmetrically binds to two of its GFRα
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simultaneously and then recruits RET and thus activating kinase domains. An alternative model
suggests a stepwise approach in which a circulating homodimer GFL binds to a single GFRα
receptor at which time RET is recruited and then additional molecules of GFRα and RET dimerize
in the lipid raft.251 In the case of signaling through the soluble receptor one of the GFLs bind to
their native GFRα at which time the GFL: GFRα complex then binds to ret and the ternary complex
is recruited to a lipid raft.223 The activation of RET and its signaling plays roles in cell survival,
differentiation, proliferation, and migration.241,249,250 Given the possibility of separate function by
the soluble GFRAL receptor additional functions of this complex may exist.220
1.3.3 Targeting the GDF15:GFRAL Complex (Agonism and Antagonism)
Given the complex role the GDF15:GFRAL pathway plays in energy homeostasis it is an
ideal target for the treatment of various diseased states. The pathways resistance to obesity and
glucose intolerance highlights its application in the treatment of comorbid disease obesity and
diabetes. The pathways influence on anorexia and cachexia in states of high GDF15 serum levels
provides another avenue for pharmaceutical development. Approximately 50-90% of all
pregnant women experience nausea and vomiting as a result of the pregnancy itself. Nearly 1/5th
of this population require medication to treat such side effects. Hyperemesis gravidarum (HG) is
a severe case that occurs in 0.3-2.0% of pregnancies. In a genome wide study GDF15 was found
to be upregulated suggesting a role in the condition.252
1.4 H188 FRET Assays and Fluorescent Probes of Neuroendocrine Hormones
To determine the agonism of Corrin-Ex4 conjugates at the GLP-1R, HEK293 cells stably
transfected with the receptor were utilized. The cells were infected with the H188 adenovirus,
the most sensitive exchange protein directly activated by cAMP (EPAC) fluorescence resonance
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energy transfer (FRET) reporter.253l This reporter consists of a cAMP binding domain flanked by
a mTurquise2∆ FRET donor chromophore at the N-terminus and a tandem cp173 Venus-Venus
FRET acceptor chromophore at the C-terminus of fluorescent proteins (Figure 14). When cAMP
binds the EPAC, a conformational change occurs, causing the two chromophores to move closer,
creating an increase in FRET response.254 This EPAC was chosen based on its higher sensitivity
(~70%) than other FRET assays such as AKAR3 (~20%).254

Figure 14. Domain structures of the H88 adenovirus. Used with permission of author.254

Currently there is an unmet need for the development of fluorescent probes to better
understand the neurocircuitry involved in the suppression of reward circuits. While it is known
that the GIT generates a number of signals to trigger satiation, the mechanisms behind and
underpinning such signaling is complicated by a lack of tools to track where and when certain
pathways are activated or inhibited. The development of a library of different fluorescent Ex4s,
for example, offers an opportunity to explore whether, and when, this peptide binds to its
cognate receptor as a monomer or dimer.
In the case of leptin, a hormone produced by adipose tissue that helps to prevent food
consumption there continues to be debate on leptin receptor distribution, especially in cells in
the brain not typically associated with leptin signaling.
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Another relevant example to this work is that of oxytocin, well known for its role in
childbirth and ‘bonding’, but much less explored in terms of a role in energy homeostasis. The
design of a fluorescent, functional, oxytocin would allow for the further investigation of this
multifunctional peptide, especially given oxytocin antibody have failed to provide adequate data
from ex vivo studies. The design and synthesis of fluorescent probes of these three peptide
hormones is discussed herein (Chapter 5).
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Chapter 2: A Second-generation Glucagon-like Peptide-1 Receptor Agonist Mitigates Vomiting
and Anorexia While Retaining Glucoregulatory Potency in Lean Diabetic and Emetic
Mammalian Models
The work reported in this chapter resulted in a peer-reviewed research paper: Tito
Borner, Evan D. Shaulson, Ian C. Tinsley, Lauren Stein, Charles C. Horn, Matthew R. Hayes, Robert
P. Doyle,* and Bart C. De Jonghe*. A second-generation glucagon-like peptide-1 receptor agonist
mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and
emetic mammalian models. Diabetes, Obesity, and Metabolism 2020, 22 (10), 1729-1741
All synthetic work, including synthesis of all tested compounds and the fluorescent
analog, their purification, chemical and in vitro biochemical characterization, and preparation for
in vivo testing was conducted by the author. In addition, the author assisted in in vivo data
collection specifically included in Figures 4 and 5, and conducted with Dr. Tito Borner of the
University of Pennsylvania.

This work was presented by the author (Left) and Dr. Tito Borner (Right; University of
Pennsylvania) at the Keystone Symposia on Molecular and Cellular Biology, Banff, Alberta,
Canada, February 2019.
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2.1 Introduction
Nausea and vomiting are omnipresent side effects of human diseases and
pharmacotherapies that have spawned significant drug discovery efforts to combat their many
causes.1 Glucagon-like peptide-1 receptor (GLP-1R)-based therapies for the treatment of type 2
diabetes mellitus (T2DM), such as Exendin-4 (Ex4) and liraglutide, are no exception,2 causing
nausea and vomiting in ≈25% to 50% of patients prescribed these drugs.3–7
A recently reported vitamin B12 (B12) conjugate of Ex4 (hereafter called ‘B12-Ex4’)
reported by the Doyle group 8,9 showed retention of glucoregulation comparable with native Ex4
without producing Ex4-associated anorexia or conditioned taste avoidance (CTA) in lean, healthy
rats.8 Furthermore, B12-Ex4 co-localized with insulin-containing β-cells within the pancreas,
while brain penetrance of a fluorescently tagged B12-Ex4 was not detected within the
hypothalamus, area postrema (AP), or nucleus tractus solitarius (NTS) of the brain stem.8 These
results corroborated prior in vitro, ex vivo and functional in vivo observations that the incretin
action on the pancreas10–12 and hypoglycemic effects of Ex4 remained intact when bound to B12,
while central sites of Ex4 action controlling energy homeostasis and nausea/malaise (e.g. the
brainstem AP and NTS, as well as hypothalamic nuclei)13–15 were putatively not agonized
following B12-Ex4 treatment. The B12-Ex4 construct may be of considerable clinical utility given
the potential for retained glycemic control in combination with improved tolerability and
associated patient compliance through a mechanism of action that simultaneously limits central
nervous system (CNS) penetrance and retains peripheral (i.e., pancreatic) pharmacodynamics.
Weight loss is considered desirable for many patients with T2DM considered overweight
or obese, as they may benefit from improvements in insulin signaling and overall health with
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concomitant adipose tissue loss.16,17 However, patients with T2DM who also suffer from comorbidities associated with cachexia (e.g. cancer,18 cystic fibrosis,19 HIV,20 chronic obstructive
pulmonary disease,21 and sarcopenia22), would also benefit from use of the front-line treatments
for T2DM in the form of GLP1-R agonists, without affecting their body weight. In addition, ≈10%
of patients with T2DM, such as those potentially with polygenic/inherited T2DM, are not
overweight/obese,23 and weight loss below normal weight status is undesirable. To this end,
given previously reported work in healthy, lean rats, showing comparable glycemic control
without anorexia/weight loss following acute B12-Ex4 treatment compared with native Ex4,8 we
sought to employ the use of the Goto-Kakizaki (GK) rat, a model of spontaneous insulin resistance
and T2DM.24 These animals develop T2DM early in life and maintain a lean phenotype (see
Ostenson and Efendic25 for a discussion/review), making this strain ideal to model T2D without
concomitant obesity.
The musk shrew (Suncus murinus) is a well-established model of emesis26 and feeding
behavior27 and is suitable for examination of the GLP-1 system as this species exhibits
glucoregulatory, hypophagic and emetic responsivity following administration of current Food
and Drug Administration-approved GLP-1R agonists such as Ex4.14,15 Immunohistochemical and
pharmacological analyses were performed to examine the effects of B12-Ex4 versus Ex4
administration on glycemic control, emesis and feeding behavior in shrews.
2.2 Design and Synthesis of B12-Ex4
B12-Ex4 was synthesized, characterized, and screened for receptor agonism as previously
described.9 Briefly, the 5′ hydroxyl group of B12 was selectively oxidized to a carboxylic acid
(B12CA) using 2-iodoxybenzoic acid, as previously described.28 Subsequent coupling of 1-amino-
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3-butyne to B12CA with 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDC) and 1hydroxybenzo-triazole (HOBt) produced B12 with a terminal alkyne at the ribose 5′-position
(B12AB). A K12 azido modified Ex4 was conjugated to B12AB utilizing Huisgens/Sharpless29–31
click chemistry to produce B12-Ex4.
2.3 In Vivo Effects of Ex4 and B12-Ex4 in Shrews
2.3.1 Systemically Delivered B12-Ex4 Enhances Glucose Clearance Relative to Ex4
I first tested whether B12-Ex4 reduces blood glucose (BG) following an IPGTT in shrews. I
observed that shrews treated with equimolar (5 nmol/kg) B12-Ex4 and native Ex4 (5 nmol/kg, i.e.
≈20 μg/kg) display similar improvements in glucose clearance following glucose load compared
with saline controls (Figure 1). Post hoc analyses showed that both compounds significantly
suppressed BG at 20, 40 and 60 minutes after glucose administration compared with saline
treatment (all P < .001). Furthermore, the area under the curve (AUC) for B12-Ex4 did not differ
from native Ex4 following glucose administration (Figure 1).

Figure 1. Systemically delivered B12-Ex4 enhances glucose clearance during an intraperitoneal
glucose tolerance test (IPGTT). In an IPGTT, Ex4 (5 nmol/kg, i.e., ≈20 μg/kg) and B12-Ex4 (5
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nmol/kg) showed a similar potency in suppressing BG levels after intraperitoneal (IP) glucose
administration (2 g/kg, IP) compared with saline; saline versus B12-Ex4: *** P < .001; saline versus
Ex4: ### P < .001. AUC analysis from 0 (i.e., post-glucose bolus) to 120 minutes; B12-Ex4 and Ex4
similarly reduced AUCs compared with saline. All data are expressed as mean ± standard error
of mean (SEM). IPGTT data was analyzed with repeated measurements two-way ANOVA followed
by Tukey's post hoc test. AUC data was analyzed with repeated measurements one-way ANOVA
followed by Tukey's post hoc test. Means with different letters are significantly different (P < .05).
In IPGTT, n = 13, within subject design; AUC, n = 5, within subject design).

To investigate the effects of B12-Ex4 and Ex4 on baseline glucose homeostasis, equimolar
Ex4, B12-Ex4 or saline were administered without subsequent glucose injection and observed
that both Ex4 and B12-Ex4 did not produce basal BG change or impact the glucose AUC (Figure
2).

Figure 2. Equimolar dosing of Ex4 (5 nmol/kg, i.e., ≈20 μg/kg), B12-Ex4 (5 nmol/kg) or saline were
administered without subsequent glucose administration. Both Ex4 and B12-Ex4 treatments
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were no longer effective in reducing BG levels and had no effect on AUC. All data are expressed
as mean ± SEM. Blood glucose data was analyzed with repeated measurements two-way ANOVA
followed by Tukey's post hoc test. AUC data was analyzed with repeated measurements one-way
ANOVA followed by Tukey's post hoc test. Means with different letters are significantly different
(P < .05). In IPGTT, n = 13, within subject design; AUC, n = 5, within subject design.
2.3.2 Systemically Delivered B12-Ex4 Co-localizes with Insulin in Pancreatic β-cells
To assess whether B12-Ex4 is taken up by insulin-producing cells in the pancreas, shrews
were injected IP with a fluorescently labelled version of B12-Ex4 (Cy5-B12-Ex4, 5 nmol/kg) and
sacrificed 3 hours after delivery. Results show that upon systemic administration, Cy5-B12-Ex4
co-localized with insulin in pancreatic β-cells (Figure 3).

Figure 3. Systemically injected fluorophore-labelled B12-Ex4 (Cy5-B12-Ex4, 5 nmol/kg) colocalized with insulin in shrew pancreatic tissue supporting the hypothesis that B12-Ex4 acts at
the pancreas to improve glycemic control.
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2.3.3 B12-Ex4 does not alter food intake or body weight, dissimilar to administration of Ex4
Shrews received an IP injection of Ex4 (5 nmol/kg, i.e., ≈20 μg/kg), B12-Ex4(5 nmol/kg ) or
saline, to test whet her B12-Ex4 administration alters food intake or body weight in this species.
In line with previous reports, systemic administration of Ex4 produced hypophagia in shrews at
all measured time points and bodyweight loss 24 hours after injection (Figure 4). By contrast, no
significant effects on food intake or body weight were observed following B12-Ex4 treatment
(Figure 4).

Figure 4. Pharmacological doses of B12-Ex4 do not affect feeding and body weight in shrews. Ex4
(5 nmol/kg, i.e. ≈20 μg/kg) suppressed feeding at 3, 6, 12 and 24 hours, whereas equimolar doses
of B12-Ex4 (5 nmol/kg) had no effect on food intake. Ex4-induced anorexia was accompanied by
body weight loss. No significant changes in body weight were observed after B12-Ex4
administration compared with controls. All data are expressed as mean ± SEM. Data was analyzed
with repeated measurements one-way ANOVA followed by Tukey's post hoc test. Means with
different letters are significantly different (P < .05). In food intake studies, n = 8, within subject
design; in body weight change studies, n = 6, within subject design.

85

In a second experiment, shrews were injected IP with a supra-pharmacological dose of Ex4 (50
nmol/kg, i.e., ≈200 μg/kg), B12-Ex4 (50 nmol/kg) or saline. Ex4 induced anorexia at all measured
time points, and 24 hours body weight loss (Figure 5). By contrast, administration of equimolar
doses of B12-Ex4 did not induce hypophagia or body weight loss compared with saline-treated
animals (Figure 5).

Figure 5. Supra-pharmacological doses of B12-Ex4 do not affect feeding and body weight in
shrews. Ex4 (50 nmol/kg, i.e. ≈200 μg/kg) suppressed eating at all measured time points. By strict
contrast, supra-pharmacological equimolar doses of B12-Ex4 did not show any effects. While
severe body weight loss occurred following supra-pharmacological doses of Ex4, no significant
changes occurred in the B12-Ex4–treated animals. All data are expressed as mean ± SEM. Data
was analyzed with repeated measurements one-way ANOVA followed by Tukey's post hoc test.
Means with different letters are significantly different (P < .05). In food intake studies, n = 8,
within subject design; in body weight change studies, n = 6, within subject design.
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2.3.4 B12-Ex4 treatment produces slight emesis compared with the emetic effects of Ex4
Ex4 (5 nmol/kg, i.e., ≈20 μg/kg) induced emesis in most of the shrews tested (Figure 6).
By contrast, only one shrew experienced emesis after equimolar B12-Ex4 (5 nmol/kg)
administration (P < .001). The number of single emetic episodes and emetic bouts in the 90
minutes window after drug administration were also significantly reduced after B12-Ex4
compared with Ex4 and did not differ from the control condition (Figure 6). Ex4 triggered emesis
with an average latency of 19 ± 5 minutes (Figure 6). A heat map representation of the Ex4 and
B12-Ex4 effects on emetic intensity and latency for each individual animal across time can be
seen in Figure 6.

Figure 6. Emesis in shrews is significantly reduced following pharmacological B12-Ex4 (5 nmol/kg)
treatment compared with native Ex4 (5 nmol/kg, i.e. ≈20 μg/kg), denoting improved tolerance.
The percentage of shrews experiencing emesis was significantly different between Ex4 and
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equimolar B12-Ex4 (*** P < .001). None of the animals experienced emesis following saline
administration (data not shown). The number of single emetic episodes following Ex4 (5 nmol/kg,
i.e. ≈20 μg/kg), equimolar B12-Ex4 (5 nmol/kg) or saline systemic administration was recorded
for 90 minutes. Ex4 induced robust emetic responses that were not observed after B12-Ex4 or
saline injections. The number of emetic bouts was also lower after B12-Ex4treatment compared
with Ex4 and it did not differ from saline controls. Latency to the first emetic episode in Ex4
animals that exhibited emesis. Heatmap showing the emetic latency and intensity, as well as the
number of emetic episodes induced by Ex4 or B12-Ex4 for each animal across time. Evidence of
emesis was analyzed with Fisher's exact test. Emetic episodes and bouts were analyzed with
repeated measurements one-way ANOVA followed by Tukey's post hoc test. Emesis studies, n =
16, within subject design. Means with different letters are significantly different (P < .05)

Next, we tested a supra-pharmacological dose of Ex4 (50 nmol/kg, i.e. ≈200 μg/kg) and B12-Ex4
(50 nmol/kg) and observed that Ex4 induced profound emesis, reflected by both the number and
severity of emetic episodes, in 100 % (i.e. 8/8, P < .001) of the shrews tested, while an equimolar
dose of B12-Ex4 did not induce emesis in shrews. The average latency to first emetic episode
induced by Ex4 was 52 ± 8 minutes (Figure 7). The emetic profiles of each animal following B12Ex4 or Ex4 administration are represented in Figure 7.
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Figure 7. Emesis in shrews is significantly reduced following supra-pharmacological B12-Ex4 (50
nmol/kg) treatment compared with native Ex4 (50 nmol/kg, i.e. ≈200 μg/kg), denoting improved
tolerance. Astonishingly, no emesis occurred after B12-Ex4 administration. The percentage of
shrews experiencing emesis was completely reversed between Ex4 and equimolar B12-Ex4 (***
P < .001). No animal experienced emesis following saline injection (data not shown). The number
of emetic episodes and bouts following Ex4, equimolar B12-Ex4 or saline administration was
analyzed over 90 minutes. Also, at this dosage Ex4 induced robust emetic responses. Latency to
the first emetic episode in Ex4 shrews that exhibited emesis. Heatmap showing the emetic
latency and intensity, as well as the number of emetic episodes for each animal across time. All
data are expressed as mean ± SEM. Emetic episodes and bouts were analyzed with repeated
measurements one-way ANOVA followed by Tukey's post hoc test. Emesis studies, n = 8, within
subject design. Means with different letters are significantly different (P < .05).
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2.3.5 Systemic Administration of B12-Ex4 does not induce c-Fos in the AP or NTS
Ex4, but not B12-Ex4, induced c-Fos immunofluorescence compared with saline-treated
controls within the NTS and AP (Figure 8). This data supports our hypothesis that conjugation of
Ex4 to B12 results in diminished access to CNS GLP-1Rs. The reduced penetrance of the CNS is an
explanation for the lack of B12-Ex4–induced emesis in the shrew. C-Fos activation following
administration of Ex4 is consistent with previously reported results. 13,32–35

Figure 8. Systemic administered B12-Ex4 does not activate the area postrema (AP) or the nucleus
tractus solitarius (NTS) in shrew. Representative immunostainings of the AP/NTS region showing
the c-Fos response following saline (n = 4), Ex4 (5 nmol/kg, n = 4) and equimolar B12-Ex4 (n = 5)
systemic treatment. Peripheral Ex4 administration significantly increased the number of c-Fos
immunoreactive (IR) cells in the AP/NTS of shrews 3 hours after injection. The number of c-Fos–
positive cells in the AP/NTS was significantly lower in B12-Ex4–treated animals and it did not
differ from saline-treated shrews. Data was analyzed with one-way ANOVA followed by Tukey
post hoc test. Means with different letters are significantly different from each other (P < .05).
Values are expressed as mean ± SEM. Scale bar 100 μm.
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2.3.6 Central Administration of B12-Ex4 and Ex4 Similarly Produce Emesis
Direct intracerebroventricular injection (ICV) administration of Ex4 (0.24 nmol) and B12Ex4 (0.24 nmol) induced emesis with similar emetogenic profiles. We observed no difference in
the percentage of shrews experiencing emesis following central B12-Ex4 or Ex4 administration
(Figure 9). Furthermore, the number of single emetic episodes, the number of emetic bouts, as
well as the latency to the first emetic response (Figure 9), were not statistically different between
B12-Ex4 and Ex4. ICV administration of artificial cerebrospinal fluid did not induce any emesis in
shrews (data not shown).

Figure 9. Systemic administration of B12-Ex4 does not result in emesis but does when delivered
centrally. Ex4 (0.24 nmol, i.e., 1 μg), equimolar B12-Ex4 or vehicle was infused into the lateral
ventricle. The percentage of shrews showing emesis was similar between Ex4 and B12-Ex.4. The
number of single emetic episodes or bouts following Ex4, B12-Ex4 or saline was recorded for 120
minutes. Both Ex4 and B12-Ex4 induced comparable emetic responses, while none of the animals
experienced emesis following vehicle delivery (data not shown). Latency to the first emetic
episode in Ex4- and B12-Ex4–treated animals that exhibited emesis did not differ. Evidence of
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emesis was analyzed with Fisher's exact test. Emetic episodes and bouts were analyzed with
Student t-test (n=8, within subject design). Values are expressed as mean ± SEM.

2.4 In Vivo Effects of Ex4 and B12-Ex4 in Lean Diabetic Goto-Kakazaki (GK) Rats
2.4.1 B12-Ex4 enhances glucose clearance during an OGTT without inducing anorexia and
bodyweight loss
We tested the effects of Ex4, B12-Ex4 and liraglutide on oral glucose tolerance, food
intake and body weight in GK rats. Like the effects of liraglutide (100 μg/kg), B12-Ex4 reduced the
glucose level following an OGTT compared with saline at 20 and 40 minutes after glucose load,
and to native Ex4 (5 nmol/kg) at 120 and 180 minutes after glucose load (Figure 10.However,
while both liraglutide and native Ex4 suppressed 24 hours food intake leading to 24 hours body
weight loss (all P < .05), no hypoghagic or body weight suppressive effects were observed after
B12-Ex4 administration in this lean diabetic model (Figure 10).
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Figure 10. B12-Ex4 enhances glucose clearance during an oral glucose tolerance test (OGTT)
without inducing anorexia and body weight loss in the Goto-Kakizaki lean diabetic rat model. In
an OGTT, liraglutide (100 μg/kg, i.e., 26.6 nmol/kg) and 5 nmol/kg B12-Ex4 suppressed blood
glucose levels after intraperitoneal (IP) glucose administration (1 g/kg, per os (PO)) compared
with 5 nmol/kg Ex4 (i.e.; ≈20 μg/kg) and saline. * saline versus others; #: Ex4 versus others; $:
liraglutide versus others. *, #, $: P < .05; **, ##, $$: P < .01; ***, ###, $$$: P < .001.Liraglutide and
Ex4 induced a strong anorectic effect, which was not observed after B12-Ex4 treatment.
Hypophagia was accompanied by body weight loss in liraglutide- and Ex4-treated animals, while
no significant body weight change was observed following B12-Ex4. Data were analyzed with
repeated measure two-way ANOVA or one-way ANOVA followed by Tukey post hoc test; n = 21,
within subject design. All data are expressed as mean ± SEM. Means with different letters are
significantly different from each other (P < .05).
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2.5 Outcomes and Conclusions
Existing GLP-1-based pharmacotherapies are excellent glucoregulatory drugs for treating
hyperglycaemia in most patients with T2D despite reported nausea and vomiting. These
phenomena, however, are gaining notoriety as overlooked major side effects in many patients,
which reduce patient compliance and make current GLP-1R agonists ‘suboptimal’.3–7,36,37
Designing and testing second-generation GLP-1-based drugs aimed at improving patient
tolerance while preserving or enhancing glucoregulatory control therefore provides clear clinical
value. B12-Ex4 produced comparable glycemic control, and better tolerance, in an emetic
mammalian species and in a lean polygenetic rat model of T2DM than Ex4.
In line with previous reports in lean, non-diabetic rats and shrews,8,14,36,37 both native Ex4
doses (5 and 50 nmol/kg) tested here induced anorexia and body weight loss over 24 hours in
shrews. By contrast, no such effects occurred after B12-Ex4 treatments, even at suprapharmacological doses (i.e., 50 nmol/kg). The lack of short-term effects on feeding was
unexpected given reports of a role of vagal afferent signaling in the mediation of the early-phase
anorexia induced by both GLP-1 and native Ex4 in rats.38,39 Previous reports also observed this
effect in lean, healthy rats treated with the highest dose of B12-Ex4.8 This incongruency,
however, could be explained by broad species differences in metabolism between rats and
shrews, rather than by the direct action of the drug.
Furthermore, B12-Ex4 administration resulted in a near complete absence of emesis
compared with potent emetic effects of Ex4 in the shrew. In fact, we observed that ≈10-fold the
threshold concentration necessary for glucoregulation did not cause emesis with B12-Ex4, while
all animals tested with this dose of Ex4 experienced emesis. Together, these findings show that
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it is possible to both physiologically and pharmacologically separate the emetic potential of GLP1R agonists like Ex4 from their glucoregulatory role, and that a wide range of B12-Ex4 doses
produce limited anorectic or emetic side effects. This data suggests that a B12-Ex4 conjugate
could improve T2DM medication adherence compared with existing GLP-1 mimetic drugs. This is
particularly relevant given the pleiotropic nature of GLP-1, with a myriad of effects, mainly
beneficial, which render GLP-1 analogues as one of the best current treatments for T2DM.
Indeed, alternative therapies approved for the treatment of T2DM (e.g., dipeptidyl peptidase-4
inhibitors, metformin and sulfonylureas) do not achieve the same overall positive outcome on
glucose handling compared with GLP-1R agonists.40,41 Importantly, these alternative strategies
also lead to modest but significant body weight reductions.40,41
Preventing access to CNS GLP-1Rs is the probable explanation for the lack of B12-Ex4–
induced emesis in the shrew. Our immune-histological evidence supports this notion as we
observed sparse c-Fos activation following systemic B12-Ex4 administration in the AP and NTS,
two hindbrain nuclei known to mediate feeding behavior and emesis,13,32–35 while native Ex4
produced robust activation of these nuclei. To provide functional evidence that B12 conjugation
itself does not impact the emetic nature of Ex4, we centrally administered B12-Ex4 directly into
the lateral ventricle of the shrew, which produced a comparable emetic profile with that of native
Ex4(e.g. the number of emetic episodes, latency to vomit, and the proportion of treated animals
experiencing emesis). This data suggests that when centrally delivered, and thus bypassing the
blood–brain barrier, B12-Ex4 is a stimulus that can produce an emetic profile consistent with Ex4
alone.
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To speculate how conjugation to B12 reduces CNS penetrance of Ex4, increased polarity
may be an important variable rather than the increased molecular size alone, given that GLP-1R
agonists with greater molecular masses, such as liraglutide, have been shown to penetrate the
hindbrain and to stimulate direct GLP-1R activation.42–44 It is also possible that the binding of B12Ex4 to the B12 carrier proteins transcobalamin (TC) or haptocorrin (HC) in serum, previously
confirmed for this construct,8 further reduces brain penetrance because its size (now >60 KDa)
either actively transports the conjugate to systemic targets (via TC), maintains the conjugate in
serum (via HC), or protects the conjugate from proteolytic degradation (via TC or HC),9 as is
typical for dietary B12 alone.45 As noted, however, the shrew has both TC and HC, unlike rodents,
which have only TC. In comparison with studies performed for B12-Ex4 in rodents,8 we see
comparable pharmacodynamics (in terms of illness behaviors and glucoregulation), suggesting
that the presence of both TC and HC is not specifically necessary for the conjugate. It may be that
the benefits of conjugation lie solely with the B12 molecule itself, or simply through the effects
of binding to any B12 binding protein in terms of protection and/or mitigation of hindbrain
access. This data suggests that it is the unique structure of B12-Ex4, rather than simply mass,
which drives its unique pharmacodynamic profile and underlying properties.
Pancreatic β-cells expressing the GLP-1R represent the probable cellular substrate
mediating the hypoglycemic effects of B12-Ex4 in shrews. A previously reported fluorescently
tagged B12-Ex4 conjugate (Cy5-B12-Ex4) was shown to co-localizes with insulin in the shrew
pancreatic β-cells.8 By employing fluorescently tagged Ex4 in combination with Cy5-B12-Ex4,
further investigations are warranted to examine the binding specificity of B12-Ex4 in the
pancreas. Nevertheless, the current data supports previous work shown in rodents8 and
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strengthens the notion that the incretin effect occurring after GLP-1 analogue administration is
mediated by direct activation of GLP-1Rs expressed on pancreatic β-cells, mimicking the
paracrine actions of pancreatic-derived GLP-1.10–12
It is also possible that GLP-1Rs expressed in other peripheral tissues may be engaged by
B12-Ex4 and thus contribute to its beneficial effects on glucose homeostasis. For instance, it has
been shown that low doses of Ex4 that mimic endogenous GLP-1 release can modulate glycaemia
and gastric emptying via vagal afferent signaling.39 Further, GLP-1Rs are also abundantly
expressed on enteric neurons, and emerging evidence suggests a role of the enteric nervous
system in the mediation of effects induced by GLP-1 analogues.46–49 Whether B12-Ex4 acts on
GLP-1Rs expressed in the periphery beyond the pancreas, possibly within the peripheral and
enteric nervous system, and to what degree these hypothetical actions contribute to the
observed augmented glucoregulation, requires further investigation.
I also report that B12-Ex4 improves glucose clearance relative to Ex4 in a lean, polygenetic
model of T2DM, the GK rat. Like liraglutide, B12-Ex4 does not produce the transient stressinduced hyperglycemic response in the GK rat commonly observed from Ex4 across rat models
(lean, obese or GK),50,51 a phenomenon tied to the high CNS penetrance of Ex4. Consistent with
the lack of a CNS stress-mediated hyperglycaemia reported for Ex4,50,51 B12-Ex4 did not produce
the documented CNS-dependent outcomes of anorexia and body weight loss in this lean model
of T2DM.
In summary, I report both the preservation of hypoglycemic responses and superior
tolerance of B12-Ex4 over native Ex4 in musk shrews and the GK rat. The data presented here in
shrews and GK rats support our hypothesis that limiting or blocking Ex4 entry into the brain
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dramatically reduces the side effects of the Ex4 drug (i.e. prevents anorexia and emesis), while
maintaining the glucoregulatory efficacy of the compound without influencing energy balance in
shrews. The overall outcomes of this work highlight the translational potential of B12-Ex4–based
pharmacotherapies for use in lean T2D patients where weight loss is an undesirable outcome,
although chronic studies are needed to elucidate the efficacy, tolerability, and
pharmacodynamics of B12-Ex4 in long-term treatment. Albeit small, there is the possibility that
B12-Ex4 chronic exposure would interfere with normal B12 physiology, potentially reducing the
amount of dietary B12 available in the body.52 Further, while I do not predict tachyphylaxis, the
extent to which the observed positive effects will be maintained requires future empirical testing.
Nonetheless, the presented data underlie the potential use of B12-Ex4 for patients with T2DM
who either do not tolerate current GLP-1 agonists or suffer from co-morbidities associated with
an anorectic/cachectic state, for which the body weight-suppressing effects of a standard GLP1R agonist are an unwanted side effect, with the loss of nausea/emesis an additional benefit.
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3.1 Introduction
The dramatic rise of type 2 diabetes mellitus (T2DM) and obesity as comorbidities has
driven a concomitant rise in new pharmaceutical interventions to treat such disorders, either
together or individually.1–7 Type 2 diabetes mellitus (T2DM) management involves lifelong
pharmaceutical interventions,6,7 including those based on glucagon-like peptide-1 (GLP-1), an
incretin hormone produced in the intestine and brainstem.8,9 One extremely successful family of
pharmaceuticals in this field has been that of glucagon-like peptide-1 receptor agonists (GLP1RAs),8–13 such as exenatide (i.e., Exendin-4; Ex4), liraglutide,14–16 and semaglutide.14,17,18 Existing
US Food and Drug Administration (FDA)-approved GLP-1 receptor (GLP-1R) agonists enhance
postprandial insulin secretion and reduce food intake.8,12,13 Exenatide and liraglutide confer
glucoregulation in tandem with a body weight reduction of 5−6% over ∼1 year,14,18 while
semaglutide can produce a weight loss of 10− 12% over the same time period.14,18 While weight

loss is attractive when considering GLP-1R agonists for obesity treatment, the hypophagic effects
of all known GLP-1R agonists are accompanied by nausea and vomiting, which affects ≈20%–50%
of patients and leads to discontinuation of drug treatment in ≈6%–10% and reduced dose
tolerance in another ≈15% of patients.19–25 Evidence-based medical reports are now clear that
nausea and emesis are the principal side effects of existing GLP-1 therapeutics as a result of
central nervous system (CNS) penetrance.26–30 Even with common approaches to mitigate side
effects such as slow-dose escalation or titration, a recent report from GlaxoSmithKline concluded
that patients reported GI-related issues that ‘‘made me feel sick’’ (64.4%) and ‘‘made me throw
up’’ (45.4%) as their major reasons for treatment discontinuation.31 Importantly, such adverse
gastrointestinal events of GLP-1R agonists are persistent in the profile of current second-
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generation GLP-1R-based drugs such as dulaglutide, semaglutide, and albiglutide.32–34
Importantly, for some diabetic patients with comorbidities such as cancer, cystic fibrosis, HIV, or
general disease-cachexia, any further weight loss and malaise are unacceptable side effects that
necessitate the creation of a new class of GLP-1 therapeutic.35–39
There is convincing evidence that a significant portion of the increase in glucosestimulated insulin secretion following administration of current exogenous GLP-1R ligands is
mediated by direct activation of GLP-1R expressed on pancreatic β-cells,8,13,40,41 mimicking the
paracrine effects of pancreatic derived GLP-1 that may not occur with endogenous L-cell derived
GLP-1.42–44 In contrast, GLP-1Rs expressed in the central nervous system (CNS), in particular those
in the hindbrain,45,46 mediate the food intake- and body weight-suppressive effects of GLP-1R
agonists, such as liraglutide and exenatide (synthetic Ex4).27–29,47 This CNS site-of-action, and not
a vagally mediated effect, is also responsible for mediating the illness-like behaviors (e.g., nausea,
conditioned taste avoidance, emesis) of systemically delivered GLP-1R agonists.30 Thus, from a
therapeutic standpoint aimed at normalizing the chronic hyperglycemia of diabetic patients,
designing a GLP-1R agonist that does not penetrate readily into the CNS (or at least the
hindbrain), but retains enhanced pharmacological action on b-cells, would theoretically provide
an improved tool for glycemic control without eliciting unwanted nausea/malaise.
Taking advantage of the highly controlled transport and trafficking of vitamin B12 (B12)
that occurs in mammalian physiology,48–52 together with bioconjugate technology involving
peptide-based conjugation to B12 and B12 fragments, Ex4 was covalently attached to
dicyanocobinamide (Cbi), a corrin-ring containing precursor of B12, to create the compound CbiEx4. The theoretical advantage of this construct was 3-fold. First, there is no known biological
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function of Cbi in humans and Cbi does not affect intact B12 physiology.53 Second, Cbi is highly
water soluble and the uptake of Cbi-Ex4 through the blood brain barrier and into the CNS would
putatively be extremely low.53 Indeed, evidence collected postmortem from human brain and
liver clearly demonstrated negligible amounts of B12 (11.3 pmol/g) and an ≈10-fold lower relative
concentration of corrinoid-type analogs (1.3 pmol/g; including cobinamide) in the brain, with the
liver being the main site of concentration for both B12 and corrinoid analogs (total >600
pmol/g).54 These first two advantages of Cbi-Ex4 provide support for the third and most
important hypothesized benefit—namely that Cbi-Ex4 should theoretically be a GLP-1R agonist
that retains a peripheral site of action when systemically administered, providing a pancreaticmediated mechanism for Cbi-Ex4 to improve hyperglycemia, without producing any CNSmediated illness-like behaviors.
Cbi has been identified in humans,55 but has no influence on normal B12 homeostasis53
since it is not recognized by the B12 blood transporting protein transcobalamin (TC), critical for
blood-brain barrier penetrance and cell entry via the CD320 receptor.53 Instead, Cbi is recognized
in blood only by the B12 binding protein haptocorrin (HC). The function of circulating HC is
unknown and no known specific receptor for the Cbi-HC complex has been identified.56 Indeed,
congenital defects in plasma HC are asymptomatic, suggesting that HC and Cbi are not
physiologically relevant in humans.57 Further, the plasma-binding capacity of HC for molecular
forms of B12, including Cbi, in humans is very limited (reference interval 90–270 pM).58 Thus,
using Cbi (in a conjugate process we coin here ‘‘corrination’’) as a pharmacodynamic/
pharmacokinetic modifier of a target peptide pharmaceutical, we have created an ‘‘inert’’ carrier
in terms of affecting B12 homeostasis, but one that would have the advantage of putatively
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reducing/avoiding CNS permeability/localization while improving the general proteolytic survival
and/or reduce clearance of the bound peptide. Unfortunately, rodents do not represent ideal
models to test Cbi-Ex4 as (1) they lack the separate HC and TC proteins as found in human blood59
and (2) they lack the emetic reflex.60 The musk shrew (Suncus murinus) was therefore chosen as
the model system to evaluate the in vivo efficacy and tolerability of Cbi-Ex4, as shrews are capable
of emesis and were believed, through bioinformatics, to have the same B12 binding profile in
blood as humans (vide infra). Importantly, in the context of modeling the GLP-1 system, the shrew
also shows hypoglycemia, anorexia, and emetic sensitivity to existing GLP-1R agonists.61,62
3.2. Synthesis of Dicyanocobinamide (Cbi)
Synthesis of Dicyanocobinamide (Cbi) (2). The synthesis of dicyanocobinamide (Cbi) was
performed according to previously reported methods.63 Briefly, to a 10 mL microwave reaction
vessel containing a magnetic stir bar were added B12 (cyanocobalamin) (303.8 mg, 0.225 mmol),
sodium cyanide (NaCN) (36.9 mg, 0.7096 mmol), and 5 mL of EtOH, and the vessel was sealed.
The reaction was heated to 120 °C for 10 min. Following completion of the microwave reaction,
the remaining solution was transferred and diluted using isopropyl alcohol (iPrOH). The reaction
was purified utilizing a normal-phase silica column. The reaction was eluted using 100% methanol
(MeOH). The product eluted as a purple product. The isolated product was precipitated utilizing
diethyl ether (Et2O) and allowed to dry producing a solid, purple product, 2, in 80% yield (187.4
mg, 0.1795 mmol) (Figure 1). Solubility was measured to be 400 mg/mL in deionized water. 2 was
purified by RP-HPLC as described for method A1, to 98%; tR: 5.2 and 6.7 min (Figure 2); ESI-MS
expected m/z = 1042, observed m/z = 1016 [M−CN]+1 (Figure 3).
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Figure 1. Synthetic scheme for Cbi. Cbi was formed via microwave from B12.

Figure 2. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse XDB-C18 5μm,
4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 70% CH3OH/H2O + 0.1% TFA in 15
min)) showing the α- and β-isomer products at 5.2 and 6.7 minutes. Purity 98%.
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Figure 3. ESI-MS (Shimadzu LCMS-8040) of Cbi, expected m/z = 1042, observed m/z = 1016 [MCN]+1.
3.3 Design and Synthesis of Cbi-Ex4
Corrination of Ex4 with the Cbi compound dicyanocobinamide was successfully
synthesized to produce a GLP-1R agonist, namely, Cbi-Ex4. The conjugate is linked between the
K12 residue of Ex4 and the terminal f-branch of Cbi. These two positions were previously
reported by us49 and others64,65 to support high-efficiency conjugation. While no spacer
optimization was conducted, we utilized a spacer length that was already established by us to
yield a high-potency B12-Ex4 conjugate.48,66
3.3.1 Synthesis of Cbi-Aminobutyne (Cbi-AB)
The purple Cbi produced was activated with an excess of 1,1′-carbonyl-di-(1,2,4-trizole)
(CDT) in dry N-methyl-2-pyrrolidone (NMP) and heating at 40 °C under argon for ∼10 min or until
complete dissolution was observed. Upon dissolution, 1-amino-3-butyne was added in large

excess (20×) relative to the activated Cbi along with triethylamine (TEA), and the reaction was
allowed to proceed for 1 h, again at 40 °C under argon with stirring. Initially, it was observed via
RP-HPLC tracking on a C18 column (data not shown) that the reaction proceeded slowly, so in
subsequent experiments, a second equivalent of linker (20×) and TEA were added at the 1 h time

113

point, and the reaction was allowed to proceed, as before, for an additional hour. Based on the
additional step, yields for Cbi-AB was 53% with facile purification to produce the Cbi-AB (Figure
4) with purities at, or in excess of, 97% (as tracked by RP-HPLC) (Figure 5). ESI-MS analysis showed
expected m/z = 1129, observed m/z = 1111 [M+-H2O]+ (Figure 6). It should also be noted that a
color change was observed upon formation of the Cbi-linkers, going from purple to orange upon
purification of the Cbi-AB in water. This color change was previously reported by Zhou and
Zelder67 and assigned to the formation of isomers, namely, α-cyano-β-aqua- and α-aqua-β-cyanoCbi (as indicated in Figure 4). This suggestion of isomer formation was supported by the HPLC
traces of Cbi-AB (Figure 5), which clearly showed the presence of both isomers. Given the fact
that such isomers were not expected to negatively affect the subsequent chemistry or biology,
isomers were combined prior to peptide coupling.

Figure 4. Synthetic scheme for Cbi-AB synthesis, 1-amino-3-butyne was coupled to Cbi through
secondary alcohol to create carbamate linkage utilizing 1,1’-carbonyl-di-(1,2,4-triazole) (CDT),
priming the Cbi for conjugation to Ex4.
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Figure 5. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse XDB-C18 5μm,
4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 70% CH3OH/H2O + 0.1% TFA in 15
min)) showing the α- and β- isomers of the Cbi-AB Product at 7.4 and 7.9 minutes. Purity 97%..

Figure 6. ESI-MS (Shimadzu LCMS-8040) of Cbi-Alkyne, expected m/z = 1129, observed m/z =
1111 [M+-H2O]+.

3.3.2 Synthesis and Characterization of Cbi-Ex4
Coupling of K12-azido-modified Ex4 (noted throughout here simply as Ex4 ) to produce
conjugate Cbi-Ex4 was achieved via copper(I)- mediated alkyne-azide cycloaddition (CuAAC) over
16 h at room temperature in a 4:1 dimethylformamide (DMF)/H2O solvent system in the presence
of the tertiary amine tris((1-benzyl-4- triazolyl)methyl)amine (TBTA) to stabilize copper(I) (Figure
7).68 Yield obtained were quantitative based on the starting peptide, and Cbi-Ex4 were produced
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to at least 97% purity prior to biological or in vivo evaluation (as tracked by RP-HPLC) (Figure 8).
ESI-MS analysis showed expected m/z = 5354, observed m/z = 1339 [M++3H+]+4, 1071 [M++4H+]+5
(Figure 9).

Figure 7. Synthetic scheme for Cbi-Ex4, Cbi-AB was clicked onto an azido Exendin-4 utilized
CuAAC.

Figure 8. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse XDB-C18 5μm,
4.6 x 150 mm) (RP-HPLC, from 1% CH3CN/H2O + 0.1% TFA to 70% CH3CN/H2O + 0.1% TFA in 15
min)) showing the Cbi-Ex4 Product at 11.7 min. Purity 98%.
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Figure 9. ESI-MS (Shimadzu LCMS-8040) of Cbi-Ex4, expected m/z = 5354, observed m/z = 1339
[M++3H+]+4, 1071 [M++4H+]+5.

3.4 Agonism and Function at the GLP-1R
Cbi-Ex4 produces half maximal effective concentration (EC50) of ≈200 pM in fluorescence
resonance energy transfer (FRET) assays that monitor levels of cAMP in HEK-239 cells stably
transfected with the human GLP-1R (Figure 10).
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Figure 10. Dose-dependent Cbi-Ex4 agonism at the human GLP-1 receptor, as monitored in FRET
assays using the cAMP biosensor H18869 expressed in HEK293 cells.70 EC50 value for Cbi-Ex4 was
determined to be 200 ± 0.09 pM (mean ± SEM).

3.5 Cobalamin Binding Capacity in Shrew Blood
Initially, we confirmed the presence of both HC and TC in shrew blood by performing
radio-57Co-B12 binding assays and serum B12 protein isolation and identification. In addition to
confirming the presence of HC (and separately TC, the profile found in humans, but not rodents,71
we showed that the total blood B12 binding in S. murinus was ≈12 nM, of which ≈4.5 nM was due
to apo-HC (Table 1).

Table 1. B12 and its binding proteins, transcobalamin (TC) and haptocorrin (HC) as measured in
shrew serum, and their inhibition by increasing concentration of Cbi-Ex4. The sum of Apo TC +
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Apo HC ~equals B12 binding capacity. * Conducted by Dr. Ebba Nexo at University of Aarhus,
Denmark.

3.6 Binding Affinity for Cbi Transport Proteins
We also demonstrate that, as hypothesized, only HC (Ka 0.45 nM Cbi-Ex4 versus 0.036 nM
for Cbi), not TC (Ka for Cbi-Ex4 > 0.2 mM), binds Cbi-Ex4, and that such binding to HC was ≈10fold lower in affinity than for Cbi alone (Figure 11).

Figure 11. Binding affinity plots of Cbi ((CN)2Cbi) and Cbi-Ex4 by the B12 binding proteins
transcobalamin (TC) and haptocorrin (HC). Figure 11 shows the binding affinity (Ka) of B12
binding proteins transcobalamin and haptocorrin to endogenously occurring Cbi and the Cbi
conjugated Ex4 (Cbi-Ex4). HC is known to be the only physiologically relevant binder of Cbi and
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this is reflected in the binding constant of HC with Cbi (Ka 0.036 nM). HC also binds Cbi-Ex4 (Ka
0.456), albeit with ~ 10-fold lower affinity. Consistent with the known binding profile of TC, only
weak binding occurs for TC with Cbi or Cbi-Ex4 (Ka > 2 µM). * Conducted by Dr. Ebba Nexo
at University of Aarhus, Denmark.

3.7 In Vivo Investigations of Ex4 versus Cbi-Ex4 in Shrews
3.7.1 Ex4 versus Cbi-Ex4 in Intraperitoneal (I.P.) Glucose Tolerance Test (IPGTT)
Glucose-stimulated insulin secretion following administration of a GLP-1 analog is
mediated principally by activation of GLP-1Rs expressed on pancreatic β-cells.42–44 Therefore, as
a proof of concept, we first tested whether Cbi-Ex4 retains its in vivo ability to reduce blood
glucose following an intraperitoneal (i.p.) glucose tolerance test (IPGTT) across different doses
compared to equimolar doses of native Ex4. We observed that shrews treated with Cbi-Ex4 and
native Ex4 display improved glucose clearance following i.p. glucose administration compared
to vehicle injections (Figure 12). Furthermore, the plasma glucose clearing rate of Cbi-Ex4 did
not differ from the relative equimolar dose of native Ex4 following acute administration, which
is indicative of a retained glucoregulatory potency (Figure 12, 13).
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Figure 12. Ex4 (1.25, 5, and 50 nmol/kg, i.p.; i.e., ≈5, 20, and 200 mg/kg; respectively) dosedependently suppressed blood glucose (BG) levels following glucose administration (2 g/kg, i.p.).
Saline versus 5 nmol/kg Ex4: **p < 0.01, ***p < 0.001; saline versus 50 nmol/kg Ex4: ###p < 0.001;
saline versus 1.25 nmol/kg Ex4: §§p < 0.01; 1.25 nmol/kg Ex4 versus 50 nmol/kg Ex4: @@@p <
0.001; 1.25 nmol/kg Ex4 versus 5 nmol/kg Ex4: Φp < 0.05, ΦΦp < 0.01, ΦΦΦp < 0.001. Area
under the curve (AUC) from 0 (i.e., post-glucose bolus) to 120 min after Ex4. In an IPGTT Cbi-Ex4
dose-dependently reduced BG levels comparably to equimolar doses of Ex4. Saline versus 5nmol/kg Cbi-Ex4: **p < 0.01, ***p < 0.001; saline versus 50 nmol/kg Cbi-Ex4: ###p < 0.001; saline
versus 1.25 nmol/kg Cbi-Ex4: §p < 0.05; 1.25 nmol/kg Cbi-Ex4 versus 50 nmol/kg Cbi-Ex4: @@@
p < 0.001. AUC from 0 to 120 min following Cbi-Ex4. All data expressed as mean ± SEM. Data in
IPGTT was analyzed with repeated-measurements two-way ANOVA followed by Tukey’s post hoc
test. AUC data in was analyzed with repeated-measurements one-way ANOVA followed by
Tukey’s post hoc test. Means with different letters are significantly different (p < 0.05).
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Figure 13. In an IPGTT, Ex4 (5 nmol/kg, i.e. 20 μg/kg) and equimolar doses of Cbi-Ex4 suppressed
blood glucose (BG) levels after IP glucose administration (2 g/kg, IP) compared to saline; vehicle
vs Cbi-Ex4: *** P < 0.001; vehicle vs Ex4: ### P < 0.001; Ex4 vs Cbi-Ex4: §§ P < 0.01). Area under
the curve (AUC) analyses from 0 (i.e., post-glucose bolus) to 60 and 0 to 120 min; respectively.
Cbi-Ex4 and Ex4 similarly reduced AUCs compared to vehicle. All data expressed as mean ± SEM.
IPGTT data in was analyzed with repeated measurements two-way ANOVA followed by Tukey's
post-hoc test. All other data was analyzed with repeated measurements one-way ANOVA
followed by Tukey’s post hoc test. Means with different letters are significantly different (P <
0.05).
3.7.2 Ex4 versus Cbi-Ex4 in Delayed IPGTT
Based on these observations, we then further hypothesized that Cbi-Ex4 may also retain
a plasma glucose-lowering action for a longer duration compared to native Ex4. Therefore, a
‘‘delayed’’ IPGTT was performed, in which an i.p. glucose bolus was administered 360 min after
drug administration to determine whether a longer time window exists for Cbi-Ex4 to facilitate
glucose clearance relative to native Ex4. Results show a significant suppression in plasma glucose
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concentrations 6 h following Cbi-Ex4 administration in an IPGTT, with no effect on plasma glucose
tolerance being observed after a 6h time delay of native Ex4 administration (Figure 14).

Figure 14. In a delayed glucose load IPGTT, Ex4, Cbi-Ex4 (5 nmol/kg) or vehicle were injected 6 h
before glucose load. While Ex4-treatment was no longer effective in reducing BG levels, Cbi-Ex4
retained its BG lowering properties; saline versus Cbi-Ex4: **p < 0.01, ***p < 0.001; Ex4 versus
Cbi-Ex4: §§p < 0.01), §§§p < 0.001. AUC analyses from 0 to 60 min and 0 to 120 min,
respectively. Cbi-Ex4-treated animals had lower AUC 0-120 compared to Ex4-treated animals
and a lower AUC 0–60 compared to Ex4-treated animals and controls. All data expressed as
mean ± SEM. Data in IPGTT was analyzed with repeated-measurements two-way ANOVA
followed by Tukey’s post hoc test. AUC data in was analyzed with repeated-measurements oneway ANOVA followed by Tukey’s post hoc test. Means with different letters are significantly
different (p < 0.05).

3.7.3 Ex4 versus Cbi-Ex4 effect on Feeding Behavior
Direct activation of GLP-1R expressed in various nuclei of the CNS (including, but not
limited to those of the hypothalamus and dorsal vagal complex [DVC]), contributes to the body
weight and food intake suppressive effects of exogenously administered first-generation GLP-1R
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agonists.27–29,49 Indeed, both liraglutide and Ex4 penetrate into the CNS and activate GLP-1Rexpressing nuclei to induce hypophagia and body weight loss.27,42,49 In line with previous
reports,62 systemic administration of native Ex4 produced a strong hypophagic response in the
shrew, leading to body-weight loss in a dose-dependent fashion (Figure 15). This effect is due in
part to the ability of native Ex4 to significantly increase the latency of the shrew to initiate feeding
compared to vehicle injections (Figure 16). In contrast, Cbi-Ex4 did not significantly affect 24 h
food intake or latency to eat, suggesting a lack of neural activation within the CNS (Figure 15).

Figure 15. Ex4 dose-dependently induced anorexia leading to weight loss. (J and K) Equimolar
doses of Cbi-Ex4 had no effect on food intake or body weight. All data expressed as mean ±
SEM. Data was analyzed with repeated-measurements two-way ANOVA followed by Tukey’s
post hoc test.
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Figure 16. Ex4 (5 nmol/kg) induced anorexia at 3h, 6h, 12h and 24h post injection, whereas CbiEx4 had no effect on food intake. Latency to eat was increased only in Ex4-treated animals. All
data expressed as mean ± SEM. Food intake was analyzed with repeated measurements twoway ANOVA followed by Tukey's post-hoc test. All other data were analyzed with repeated
measurements one-way ANOVA followed by Tukey’s post hoc test. Means with different letters
are significantly different (P < 0.05).

3.7.4 Conjugation to Cbi Improves the Pharmacokinetic Properties of Ex4
Cbi-Ex4 exhibited reduced plasma clearance (as evidenced by the area under the curve
[AUC] and elimination constants) relative to native Ex4 (Figure 17, Table 2). This finding is likely
due, at least in part, to improved stability of the conjugate to proteolytic activity, as has been
demonstrated previously for full B12 conjugates,48 and/or reduced renal clearance, both major
routes of Ex4 clearance in vivo.72,73 ELISA-based pharmacokinetic studies demonstrated that CbiEx4 had a reduced rate of elimination as evidenced by the elimination constants (Ke) of 0.034 h-1
for Cbi-Ex4 versus 0.047 h-1 for Ex4, and reduced clearance (0.0044 L/h for Cbi-Ex4 versus 0.0056
L/h for Ex4) with no significant difference in volume of distribution between either drug (Table
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2). Overall, Cbi-Ex4 provided greater drug exposure over time, as evidenced by the greater AUC0360

(2.82 mg*h/L for Ex4 versus 4.55 mg*h/L for Cbi-Ex4), all above the values reported for the 50

nmol/kg dose (Figure 17, Table 2) . We noted also that the Cmax values for both the 25 nmol/Kg
and 50 nmol/Kg doses of Cbi-Ex4 were 17.25 and 30.96 nmol/L (4- to 7-fold greater than the
maximum apo-HC levels measured and recorded above [Table 1]), suggesting that the effects of
corrination are due to the Cbi itself, and are not primarily dependent on binding to HC (the only
known binder of Cbi) in vivo. At this point it is interesting to note that Herbert and Herzlich74 first
suggested that HC may play a role in removing corrinoids from the human brain, an idea
supported by subsequent work by Hansen et al.,75 who showed HC was found in human colony
stimulating factor (CSF; CSF-HC) at concentrations ranging from 10 to 41 pmol/L (median 21
pmol/L)75 with plasma/ CSF ratios suggesting such HC was produced in the CNS directly. Overall,
these results may be a consequence of naturally less penetrance of Cbi-Ex4 due to the presence
of the highly polar Cbi group, a lack of facilitated transport into the brain for Cbi-Ex4, and/or
binding by CSF-HC and subsequent removal or deactivation of Cbi-Ex4 in the CNS.
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Figure 17. Pharmacokinetic profile of two equimolar doses (25 nmol/kg and 50 nmol/kg) of Ex4
and Cbi-Ex4. Data expressed as mean ± SEM. Full PK parameters are given in Table 2.

Table 2. Pharmacokinetic parameters measured for Ex4 and Cbi-Ex4 in S. murinus. AUC indicates
area under the curve between 0 and 360 or 0-1440 minutes; CMax is the maximum measured
concentration; T1/2 is the elimination half-life; Vd is volume of distribution, Cl is clearance and Ke
is elimination rate constant.

3.7.5 Prevalence of Emesis in Shrews Following Administration of Ex4 versus Cbi-Ex4
The most common side effects of all existing FDA-approved GLP-1R agonists are nausea,
vomiting, and malaise, with approximately 20%–50% of T2DM patients that had been prescribed
GLP-1-based medication, experiencing nausea and/or vomiting.19–23 These adverse events are
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surprisingly under-investigated, as they limit the widespread use, efficacy, and potential
ubiquitous utility of existing GLP-1R agonists for treating metabolic disease. Notably, GLP-1
mediated malaise is not caused by GLP-1-mediated vagal afferent signaling, but is rather
promoted by direct central GLP-1R activation,30 primarily in the brainstem. We therefore
hypothesized that the conjugation of Cbi to Ex4 would modify CNS penetrance of Ex4, due to the
B12-selective transport system involving TC binding (and the receptor CD320), a system that does
not specifically support Cbi binding/transport in general,49 and specifically not in the case of CbiEx4 as measured herein (Figure 11, Table 1).
Ex4 dose-dependently induced emesis with the majority of the shrews experiencing
emesis after 5- and 50-nmol/kg Ex4 dosing (Figure 18). Indeed, 29% of the animals exhibited
emesis upon administration of the lowest dose of native Ex4, 79% with the intermediate one,
and 93% with the highest dose tested. All doses of native Ex4 triggered emesis within minutes
after administration (1.25 nmol/kg Ex4: 21 ± 15; 5 nmol/kg Ex4: 10 ± 5 min; 50 nmol/kg: 12 ± 5
min) (Figure 18). In contrast to the profound emesis observed after Ex4, both the prevalence and
the number of emetic episodes following equimolar injections of Cbi-Ex4 were significantly
reduced (5 nmol/kg Ex4 versus Cbi-Ex4: p = 0.005, 50 nmol/kg Ex4 versus Cbi-Ex4: p = 0.0003)
(Figure 18). Only one shrew experienced emesis after 1.25 nmol/kg Cbi-Ex4 (i.e., 7%), 28% after
5 nmol/kg Cbi-Ex4, and 64% after 50 nmol/kg Cbi-Ex4. In animals that displayed emesis after CbiEx4 treatment, the latency was similar to native Ex4 (Figure 18). However, the severity and
occurrence of the emetic episodes was less severe, as represented by the heatmaps of Ex4 and
Cbi-Ex4 depicting emetic intensity and latency for each individual animal across time (Figure 18,
19). These differences are particularly striking at the 5 nmol/kg dose of Cbi-Ex4, which shows a
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virtual absence of emetic events with the concurrence of strong glycemic effects (Figure 13, 19).
Thus, the conjugation of Ex4 to Cbi renders a GLP-1R agonist that, at pharmacological doses,
retains glucoregulatory ability without CNS-mediated emesis.
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Figure 18. Ex4 (1.25, 5, and 50 nmol/kg) induced emesis during 120 min after injection in a doserelated fashion. The number of animals exhibiting emesis, expressed as a fraction of the total
number of animals tested, is indicated above each treatment group. Latency to the first emetic
episode of shrews that exhibited emesis after Ex4 treatment. Number of shrews experiencing
emesis following Cbi-Ex4 (1.25, 5, and 50 nmol/kg) during 120 min after injection. The ratio of
animals exhibiting emesis is indicated above each treatment group. Latency to the first emetic
episode of shrews that experienced emesis after Cbi-Ex4 treatment. Heatmaps showing latency,
number, and intensity of emesis following Ex4 and Cbi-Ex4 dosing for each individual animal
across time. All data expressed as mean ± SEM. Means with different letters are significantly
different (p < 0.05). Emetic episode data was analyzed with repeated-measurements one-way
ANOVA followed by Tukey’s post hoc test.
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Figure 19. Cbi-Ex4 vs. Ex4 direct comparison on emesis. The number of single emetic episodes
following, Ex4 (5 nmol/kg, i.e. 20 μg/kg), Cbi-Ex4 or saline administration was recorded for 120
min. Ex4 induced robust emetic responses that were not observed after Cbi-Ex4 or saline
injections. The number of emetic bouts was also lower in Cbi-Ex4-treated animals compared to
Ex4 and it did not differ from controls. Graphical representation of latency to the first emetic
episode between Ex4 and Cbi-Ex4-treated animals that exhibited emesis. The percentage of
shrews experiencing emesis was significantly different between Ex4 and Cbi-Ex4. Heatmap
showing latency, number and intensity of emesis for each animal across time. All data expressed
as mean ± SEM. Means with different letters are significantly different (P < 0.05). Emetic episode
and bout data was analyzed with repeated measurements one-way ANOVA followed by Tukey’s
post hoc test. Frequency of emesis in animals was analyzed with Fisher’s exact test
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3.7.6 C-Fos Staining of AP/NTS
Further support for this hypothesis is found by the near absence of c-Fos protein
immunofluorescence (i.e., neuronal activation) in the DVC by Cbi-Ex4 compared to the robust cFos activation by native Ex4 (Figure 20). The DVC is a set of brainstem nuclei (comprised of the
nucleus tractus solitarius [NTS], area postrema [AP], and dorsal motor nucleus of the vagus)
implicated in regulation of food intake and the processing of aversive stimuli and emetic
events.60,76–78 Figure 20 shows that systemic native Ex4 induces robust c-Fos expression in both
the NTS and AP, whereas an equimolar dose of Cbi-Ex4 did not significantly induce greater c-Fos
expression compared to vehicle injections.

Figure 20. Quantification of c-Fos positive neurons in the rostral, medial, and caudal NTS and
medial AP. Peripheral Ex4 administration significantly increased the number of c-Fos
immunoreactive cells in the AP/NTS of shrews 3 h after injection. The number of c-Fos positive
cells in the AP/NTS was significantly lower in Cbi-Ex4 treated animals. All data expressed as mean
± SEM. Data was analyzed with one-way ANOVA followed by Tukey’s post hoc test. Scale bar, 100
mm.
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3.8 Prebinding Cbi-Ex4 to Haptocorrin (HC)
Given the possibility of Cbi-Ex4 becoming bound by CSF-HC and subsequent removal or
deactivation of the construct we sought to assay Cbi-Ex4 prebound to HC (HC-Cbi-Ex4) at the GLP1R and noted an EC50 of ≈3 nM, essentially rendering a physiologically irrelevant construct.

Figure 21. Dose response and regression plot for HC-Cbi-Ex4 agonism at the GLP-1R.

3.9 Outcomes and Conclusions
In summary, by exploiting a biosynthetic precursor of B12 found naturally in humans, but
that is inert in the normal physiology of the vitamin, we generated a potent and metabolically
stable GLP-1 receptor agonist via corrination, with enhanced and prolonged peripheral
glucoregulatory actions at doses that do not affect feeding and, astonishingly, is virtually devoid
of emetic responses. Chronic animal studies as well as clinical trials are required to fully elucidate
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the long-term efficacy and tolerability of Cbi-Ex4. Given the high prevalence of obesity/
overweight among T2DM patients, the lack of major effects on feeding and body weight could
be considered a negative outcome of the corrination technology. For these patients, ‘‘classic’’
GLP-1R analogs, if well tolerated, may be most favorable as weight loss contributes to improved
overall health. Nevertheless, our data highlights the incredible potential of corrination,
exemplified herein with the development of Cbi-Ex4, as a treatment that would be most
beneficial in treating lean T2DM patients, T2DM patients suffering from other comorbidities
associated with an anorectic/cachectic state (cancer, COPD, and cystic fibrosis), and T2DM
patients seeking glycemic control without emesis.
T2DM and cancer anorexia-cachexia syndrome show similarities in metabolic
alterations.79,80 Insulin resistance and reduced glucose tolerance in cancer patients are wellknown phenomena. As early as the 1920s, glucose intolerance became a recognized metabolic
alteration observed in cancer patients.81 Data from tumor-bearing rodents, partially
recapitulating the human clinical state, showed some beneficial effects of Ex4 treatment in
attenuating

muscle

atrophy

and

in

counteracting

cancer-induced-insulin-signaling

dysregulation.82 However, the CNS-mediated anorectic and emetic effects induced by native Ex4
represents a substantive limitation for possible applications in humans. Cbi-Ex4 could therefore
represent an interesting and new GLP-1R-based approach for future investigations into the
treatment of cancer-induced insulin resistance.

134

3.10 Optimization of Cbi-Ex4 Construct
The previously discussed conjugation of Cbi with Ex4, to produce Cbi-Ex4 (1),83 and its
effects were tested in vivo in the musk shrew (Suncus murinus), a mammal capable of emesis84,85
and responsive to GLP-1R targeting therapeutics.61,62,83 The data showed that Cbi-Ex4 enhanced
the glucoregulatory response following an intraperitoneal glucose tolerance test (IPGTT), without
producing hypophagia, anorexia, body weight loss, and, more importantly, without emesis, all
characteristics of classical Ex4-based therapies.83 We hypothesized that these results are due to
reduced drug penetrance into the CNS.48–51,83 This proof-of concept corrinated Ex4 (1) was,
however, notably less potent an agonist for the GLP-1R than Ex4 alone (200 vs 30 pM,
respectively, in the same GLP-1R FRET assay).83 With that in mind, we set out to optimize 1 in
terms of receptor binding and agonism for the purposes of future translation. As such, we needed
to synthesize and characterize a new library of Cbi-Ex4 conjugates. Of note here is that there is a
dearth of synthetic cobinamide chemistry in the literature, mostly focusing on the novel
cobinamides to treat hydrogen sulfide86,87 or cyanide poisoning,88–95 and even less so in terms of
conjugation chemistry (an excellent exception being that from the Gryko group using CbiPNA);64,96 hence, we wanted to produce Cbi-linkers that would be readily amenable to
conjugation to Ex4 but indeed any targeted peptide moving forward. In these subsequent studies,
we have looked to optimize 1 with a focus on agonism and binding at the GLP-1R while also
expanding to the little explored chemistry pertaining to the synthesis of Cbi conjugates. As such,
the structure−activity data presented in these studies integrates synthesis, receptor agonism,
receptor binding, ex vivo insulin secretion, in vivo glucoregulation, emetic response, and food
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intake to explore the role of the peptide conjugate site and/or the role of a specific set of spacers
(linkers).
3.11 Selection of Linkers for New Library of Cbi-Ex4/40 Constructs
In terms of the linkers, there are three subsets that were chosen to sample space across
structural features, namely, steric, hydrophobic, and amphiphilic (Figure 22). The Ex4 conjugate
site was restricted to K12 and a K40 residue added to the C-terminus of Ex4 (Ex40) since both
sites were proven to be amenable to modification with minimal loss of function in our hands48–
51,83

and in prior literature.97–99

Figure 22. (Left) Structure of the Cbi ((CN)2Cbi) starting material, a purple solid prepared via
microwave chemistry from B12, with the hydroxyl group boxed used as a site of conjugation to
linker series. (Right) Library of linkers used in the conjugation of Cbi to Ex4 peptides. The library
of linkers chosen in this study included short hydrophobic alkane chains, amphiphilic PEG, and
rigid substituted ethynyl phenyl methanamines, which were coupled to the Cbi hydroxyl group
via CDT-mediated amide formation, resulting in Cbi compounds (4−11) with an available alkyne
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group for subsequent reaction with azido-modified Ex4 peptides via copper-mediated alkyneazide click chemistry (Figure 23).

3.12 Synthesis and Characterization of New Cbi-Ex4/40 Constructs
The Cbi linker compounds (4−11) and Ex4 conjugates of such (12−27) amounted to a
library of 32 compounds. These newly form compounds were synthesized as previously described
above. The experimental details are shown in Figure 23, with linkers (Figure 22) indicated as Rgroups.

Figure 23. Synthetic Scheme of Cbi Linkers (4−11) and Cbi-Peptide Conjugates (12−27).
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3.13 The Effect of Corrination on the Secondary Structure of Ex4
All conjugates were investigated for the effects of corrination on helicity at a
concentration of 40 μM in water at pH 7.0. Immediately, it was evident that there was minimal
variation in percent helicity whereupon the Cbi was conjugated at the Ex4 C-terminal K40 (20−27;
% helicity ranged from ∼28 to 36%; Ex40 control 33.1%; Figure 24, Table 3). There was however
a noticeable variation in the percent helicity for the conjugates (12−19) whereupon Cbi was
conjugated to the K12 within the Ex4 helix (% helicity range ∼20−46%; Ex4 control 24.3; Figure

24, Table 3). These results are consistent with the fact that conjugation at the C-terminus renders
less consequence to the linker type or spacer distance between Cbi and the peptide, given that
this region is away from the helical region of Ex4 and does not interfere with the role of this
region with receptor binding/agonism. The variation noted upon conjugation at the K12 residue
renders the linker critical with the highest % helicity noted as 41% with the amphiphilic PEG
spacer 3F (Figure 24, Table 3) and the lowest percent helicity noted with the small alkyl spacers
3B−3D (Figure 24, Table 3). No overall correlation between the structure and agonism or binding
was observed upon data fitting (not shown).
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Figure 24. Effect of Cbi conjugation on the secondary structure of Ex4 or Ex40. CD spectra were
collected with a sample concentration of 40 μM at pH 7 between 200 and 250 nm. % helicity was
measured at 222 nm.
3.14 In Vitro Optimization of Cbi-Ex4
To determine how the conjugation site of the peptide affects its function and the role
linker choice plays in the attachment of the peptide to Cbi, we sought to screen 12−27 utilizing
in vitro assays to determine potency and binding at the GLP-1R.
3.14.1 Agonism at GLP-1R
Our previously discussed Cbi-Ex4 construct 1 resulted in agonism at the GLP-1R with an
EC50 of 200 pM.83 The design of the newly constructed conjugates, 12−27, aimed to increase the
potency of the original construct to that comparable of unconjugated Ex4 (<30 pM).48 12−27 were
assessed utilizing in vitro screening in HEK C20 cells stably expressing the human GLP-1R and
cAMP FRET reporter H188 produced in-house.69,100 To determine if the azido modification to
lysine at position K12 (Ex4) or the addition of this residue to position 40 (Ex40) had any effect on
agonism at GLP-1R, they were also screened for agonism to compare with native Ex4 (nEx4; no
azido modifications), resulting in EC50 values of 20 pM for nEx4, 12.5 ± 3.7 pM for Ex4, and 10.4
± 3.9 pM for Ex40 (Table 3). All newly synthesized compounds were functional at the GLP-1R with
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improved potency in all cases (EC50 range 13.4 ± 4.2 to 105.6 ± 4.1 pM) to that of our previously
reported construct 1 (200 pM;83 Figure 25, Table 3). In general, the Ex4 conjugates 12−20 were
inferior to the Ex40 conjugates (20−27) and displayed greater variance, with EC50 values ranging
from 31 to 106 pM for 12−19 compared to 13 to 38 pM for 20−27. As with the variance observed
in the folded state for 12−19, it is likely that proximity and/or interactions of the Cbi moiety to
the helix interferes with receptor binding and/or interactions necessary for agonism.
Conjugations performed at the C-terminal end of the peptide would be expected to place the
corrin ring away from such residues as we have shown previously with B12 conjugates of the
neuropeptide PYY3−36.51 One Cbi-Ex4 conjugate however (19), which bridged Ex4 at the K12
residue with Cbi through one of the hydrophobic, rigid linkers (3H), was shown to be equipotent
to Ex4 with an EC50 value of 31.2 ± 16.9 pM and an IC50 of 11.6 ± 2.4 nM (compared to 5.98 ± 0.94
nM for Ex4 alone; Table 3). All Ex40-based conjugates (20−27) were shown to be equipotent to
the unconjugated peptide. Such results are consistent with the fact that addition of, and
conjugation to, the K40 residue is optimal when conjugating Cbi to Ex4.

Figure 25. Conjugation of Cbi to Ex4 or Ex40 peptides maintains agonism at the GLP-1R. Nonlinear
regression analysis was performed with GraphPad Prism 8. All compounds were assayed at least
as triplicate independent runs. Data are shown as mean ± SEM.

140

3.14.2 Competitive Binding at GLP-1R
As shown in Table 3, the presence of Cbi influences the ability of the conjugate to agonize
the GLP-1R compared to that of Ex4 or Ex40. To further investigate how conjugation of Cbi affects
Ex4 or Ex40, a series of competitive binding assays against GLP-1red (a red fluorescent analog of
GLP-1) were conducted (Figure 26). nEx4 was utilized as a reference competitor with an IC50 value
of 4.97 nM. We first aimed to determine if the azido modification to lysine at position K12 and
the addition of this residue to position 40 had any effect on binding. It was found that both Ex4
and Ex40 had comparable binding to that of the reference compound with IC50 values of 5.98 ±
0.94 and 7.34 ± 1.37 nM, respectively (Figure 26, Table 3). All conjugates had decreased binding
(12−135 nM) compared to the unconjugated peptide azido-modified Ex4 (6 nM) and Ex40 (7 nM)
and nEx4 controls (5 nM). When comparing the two clusters of conjugates, 20−27 showed greater
binding affinity overall compared to 12−19. The same trend was observed when agonizing the
GLP-1R (Figure 26, Table 3) in which collectively 20−27 outperformed 12−19. Two constructs,
namely, 19 and 22, did show promising binding with IC50 values of 11.6 ± 2.4 and 11.9 ± 2.5 nM,
respectively. The increased binding observed in these two conjugates was consistent with their
agonism (31 ± 16.9 and 20.7 ± 8.3 pM, respectively) of the GLP-1R (Figure 26, Table 3).
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Figure 26. In vitro dose escalation competition binding studies of 12-27 compared with Ex4 and
Ex40 controls against fluorescent GLP-1red. * Conducted by EuroscreenFast.

3.15 Identification of New Lead Candidate
Based on overall binding potent agonism, facile synthesis, and high yield observed for 22,
especially related to those of 19, we chose to further investigate 22 in ex vivo and in vivo
experiments.

Table 3. EC50 and IC50 Values with Hill Slopes and % Helicity of Cbi Conjugates 12−27. aData
represents EC50 obtained using nonlinear regression analysis of data from highest FRET values
obtained for each data point. Experiments were performed as three independent runs. bData
represents the Hill slope obtained using nonlinear regression analysis of data from highest FRET
values obtained for each data point. Experiments were performed as three independent runs.
cData

represents mean residue ellipticity [θ]222 determined from the CD spectra of a 40 μM

solution of peptide in H2O at RT pH 7.0. Average [θ]222 values utilized to calculate percent helicity
were obtained by performing the experiment in triplicate. Percent helicity was calculated using

142

100 × ([θ]222/max[θ]222).

max[θ]

222

= −40,000 [1 −(2.5/n)], where n is the residue number.

Experiments were performed as three independent runs. dData represents IC50 values obtained
from competitive binding assays against red fluorescent GLP-1 using nonlinear regression
analysis from highest values obtained for each data point. Experiments were performed as two
independent runs. eHill slopes were obtained using nonlinear regression analysis from highest
values obtained for each data point. Results are expressed as mean ± SEM.

3.16 Glucose-Stimulated Insulin Secretion (GSIS) in Rat Pancreatic Islets
The effects of 22 on GSIS were evaluated using rat pancreatic islets (Figure 27).101,102 At
10 mM glucose, both 22 and nEx4 increased GSIS in a dose-responsive manner. The effect from
22 was observed to be one-third lower than that of nEx4. To investigate whether there was a
difference between Ex40 and 22, specific to the rat GLP-1R, we assayed each for functional (EC50)
agonism. We observed a slight drop-off in potency with EC50 values of 7.8 and 22 pM recorded
for Ex40 and 22 (data not shown), respectively. nEx4 control had an EC50 of 48 pM at the rat GLP1R.103
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Figure 27. 22 increases glucose-stimulated insulin secretion in rat islets relative to glucose
controls. Insulin secretion rate from static cultures of Sprague−Dawley rat islets incubated in
media containing glucose (10 mM) and Ex4 (10 or 50 nM) or 22 (10 or 50 nM).104 Data was
calculated from three independent experiments and analyzed with repeated-measurements
two-way ANOVA followed by Tukey’s post hoc test. Results are expressed as mean ± SEM, ****
p <0.0001. * Conducted by Varun Kamat under the guidance of Dr. Ian R. Sweet at University of
Washington.

3.17 In Vivo Functional Experiments
3.17.1 22 versus 1 and Ex4 in IPGTT
Our first in vivo experiment the investigated the effects of Ex4, 1 and 22 on plasma glucose
levels following an IPGTT in shrews. We observed that shrews treated with 1, 22, or nEx4 display
similar improvements in glucose handling following glucose load compared to vehicle controls
(Figure 28). Post hoc analyses showed that all three compounds significantly suppressed blood
glucose (BG) at 20 and at 40 min after glucose administration versus vehicle treatment (all p <
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0.001). Remarkably, BG values at 20 min post glucose injection in animals receiving 22 were
significantly lower than those in animals treated with 1, denoting an improved glucose
tolerance/superior pharmacological efficacy (p < 0.01). Additionally, the variation in plasma
glucose concentrations, represented as area under the curves (0−60′ and 0−120′, respectively)
for 22, did not differ from nEx4 and were significantly lower than controls (Figure 28, all p < 0.05).

Figure 28. Cbi-Ex4 enhances glucose clearance without inducing emesis or body weight loss. (A)
In an IPGTT, Ex4, 1, and 22 (50 nmol/kg, IP) showed similar potency in suppressing BG levels after
glucose administration (2 g/kg, IP) compared to saline; vehicle vs 1: *** P < 0.001; vehicle vs 22:
### P < 0.001; vehicle vs Ex4: §§§ P < 0.001; 1 vs 22: ΦΦ P < 0.01 (n = 12 shrews). Area under the
curve (AUC) analysis from 0 (i.e., post-glucose bolus) to 60 min following 1, 22, and Ex4. AUC
analysis from 0 to 120 min; 22 and Ex4 similarly reduced AUCs compared to vehicle (P < 0.05). All
data expressed as mean ± SEM (n = 10). IPGTT data was analyzed with repeated-measurements
two-way ANOVA followed by Tukey’s posthoc test. AUC data was analyzed with repeated
measurements one-way ANOVA followed by Tukey’s posthoc test. Means with different letters
are significantly different (P < 0.05).
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3.17.2 22 Effects on Food Intake and Body Weight Change versus 1 and Ex4
We then analyzed the effects of 1, 22, and Ex4 on food intake and body weight at a single,
proof-of-concept, dose, in line with previous reports.48–50,83 Ex4 administration produced
anorexia in shrews at all measured time points (Figure 29), while 1 had no impact on feeding. 22
treatment suppressed food intake similar to Ex4 at 6, 24, and 48 h. The anorectic effect of Ex4
treatment was paralleled by a significant reduction in body weight at 24 h (p < 0.05), which was
not observed following treatment with 1 or 22 (Figure 29).

Figure 29. Ex4 and 22 (5 nmol/kg, IP) induced anorexia at 6, 24, and 48 h (and at 72 h for Ex4
only), whereas 1 had no effect on food intake (n = 10). Ex4-induced anorexia was accompanied
by significant body weight loss at 24 h. No significant changes in body weight occurred after 1
and 22 administration compared to controls. All data expressed as mean ± SEM (n = 10). Data
was analyzed with repeated-measurements two-way ANOVA followed by Tukey’s post hoc test.
Means with different letters are significantly different (P < 0.05).
3.17.3 22 Prevalence of Emetic Episodes Following Administration of 1, 22, and Ex4
To test whether 22 treatment retained the non-emetic properties of the lead conjugate
1, indicative of an altered pharmacodynamic profile, despite its comparable potency and GLP-1R
binding affinity compared to 1, and comparable to nEx4, we compared the emetogenic properties
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of 1, 22, and native Ex4 in shrews. Ex4 induced profound emesis in most of the shrews tested
(Figure 30). Indeed, 80% of the animals exhibited emesis upon administration of native Ex4 within
minutes after injection (29 ± 16 min). In line with our previous presented data, treatment with 1
did not cause emesis in any of the shrews tested. Importantly, the number of single emetic
episodes occurring in the 120 min window after drug administration was also significantly
reduced after 22 administration compared to Ex4 and did not differ from vehicle- or 1-treated
groups. Only two animals that received 22 experienced emesis with an average latency of 70 ±
29 min. The greater emetic effect observed for 22 over 1 is likely a consequence of the greater
binding and agonism of 22 at the GLP-1R, an effect that is likely to be mitigated, without loss of
glucoregulation, by use of lower doses of 22 (on-going work). The difference in the emetogenic
profiles of the corrinated constructs versus native Ex4 is further emphasized by the graphical
visualization of emetic intensity, recurrence, and latency for each individual animal across time
(Figure 30).
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Figure 30. The number of single emetic episodes following Ex4, 1, 22, or saline systemic
administration was recorded for 120 min. The number of animals exhibiting emesis, expressed
as a fraction of the total number of animals tested, is indicated above each treatment group.
Ex4 induced robust emetic responses that were not observed after 1 or saline injections. 22
induced emesis in two of the animals tested; however, the number of emetic episodes was
significantly lower than that of Ex4 and did not differ from animals treated with vehicle or 1 (n =
10). Heatmaps showing latency, number, and intensity of emesis following Ex4, 1, and 22
dosing for each individual animal across time. All data expressed as mean ± SEM (n = 10).
Emetic episode data was analyzed with repeated measurements one-way ANOVA followed by
Tukey’s post hoc test. Means with different letters are significantly different (P < 0.05).
3.18 Outcomes and Conclusions
Neuroendocrine associated pharmacological side effects such as nausea and emesis are
often downplayed or dismissed, left in the shadow of the overriding target, be it glucoregulation,
weight loss, etc. Indeed, the weight loss gleaned from GLP-1RAs, for example, has proven to be
a beneficial “side effect” of T2DM treatment due to the high comorbidity of T2DM with
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obesity.105 In many cases, however, such as lean T2DM patients, or patients with comorbidities
where nutritional status is critical (cystic fibrosis, cancer-cachexia, sarcopenia, chronic
obstructive pulmonary disease, etc.), removal of the CNS associated side effects would be greatly
beneficial. Indeed, GLP-1RAs have proven to be life-altering, and the ability to expand their use,
or increase patient compliance when using, should not be understated. Herein, we conceived 16
new Cbi-Ex4/Ex40 conjugates with the aim of designing a construct with equipotent binding and
agonism of the GLP-1R to that of Ex4 with a view of maintaining activity at peripheral GLP-1R
populations and mitigating such activity in CNS populations. We were able to successfully design
several constructs with comparable binding and agonism at GLP-1R as Ex4, with one conjugate,
22 (IC50 11.9 ± 2.5 nM, EC50 20.7 ± 8.3 pM), translated into ex vivo and in vivo studies. 22 increased
glucose secretion compared to vehicle controls in a glucose-dependent insulin secretion assay in
rat islets. In an in vivo IPGTT, 22 provided glucoregulation comparable to Ex4. Critically, 22
showed a near absence of emesis and mild body weight lowering actions compared to profound
emesis and body weight loss observed for nEx4.
While corrination is poorly explored, especially as it pertains to applications that seek to
prevent CNS penetration while maintaining peripheral activity of a target drug, it shows
considerable promise as a platform technology, moving beyond GLP-1RAs. An additional highlight
of Cbi is its water solubility (400 mg/mL), akin to glucose (450 mg/mL).106 Use of Cbi conjugation
with drugs with physical properties not suited to drug development, such as glucagon107–109 for
rescue of hypoglycemia, offers great scope for exploration.
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Chapter 4: Peptide Ligands of the GDNF Family Receptor α-like (GFRAL)

The work in this chapter resulted in the non-provisional patent WO 2020/163502 A1:
Tinsley , I. C.; Borner, T.; De Jonghe, B. C.; Hayes, M. R.; Doyle, R. P. Peptide Ligands of the GDNF
Family Receptor A-Like (GFRAL) Receptor.
As a result of this patent a spin-out company was named Cantius Therapeutics LLC was
created and is working to translate this work into clinical trials for Cachexia and Hyperemesis
gravidarum.

Peptide antagonist sequences were designed by the author and Dr. Robert P. Doyle. All
synthetic work, including synthesis of all tested compounds and the fluorescent analog, their
purification, chemical characterization, and preparation for in vivo testing was conducted by the
author. The in-solution NMR structure was solved by Dr. Deborah Kerwood of Syracuse University
using samples produced by the author. All in vivo work was performed by Dr. Tito Borner of the
University of Pennsylvania
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4.1 Introduction
Growth differentiation factor 15 (GDF15), also known as macrophage inhibitory cytokine-1
(MIC-1), is a stress response cytokine expressed in a variety of tissue and secreted into circulation
in response to many stimuli as part of a wide variety of disease processes, including cancer and
obesity.1–4 GDF15 signaling has gained significant attention in recent years with multiple
simultaneous papers in 2017 identifying the GDNF family receptor α-like (GFRAL) as binding
GDF15 selectively and with high affinity.5–7 Since then, numerous reports quickly populated the
literature suggesting promise for GDF15-GFRAL signaling as a potential treatment of obesity.4,8,9
Data from Hsu et al.6 suggested that GFRAL KO mice were insensitive to long-term anorexia and
cachexia/weight loss produced by the highly emetogenic chemotherapy agent cisplatin.10 In this
context, the reported restrictive expression of the GFRAL receptor to the area postrema (AP) and
nucleus tractus solitarius (NTS) of the brainstem,7,11 areas highly critical to both energy balance
and emesis/nausea, suggests that GDF15-GFRAL signaling may be an important factor in body
weight regulation, as well as processing of illness behaviors.
A recently published article identified that GDF15 induces anorexia through nausea and
emesis.12 To this end, as the GDF15 system is a clear priority targeted by Big Pharma and several
academic groups as a potential treatment for metabolic diseases and clinical applications of
cachexia (i.e., via GDF15 antibody development), understanding how GDF15 causes sickness and
anorexia is paramount to determining the mechanism of GDF15 to induce weight loss.
Compelling evidence links GDF15 signaling with chemotherapy-induced nausea and
anorexia, which remain important clinical problems despite relatively well-controlled
chemotherapy-induced vomiting,13–15 by showing that: 1) GDF15 signaling causes nausea and
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emesis;12 2) an AP/NTS site of action is responsible for mediating the feeding effects of GDF15
signaling through binding of the GFRAL receptor complex;5–7 and 3) obesity, cancer, and
chemotherapy increases circulating GDF15 in rodents and humans.6,16
Neural substrates within the AP/NTS are well documented mediators of cancer anorexiacachexia syndrome (CACS), a condition paralleled by increased plasma GDF15.17 Data from Tsai
et al.18 intriguingly show that lesions of the AP/NTS were able to block GDF15-induced anorexia
and body weight loss in mice. No doubt the effects of AP lesion are due in large part to ablation
of GFRAL receptors within the brainstem. Together, these reports begin to elucidate a peptide
system that is a prominent contributor to treatment-induced nausea and anorexia, and/or
vomiting, and weight loss. Thus, a critical question must be asked by the field: Can targeting the
GDF15-GFRAL system represent a realistic treatment for obesity and co-morbid metabolic
diseases without producing unwanted nausea/emesis side effects?
4.2 Design of a GFRAL Antagonist

The use of a peptide for the antagonism of the GFRAL receptor has several benefits
compared to its antibody counterpart. Notably, low manufacturing costs, greater stability in vivo,
lack of offsite interactions, better tissue penetration, especially the brain where antibodies
produced to target GFRAL cannot penetrate.19 Using structure-based computational design (i.e.,
rational design) focusing on reported6 GDF15 interactions with the GFRAL receptor (binding) and
subsequent RET interactions (recruitment), a small library of peptides were designed with the
aim to bind GFRAL, but not recruit RET. Regions of GDF15 known to be critical for the reported
GFRAL receptor specificity were incorporated in the initial library. Initial design strategies focused
on interactions with GFRAL residues 201-203 [SKE]), which are unique to GFRAL and replace the
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‘RRR’ motif critical for selectivity in other TNF-β receptors.6 In order to selectively bind to GFRAL
we ensured critical residues targeting ‘SKE’ were included. Finally, we ensured no means to
recruit RET, by both omitting important GDF15 residues (e.g. W32)6,7 from the final sequences
and also by placing in bulky hydrophilic residues and sequences capable of binding metal ions
(particularly zinc) to further block this interaction. Azido modified lysine residues were included
in the sequences to allow for future conjugation allowing for mechanistic studies (Table 1).

Table 1. Designed GFRAL antagonists. Sequences were designed using amino acids of native
ligand, GDF15, known to interact with GFRAL receptor. Note: Sequences are confidential (Office
of Technology Transfer, Syracuse University).
Peptide
GRASP-01
GRASP-02
GRASP-03
GRASP-04
GRASP-05

Sequence
EDDVSFQK(azido)LDDNVRYHTLRK
DDDLSFQK(azido)LDDNVYYHLLRK
K(azido)LDDNVYYHLLRK
K(azido)PMVLIQKTDTGVSLQTYD
TK(azido)EELIHAHADPMVLIQKTDTGVSLQTYD

4.3 In Vivo screening of GFANT peptides

The series of GRASP antagonists were tested for their ability to attenuate both anorexia
and pica. The GFRAL receptor is known to be expressed in the area postrema and some
evidence suggests it is also expressed in the nucleus of the solitary tract. The peptide
antagonist’s ability to reach this portion of the central nervous system was unknown and thus
were delivered directly into the brain via intracerebroventricular (ICV) injection, specifically the
fourth ventricle (Figure 1).
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Figure 1. The AP lies at the caudal end of the fourth ventricle adjacent to the NTS. Direct
injection via the fourth ventricle allows for activation of neurons found in the AP and NTS.

Initial testing occurred by injecting equimolar concentrations of both MIC-1/GDF15 and GFANT
(30 pM). In vivo screening in the rat of the five designed peptides led to confirmation of GFRAL
antagonism for one sequence, labelled herein as GRASP-05 (Figure 2). Initial results suggested
that GRASP-01 – GRASP-04 no therapeutic effect (data not shown).

Figure 2. GRASP-05 reduces GDF15-induced kaolin intake. 4th ICV GRASP-05 (300 pmol)
significantly reduces 4th ICV GDF15 (30 pmol)-induced kaolin intake in the rat (n=9/group, withinsubject design) Data expressed as mean ± SEM. Means with different letters are significantly
different (P < 0.05).
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To further investigate the ability of these peptides to work as antagonists the concentration of
peptides administered was increased while maintaining 30pM concentration of MIC-1/GDF15.
Injections up to 3 nM of GRASP-01 – GRASP-04 produced no antagonistic effects (data not
shown).

4.4 Fluorescent tagging of GRASP-05
To perform subsequent mechanistic studies a fluorescently tagged GRASP-05 construct
was designed and synthesized (GRASP-555).

4.4.1 Design and Synthesis of GRASP-555
Utilizing strained promoted alkyne-azide cycloaddition (SPAAC), a fluorescently labelled
GRASP-05 was successfully synthesized. In short, a DBCO modified AlexaFluor®564 (DBCO-AF546)
was conjugated to GRASP-05 by dissolving in 4:1 DMF: H2O and allowed to stir overnight at room
temperature to produce GRASP-555 (Figure 3). GRASP-555 was purified using RP-HPLC (H2O +
0.1% TFA and MeOH from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O + 0.1% TFA in 25 min)
to produce GRASP-555 in 99% purity in stochiometric yields (Figure 4). ESI-MS expected m/z =
4386, observed m/z = [M+2H++Na+]+3: 1487, [M+3H]+3: 1463, [M+4H++H2O]+4: 1116, [M+4H]+4:
1097, [M+5H]+5: 878 (Figure 5). Successfully linkage of GRASP-05 to DBCO-AF546 resulted in an
excitation-maxima shift from 554 nm to 560 nm and emission maxima shift from 570 nm to 571
nm (Figure 6).
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Figure 3. Synthetic scheme for GRASP-555. DBCO AF-546 was successfully “clicked” to GRASP-05
utilizing SPAAC.

Figure 4. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse XDB-C18 5μm,
4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O + 0.1% TFA in 25
min)) showing GRASP-555 product at 10.9 min. Purity 99%.
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Figure 5. ESI-MS (Shimadzu LCMS-8040) of GRASP-555, expected m/z = 4386, observed m/z =
[M+2H++Na+]+3: 1487, [M+3H]+3: 1463, [M+4H++H2O]+4: 1116, [M+4H]+4: 1097, [M+5H]+5: 878.

Figure 6. GRASP-555 electronic absorption spectra were obtained on a Varian Cary 50 Bio
spectrophotometer in a 2mL quartz cuvette between 400 nm – 700 nm in aqueous acetonitrile.
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4.4.2 In vivo Injection of GRASP-555 in Rats
Successful synthesis of GRASP-555 allowed for in vivo mechanistic studies in rats.
Following systemic administration, it was found that GRASP-555 successfully penetrated into the
hindbrain (AP/NTS) and colocalized with GFRAL receptors (Figure 7).

Figure 7. GRASP-555 10 mg/kg; IP shows co-localization with GFRAL-expressing neurons in the
AP and NTS of rats.

4.5 In-solution Structure of GRASP-05 Utilizing Nuclear Magnetic Resonance (NMR)
In addition to data supporting in vivo antagonism/ binding of GFRAL using fluorescent
analog GRASP-555, the in-solution structure of GRASP was solved in collaboration with Dr.
Deborah Kerwood (Syracuse University), utilizing NMR and revealed a significant secondary
structure including a clear ‘loop’ region producing a ‘hairpin-like’ fold (Figure 8).
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Figure 8. Solution state structure of GRASP solved by NMR revealing secondary ‘Hairpin-like’
structure with GDF15 like ‘loop’. Structure solved by Dr. Deborah Kerwood, Syracuse University.

The structure was the result of a 15 ns implicit solvent AMBER18 run,20,21 where NMR (NOE)
based distance restraints and TALOS+ based PHI and PSI angle ranges were incorporated.22
Utilizing a high-ambiguity driven protein-protein docking (HADDOCK) modeling approach,23 we
docked GRASP into the extra-cellular binding domain of GFRAL, with and without GDF15 already
bound (PDB 5VZ4).6 We noted that GRASP docked proximal to GDF15 and indeed appears to
block access to the W32 residue containing RET binding region of GDF15, suggesting that GRASP
is a non-competitive antagonist that functions via inhibition of RET recruitment (Figure 9).
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Figure 9. GDF15 (green) binding to GFRAL (blue/purple) (PDB 5VZ4) with bound GRASP (Red)
simulated using HADDOCK 2.2. A close-up rendering shows GRASP ‘blocking’ the region of GDF15
(W32) known to be vital for RET recruitment.

4.6 Microsomal Stability Assays of GRASP-05
An in vitro rat microsome (0.45 mg/mL) PK stability assay was also performed to test the

pharmacokinetic (PK) properties of GRASP-05 (Figure 10).24 Results of the PK stability assay on
GRASP-05 determined half-life (104.4 min) and intrinsic-clearance (CLint) (3.39 µL/min/mg
protein), both suggesting an excellent PK lead peptide.
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Figure 10. Microsomal stability assay in rats. The half-life was calculated to be: 104.43 min.
Reaction velocity (V) was calculated to be 511 µL/mg. Intrinsic clearance (Clint) was determined
to be 339 µL/min/mg protein.

4.7 Lipidation of GRASP-05

Given the successful design approach leading to GRASP-05, validation of our
computational modelling to date, solving of the solution structure of GRASP-05 via NMR, and
facile reproduction of established in vitro assays (data not shown) we sought to further improve
in vivo functionality. Initial in vivo function was monitored for 24 h, but we sought to develop a
therapeutic with extended half life, beyond the already excellent PK paramenters obtained, and
thus designed and succesfully synthesized a lipidated (dipalmitic acid) analog of GRASP (LipGRASP-05). Lip-GRASP-05 is predicted to have an extensively greater half-life, while not effecting
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brain penetrance as has been established for lipidated pharmaceutical peptides such as
liraglutide.25

4.7.1 Design and Synthesis of Lipidated GRASP-05 (Lip-GRASP-05)
Utilizing SPAAC, a Lip-GRASP-05 successfully synthesized. In short, a DBCO modified 16:0
dipalmittic acid (DBCO 16: PE) was conjugated to GRASP-05 by dissolving in 9:1 DMF: H2O and
allowed to stir overnight at room temperature to produce Lip-GRASP-05 (Figure 11). ESI-MS
expected m/z = 4258, observed m/z = [M+3H+]+3: 1420, [M+4H+]+4: 1065, [M+5H+]+5: 852 (Figure
12).

Figure 11. Synthetic scheme for Lip-GRASP-05. DBCO AF-546 was successfully “clicked” to GRASP05 utilizing SPAAC.

Figure 12. ESI-MS (Shimadzu LCMS-8040) of Lip-GRASP-05, expected m/z = 4258, observed m/z
= [M+3H+]+3: 1420, [M+4H+]+4: 1065, [M+5H+]+5: 852.
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4.8 Developing an ELISA for monitoring GRASP

To successfully monitor the binding of GDF15 to the GFRAL receptor and subsequent
antagonism by GRASP-05 as well as future GRASP iterations an “in house” enzyme-linked
immunosorbent assay (ELISA) was developed. Specific details on the protocol can be found in the
experimental chapter. Our “in-house” ELISA confirmed FDG15 binding at GFRAL with an ED50 of
≈1 ng/mL, consistent with previously reported values (Figure 13).5,7,11

Figure 13. ELISA assay of GDF15 binding to human recombinant GFRAL (0.1 μg/mL).

To directly monitor GRASP-05’s ability to bind and antagonize the GFRAL receptor a new primary
antibody was developed by GenScript USA (Figure 14).

Figure 14. GenScript Generated Primary Antibody.

179

4.9 Outcomes and Conclusions
The designing of an antagonist of the GFRAL receptor is a unique approach in the
important and rapidly growing research area of GDF15/GFRAL signaling. GRASP-05 is currently
the only peptide antagonist of its kind known to date and is promising approach to address the
questions centered on blocking the GFRAL-RET complex as a means to treat nausea/emesis and
sickness behaviors.
The initial work performed thus far continues to probe the fundamental understanding
of how GDF15 reduces food intake. I was successfully able to design an antagonist of the GFRAL
receptor what suppressed kaolin intake in an in vivo investigation in rats. Following fluorescent
tagging of GRASP-05 it was shown that following systemic administration GRASP-05 is able to
readily penetrate the blood brain barrier, a limitation by current antibody approaches. In order
to improve on the pharmacokinetic profile of GRASP-05 a lapidated variant, Lip-GRASP-05, was
designed and current in vivo analysis is ongoing. The ability to antagonize the GFRAL receptor can
now be readily monitored utilizing a newly developed ELISA.
Both GRASP-05 and its future derivatives have the potential to mitigate several
undesirable sickness behaviors induced by GDF15, including CNS-derived GDF15. While GRASP05 shows potential as a standalone therapeutic it also shows promise as a pairing compound to
mitigate side effects of currently approved therapeutics. Addressing this clinically unmet need
will go hand-in-hand with significant advancement for the fields of ingestive behavior, obesity
research, and potential tolerability of metabolic disease treatment as it pertains to the GFRALRET complex.
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Chapter 5: Fluorescent Probes of Neuroendocrine Hormones for the Identification of
Receptor Distribution and Function
The work reported in this chapter resulted in a peer-reviewed research paper: Stein, L.
M.; Lhamo, R.; Cao, A.; Workinger, J.; Tinsley, I.; Doyle, R. P.; Grill, H. J.; Hermann, G. E.; Rogers,
R. C.; Hayes, M. R. Dorsal Vagal Complex and Hypothalamic Glia Differentially Respond to Leptin
and Energy Balance Dysregulation. Transl. Psychiatry 2020, 10 (1), 90.

All synthetic work, including syntheses of all compounds and fluorescent analogs, their
purification, chemical characterization, and preparation for in vivo testing was conducted by the
author. All in vivo data collection was conducted at the University of Pennsylvania (USA) or the
University of Gothenburg (Sweden).

The author at the University of Pennsylvania center for neurobiology and behavior where in vivo
experiments utilizing probes described in this chapter was, in-part, performed.
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5.1 Introduction
Identification of target receptors, their cell populations, and cognate ligands often
benefits from the use of fluorescent probes.1 Key questions that can be answered include: Is the
leptin receptor present on astrocytes in the brain?; Where are oxytocin receptors located in the
brain?; Does ligand oligomerization occur for particular neuropeptides and if so, does this effect
receptor activation? The development of specific probes to address the above questions was the
aim of the work described herein. In all cases, the goal was to produce a fluorescent, functional
receptor or ligand that would allow for ex vivo analysis of targeted brain cells in the hind-brain
and brain stem. All three peptides investigated, leptin, oxytocin and exendin-4, are
neuropeptides that play a role in energy metabolism via neuronal circuitry that remains opaque
or not fully understood. The outcomes of this work as described in Chapter 5 identified a new
population of astrocytes within the dorsal vagal complex (DVC) expressing the leptin receptor
(LepR) utilizing fluorescently tagged (Cy5) leptin.2 Also discussed are the design and synthesis of
fluorescently tagged (AF546) oxytocin and Exendin-4 (Ex4) used in collaboration with Prof.
Karolina Skibicka of the University of Gothenburg and Prof. Matthew Hayes and Dr. Lauren Stein
of the University of Pennsylvania, respectively.

5.2 Leptin
Leptin is a neuroendocrine hormone used in energy homeostasis by inhibiting hunger and
the regulation of fat stores (Figure 1).3,4 Research focused on the regulation of food intake and
body weight has been confined to the hypothalamus. The role of leptin signaling and agonism of
the LepR within the hypothalamus has been investigated and defined, but its role within the DVC,
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specifically the area postrema (AP) and nucleus tractus solitarius (NTS), regions associated with
energy homeostasis, is less explored.2 The DVC has been shown to suppress food intake and
potentiate the intake suppressive effects of within-meal satiation signals.5–8 Despite the DVCs
role in energy homeostasis, the distribution and identification of the LepR within cell populations
has yet to be identified. In collaboration with the group of Prof. Matthew Hayes and postdoctoral
researcher Dr. Lauren Stein of the University of Pennsylvania, the expression of LepR on
astrocytes in the DVC was assessed along with the role of DVC astrocytes in mediating the
anorectic effects of leptin using a fluorescent leptin probe, deemed Cy5-Leptin.2

Figure 1. Structure of leptin. PDB code 1AX8.4 Image generated by the author using PyMol.

5.2.1 Design, Synthesis, and Characterization of a Fluorescent Leptin (Cy5-Leptin)
Cy5-leptin was synthesized utilizing mouse recombinant leptin dissolved in pH 7.8
phosphate buffer and allowed to rock at room temperature. Cy5 labeling of the protein occurred
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via NHS-Ester-Sulfo-Cy5 dissolved in 50 µL of DMSO and added to the rocking solution in 10 µL
aliquots over one hour. Following the final addition of Cy5 the reaction rocked for an additional
2 hours to produce the final product, Cy5-Leptin. The reaction was always protected from light.
Cy5-Leptin was purified using RP-HPLC (H2O + 0.1% TFA and MeOH from 1% CH3OH/H2O + 0.1%
TFA to 90% CH3OH/H2O + 0.1% TFA in 20 min) (Figure 2). The mass of the Cy5-Leptin was
confirmed via SDS-PAGE analysis (Figure 3). The mass observed ranged between 15-20 kDa,
consistent with the addition of Cy5 to several lysine residues available for modification in the
structure. Successfully linkage of Cy5 to Leptin resulted in an excitation-maxima shift from 646
nm to 650 nm and emission maxima shift from 662 nm to 669 nm (Figure 4).

Figure 2. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse XDB-C18 5μm,
4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O + 0.1% TFA in 25
min)) showing Cy5-Leptin product at 9.9 min. Purity 98%.
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Figure 3. Cy5-Leptin mass was found to be between 15-20 kDa and confirmed utilizing 12.5% SDSPAGE.
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Figure 4. Cy5-Leptin electronic absorption spectra were obtained on a Varian Cary 50 Bio
spectrophotometer in a 2mL quartz cuvette between 500 nm – 800 nm in aqueous acetonitrile.

The synthesized and characterized Cy5-leptin was successfully utilized in vivo and published
‘Dorsal Vagal Complex and Hypothalamic Glia Differentially Respond to Leptin and Energy
Balance Dysregulation’ Transl. Psychiatry 2020, 10 (1), 90. The use of this fluorescent probe
helped to identify the expression of LepR within the DVC (Figure 5) and how its role differs
from the receptor population observed within the hypothalamus.
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Figure 5. Immunohistochemical visualization of Cy5-Lep colocalized to DVC astrocytes. Used with
permission of publisher under the Creative Commons license.2

5.3 Function of Exendin-4 (Ex4) at the Glucagon-like Peptide-1 (GLP-1) Receptor (GLP-1R)
Ex4 simulates insulin secretion through the agonism of the GLP-1R in a glucose-dependent
manner.9 The signaling of the GLP-1R is highly dependent on receptor dimerization.10 The
residence time, or length of time an agonist is bound to its receptor, influences period of action
and is suggested to contribute to prolonged signaling following internalization.11 Like many other
G-protein coupled receptors (GPCR), the GLP-1R undergoes agonist mediated endocytosis.11
Following internalization, the GLP-1R has been shown to maintain signaling with no effect on
insulin secretion.12 Upon endocytosis, portions of the GLP-1R are degraded in the lysosome12
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while remaining portions are recycled back to the plasma membrane.13 Distribution of the GLP1R in a monomeric or dimeric state has yet to be elucidate. Of note, this property has yet to be
identified in any class B GPCR.10 Current work suggests that these GPCRs exist in an equilibrium
of monomer and dimeric state.14–17 To further investigate the residency time of Ex4 at the GLP1R and the internalization of the receptor, a fluorescent Ex4, designated here as REX, was
developed to be used in collaboration with Dr. George Holz of SUNY Upstate Medical University.
Parallel investigations are occurring in collaboration with Dr. Lauren Stein of the University of
Pennsylvania to monitor the distribution of the GLP-1R in both the monomeric and dimeric state.
5.3.1 Design, Synthesis, and Characterization of AF546-Ex4 (REX)
Utilizing strained promoted alkyne-azide cycloaddition (SPAAC) a DBCO modified
AlexaFluor®564 (DBCO-AF546) was “clicked” Ex4 where the twelfth residue, lysine, was
substituted by an azido modified lysine by dissolving in 4:1 DMF: H2O (1200µL) and allowed to
stir overnight at room temperature to produce AF546-Ex4 (REX) (Figure 6). REX was purified using
RP-HPLC (H2O + 0.1% TFA and MeOH from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O + 0.1%
TFA in 25 min) to produce REX in 97% purity in stochiometric yields (Figure 7). ESI-MS expected
m/z = 5319, observed m/z = [M+3H]+3: 1773, [M+4H]+4: 1331 (Figure 8). Successfully linkage of
Ex4 to DBCO-AF546 resulted in an excitation-maxima shift from 554 nm to 560 nm and emission
maxima shift from 570 nm to 575 nm (Figure 9).
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Figure 6. Synthetic scheme for REX.

Figure 7. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse XDB-C18 5μm,
4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O + 0.1% TFA in 25
min)) showing REX product at 14.1 min. Purity 97%.
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Figure 8. ESI-MS (Shimadzu LCMS-8040) of REX, expected m/z = 5319, observed m/z = [M+3H+]+3:
1773, [M+4H+]+4: 1331.

Figure 9. REX electronic absorption spectra were obtained on a Varian Cary 50 Bio
spectrophotometer in a 2mL quartz cuvette between 400 nm – 700 nm in aqueous acetonitrile.

Upon completion and characterization of REX its ability to maintain function was tested in GLP1R stably transfected HEK-293-H188 c20 cells. REX was shown to maintain function at the GLP1R as shown by tracking cAMP elevation utilizing a viral H188 reporter (Figure 10).
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Figure 10. In vitro dose escalation study of REX showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.

5.4 Signaling of Oxytocin at the Oxytocin Receptor
Oxytocin (Oxy) is cyclic nine amino acid neuropeptide known for its role in reproductive
and maternal behaviors.18 Recently oxy has emerged as an important regulator of energy
homeostasis.19 The majority of studies evaluating the role of Oxy in metabolism have focused on
the hypothalamus as the primary source of the peptides actions throughout the central nervous
system (CNS).20 However, both Oxy and its receptor (OxyR) have been found in the human
gastrointestinal tract (GIT) and expressed along the vagal afferents, respectively.20,21 While
identified, the function of the OxyR expressed along the vagal afferents have yet to be
elucidated.21 Initial investigations in collaboration with Dr. Karolina Skibicka of the University of
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Gothenburg have led to the hypothesis that vagal OxyR are a key relay of gut to brain satiation
signaling. To investigate this hypothesis, a fluorescent oxytocin, termed ROxy, was designed and
synthesized to investigate the function of this receptor sub-population. In addition, ROxy will also
be utilized to identify the role of enteric Oxy. To fully elucidate the role of Oxy in the peripheral
nervous system, a CNS impermeant Oxy will be developed and administered (for further
discussion-see chapter 7).
5.4.1 Design, Synthesis, and Characterization of AF546-Oxytocin (ROxy)
Utilizing SPAAC, a fluorescently labelled oxytocin was successfully synthesized. In short, a
DBCO modified AlexaFluor®564 (DBCO-AF546) was conjugated to an azido modified lysine in
position eight of oxytocin by dissolving in 4:1 DMF: H2O and allowed to stir overnight at room
temperature to produce AF546-Oxy (ROxy) (Figure 11). Roxy was purified using RP-HPLC (H2O +
0.1% TFA and MeOH from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O + 0.1% TFA in 25 min)
to produce Roxy in 99% purity in stochiometric yields (Figure 12). ESI-MS expected m/z = 2154,
observed m/z = [M+H2O+2H+]+2: 1097, [M+2H]+2: 1078 (Figure 13). Successfully linkage of OTaz
to DBCO-AF546 resulted in an excitation-maxima shift from 554 nm to 558 nm and emission
maxima shift from 570 nm to 572 nm (Figure 14).
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Figure 11. Synthetic scheme for ROxy. B12-DBCO was successfully “clicked” to OTaz utilizing
SPAAC.

Figure 12. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse XDB-C18
5μm, 4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O + 0.1% TFA
in 25 min) showing ROxy product at 12.0 min. Purity 99%.
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Figure 13. ESI-MS (Shimadzu LCMS-8040) of B12-Oxy, expected m/z = 2154, observed m/z =
[M+H2O+2H+]+2: 1097, [M+2H+]+2: 1078.

Figure 14. ROxy electronic absorption spectra was obtained on a Varian Cary 50 Bio
spectrophotometer in a 2mL quartz cuvette between 400 nm – 700 nm in aqueous acetonitrile.

5.5 Conclusions
In conclusion three functional probes were successfully designed and synthesized. Cy5leptin successfully identified a new population of astrocytes expressing LepR within the DVC

199

and was included in the publication: Dorsal Vagal Complex and Hypothalamic Glia Differentially
Respond to Leptin and Energy Balance Dysregulation. Transl. Psychiatry 2020, 10 (1), 90. The
successful development of REX has lead to ongoing investigations with active collaborators Dr.
George Holz of SUNY Upstate Medical University and Dr. Lauren Stein of the University of
Pennsylvania. ROxy continus to be used in investigation in vivo in Gothenburg.
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Chapter 6: Experimental
6.1 General Methods
All commercial reagents and anhydrous solvents purchased were used without further
purification. All reactions containing air and/or moisture sensitive reactants were performed
under argon or nitrogen. Compounds were purified using a Shimadzu Prominence HPLC using a
C18 column (Eclipse XDB-C18 5μm, 4.6 x 150 mm). All compounds were purified to or in excess
of, 97% (as tracked by RP-HPLC-see supplementary materials). Products were analyzed for mass
using Shimadzu LCMS-8040 or a Bruker Autoflex III Smartbeam matrix assisted laser
desorption/ionization time of flight mass spectrometer (MALDI). 1H NMR and 13C NMR spectra
were acquired on a Bruker NMR spectrometer (Avance 400 MHz) in D2O at a D1 of 3 for all
compounds. EAS was collected on a Varian, Cary 50bio UV-Visible Spectrophotometer in a 1 mL
quartz cuvette with baseline correction. Circular dichroism (CD) spectra were recorded with a
Jasco J-715 Circular Dichroism Spectropolarimeter in 40 μM H2O in a 0.1 cm quart cuvette. Data
was analyzed and fit using GraphPad Prism 8.0. The novel HEK293 cloned cells designated as
HEK293-GLP-1R-H188-C20 were obtained by G418 antibiotic resistance selection after cotransfection of cells with the human GLP-1R and the cAMP FRET reporter H188.1 Cells were grown
in a Memmert Incubator I (Schwabach, Germany) at 37 °C gassed with 5% CO2 at ~ 95% humidity.
FRET assays were conducted utilizing a Molecular Devices, FlexStation 3 Multi-Mode Microplate
Reader. Data was analyzed utilizing Molecular Devices, SoftMax Pro v.5.4.6. Linear regression
analyses were performed utilizing GraphPad Prism 8. All peptides were synthesized by Fmoc/tBu
solid-phase peptide synthesis methodology on a CEM Liberty Blue automated microwave peptide
synthesizer (CEM Corporation, Matthews, NC) starting with Fmoc-Rink Amide Protide Resin (LL)
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and employing repetitive N,Nʹ-Diisopropylcarbodiimide (DIC)/ Ethyl cyanohydroxyiminoacetate
(Oxyma) activation. Peptides were cleaved from the resin and deprotected using a CEM
Corporation Razor: rapid peptide cleavage system with treatment of 92.5% TFA trifluoroacetic
acid (TFA) containing 2.5% triisopropylsilane (TIPS), 2.5% water, 2.5% 2,2’-(Ethylenedioxy)diethenethiol (DODT). The obtained solution was precipitated with cold diethylether at
centrifuged at 4000 rpm for 5 min. The diethylether supernatant was discarded and the remaining
precipitate was redissolved in water and placed on a Labconco FreeZone 1 lyopholizer. All
peptides were purified using Agilent ZORBAX 300SB-C8 (5 μm, 9.4 × 250 mm) column.
6.2 Materials
Purchased from Sigma Aldrich: acetonitrile (Cat # 14851), diethyl ether (Cat # 673811),
ethanol (Cat # 459844), ethyl acetate (Cat # 319902), isopropyl alcohol (Cat # 34863), methanol
(Cat # 34885), n-methyl-2-pyrrolidone (Cat # 328634), triethylamine (Cat # 8.08352), vitamin B12
(Cat # V2876), 2-iodoxybenzoic acid (Cat #661384), sodium cyanide (Cat # 205222), 1,1’-carbonyldi-(1,2,4-trizole) (Cat # 21863), propargylamine (Cat # P50900), 1-amino-3-butyne (Cat # 715190),
4-pentyne-1-amine (Cat # 779407), hex-5-yne-1-amine (Cat # COM497512576), bovine serum
albumin (Cat # A7030), Dulbecco’s modified eagle medium (Cat # D6429), fetal bovine serum (Cat
# 12303C), G-418 disulfate salt solution (Cat # G8168), HEPES (Cat # H0887). Purchased from
ThermoFisher Scientific: penicillin-streptomycin (Cat # 15140122), trypsin-EDTA (Cat #
25200072). Purchased from Fisher Scientific: calcium chloride dihydrate (Cat # BP510),
magnesium chloride hexahydrate (Cat # BP214), potassium chloride (Cat # BP366), sodium
chloride (Cat # BP358-1). Purchased from BroadPharm: propargyl-PEG2-amine (Cat # BP22519),
propargyl-PEG4-amine

(Cat

#

BP22520).

Purchased

from

Enamine:

(4-
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ethynylphenyl)methanamine (Cat # EN300-233648), (3-ethynylphenyl)methanamine (Cat #
EN300-248722). Krebs-Ringer Bicarbonate (KRB) buffer was prepared as described previously. DGlucose (Cat # G 5767) and nEx4 (Cat # E7144) were purchased from Sigma-Aldrich. Ex4 K12-azido
and Ex40 K40-azido were produced by Genscript (Piscathaway, New Jersey, United States). Rat
insulin radioimmunoassay (RIA) kit was purchased from Millipore Sigma, Burlington, MA Cat no.
RI-13K. The human GLP-1R plasmid was provided by M. Beinborn, Tufts University School of
Medicine. The H188 plasmid was provided by K. Jalink, Netherlands Cancer Institute. All amino
acids and activating agents were purchased from CEM Corporation (Matthews, NC, United
States).
6.3 Ethics Statement
All in vivo experiments were approved by the Institutional Care and Use Committee of
the University of Pennsylvania and were conducted using the approved procedures.
6.4 RP-HPLC Methods
Compounds were purified using a Shimadzu Prominence HPLC using a C18 column (Eclipse
XDB-C18 5μm, 4.6 x 150 mm). Two differing purification methods were used: A1, H2O + 0.1% TFA
and MeOH from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O + 0.1% TFA in 25 min.; A2, H2O +
0.1% TFA and CH3CN from 1% CH3CN/H2O + 0.1% TFA to 70% CH3CN/H2O + 0.1% TFA in 15 min.
6.5 Experimental-Chapter 2
6.5.1 Synthesis of B12-Ex4
6.5.1.1 Synthesis of B12-Carboxylic Acid (B12-CA)
B12-CA was synthesized as previously described.2
6.5.1.2 Synthesis of B12-Aminobutyne (B12-AB)
B12-AB was synthesized as previously described.2
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6.5.1.3 Synthesis of B12-Ex4
B12-Ex4 was synthesized as previously described.2
6.5.1.4 Synthesis of B12-Ex4-Cy5
B12-Ex4-Cy5 was synthesized as previously described.3
6.6 Experimental-Chapter 3
Note: Numbering Corresponds to that used in Chapter 3
6.6.1 Synthesis of Dicyanocobinamide (Cbi) (2)
To a 10mL microwave reaction vessel containing a magnetic stir bar was added B12
(cyanocobalamin) (303.8 mg, 0.225 mmol) sodium cyanide (NaCN) (36.9 mg, 0.7096 mmol) and
5 mL of EtOH and the vessel was sealed. The reaction was heated to 120°C for 10 min. Following
completion of the microwave reaction the remaining solution was transferred and diluted using
isopropyl alcohol (iPrOH). The reaction was purified utilizing a normal phase silica column. The
reaction was eluted using 100% methanol (MeOH). The product eluted as a purple product. The
isolated product was precipitated utilizing diethyl ether (Et2O) and allowed to dry producing a
solid, purple product, 2, in 80% yield (187.4mg, 0.1795 mmol). Solubility was measured as
400mg/mL in distilled water. 2 was purified by RP-HPLC as described for method A1, to 98%; tR:
5.2 and 6.7 min (Figure 1); ESI-MS expected m/z = 1042, observed m/z = [M-CN]+1 1016 (Figure
2). EAS Ext Coeff354 = 28,400 M-1 cm-1 (Figure 3). 1H NMR (400 MHz, D2O): δ 5.90 (s, 1H), 3.95-3.87
(m, 1H), 3.85 (d, J= 8.4. Hz, 1H), 3.75 (d, J= 10.4 Hz, 1H), 3.41 (m, 1H), 3.36 (s, 5H), 3.30 (m, 2H),
3.25 (d, J=4.7 Hz, 1H), 3.17 (dd, J= 6.8, 6.9 Hz, 1H), 2.92-2.86 (m, 1H), 2.75-2.73 (m, 2H), 2.652.39 (m, 7H), 2.32-2.26 (m, 15H), 2.19-2.08 (m, 5H), 2.03-1.95 (m, 1H), 1.91-1.76 (4H), 1.69 (s,
3H), 1.54 (s, 3H), 1.50 (s, 3H), 1.44 (s, 3H), 1.32 (s, 3H), 1.19 (s, 4H), 1.16 (d, J=6.4 Hz, 4H) (Figure
4). 13C NMR (400 MHz, D2O): 178.6, 178.4, 177.9, 177.5, 177.3, 176.8, 175.1, 175.0, 172.1, 163.4,
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162.9, 105.1, 103.1, 91.0, 83.1, 75.0, 66.2, 64.2, 58.8, 56.3, 55.2, 53.2, 49.2, 48.9, 46.8, 46.3, 46.1,
43.7, 42.2, 39.0, 34.9, 32.5, 32.4, 31.9, 31.7, 31.5, 30.5, 26.6, 25.7, 24.9, 23.8, 21.7, 19.4, 18.7,
18.5, 17.4, 16.5, 15.1, 14.8 (Figure 5).

Figure 1. RP-HPLC trace showing the α- and β-isomer products of 2 at 5.2 and 6.7 min.

Figure 2. ESI-MS of 2, expected m/z = 1042, observed m/z = [M-CN]+1 1016.
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Figure 3. Electronic absorption spectroscopy of 2.
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Figure 4. H NMR of 2 (400 MHz, 298K, D2O).
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Figure 5. 13C NMR of 2 (400 MHz, 298K, D2O).
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6.6.2 Synthesis of Cbi-Ex4/40
6.6.2.1 Synthesis of Cbi-Propargylamine (Cbi-Pro) (4)
4 was prepared by combining 2 (16.8 mg, 0.0161 mmol) with CDT (51.4 mg, 0.3000 mmol)
and allowed to stir for one hour at which time propargylamine (19.2 μL, 16.5 mg, 0.300 mmol)
and TEA (50 μL) were added and stirred for one hour after which point a second equivalent
amount propargylamine and TEA were added and allowed to stir for one hour to give the target
compound, which was purified using RP-HPLC method A1 to produce 4 as an orange solid to 97%
purity. Yield 43% (7.8 mg, 0.007 mmol). The product obtained was in the form of two different
isomers with the aquo-group located on the alpha and beta positions (α-cyano-β-aqua- and αaqua-β-cyano-). tR: 8.8 and 9.5 min (Figure 6); ESI-MS expected m/z = 1115, observed m/z = [M+H2O]+1: 1096, [M+-H2O+H+]+2: 549 (Figure 7). EAS Ext Coeff354 = 14,500 M-1 cm-1 (Figure 8). 1H NMR
(400 MHz, D2O): δ 6.50 (1H, s, Ar-H, β-aqua isomer) 6.42 (1H, s, Ar-H, α-aqua isomer) (Figure 9,
10).

Figure 6. RP-HPLC trace showing the α- and β-isomer products of 4 at 8.8 and 9.5 min.
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Figure 7. ESI-MS of 4, expected m/z = 1115, observed m/z = [M+-H2O]+1: 1096, [M+-H2O+H+]+2:
549.

Figure 8. Electronic absorption spectroscopy of 4.
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Figure 9. 1H NMR of 4 (400 MHz, 298K, D2O).
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Figure 10. 1H NMR of 4 (400 MHz, 298K, D2O) (Aromatic). Characteristic signals (H19) of β- (6.50) and α- (6.42) aquo-isomers of 4 are
observed.4
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6.6.2.2 Synthesis of Cbi-Butyne (Cbi-But) (5)
5 was prepared by combining 2 (20.5 mg, 0.0197 mmol) with CDT (61.3 mg, 0.3740 mmol)
and allowed to stir for one hour at which time 1-amino-3-butyne (32.0 μL, 27.0 mg, 0.391 mmol)
and TEA (50 μL) were added and stirred for one hour after which point a second equivalent of 1amino-3-butyne and TEA were added and allowed to stir for one hour to give the target
compound, which was purified using RP-HPLC method A1 to produce 5 as an orange solid to 95%
purity. Yield 53% (11.4 mg, 0.010 mmol). The product obtained was in the form of two different
isomers with the aquo-group located on the alpha and beta positions (α-cyano-β-aqua- and αaqua-β-cyano-). tR: 7.4 and 7.9 min (Figure 11); ESI-MS expected m/z = 1129, observed m/z = [M+H2O]+1: 1111, [M+-H2O+H+]+2: 556 (Figure 12). EAS Ext Coeff354 = 19,804 M-1 cm-1 (Figure 13). 1H
NMR (400 MHz, D2O): δ 6.49 (1H, s, Ar-H, β-aqua isomer) 6.42 (1H, s, Ar-H, α-aqua isomer) (Figure
14, 15).

Figure 11. RP-HPLC trace showing the α- and β-isomer products of 5 at 7.4 and 7.9 min.
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Figure 12. ESI-MS of 5, expected m/z = 1129, observed m/z = [M+-H2O]+1: 1111, [M+-H2O+H+]+2:
556.

Figure 13. Electronic absorption spectroscopy of 5.
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Figure 14. 1H NMR of 5 (400 MHz, 298K, D2O).
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Figure 15. 1H NMR of 5 (400 MHz, 298K, D2O) (Aromatic). Characteristic signals (H19) of β-(6.49) and α- (6.42) aquo-isomers of 5 are
observed.4
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6.6.2.3 Synthesis of Cbi-Pentyne (Cbi-Pent) (6)
6 was prepared by combining 2 (17.3 mg, 0.0166 mmol) with CDT (49.1 mg, 0.299 mmol)
and allowed to stir for one hour at which time 4-pentyne-1-amine (29.0 μL, 24.9 mg, 0.300 mmol)
and TEA (50 μL) were added and stirred for one hour after which point a second equivalent
amount 4-pentyne-1-amine and TEA were added and allowed to stir for one hour to give the
target compound, which was purified using RP-HPLC method A1 to produce 6 as an orange solid
to 97% purity. Yield 21% (4.0 mg, 0.003 mmol). The product obtained was in the form of two
different isomers with the aquo-group located on the alpha and beta positions (α-cyano-β-aquaand α-aqua-β-cyano-). tR: 10.4 and 11.0 min (Figure 16); ESI-MS-expected m/z = 1143, observed
m/z = [M+-H2O]+1: 1124, [M+-H2O+H+]+2: 563 (Figure 17). EAS Ext Coeff354 = 15,001 M-1 cm-1 (Figure
18). 1H NMR (400 MHz, D2O): δ 6.50 (1H, s, Ar-H, β-aqua isomer) 6.43 (1H, s, Ar-H, α-aqua isomer)
(Figure 19,20).

Figure 16. RP-HPLC trace showing the α- and β-isomer products of 6 at 10.4 and 11.0 min.
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Figure 17. ESI-MS of 6, expected m/z = 1143, observed m/z = [M+-H2O]+1: 1124, [M+-H2O+H+]+2: 563.

Figure 18. Electronic absorption spectra of 6.
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Figure 19. 1H NMR of 6 (400 MHz, 298K, D2O).
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Figure 20. 1H NMR of 6 (400 MHz, 298K, D2O) (Aromatic). Characteristic signals (H19) of β- (6.50) and α- (6.43) aquo-isomers of 6 are
observed.4
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6.6.2.4 Synthesis of Cbi-Hexyne (Cbi-Hex) (7)
7 was prepared by combining 2 (15.8 mg, 0.0151 mmol) with CDT (51.6 mg, 0.314 mmol)
and allowed to stir for one hour at which time 5-hexyn-1-amine (36.5 μL, 29.2 mg, 0.300 mmol)
and TEA (50 μL) were added and stirred for one hour after which point a second equivalent
amount 5-hexyn-1-amine and TEA were added and allowed to stir for one hour to give the target
compound, which was purified using RP-HPLC method A1 to produce 7 as an orange solid to 98%
purity. Yield 35% (6.0 mg, 0.005 mmol). The product obtained was in the form of two different
isomers with the aquo-group located on the alpha and beta positions (α-cyano-β-aqua- and αaqua-β-cyano-). tR: 11.3 and 11.8 min (Figure 21); ESI-MS-expected m/z = 1157, observed m/z =
[M+-H2O]+1: 1139, [M+-H2O+H+]+2: 570 (Figure 22). EAS Ext Coeff354 = 17,982 M-1 cm-1 (Figure 23).
1H

NMR (400 MHz, D2O): δ 6.49 (1H, s, Ar-H, β-aqua isomer) 6.42 (1H, s, Ar-H, α-aqua isomer)

(Figure 24, 25).

Figure 21. RP-HPLC trace showing the α- and β-isomer products of 7 11.3 and 11.8 min.
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Figure 22. ESI-MS of 7, expected m/z = 1157, observed m/z = [M+-H2O]+1: 1139, [M+-H2O+H+]+2:
570.

Figure 23. Electronic absorption spectra of 7.
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Figure 24. 1H NMR of 7 (400 MHz, 298K, D2O).
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Figure 25. 1H NMR of 7 (400 MHz, 298K, D2O) (Aromatic). Characteristic signals (H19) of β- (6.49) and α- (6.42) aquo-isomers of 7 are
observed.4
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6.6.2.5 Synthesis of Cbi-PEG2 (8)
8 was prepared by combining 2 (19.9 mg, 0.0191 mmol) with CDT (67.1 mg, 0.409 mmol)
and allowed to stir for one hour at which time propargyl-PEG2-amine (25.1 μL, 25.4 mg, 0.177
mmol) and TEA (50 μL) were added and stirred for one hour after which point a second equivalent
amount propargyl-PEG2-amine and TEA were added and allowed to stir for one hour to give the
target compound, which was purified using RP-HPLC method A1 to produce 8 as an orange solid
to 98% purity. Yield 39% (8.8 mg, 0.007 mmol). The product obtained was in the form of two
different isomers with the aquo-group located on the alpha and beta positions (α-cyano-β-aquaand α-aqua-β-cyano-). tR: 18.4 and 19.3 min (Figure 26); ESI-MS-expected m/z = 1204, observed
m/z = [M+-H2O]+1: 1185, [M+-H2O+H+]+2: 593 (Figure 27). EAS Ext Coeff354 = 22,919 M-1 cm-1 (Figure
28). 1H NMR (400 MHz, D2O): δ 6.50 (1H, s, Ar-H, β-aqua isomer) 6.43 (1H, s, Ar-H, α-aqua isomer)
(Figure 29, 30).

Figure 26. RP-HPLC trace showing the α- and β-isomer products of 8 at 18.4 and 19.3 min.

228

Figure 27. ESI-MS of 8, expected m/z = 1204, observed m/z = [M+-H2O]+1: 1185, [M+-H2O+H+]+2:
593.

Figure 28. Electronic absorption spectra of 8.

229

Figure 29. 1H NMR of 8 (400 MHz, 298K, D2O).
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Figure 30. 1H NMR of 8 (400 MHz, 298K, D2O) (Aromatic). Characteristic signals (H19) of β- (6.50) and α- (6.43) aquo-isomers of 8 are
observed.4
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6.6.2.6 Synthesis of Cbi-PEG4 (9)
9 was prepared by combining 2 (15.5 mg, 0.0149 mmol) with CDT (51.3 mg, 0.313 mmol)
and allowed to stir for one hour at which time propargyl-PEG4-amine (18.8 μL, 19.5 mg, 0.0843
mmol) and TEA (50 μL) were added and stirred for one hour after which point a second equivalent
amount propargyl-PEG4-amine and TEA were added and allowed to stir for one hour to give the
target compound which was purified using RP-HPLC method A1 to produce 9 as an orange solid
to 97% purity. Yield 32% (6.1 mg, 0.005 mmol). The product obtained was in the form of two
different isomers with the aquo-group located on the alpha and beta positions (α-cyano-β-aquaand α-aqua-β-cyano-). tR: 20.0 and 21.8 min (Figure 31); ESI-MS-expected m/z = 1292, observed
m/z = [M+-H2O]+1: 1273, [M+-H2O+H+]+2: 637 (Figure 32). EAS Ext Coeff354 = 19,439 M-1 cm-1(Figure
33). 1H NMR (400 MHz, D2O): δ 6.50 (1H, s, Ar-H, β-aqua isomer) 6.43 (1H, s, Ar-H, α-aqua isomer)
(Figure 34, 35).

Figure 31. RP-HPLC trace showing the α- and β-isomer products of 9 at 20.0 and 21.8 min.
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Figure 32. ESI-MS of 9, expected m/z = 1292, observed m/z = [M+-H2O]+1: 1273, [M+-H2O+H+]+2:
637.

Figure 33. Electronic absorption spectra of 9.
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Figure 34. 1H NMR of 9 (400 MHz, 298K, D2O).
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Figure 35. 1H NMR of 9 (400 MHz, 298K, D2O) (Aromatic). Characteristic signals (H19) of β- (6.50) and α- (6.43) aquo-isomers of 9 are
observed.4
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6.6.2.7 Synthesis of Cbi-4EPMA (10)
10 was prepared by combining 2 (14.9 mg, 0.0143 mmol) with CDT (50.1 mg, 0.305 mmol)
and allowed to stir for one hour at which time (4-ethynylphenyl)methanamine (23.8 mg, 0.181
mmol) and TEA (50 μL) were added and stirred for one hour after which point a second equivalent
amount (4-ethynylphenyl)methanamine and TEA were added and allowed to stir for one hour to
give the target compound, which was purified using RP-HPLC method A1 to produce 10 as an
orange solid to 97% purity. Yield 10% (1.5 mg, 0.001 mmol). The product obtained was in the form
of two different isomers with the aquo-group located on the alpha and beta positions (α-cyanoβ-aqua- and α-aqua-β-cyano-). tR: 12.4 and 12.8 min (Figure 36); ESI-MS-expected m/z = 1191,
observed m/z = [M+-H2O]+1: 1173 (Figure 37). EAS Ext Coeff354 = 15,886 M-1 cm-1 (Figure 38). 1H
NMR (400 MHz, D2O): δ 6.49 (1H, s, Ar-H, β-aqua isomer) 6.43 (1H, s, Ar-H, α-aqua isomer) (Figure
39, 40).

Figure 36. RP-HPLC trace showing the α- and β- isomer products of 10 at 12.4 and 12.8 min.
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Figure 37. ESI-MS of 10, expected m/z = 1191, observed m/z = [M+-H2O]+1: 1173.

Figure 38. Electronic absorption spectra of 10.
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Figure 39. 1H NMR of 10 (400 MHz, 298K, D2O).
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Figure 40. 1H NMR of 10 (400 MHz, 298K, D2O) (Aromatic). Characteristic Signals (H19) of and β- (6.49) and α- (6.43) aquo-isomers of
10 are observed.4 Additional peak groupings between 7.56-7.51 and 7.35-7.28 are indicative of the phenyl ring linker.
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6.6.2.8 Synthesis of Cbi-3EPMA (11)
11 was prepared by combining 2 (15.7 mg, 0.0151 mmol) with CDT (51.1 mg, 0.311 mmol)
and allowed to stir for one hour at which time (3-ethynylphenyl)methanamine (21.0 μL, 21.2 mg,
0.162 mmol) and TEA (50 μL) were added and stirred for one hour after which point a second
equivalent amount (3-ethynylphenyl)methanamine and TEA were added and allowed to stir for
one hour to give the target compound, which was purified using RP-HPLC method A1 to produce
11 as an orange solid to 97% purity. Yield 14% (2.6 mg, 0.002 mmol). The product obtained was
in the form of two different isomers with the aquo-group located on the alpha and beta positions
(α-cyano-β-aqua- and α-aqua-β-cyano-). tR: 12.6 and 13.0 min (Figure 41); ESI-MS-expected m/z
= 1191, observed m/z = [M+-H2O]+1: 1172, [M+-H2O+H+]+2: 587 (Figure 42). EAS Ext Coeff354 =
15,669 M-1 cm-1 (Figure 43). 1H NMR (400 MHz, D2O): δ 6.49 (1H, s, Ar-H, β-aqua isomer) 6.42 (1H,
s, Ar-H, α-aqua isomer) (Figure 44, 45).

Figure 41. RP-HPLC trace showing the α- and β- isomer products of 11 at 12.6 and 13.0 min.

240

Figure 42. ESI-MS of 11, expected m/z = 1191, observed m/z = [M+-H2O]+1: 1172, [M+-H2O+H+]+2:
587.

Figure 43. Electronic absorption spectra of 11.
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Figure 44. 1H NMR of 11. (400 MHz, 298K, D2O).
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Figure 45. 1H NMR of 11. (400 MHz, 298K, D2O) (Aromatic). Characteristic signals (H19) of β- (6.49) and α- (6.42) aquo-isomers of 11
are observed.4 Additional peak groupings between 7.48-7.37 are indicative of the phenyl ring linker.
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6.6.2.9 Synthesis of Cbi-Pro-Ex4 (12)
12 was prepared by combining 4 (1.1 mg, 0.001 mmol) with CuI (4.0 mg, 0.021 mmol),
TBTA (7.5 mg, 0.014 mmol), and Ex4 (3.1 mg 0.0007 mmol) gave the target compound, which was
purified using RP-HPLC method A2 to produce 12 as a red solid to 98% purity. tR: 11.7 min (Figure
46); ESI-MS-expected m/z = 5327, observed m/z =[M+-H2O+2H+]+3: 1771, [M+-H2O+3H+]+4: 1328
(Figure 47). In vitro function of 10 was determined in GLP-1R stably transfected HEK-293-H188
c20 cells (Figure 48).

Figure 46. RP-HPLC trace showing product 12 at 11.7 min.

Figure 47. ESI-MS of 12, expected m/z = 5327, observed m/z = [M+-H2O+2H+]+3: 1771, [M+H2O+3H+]+4: 1328.
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Figure 48. In vitro dose escalation study of 12 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.
6.6.2.10 Synthesis of Cbi-But-Ex4 (13)
13 was prepared by combining 5 (5.7 mg, 0.005 mmol) with CuI (4.2 mg, 0.022 mmol),
TBTA (7.5 mg, 0.014 mmol), and Ex4 (4.2 mg 0.0010 mmol) gave the target compound, which was
purified using RP-HPLC method A2 to produce 13 as a red solid to 98% purity. tR: 12.0 min (Figure
49); ESI-MS-expected m/z = 5341, observed m/z =[M+-H2O+2H+]+3: 1775, [M+-H2O+3H++CH3OH]+4:
1364, [M+-H2O+3H+]+4: 1332 (Figure 50). In vitro function of 13 was determined in GLP-1R stably
transfected HEK-293-H188 c20 cells (Figure 51).
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Figure 49. RP-HPLC trace showing product 13 at 12.0 min.

Figure 50. ESI-MS of 13, expected m/z = 5341, observed m/z = [M+-H2O+2H+]+3: 1775, [M+H2O+3H++CH3OH]+4: 1364, [M+-H2O+3H+]+4: 1332.
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Figure 51. In vitro dose escalation study of 13 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.
6.6.2.11 Synthesis of Cbi-Pent-Ex4 (14)
14 was prepared by combining 6 (4.9 mg, 0.0043 mmol) with CuI (3.6 mg, 0.019 mmol),
TBTA (6.2 mg, 0.012 mmol), and Ex4 (3.9 mg 0.0009 mmol) gave the target compound, which was
purified using RP-HPLC method A2 to produce 14 as a red solid to 98% purity. tR: 12.0 min (Figure
52); ESI-MS-expected m/z = 5355, observed m/z =[M+-H2O+2H+]+3: 1780, [M+-H2O+3H+]+4: 1335
(Figure 53). In vitro function of 15 was determined in GLP-1R stably transfected HEK-293-H188
c20 cells (Figure 54).
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Figure 52. RP-HPLC trace showing product 14 at 12.0 min.

Figure 53. ESI-MS of 14, expected m/z = 5355, observed m/z = [M+-H2O+2H+]+3: 1780, [M+H2O+3H+]+4: 1335.
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Figure 54. In vitro dose escalation study of 14 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.
6.6.2.12 Synthesis of Cbi-Hex-Ex4 (15)
15 was prepared by combining 7 (9.7 mg, 0.0084 mmol) with CuI (3.5 mg, 0.018 mmol),
TBTA (6.6 mg, 0.012 mmol), and Ex4 (5.3 mg 0.0013 mmol) gave the target compound, which was
purified using RP-HPLC method A3 to produce 15 as a red solid to 98% purity. tR: 12.0 min (Figure
55); ESI-MS-expected m/z = 5369, observed m/z =[M+-H2O+2H+]+3: 1784, [M+-H2O+3H+]+4: 1339
(Figure 56). In vitro function of 22 was determined in GLP-1R stably transfected HEK-293-H188
c20 cells (Figure 57).
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Figure 55. RP-HPLC trace showing product 15 at 12.0 min.

Figure 56. ESI-MS of 15, expected m/z = 5369, observed m/z = [M+-H2O+2H+]+3: 1784, [M+H2O+3H+]+4: 1339.
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Figure 57. In vitro dose escalation study of 15 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.
6.6.2.13 Synthesis of Cbi-PEG2-Ex4 (16)
16 was prepared by combining 8 (2.0 mg, 0.0017 mmol) with CuI (3.6 mg, 0.019 mmol),
TBTA (7.1 mg, 0.013 mmol), and Ex4 (3.0 mg 0.0007 mmol) gave the target compound, which was
purified using RP-HPLC method A2 to produce 16 as a red solid to 98% purity. tR: 11.7 min (Figure
58); ESI-MS-expected m/z = 5416, observed m/z =[M+-H2O+2H+]+3: 1800, [M+-H2O+3H+]+4: 1350
(Figure 59). In vitro function of 22 was determined in GLP-1R stably transfected HEK-293-H188
c20 cells (Figure 60).
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Figure 58. RP-HPLC trace showing product 16 at 11.7 min.

Figure 59. ESI-MS of 16, expected m/z = 5416, observed m/z = [M+-H2O+2H+]+3: 1800, [M+H2O+3H+]+4: 1350.
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Figure 60. In vitro dose escalation study of 16 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.
6.6.2.14 Synthesis of Cbi-PEG4-Ex4 (17)
17 was prepared by combining 9 (3.0 mg, 0.0023 mmol) with CuI (3.4 mg, 0.018 mmol),
TBTA (7.3 mg, 0.014 mmol), and Ex4 (4.1 mg 0.0010 mmol) gave the target compound, which was
purified using RP-HPLC method A2 to produce 17 as a red solid to 98% purity. tR: 12.3 min (Figure
61); ESI-MS-expected m/z = 5504, observed m/z =[M+-H2O+2H++CH3CN]+3: 1870, [M+H2O+3H++CH3OH]+4: 1404, [M+-H2O+4H+]+5: 1098 (Figure 62). In vitro function of 22 was
determined in GLP-1R stably transfected HEK-293-H188 c20 cells (Figure 63).
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Figure 61. RP-HPLC trace showing product 17 at 12.3 min.

Figure 62. ESI-MS of 17, expected m/z = 5504, observed m/z = [M+-H2O+2H++CH3CN]+3: 1870,
[M+-H2O+3H++CH3OH]+4: 1404, [M+-H2O+4H+]+5: 1098.
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Figure 63. In vitro dose escalation study of 17 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.
6.6.2.15 Synthesis of Cbi-4EPMA-Ex4 (18)
18 was prepared by combining 10 (3.3 mg, 0.0028 mmol) with CuI (3.6 mg, 0.019 mmol),
TBTA (7.2 mg, 0.014 mmol), and Ex4 (3.0 mg 0.0007 mmol) gave the target compound, which was
purified using RP-HPLC method A2 to produce 18 as a red solid to 98% purity. tR: 12.2 min (Figure
64); ESI-MS-expected m/z = 5403, observed m/z =[M+-H2O+2H+]+3: 1796, [M+-H2O+3H+]+4: 1347
(Figure 65). In vitro function of 22 was determined in GLP-1R stably transfected HEK-293-H188
c20 cells (Figure 66).
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Figure 64. RP-HPLC trace showing product 18 at 12.2 min.

Figure 65. ESI-MS of 18, expected m/z = 5403, observed m/z = [M+-H2O+2H+]+3: 1796, [M+H2O+CH3OH+3H+]+4 : 1379, [M+-H2O+3H+]+4: 1347.
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Figure 66. In vitro dose escalation study of 18 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.
6.6.2.16 Synthesis of Cbi-3EPMA-Ex4 (19)
19 was prepared by combining 11 (3.0 mg, 0.0025 mmol) with CuI (4.5 mg, 0.024 mmol),
TBTA (7.6 mg, 0.014 mmol), and Ex4 (2.7 mg 0.0006 mmol) gave the target compound, which was
purified using RP-HPLC method A2 to produce 19 as a red solid to 97% purity. tR: 12.6 min (Figure
67);

ESI-MS-expected

m/z

=

5403,

observed

m/z

=[M+-H2O+2H+]+3:

1796,

[M+-

H2O+2H++CH3OH]+3:1379, [M+-H2O+3H+]+4: 1347 (Figure 68). In vitro function of 22 was
determined in GLP-1R stably transfected HEK-293-H188 c20 cells (Figure 69).
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Figure 67. RP-HPLC trace showing product 19 at 12.6 min.

Figure 68. ESI-MS of 19, expected m/z = 5403, observed m/z = [M+-H2O+2H+]+3: 1796, [M+H2O+CH3OH+3H+]+4: 1379, [M+-H2O+3H+]+4: 1347.
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Figure 69. In vitro dose escalation study of 19 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.

6.6.2.17 Synthesis of Cbi-Pro-Ex40 (20)
20 was prepared by combining 4 (3.0 mg, 0.0027 mmol) with CuI (3.6 mg, 0.019 mmol),
TBTA (7.0 mg, 0.013 mmol), and Ex40 (3.0 mg 0.0007 mmol) gave the target compound, which
was purified using RP-HPLC method A2 to produce 20 as a red solid to 97% purity. tR: 11.8 min
(Figure 70); ESI-MS-expected m/z = 5456, observed m/z =[M+-H2O+2H+]+3: 1813, [M+-H2O+3H+]+4:
1360, [M+-H2O+4H+]+5: 1088, [M+-H2O+5H+]+6: 907, [M+-H2O+6H+]+7: 777 (Figure 71). In vitro
function of 20 was determined in GLP-1R stably transfected HEK-293-H188 c20 cells (Figure 72).
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Figure 70. RP-HPLC trace showing product 20 at 11.8 min.

Figure 71. ESI-MS of 20, expected m/z = 5456, observed m/z = [M+-H2O+2H+]+3: 1813, [M+H2O+3H+]+4: 1360, [M+-H2O+4H+]+5: 1088, [M+-H2O+5H+]+6: 907, [M+-H2O+6H+]+7: 777.
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Figure 72. In vitro dose escalation study of 20 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.
6.6.2.18 Synthesis of Cbi-But-Ex40 (21)
21 was prepared according to the general procedure described above; combining 5 (3.4
mg, 0.0030 mmol) with CuI (4.0 mg, 0.021 mmol), TBTA (6.5 mg, 0.012 mmol), and Ex40 (3.3 mg
0.0007 mmol) gave the target compound, which was purified using RP-HPLC method A2 to
produce 21 as a red solid to 97% purity. tR: 11.7 min (Figure 73); ESI-MS-expected m/z = 5469,
observed m/z =[M+-H2O+2H++CH3CN]+3: 1859, [M+-H2O+2H+]+3: 1819, [M+-H2O+3H++CH3OH]+4:
1395, [M+-H2O+3H+]+4: 1364, [M+-H2O+4H+]+5: 1091 (Figure 74). In vitro function of 21 was
determined in GLP-1R stably transfected HEK-293-H188 c20 cells (Figure 75).
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Figure 73. RP-HPLC trace showing product 21 at 11.8 min.

Figure 74. ESI-MS of 21, expected m/z = 5469, observed m/z = [M+-H2O+2H++CH3CN]+3: 1859,
[M+-H2O+2H+]+3: 1819, [M+-H2O+3H++CH3OH]+4: 1395, [M+-H2O+3H+]+4: 1364 [M+-H2O+4H+]+5:
1091.
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Figure 75. In vitro dose escalation study of 21 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.
6.6.2.19 Synthesis of Cbi-Pent-Ex40 (22)
22 was prepared by combining 6 (4.4 mg, 0.00388 mmol) with CuI (3.2 mg, 0.017 mmol),
TBTA (6.5 mg, 0.012 mmol), and Ex40 (4.3 mg 0.0010 mmol) gave the target compound, which
was purified using RP-HPLC method A2 to produce 22 as a red solid to 97% purity. tR: 11.8 min
(Figure 76); ESI-MS-expected m/z = 5483, observed m/z =[M+-H2O+2H+]+3: 1822, [M+-H2O+3H+]+4:
1367, [M+-H2O+5H+]+6: 912, [M+-H2O+6H+]+7: 781 (Figure 77). In vitro function of 22 was
determined in GLP-1R stably transfected HEK-293-H188 c20 cells (Figure 78).
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Figure 76. RP-HPLC trace showing product 22 at 11.8 min.

Figure 77. ESI-MS of 22, expected m/z = 5483, observed m/z = [M+-H2O+2H+]+3: 1822, [M+H2O+3H+]+4: 1367, [M+-H2O+5H+]+6: 912, [M+-H2O+6H+]+7: 781.
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Figure 78. In vitro dose escalation study of 22 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.
6.6.2.20 Synthesis of Cbi-Hex-Ex40 (23)
23 was prepared according to the general procedure described above; combining 7 (2.1
mg, 0.0018 mmol) with CuI (3.6 mg, 0.019 mmol), TBTA (7.1 mg, 0.013 mmol), and Ex40 (2.6 mg
0.0006 mmol) gave the target compound, which was purified using RP-HPLC method A2 to
produce 23 as a red solid to 97% purity. tR: 11.8 min (Figure 79); ESI-MS-expected m/z = 5497,
observed m/z =[M+-H2O+2H+]+3: 1827, [M+-H2O+3H+]+4: 1371, [M+-H2O+5H+]+6: 914, [M+H2O+6H+]+7: 784, [M+-H2O+7H+]+8: 685 (Figure 80). In vitro function of 23 was determined in GLP1R stably transfected HEK-293-H188 c20 cells (Figure 81).
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Figure 79. RP-HPLC trace showing product 23 at 11.8 min.

Figure 80. ESI-MS of 23, expected m/z = 5497, observed m/z = [M+-H2O+2H+]+3: 1827, [M+H2O+3H+]+4: 1371, [M+-H2O+5H+]+6: 914, [M+-H2O+6H+]+7: 784, [M+-H2O+7H+]+8: 685.
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Figure 81. In vitro dose escalation study of 23 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.
6.6.2.21 Synthesis of Cbi-PEG2-Ex40 (24)
24 was prepared by combining 8 (2.0 mg, 0.0017 mmol) with CuI (4.1 mg, 0.022 mmol),
TBTA (7.4 mg, 0.014 mmol), and Ex40 (4.0 mg 0.0009 mmol) gave the target compound, which
was purified using RP-HPLC method A2 to produce 24 as a red solid to 97% purity. tR: 11.6 min
(Figure 82); ESI-MS-expected m/z = 5544, observed m/z =[M+-H2O+2H++CH3CN]+3: 1884, [M+H2O+3H++CH3OH]+4: 1414, [M+-H2O+3H+]+4: 1382 (Figure 83). In vitro function of 24 was
determined in GLP-1R stably transfected HEK-293-H188 c20 cells (Figure 84).
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Figure 82. RP-HPLC trace showing product 24 at 11.6 min.

Figure 83. ESI-MS of 24, expected m/z = 5544, observed m/z = [M+-H2O+2H++CH3CN]+3: 1884,
[M+-H2O+3H++CH3OH]+4: 1414, [M+-H2O+3H+]+4: 1382.
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Figure 84. In vitro dose escalation study of 24 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.
6.6.2.22 Synthesis of Cbi-PEG4-Ex40 (25)
25 was prepared by combining 9 (3.0 mg, 0.0023 mmol) with CuI (3.3 mg, 0.017 mmol),
TBTA (6.8 mg, 0.013 mmol), and Ex40 (4.1 mg 0.0009 mmol) gave the target compound, which
was purified using RP-HPLC method A2 to produce 25 as a red solid to 97% purity. tR: 12.0 min
(Figure 85); ESI-MS-expected m/z = 5632, observed m/z =[M+-H2O+2H++CH3CN]+3: 1914, [M+H2O+3H++CH3OH]+4: 1436 (Figure 86). In vitro function of 25 was determined in GLP-1R stably
transfected HEK-293-H188 c20 cells (Figure 87).
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Figure 85. RP-HPLC trace showing product 25 at 12.0 min.

Figure 86. ESI-MS of 25, expected m/z = 5632, observed m/z = [M+-H2O+2H++CH3CN]+3: 1914,
[M+-H2O+3H++CH3OH]+4: 1436.
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Figure 87. In vitro dose escalation study of 25 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.

6.6.2.23 Synthesis of Cbi-4EPMA-Ex40 (26)
26 was prepared by combining 10 (2.1 mg, 0.0018 mmol) with CuI (3.0 mg, 0.016 mmol),
TBTA (6.7 mg, 0.013 mmol), and Ex40 (2.3 mg 0.0005 mmol) gave the target compound, which
was purified using RP-HPLC method A2 to produce 26 as a red solid to 98% purity. tR: 11.9 min
(Figure 88); ESI-MS expected m/z = 5531, observed m/z =[M+-H2O+3H++CH3OH]+4: 1411, [M+H2O+3H+]+4: 1379, [M+-H2O+4H+]+5: 1104 (Figure 89). In vitro function of 26 was determined in
GLP-1R stably transfected HEK-293-H188 c20 cells (Figure 90).
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Figure 88. RP-HPLC trace showing product 26 at 11.9 min.

Figure 89. ESI-MS of 26, expected m/z = 5531, observed m/z = [M+-H2O+CH3OH+3H+]+4: 1411,
[M+-H2O+3H+]+4: 1379, , [M-H2O+4H+-CN]+4: 1353, [M+-H2O+4H+]+5: 1104.
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Figure 90. In vitro dose escalation study of 26 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.
6.6.2.24 Synthesis of Cbi-3EPMA-Ex40 (27)
27 was prepared by combining 11 (3.0 mg, 0.0025 mmol) with CuI (3.4 mg, 0.018 mmol),
TBTA (7.0 mg, 0.013 mmol), and Ex40 (2.0 mg 0.0005 mmol) gave the target compound, which
was purified using RP-HPLC method A2 to produce 27 as a red solid to 97% purity. tR: 11.9 min
(Figure 91); ESI-MS-expected m/z = 5531, observed m/z =[M+-H2O+2H++CH3CN]+3: 1880, [M+H2O+2H+]+3: 1838, [M+-H2O+3H++CH3OH]+4: 1410, [M+-H2O+3H+]+4: 1379, [M+-H2O+4H+]+5: 1103
(Figure 92). In vitro function of 27 was determined in GLP-1R stably transfected HEK-293-H188
c20 cells (Figure 93).
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Figure 91. RP-HPLC trace showing product 27 at 11.9 min.

Figure 92. ESI-MS of 27, expected m/z = 5531, observed m/z = [M+-H2O+CH3CN+2H+]+3: 1880,
[M+-H2O+2H+]+3: 1838, [M+-H2O+CH3OH+3H+]+4: 1410, [M+-H2O+3H+]+4: 1379, [M+-H2O+4H+]+5:
1103.
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Figure 93. In vitro dose escalation study of 27 showing increase in cAMP levels in GLP-1R stably
transfected HEK-293-H188 c20 cells.
6.6.3 Agonism (EC50) at Human GLP-1R
Agonism at the GLP-1R was monitored utilizing HEK-293 cells stably transfected with both
the human GLP-1R and H188 cAMP FRET reporter cultured in DMEM with 15% FBS. 1% pen/strep
and 250 μg/mL geneticin/G-418. Cells were placed in 96-well plate in suspension at 200 μL
standard extracellular saline with 11 mM glucose and 0.1% BSA at ~60,000 cells/well. Peptides
and conjugates were injected to each well at 5x the required concentration. Agonism was
determined through an increase in 485/535 nm FRET ratio, indicative of an increase in cAMP level
through binding to the H188 cAMP FRET reporter.
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6.6.4 Competitive Binding Assay (IC50) at Human GLP-1R
IC50 values were measured in CHO-K1 cells at the human GLP-1R by Euroscreen Fast
(Gosselies, Belgium) using their proprietary Taglite fluorescent competitive binding assay (Cat No.
FAST0154B). Agonist tracer was GLP-1red at 4 nM with reference competitor native Ex-4.
Conjugates were assayed in duplicate independent runs at nine concentrations per run ranging
from 1 pM to 1 μM.
6.6.5 Ex4 and Cbi-Ex4 ELISA
Concentrations of Ex4 and Cbi-Ex4 were measured using a commercial kit purchased from
Phoenix Pharmaceuticals (Exendin-4 (Heloderma suspectum) EK-070-94). The ELISA was
performed according to the manufacturer’s protocol with the exception of shrew blood serum
that had been dosed with Cbi-Ex4. A Cbi-Ex4 standard curve was generated by matching
concentrations provided by the manufacturer’s standards.
6.6.6 Structural Studies Using Circular Dichroism (CD)
All CD spectra were recorded in three independent runs in 100 μL of H2O with a final
concentration of 40 μM using a Jasco J-715 circular dichroism spectropolarimeter at 25 °C in a
0.1 cm path-length cuvette. The spectra were recorded from 250 to 200 nm and averaged over
6 scans with a resolution of 1.0 nm, a band width of 1.0 nm, and a response time of 4 s. The mean
residue ellipticity was plotted versus wavelength using Prism GraphPad 8.
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6.7 Experimental of Chapter 4
6.7.1 Determining Structure of GRASP-05 Utilizing 2D NMR
Experiments were done on the 800MHz instrument at SUNY College of Environmental
Science and Forestry (ESF) with the cryoprobe at 25 and 30 °C.

To assign the peaks, the following experiments were performed:

Nuclear overhauser effect spectroscopy (NOESY) using excitation sculpting for water
suppression. The spectral width in both dimensions was 12.4971 ppm centered at 4.691 ppm.
Number of points acquired in the direct dimension was 2048 and 512 in the remote dimension.
The relaxation delay was set to 2 seconds and the mixing time to 200 ms.

Total correlation spectroscopy (TOCSY) using excitation sculpting for water suppression
and MLEV17 for the TOCSY transfer. The spectral width in both dimensions was 12.4971 ppm
centered at 4.691 ppm. Number of points acquired in the direct dimension was 1024 and 512 in
the remote dimension. The relaxation delay was set to 1.5 seconds and the TOCSY mixing time
to 90 ms.

Correlation spectroscopy (COSY) using excitation sculpting for water suppression. The
spectral width in both dimensions was 12.4971 ppm centered at 4.691 ppm. Number of points
acquired in the direct dimension was 1024 and 512 in the remote dimension.
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Heteronuclear single quantum coherence (HSQC) with multiplicity editing. The spectral
width for the proton dimensions was 11.001 ppm centered at 4.691 ppm and for the carbon
dimension 169.9983 ppm centered at 80 ppm. Number of points acquired in the direct
dimension was 1024 and 512 in the remote dimension.

2D HSQC-TOCSY using DISPI2 sequence for the TOCSY transfer. The spectral width for the
proton dimensions was 11.001 ppm centered at 4.691 ppm and for the carbon dimension
169.9983 ppm centered at 80 ppm. Number of points acquired in the direct dimension was 1024
and 512 in the remote dimension. The relaxation delay was set to 1.5 seconds and the TOCSY
mixing time to 80 ms.
6.7.2 Synthesis of AF546-GRASP-05
DBCO modified AlexaFluor®564 (DBCO-AF546) (1.0 mg, 0.910 nmol) was “clicked” to
GRASP-05 (3.0 mg, 0.920 nmol) by dissolving in 4:1 DMF: H2O (1200µL) and allowed to stir
overnight at room temperature to produce AF546-GRASP-05 (GRASP-555). GRASP-555 was
purified using RP-HPLC (H2O + 0.1% TFA and MeOH from 1% CH3OH/H2O + 0.1% TFA to 90%
CH3OH/H2O + 0.1% TFA in 25 min) to produce GRASP-555 in 99% purity in stochiometric yields.
ESI-MS expected m/z = 4386, observed m/z = [M+2H++Na+]+3: 1487, [M+3H]+3: 1463,
[M+4H++H2O]+4: 1116, [M+4H]+4: 1097, [M+5H]+5: 878. Successfully linkage of GRASP-05 to DBCOAF546 resulted in an excitation-maxima shift from 554 nm to 560 nm and emission maxima shift
from 570 nm to 571 nm (Figures found in Chapter 4).
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6.7.3 Development by this author of an in-house ELISA for GDF15 Binding
ELISA PROTOCOL FOR GDF15/ GRASP ANTAGONISTS
1. Dilute the 20x EIA/ELISA Buffer (Phoenix Pharmaceuticals EK-BUF) with distilled water to a final
concentration of 1x (amount may vary based on needs).
•

Prior to diluting this buffer be sure no crystals are found in the sample. If crystals are
found place in a warm water bath until they are completely dissolved.

•

This buffer will be used to dilute or reconstitute all peptides or antibodies using during
this assay.

•

This buffer will also be used for washing the 96-well plate.

2. Reconstitute the recombinant human GDF-15 (R&D systems 9279-GD-50) in the 1x assay buffer
to desired concentration and vortex thoroughly. Allow the solution to sit at room temperature
for 30min to ensure all peptide has been completely dissolved.
•

This is your standard peptide stock. Use this stock to perform a serial dilution to
desired concentrations of peptide to be tested.

3. Reconstitute the primary antibody (Abcam ab206414) in the appropriate amount of 1x assay
buffer to reach desired concentration. All the solution to sit at room temperature for 5min to
ensure all the antibody has been completely dissolved.
4. Reconstitute the recombinant human GFRα-like His-tag receptor (R&D 9647-GR-050) in the
appropriate amount of 1x assay buffer to reach desired concentration. Allow the solution to sit
at room temperature for 30min to ensure all of the receptor has been completely dissolved.
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5. Reconstitute the positive control (Abcam ab206414) in the appropriate amount of 1x assay
buffer to reach desired concentration. All the solution to sit at room temperature for 5min to
ensure all the antibody has been completely dissolved.

To a PierceTM Nickel Coated Plat (Clear, 96-well) (ThermoFisher Scientific 15442)
1. Leave wells A1 and A2 empty on the plate.
•

These wells will serve as your blanks.

2. Add 100uL of 1x assay buffer to wells B1 and B2.
3. To all wells except A1, A2, B1, and B2 add 100μL of recombinant human GFRα-like His-tag
receptor (R&D 9647-GR-050) (0.1μg/mL).
4. Seal the 96-well plate and incubate and rock at room temperature for two hours.
5. After two hours wash the plate with 300μL of 1x assay buffer, discard the buffer, invert
immunoplate, and blot dry, repeat three times.
6. To all wells except A1, A2, B1, and B2 add 100μL of recombinant human GDF-15 (R&D systems
9279-GD-50).
7. Seal the 96-well plate and incubate and rock at room temperature for one hour.
8. After one hour wash the plate with 300μL of 1x assay buffer, discard the buffer, invert
immunoplate, blot dry, repeat three times.
9. To all wells except A1, A2, B1, and B2 add 100μL of Anti-GDF antibody [EPR19939] (Abcam
ab206414) according to manufacturer’s dilution protocol.
10. Seal the 96-well plate and incubate and rock at room temperature for one hour.
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11. After one hour wash the plate with 300μL of 1x assay buffer, discard the buffer, invert
immunoplate, blot dry, repeat three times.
12. To all wells except A1, A2, B1, and B2 add 100μL of Goat Anti-Rabbit IgG H&L (HRP) (Abcam
ab6721) according to manufacturer’s dilution protocol.
13. Seal the 96-well plate and incubate and rock at room temperature for one hour.
14. After one hour wash the plate with 300μL of 1x assay buffer, discard the buffer, invert
immunoplate, blot dry, repeat three times.
15. To all wells except A1, A2, B1, and B2 add 100μL of TMB ELISA Substrate (High Sensitivity)
(Abcam ab171523) according to manufacturer’s protocol.
16. Seal the 96-well plate and incubate and rock at room temperature for one hour.
•

Protect from light.

17. To all wells except A1, A2, B1, and B2 add 100μL of 450nm Stop Solution for TMB Substrate
(Abcam ab171529) according to manufacturer’s protocol.
18. Load the immunoplate onto the microplate reader and measure absorbance at 450nm.
Testing for Antagonism of GRASP
1. Following step five in the previously listed protocol add 100μL of antagonist at desired
concentration and allow to sit for one hour.
2. After one hour wash the plate with 300μL of 1x assay buffer, discard the buffer, invert
immunoplate, blot dry, repeat three times.
3. Proceed to step six in the previously listed protocol.
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6.8 Experimental-Chapter 5
6.8.1 Synthesis of Fluorescent Probes
6.8.1.1 Synthesis of AF546-Ex4 (Rex)
DBCO modified AlexaFluor®564 (DBCO-AF546) (1.0 mg, 0.910 nmol) was “clicked”
Exendin-4 (Ex4) where the twelfth residue, lysine, was substituted by an azido modified lysine(3.0
mg, 0.712 nmol) by dissolving in 4:1 DMF: H2O (1200µL) and allowed to stir overnight at room
temperature to produce AF546-Ex4 (REX). REX was purified using RP-HPLC (H2O + 0.1% TFA and
MeOH from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O + 0.1% TFA in 25 min) to produce REX
in 97% purity in stochiometric yields. ESI-MS expected m/z = 5319, observed m/z = [M+3H]+3:
1773, [M+4H]+4: 1331. Successfully linkage of Ex4 to DBCO-AF546 resulted in an excitationmaxima shift from 554 nm to 560 nm and emission maxima shift from 570 nm to 575 nm (Figures
found in Chapter 5).
6.8.1.2 Synthesis of Cy5-Leptin (Cy5-Leptin)
1.0 mg of mouse recombinant leptin was dissolved in 450 µL phosphate buffer pH 7.8 and
allowed to rock at room temperature. 0.2 mg of NHS-Ester-Sulfo-Cy5 (Cy5) was dissolved in 50
µL of DMSO and added to the rocking solution in 10 µL aliquots over one hour. Following the final
addition of Cy5 the reaction rocked for an additional 2 hours to produce the final product, Cy5Leptin. The reaction was always protected from light. Cy5-Leptin was purified using RP-HPLC (H2O
+ 0.1% TFA and MeOH from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O + 0.1% TFA in 20 min).
The mass of the Cy5-Leptin was confirmed via SDS-PAGE analysis. Successfully linkage of Cy5 to
Leptin resulted in an excitation-maxima shift from 646 nm to 650 nm and emission maxima shift
from 662 nm to 669 nm (Figures found in Chapter 5).
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6.8.1.3 Synthesis of AF546-Oxytocin (ROxy)
AlexaFluor®564 (DBCO-AF546) (2.0 mg, 0.002 mmol) was successfully “clicked” to an
azido modified oxytocin (OTaz) (2.5mg, 0.002 mmol) where the eighth residue, leucine, was
substituted by an azido modified lysine by dissolving both compounds in 4:1 DMF: H2O and
allowed to stir overnight at room temperature to produce AF546-Oxy (Roxy). Roxy was purified
using RP-HPLC (H2O + 0.1% TFA and MeOH from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O
+ 0.1% TFA in 25 min) to produce Roxy in 99% purity in stochiometric yields. ESI-MS expected
m/z = 2154, observed m/z = [M+H2O+2H+]+2: 1097, [M+2H]+2: 1078. Successfully linkage of OTaz
to DBCO-AF546 resulted in an excitation-maxima shift from 554 nm to 558 nm and emission
maxima shift from 570 nm to 572 nm (Figures found in Chapter 5).
6.9 Experimental-Chapter 7
6.9.1 Synthesis of Linear Oxytocin
Linear oxytocin was synthesized by Fmoc/tBu solid-phase peptide synthesis methodology
on a CEM Liberty Blue automated microwave peptide synthesizer (CEM Corporation, Matthews,
NC) starting with Fmoc-Rink Amide Protide Resin (LL) and employed repetitive DIC)/ Oxyma
activation. The side chain protecting group scheme consisted of Asn(Trt); Gln(OtBu); Tyr(tBu);
and Trp(Boc). All amino acids and activating agents were purchased from CEM Corporation
(Matthews, NC). Oxytocin was cleaved from the resin and deprotected using a CEM Corporation
Razor: rapid peptide cleavage system with treatment of 92.5% TFA trifluoroacetic acid (TFA)
containing 2.5% TIPS, 2.5% water, 2.5% DODT. The obtained solution was precipitated with cold
diethylether at centrifuged at 4000 rpm for 5 min. The diethylether supernatant was discarded
and the remaining precipitate was redissolved in water and placed on a Labconco FreeZone 1
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lyopholizer. The resulting peptide were analyzed and characterized by LC-MS (Shimadzu 8040).
ESI-MS expected m/z = 1050, observed m/z = [M+H+]+: 1050, [M+2H]+2: 525.
6.9.2 Cyclic Oxytocin - Disulfide Bridge Formation in Oxytocin
Cyclic oxytocin was formed through the formation of a disulfide bridge between cysteine
residues found at position one and six of linear oxytocin. Linear oxytocin was dissolved in 10%
DMSO in water and allowed to stir for 48 hours. The resulting solution was diluted with water
and placed on a Labconco FreeZone 1 lyophilizer. Due to DMSO concentration, a ‘film’ on the
vessel was produced following the initial lyophilization process. The film was redissolved in water
and the lyophilization process was repeated to now produce a white powder. The peptide was
purified by semi-preparative RP-HPLC (H2O + 0.1% TFA and CH3CN from 1% CH3CN/H2O + 0.1%
TFA to 65% CH3CN/H2O + 0.1% TFA in 25 min) on an Agilent ZORBAX 300SB-C8 (5 μm, 9.4 × 250
mm) column. Cyclic oxytocin was analyzed and characterized by LC-MS (Shimadzu 8040). ESI-MS
expected m/z = 1048, observed m/z = [M+H+]+: 1048.
6.9.3 Synthesis of Oxytocin Conjugates
6.9.3.1 Synthesis of B12-DBCO (B12-DBCO)
B12-DBCO was prepared by combining B12 (25.0 mg, 0.018 mmol) with CDT (10.0 mg, 0.061
mmol) and allowed to stir for one hour at which time sulfo-DBCO-amine (25.0 mg, 0.059 mmol) and TEA
(50 μL) were added and stirred overnight to give the target compound, which was purified using RP-

HPLC (H2O + 0.1% TFA and MeOH from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O + 0.1%
TFA in 25 min) to produce B12-DBCO to 92% purity in 80 % yield. ESI-MS expected m/z = 1808,
observed m/z = [M+2H+]+2: 905 (Figures found in Chapter 7).
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6.9.3.2 Synthesis of B12-Oxytocin (B12-Oxy)
B12-Oxy was prepared by combining B12-DBCO (12.0 mg, 0.011 mmol) with cyclic
oxytocin (10.0 mg, 0.010 mmol) where the eighth residue, leucine, was substituted by an azido
modified lysine (OTaz). The B12-DBCO was linked to OTaz by dissolving both compounds in 4:1
DMF: H2O and allowing to rock at room temperature overnight to produce B12-Oxytocin (B12Oxy). B12-Oxy was purified using RP-HPLC (H2O + 0.1% TFA and MeOH from 1% CH3OH/H2O +
0.1% TFA to 90% CH3OH/H2O + 0.1% TFA in 25 min) to produce B12-OXY to 99% purity in
stochiometric yields. ESI-MS expected m/z = 2856, observed m/z = [M+2H+]+2: 1429, [M+3H+]+3:
953 (Figures found in Chapter 7).
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7. Ongoing and Future Work
7.1 Building on lead candidate 22 (Chapter 3)
As shown in Chapter 3, I was able to successfully design and synthesize a glucagon-like
peptide-1 (GLP-1) receptor agonist (GLP-1RA), 22, with reduced brain penetrance, but with
comparable binding, agonism, and pharmacodynamic profile to that of Exendin-4 (Ex4).1–3 While
in vivo tests were performed to investigate the function of 22, we did not examine how conjugate
site may affect the pharmacokinetic profile of this therapeutic compared to that of Ex4. Such an
investigation was performed on our initial Cbi-Ex4 construct, 1, which showed reduced plasma
clearance.2 This effect is predicted due to improved stability of the conjugate to proteolytic
activity, a feature previously demonstrated, or reduced renal clearance.1 This experiment should
be replicated to further explore 22.
To continue to improve 22 in an in vivo setting, further conjugation techniques may be
explored. Some current long acting GLP-1RAs, including liraglutide4–7 and semaglutide,4,5,7 utilize
lipidation to improve their pharmacokinetic profile allowing for once daily or once weekly
administration, respectively.4,7 Given our previous investigations into the pharmacokinetic (PK)
profile of Cbi-Ex4,2 it would not be capable of being delivered once weekly as a therapeutic. The
successful lipidation of 22 would provide such an opportunity. Current synthetic attempts have
been made to produce such a product. While previous investigations have been performed on
optimal locations of lipidation,8 none of these studies have looked at a system in which multiple
conjugations sites would be utilized. While 22 utilizes an additional amino acid to conjugate Cbi
to Ex4,3 lipidation would occur on the native Ex4 sequence. To determine the optimal location of
lipidation (C14, C16, C18 lipids) a structure activity relationship (SAR) experiment should be
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performed aimed at maintaining function at the GLP-1R and pharmacodynamic profile while
improving the therapeutics PK profile. Such a construct, with once weekly administration, would
be utilized for glucoregulation without nausea and emesis in individuals suffering from additional
diseases i.e., cystic fibrosis.9
In addition, the effects of small amphiphilic or flexible spacers placed between the lipid
and peptide backbone has proven highly important in successfully taking strong
pharmacodynamic leads and adding clinically relevant PK properties. Key linkers of choice here
would be the use of y-Glu monomers or dimers, with or without di-PEG units initially.10

7.2 Prebinding of Corrinated Conjugates to Human Haptocorrin for Improved Pharmacokinetics
The use of peptides as therapeutics offers specificity and often increased potency
compared to synthetic small molecules.11 However, peptides are often limited by their solubility
and short half-life.12,13 The short half-life of peptides is commonly attributed to the fact that they
are readily degraded by enzymes in vivo.12,13 To combat such issues amino acid substitutions or
further chemical modification is often utilized.14 Corrination offers additional avenues for
improved PK.1–3,15–19 The conjugation to corrins may be further exploited by prebinding to one of
the proteins found in the B12 uptake pathway.1 Previous work by Bonaccorso et al. showed that
a B12-Ex4 conjugate prebound to intrinsic factor was protected from proteolytic degradation and
maintained function in an in vitro assay.1 Haptocorrin (HC) has a half-life of 9-11 days and offers
an ideal target for selectively prebinding a corrin conjugate.20 An initial attempt was made to
explore this avenue, see chapter 3, which yielded a non-functional construct.2 Given our newly
identified conjugation site, K40 in Ex4, further investigations should be performed to determine
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if conjugation site effects the ability of the peptide to be prebound to a protein.3 An alternative
approach would be to perform an SAR with the aim of producing an optimal prebound construct.
Such a construct may not be the optimal construct while unbound to the protein but would once
bound by HC. Given HC’s ability to bind not only B12, but also other corrins, both B12, Cbi, and
possibly other corrin constructs may be utilized.21–23
7.3 The Future of Corrination
The use of corrination is little explored and to date has primarily focused on conjugates
of peptides.1–3,18,19 Corrination shows promise as a platform technology for conjugation to
therapeutics, especially if one seeks to target the peripheral nervous system while avoiding the
central nervous system. One such corrin of interest is Cbi, due to its high-water solubility (400
mg/mL),3 it offers the ability to improve therapeutics limited by their physical properties, one
such example is glucagon. To further maximize the potential that corrination offers, new avenues
should be investigated including, conjugation to small molecules.
While the ability of corrination to impact the use of the peptide therapeutics its
conjugation has application beyond protection from proteolytic degradation and solubility
improvements. Peptides conjugated to both B12 and Cbi have drastically diminished CNS
penetrance while maintaining function in the peripheral.2,3,18,19 Such a construct makes it an ideal
mechanistic tool for differentiating the function of a therapeutic at multiple activation sites. One
current avenue being explored is through the conjugation of oxytocin (Oxy) to B12.
7.3.1 Satiation Signaling via Vagal Oxytocin Receptors
A body of evidence indicates that the GIT generates several post-ingestive signals capable
of triggering satiation and suppression of central reward circuits. Oxy is well investigated and
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recognized for its role in bonding behaviors,24 but its role in energy homeostasis is much less
defined.25 To investigate the role oxy may play in this system a B12-Oxytocin (B12-Oxy) construct
was designed to target the oxy receptor expressed in the vagal afferents.26
7.3.1.1 Design, Synthesis, and Characterization of B12-Oxytocin (B12-Oxy)
The design and synthesis of a B12-Oxy construct had to consider the fact that oxy readily
binds copper metal in the “tail” portion of its structure. Thus, previously design B12 constructs
that utilized copper-catalyzed alkyne-azide cycloaddition (CuAAC) could not be utilized, and a
new “clickable” construct needed to be developed. I utilized a dibenzylcyclooctyne (DBCO) linker
to produce B12-DBCO linker with the aim of utilizing strained promoted alkyne-azide
cycloaddition (SPAAC) to produce a B12-Oxy.
7.3.1.2 Synthesis of B12-DBCO Linker
B12-Sulfo-DBCO-Amine (B12-DBCO) was synthesized by conjugating off the 5’ hydroxyl
group found in the ribose ring of the f-side chain of B12. The alcohol was activated with CDT at
40° C for 1 hour in DMSO then Sulfo-DBCO-Amine and triethylamine (TEA) was added, and the
reaction was stirred overnight to give the target compound (Figure 1), which was purified using
RP-HPLC (H2O + 0.1% TFA and MeOH from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O + 0.1%
TFA in 25 min) to produce B12-DBCO to 92% purity in 80 % yield (Figure 2). ESI-MS expected m/z
= 1808, observed m/z = [M+2H+]+2: 905 (Figure 3).
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Figure 1. Synthetic scheme for B12-DBCO. B12 was functionalized with a DBCO linker through
CDT activation of the 5’-alcohol of the f-sidechain.

Figure 2. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse XDB-C18 5μm,
4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O + 0.1% TFA in 25
min)) showing B12-DBCO linker product at 10.5 min. Purity 92%.
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Figure 3. ESI-MS (Shimadzu LCMS-8040) of B12-DBCO, expected m/z = 1808, observed m/z =
[M+2H]2+: 905.
7.3.1.3 Synthesis of B12-Oxytocin (B12-Oxy)
Utilizing strained promoted alkyne-azide cycloaddition (SPAAC), B12-DBCO was
successfully “clicked” to an azido modified oxytocin (OTaz) where the eighth residue, leucine,
was substituted by an azido modified lysine. The B12-DBCO was linked to OTaz by dissolving both
compounds in 4:1 DMF: H2O and allowing to rock at room temperature overnight to produce
B12-Oxytocin (B12-Oxy) (Figure 4). B12-Oxy was purified using RP-HPLC (H2O + 0.1% TFA and
MeOH from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O + 0.1% TFA in 25 min) to produce
B12-OXY to 99% purity in stochiometric yields (Figure 5). ESI-MS expected m/z = 2856, observed
m/z = [M+2H+]+2: 1429, [M+3H+]+3: 953 (Figure 6).
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Figure 4. Synthetic scheme for B12-Oxy. B12-DBCO was successfully “clicked” to OTaz utilizing
SPAAC.

Figure 5. RP-HPLC Trace (Shimadzu Prominence HPLC using a C18 column (Eclipse XDB-C18
5μm, 4.6 x 150 mm) (RP-HPLC, from 1% CH3OH/H2O + 0.1% TFA to 90% CH3OH/H2O + 0.1% TFA
in 25 min)) showing B12-Oxy product at 11.2 min. Purity 99%.
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Figure 6. ESI-MS (Shimadzu LCMS-8040) of B12-Oxy, expected m/z = 2856, observed m/z =
[M+2H+]+2: 1429, [M+3H+]+3: 953.
7.3.1.4 In Vivo investigations of B12-Oxy in Male and Female Rats
To date initial in vivo experiments have focused on examining the role peripheral oxy
plays in energy homeostasis. Following intraperitoneal (IP) injection, oxytocin was found to
induce a hypophagic effect both male and female rats. Female rats were more sensitive to oxy
administration, 250 µg/kg, than their male counterparts (Figure 7).

Figure 7. Peripherally administered, IP, oxytocin reduces food intake in male and female rats.
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Following the production of B12-Oxy (Figure 4) the hypophagic effects of oxytocin and B12-oxy
were examined. Following IP injection of equimolar, 0.5 mg/kg, oxy and B12-Oxy in female rats,
B12-oxy was shown to reduce food intake with prolonged duration and sensitivity compared to
that of unconjugated native oxy (Figure 8).

Figure 8. CNS penetrance is not required for the hypophagic effect of oxy. All rats receiving B12Oxy reduced food intake compared to their intake on vehicle (saline). Equimolar dose of oxy also
reduced food intake, with preliminary indication of a more potent and longer-lasting feeding
behavior impact of B12-OT.

These results support the notion that CNS penetrance is not required for the hypophagic effects
of oxy. This also suggests that the feeding control associated with oxy receptor (Oxy-R) agonism
is specific to the receptor population found on the vagal afferents and not populations
observed in the CNS.
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ABSTRACT: Corrination is the conjugation of a corrin ring containing molecule, such as
vitamin B12 (B12) or B12 biosynthetic precursor dicyanocobinamide (Cbi), to small
molecules, peptides, or proteins with the goal of modifying pharmacology. Recently, a
corrinated GLP-1R agonist (GLP-1RA) exendin-4 (Ex4) has been shown in vivo to have
reduced penetration into the central nervous system relative to Ex4 alone, producing a
glucoregulatory GLP-1RA devoid of anorexia and emesis. The study herein was designed
to optimize the lead conjugate for GLP-1R agonism and binding. Two speciﬁc conjugation
sites were introduced in Ex4, while also utilizing various linkers, so that it was possible to
identify Cbi conjugates of Ex4 that exhibit improved binding and agonist activity at the
GLP-1R. An optimized conjugate (22), comparable with Ex4, was successfully screened
and subsequently assayed for insulin secretion in rat islets and in vivo in shrews for
glucoregulatory and emetic behavior, relative to Ex4.

■

INTRODUCTION
The dramatic rise of type 2 diabetes (T2D) and obesity as
comorbidities has driven a concomitant rise in new
pharmaceutical interventions to treat such disorders, either
together or individually.1−7 One extremely successful family of
pharmaceuticals in this ﬁeld has been that of glucagon-like
peptide-1 receptor agonists (GLP-1RAs), 8−13 such as
exenatide (i.e., Exendin-4; Ex4), liraglutide,14−17 and semaglutide.16−18 Exenatide and liraglutide confer glucoregulation in
tandem with a body weight reduction of 5−6% over ∼1
year,16,17 while semaglutide can produce a weight loss of 10−
12% over the same time period.16,17 The hypophagic eﬀects of
all GLP-1RAs are however accompanied by nausea and
vomiting (emesis) in upward of 25% of patients,19−25 the
result of penetrance and direct action of the GLP-1RA in the
central nervous system (CNS), particularly in the nucleus
tractus solitarius and area postrema of the hind-brain.26−29
Thus, the development of a GLP-1RA that does not access the
CNS would be expected then to mitigate the side eﬀects of
nausea and emesis and reduce the hypophagic eﬀects. The
reasons for removing the side eﬀects are obvious, but less clear
is the fact that there is a current unmet clinical need to
broaden pharmacopoeia for certain subpopulations of T2D
patients, including lean individuals, those in a state of cachexia
(wasting of body tissues/chronic weight loss), or those who
must avoid weight loss from other life-threatening diseases
such as chronic obstructive pulmonary disease, cystic ﬁbrosis,
cancer, and HIV, among others.30−34 Thus, we set out to
create GLP-1RAs with reduced brain penetrance but with
© 2021 American Chemical Society

retained, comparable pharmacodynamic proﬁles on pancreatic
GLP-1R populations (Figure 1).35−39 Recently, we have taken
the approach of utilizing components of the vitamin B12 (B12)

Figure 1. Corrination of Ex4 (Cbi-Ex4) does not prevent GLP-1R
agonism in the pancreas but does mitigate agonism in the CNS as
tracked by emesis and anorexia.18 Ex4 alone agonizes GLP-1R
populations in both the pancreas and CNS.
Received: February 1, 2021
Published: March 6, 2021
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Scheme 1. Synthesis of Cbi Linkers (4−11) and Cbi-Peptide Conjugates (12−27). Linkers 3A−3H are shown in Figure 2

Figure 2. (Left) Structure of the dicyanocobinamide (CN2Cbi) starting material, a purple solid prepared via microwave chemistry from B12, with
the hydroxyl group boxed used as a site of conjugation to linker series. (Right) Library of linkers used in the conjugation of Cbi to Ex4 peptides.
The library of linkers chosen in this study included short hydrophobic alkane chains, amphiphilic PEG, and rigid substituted ethynyl phenyl
methanamines, which were coupled to the Cbi hydroxyl group via CDT-mediated amide formation, resulting in Cbi compounds (4−11) with an
available alkyne group for subsequent reaction with azido-modiﬁed Ex4 peptides via copper-mediated alkyne-azide click chemistry (Scheme 1).

emesis41,42 and responsive to GLP-1R targeting therapeutics.39,43,44 Our data showed that Cbi-Ex4 enhanced the
glucoregulatory response following an intraperitoneal glucose
tolerance test (IPGTT), without producing hypophagia,
anorexia, body weight loss, and, more importantly, without
emesis, all characteristics of classical Ex4-based therapies.39
We hypothesized that these results are due to reduced drug
penetrance into the CNS (see Figure 1).35−39 This proof-ofconcept corrinated Ex4 (1) was, however, notably less potent
an agonist for the GLP-1R than Ex4 alone (200 vs 30 pM,
respectively, in the same GLP-1R FRET assay).39 With that in
mind, we set out to optimize 1 in terms of receptor binding
and agonism for the purposes of future translation. As such,

dietary uptake pathway including that of the corrin ring
containing B1235−38,40 itself as well as B12 precursors such as
dicyanocobinamide (Cbi)39 in a process we have coined
“corrination”. The beneﬁts of corrination over other
conjugation modes lie in the ability to speciﬁcally target
select corrin binding proteins such as intrinsic factor,
transcobalamin, or haptocorrin for use in targeting or to
aﬀect pharmacokinetics, modify solubility, and alter drug
localization, all without having to reverse the process to allow
for maintained drug function (pending suitable design). Our
recent report explored the conjugation of Cbi with Ex4, to
produce Cbi-Ex4 (1),39 and its eﬀects were tested in vivo in
the musk shrew (Suncus murinus), a mammal capable of
3480
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Figure 3. Eﬀect of Cbi conjugation on the secondary structure of Ex4 or Ex40. CD spectra were collected with a sample concentration of 40 μM
at pH 7 between 200 and 250 nm. % helicity was measured at 222 nm.

was produced in-house via microwave-assisted reaction of B12
with sodium cyanide in EtOH as previously described.59 The
purple dicyanocobinamide (CN2Cbi) produced was then
activated with an excess of 1,1′-carbonyl-di-(1,2,4-trizole)
(CDT) in dry N-methyl-2-pyrrolidone (NMP) and heating at
40 °C under argon for ∼10 min or until complete dissolution
was observed. Upon dissolution, a speciﬁc linker (Figure 2;
3A−3H) was added in large excess (20×) relative to the
activated CN2Cbi along with triethylamine (TEA), and the
reaction was allowed to proceed for 1 h, again at 40 °C under
argon with stirring. Initially, it was observed via RP-HPLC
tracking on a C18 column (data not shown) that the reaction
proceeded slowly, so in subsequent experiments, a second
equivalent of linker (20×) and TEA were added at the 1 h
time point and the reaction was allowed to proceed, as before,
for an additional hour. Based on the additional step, yields for
all Cbi-linkers were in the 30−50% range with facile
puriﬁcation to produce the Cbi-Linkers (4−11) with purities
at, or in excess of, 97% (as tracked by RP-HPLC; see the
Supporting Information). It should also be noted, and such is
indicated in the color scheme used in Scheme 1 for the corrin
rings, that a color change was observed upon formation of the
Cbi-linkers, going from purple to orange upon puriﬁcation of
the Cbi-linkers in water. This color change was previously
reported by Zhou and Zelder60 and assigned to the formation
of isomers, namely, α-cyano-β-aqua- and α-aqua-β-cyano-Cbi
(as indicated in Scheme 1). This suggestion of isomer
formation was supported by the HPLC traces of the linkers,
which clearly showed the presence of both isomers
(subsequently conﬁrmed by nuclear magnetic resonance
(NMR); Figure S7). Given the fact that such isomers were
not expected to negatively aﬀect the subsequent chemistry or
biology, isomers were combined prior to peptide coupling and
were characterized via NMR, electrospray ionization-mass
spectrometry (ESI-MS), and electronic absorption spectroscopy (EAS).
Coupling of 4−11 with K12-azido- or K40-azido-modiﬁed
Ex4 (noted throughout here simply as Ex4 or Ex40) to
produce conjugates 12−27 was achieved via copper(I)mediated alkyne-azide cycloaddition over 16 h at room
temperature in a 4:1 dimethylformamide (DMF)/H2O solvent
system in the presence of the tertiary amine tris((1-benzyl-4triazolyl)methyl)amine (TBTA) to stabilize copper(I).61
Yields obtained were quantitative based on the starting
peptide, and all conjugates were produced to at least 97%

we needed to synthesize and characterize a new library of CbiEx4 conjugates. Of note here is that there is a dearth of
synthetic cobinamide chemistry in the literature, mostly
focusing on the novel cobinamides to treat hydrogen
sulﬁde45,46 or cyanide poisoning,47−54 and even less so in
terms of conjugation chemistry (an excellent exception being
that from the Gryko group using Cbi-PNA);55 hence, we
wanted to produce Cbi-linkers that would be readily amenable
to conjugation to Ex4 but indeed any targeted peptide moving
forward. Here, we report a set of 16 new constructs (12−27)
conjugated between Cbi and Ex4 at two positions (K12 and
K40) by various linkers with a set of diverse chemical
properties including hydrophobicity, amphiphilicity, and
rigidity. The successful design and synthesis lead to the
production of a new series of corrinated Ex4 constructs with
comparable agonism and binding to unconjugated Ex4. One
of these conjugates (22) displayed equipotency and binding at
the GLP-1R in vitro and was subsequently selected for ex vivo
screening for insulin secretion in rat islets and in vivo in
shrews for glucoregulation, food intake, body weight, and
emesis, compared to Ex4 and 1.

■

RESULTS AND DISCUSSION
Design. Our initial report on the eﬀects of corrination on
Ex4 included evidence for glucoregulation without emesis nor
a reduction in food intake.39 In these subsequent studies, we
have looked to optimize 1 with a focus on agonism and
binding at the GLP-1R while also expanding to the little
explored chemistry pertaining to the synthesis of Cbi
conjugates. As such, the structure−activity data presented in
these studies integrates synthesis, receptor agonism, receptor
binding, ex vivo insulin secretion, in vivo glucoregulation,
emetic response, and food intake to explore the role of the
peptide conjugate site (Scheme 1) and/or the role of a
speciﬁc set of spacers (linkers) as shown in Figure 2. In terms
of the linkers, there are three subsets that were chosen to
sample space across particular structural features, namely,
steric, hydrophobic, and amphiphilic. The Ex4 conjugate site
was restricted to K12 and a K40 residue added to the Cterminus of Ex4 (Ex40) since both sites were proven to be
amenable to modiﬁcation with minimal loss of function in our
hands35−39 and in prior literature.56−58
Chemistry. The Cbi linker compounds (4−11) and Ex4
conjugates of such (12−27) amounted to a library of 32
compounds. The experimental details are shown in Scheme 1,
with linkers (Figure 2) indicated as R-groups. Initially, Cbi
3481
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Table 1. EC50 and IC50 Values with Hill Slopes and % Helicity of Cbi Conjugates 12−27
Ex4
12
13
14
15
16
17
18
19
Ex40
20
21
22
23
24
25
26
27

EC50 (pM)a

EC50 Hill slopeb

% helicityc

IC50 (nM)d

IC50 Hill slopee

12.5 ± 3.7
75.4 ± 4.1
105.6 ± 4.1
33.2 ± 4.4
38.9 ± 15.6
34.1 ± 9.7
36.5 ± 7.6
40.5 ± 17.1
31.2 ± 16.9
10.4 ± 3.9
13.4 ± 4.2
37.8 ± 11.5
20.7 ± 8.3
10.7 ± 6.0
16.4 ± 3.1
26.0 ± 14.1
27.9 ± 4.2
23.1 ± 7.1

1.1970
0.9110
1.0100
1.4170
1.0470
0.9976
1.0980
1.3030
1.1130
1.1160
1.1890
1.1830
1.2090
1.0120
1.1370
0.9817
0.9957
1.2130

24.3
39.2
26.9
29.0
20.5
24.4
41.6
33.1
45.6
33.1
28.1
29.8
36.6
31.0
33.1
28.9
34.4
29.3

5.98 ± 0.94
24.6 ± 6.3
135 ± 122.5
79.5 ± 28.8
82.7 ± 15.4
36.5 ± 16.0
45.9 ± 16.3
34.3 ± 11.9
11.6 ± 2.4
7.34 ± 1.37
26.2 ± 6.3
21.4 ± 8.0
11.9 ± 2.5
27.2 ± 6.3
15.1 ± 4.1
18.5 ± 4.6
26.4 ± 8.0
24.6 ± 6.3

−1.3010
−1.1170
−0.5661
−0.7858
−1.6990
−1.1770
−1.1740
−1.1530
−1.1270
−0.9107
−1.1350
−0.8940
−1.3970
−1.1780
−1.2540
−1.0840
−1.2370
−1.2790

a
Data represents EC50 obtained using nonlinear regression analysis of data from highest FRET values obtained for each data point. Experiments
were performed as three independent runs. bData represents the Hill slope obtained using nonlinear regression analysis of data from highest FRET
values obtained for each data point. Experiments were performed as three independent runs. cData represents mean residue ellipticity [θ]222
determined from the CD spectra of a 40 μM solution of peptide in H2O at RT pH 7.0. Average [θ]222 values utilized to calculate percent helicity
were obtained by performing the experiment in triplicate. Percent helicity was calculated using 100 × ([θ]222/max[θ]222). max[θ]222 = −40,000 [1 −
(2.5/n)], where n is the residue number. Experiments were performed as three independent runs. dData represents IC50 values obtained from
competitive binding assays against red ﬂuorescent GLP-1 using nonlinear regression analysis from highest values obtained for each data point.
Experiments were performed as two independent runs. eHill slopes were obtained using nonlinear regression analysis from highest values obtained
for each data point. Results are expressed as mean ± SEM.

Figure 4. Conjugation of Cbi to Ex4 or Ex40 peptides maintains agonism at the GLP-1R. Nonlinear regression analysis was performed with
GraphPad Prism 8. All compounds were assayed at least as triplicate independent runs. Data are shown as mean ± SEM.

purity prior to biological or in vivo evaluation (as tracked by
RP-HPLC; shown in the Supporting Information).
Structural Studies Using Circular Dichroism (CD). All
conjugates were investigated for the eﬀects of corrination on
helicity at a concentration of 40 μM in water at pH 7.0
(Figure 3). Immediately, it was evident that there was minimal
variation in percent helicity whereupon the Cbi was
conjugated at the Ex4 C-terminal K40 (20−27; % helicity
ranged from ∼28 to 36%; Ex40 control 33.1%; Table 1).
There was however a noticeable variation in the percent
helicity for the conjugates (12−19) whereupon Cbi was
conjugated to the K12 within the Ex4 helix (% helicity range
∼20−46%; Ex4 control 24.3; Table 1). These results are
consistent with the fact that conjugation at the C-terminus
renders less consequence to the linker type or spacer distance

between Cbi and the peptide, given that this region is away
from the helical region of Ex4 and does not interfere with the
role of this region with receptor binding/agonism. The
variation noted upon conjugation at the K12 residue renders
the linker critical with the highest % helicity noted as 41%
with the amphiphilic PEG spacer 3F (Figure 2, Table 1) and
the lowest percent helicity noted with the small alkyl spacers
3B−3D (Figure 2, Table 1). No overall correlation between
the structure and agonism or binding was observed upon data
ﬁtting (not shown).
Biological Evaluation. To determine how the conjugation site of the peptide aﬀects its function and the role linker
choice plays in the attachment of the peptide to Cbi, we
sought to screen 12−27 utilizing in vitro assays to determine
potency and binding at the GLP-1R.
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In Vitro Functional Agonism (EC50) at Human GLP1R. Our previously published39 Cbi-Ex4 construct 1 resulted
in agonism at the GLP-1R with an EC50 of 200 pM. The
design of the newly constructed conjugates, 12−27, aimed to
increase the potency of the original construct to that
comparable of unconjugated Ex4 (<30 pM). 12−27 were
assessed utilizing in vitro screening in HEK C20 cells stably
expressing the human GLP-1R and cAMP FRET reporter
H188 produced in-house (see Methods).62,63 To determine if
the azido modiﬁcation to lysine at position K12 (Ex4) or the
addition of this residue to position 40 (Ex40) had any eﬀect
on agonism at GLP-1R, they were also screened for agonism
to compare with native Ex4 (nEx4; no azido modiﬁcations),
resulting in EC50 values of 20 pM for nEx4, 12.5 ± 3.7 pM for
Ex4, and 10.4 ± 3.9 pM for Ex40 (Table 1). All newly
synthesized compounds were functional at the GLP-1R with
improved potency in all cases (EC50 range 13.4 ± 4.2 to 105.6
± 4.1 pM) to that of our previously reported construct 1 (200
pM; Table 1 and Figure 4). In general, the Ex4 conjugates
12−20 were inferior to the Ex40 conjugates (20−27) and
displayed greater variance, with EC50 values ranging from 31
to 106 pM for 12−19 compared to 13 to 38 pM for 20−27.
As with the variance observed in the folded state for 12−19, it
is likely that proximity and/or interactions of the Cbi moiety
to the helix interferes with receptor binding and/or
interactions necessary for agonism. Conjugations performed
at the C-terminal end of the peptide would be expected to
place the corrin ring away from such residues as we have
shown previously with B12 conjugates of the neuropeptide
PYY3−36.38 One Cbi-Ex4 conjugate however (19), which
bridged Ex4 at the K12 residue with Cbi through one of the
hydrophobic, rigid linkers (3H), was shown to be equipotent
to Ex4 with an EC50 value of 31.2 ± 16.9 pM and an IC50 of
11.6 ± 2.4 nM (compared to 5.98 ± 0.94 nM for Ex4 alone;
Table 1). All Ex40-based conjugates (20−27) were shown to
be equipotent to the unconjugated peptide. Such results are
consistent with the fact that addition of, and conjugation to,
the K40 residue is optimal when conjugating Cbi to Ex4.
In Vitro Competitive Binding (IC50) at Human GLP1R. As shown in Table 1, the presence of Cbi inﬂuences the
ability of the conjugate to agonize the GLP-1R compared to
that of Ex4 or Ex40. To further investigate how conjugation of
Cbi aﬀects Ex4 or Ex40, a series of competitive binding assays
against GLP-1red (a red ﬂuorescent analog of GLP-1) were
conducted. nEx4 was utilized as a reference competitor with
an IC50 value of 4.97 nM. We ﬁrst aimed to determine if the
azido modiﬁcation to lysine at position K12 and the addition
of this residue to position 40 had any eﬀect on binding. It was
found that both Ex4 and Ex40 had comparable binding to that
of the reference compound with IC50 values of 5.98 ± 0.94
and 7.34 ± 1.37 nM, respectively. All conjugates had
decreased binding (12−135 nM) compared to the unconjugated peptide azido-modiﬁed Ex4 (6 nM) and Ex40 (7 nM)
and nEx4 controls (5 nM). When comparing the two clusters
of conjugates, 20−27 showed greater binding aﬃnity overall
compared to 12−19. The same trend was observed when
agonizing the GLP-1R (Table 1) in which collectively 20−27
outperformed 12−19. Two constructs, namely, 19 and 22, did
show promising binding with IC50 values of 11.6 ± 2.4 and
11.9 ± 2.5 nM, respectively. The increased binding observed
in these two conjugates was consistent with their agonism (31
± 16.9 and 20.7 ± 8.3 pM, respectively) of the GLP-1R.
Based on overall binding potent agonism, facile synthesis, and
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high yield observed for 22, especially related to those of 19,
we chose to further investigate 22 in ex vivo and in vivo
experiments.
Glucose-Stimulated Insulin Secretion (GSIS) in Rat
Pancreatic Islets. The eﬀects of 22 on GSIS were evaluated
using rat pancreatic islets (Figure 5). At 10 mM glucose, both

Figure 5. 22 increases glucose-stimulated insulin secretion in rat
islets relative to glucose controls. Insulin secretion rate from static
cultures of Sprague−Dawley rat islets incubated in media containing
glucose (10 mM) and Ex4 (10 or 50 nM) or 22 (10 or 50 nM). Data
was calculated from three independent experiments and analyzed
with repeated-measurements two-way ANOVA followed by Tukey’s
posthoc test. Results are expressed as mean ± SEM, **** p <
0.0001.

22 and nEx4 increased GSIS in a dose-responsive manner.
The eﬀect from 22 was observed to be one-third lower than
that of nEx4. To investigate whether there was a diﬀerence
between Ex40 and 22, speciﬁc to the rat GLP-1R, we assayed
each for functional (EC50) agonism. We observed a slight
drop-oﬀ in potency with EC50 values of 7.8 and 22 pM
recorded for Ex40 and 22 (Figures S106−S111), respectively.
nEx4 control had an EC50 of 48 pM at the rat GLP-1R.
In Vivo Functional Experiments. To functionally
compare the activity of the corrinated conjugates in vivo, we
ﬁrst tested the eﬀects of Ex4, 1 (the original proof-of-concept
conjugate),39 and 22 on plasma glucose levels following an
IPGTT in shrews. A shrew is a mammal capable of emesis41,42
with published sensitivity to GLP-1RAs39,43,44 and the same
serum B12 binding proteins (IF and Haptocorrin) as that
found in humans39 and thus was considered an ideal model
for the in vivo studies. We observed that shrews treated with 1,
22, or nEx4 display similar improvements in glucose handling
following glucose load compared to vehicle controls (Figure
6A). Posthoc analyses showed that all three compounds
signiﬁcantly suppressed blood glucose (BG) at 20 and at 40
min after glucose administration versus vehicle treatment (all
p < 0.001). Remarkably, BG values at 20 min post glucose
injection in animals receiving 22 were signiﬁcantly lower than
those in animals treated with 1, denoting an improved glucose
tolerance/superior pharmacological eﬃcacy (p < 0.01).
Additionally, the variation in plasma glucose concentrations,
represented as area under the curves (0−60′ and 0−120′,
respectively) for 22, did not diﬀer from nEx4 and were
signiﬁcantly lower than controls (Figure 6B,C, all p < 0.05).
We then analyzed the eﬀects of 1, 22, and Ex4 on food
intake and body weight at a single, proof-of-concept, dose, in
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Figure 6. Cbi-Ex4 enhances glucose clearance without inducing emesis or body weight loss. (A) In an IPGTT, Ex4, 1, and 22 (50 nmol/kg, IP)
showed similar potency in suppressing BG levels after glucose administration (2 g/kg, IP) compared to saline; vehicle vs 1: *** P < 0.001; vehicle
vs 22: ### P < 0.001; vehicle vs Ex4: §§§ P < 0.001; 1 vs 22: ΦΦ P < 0.01 (n = 12 shrews). (B) Area under the curve (AUC) analysis from 0
(i.e., post-glucose bolus) to 60 min following 1, 22, and Ex4. (C) AUC analysis from 0 to 120 min; 22 and Ex4 similarly reduced AUCs
compared to vehicle (P < 0.05). (D) Ex4 and 22 (5 nmol/kg, IP) induced anorexia at 6, 24, and 48 h (and at 72 h for Ex4 only), whereas 1 had
no eﬀect on food intake (n = 10). (E) Ex4-induced anorexia was accompanied by signiﬁcant body weight loss at 24 h. No signiﬁcant changes in
body weight occurred after 1 and 22 administration compared to controls. (F) The number of single emetic episodes following Ex4, 1, 22, or
saline systemic administration was recorded for 120 min. The number of animals exhibiting emesis, expressed as a fraction of the total number of
animals tested, is indicated above each treatment group. Ex4 induced robust emetic responses that were not observed after 1 or saline injections.
22 induced emesis in two of the animals tested; however, the number of emetic episodes was signiﬁcantly lower than that of Ex4 and did not
diﬀer from animals treated with vehicle or 1 (n = 10). (G) Heatmaps showing latency, number, and intensity of emesis following Ex4, 1, and 22
dosing for each individual animal across time. All data expressed as mean ± SEM (n = 10). Data in panels (A), (D), and (E) were analyzed with
repeated-measurements two-way ANOVA followed by Tukey’s posthoc test. Data in panels (B), (C), and (F) were analyzed with repeatedmeasurements one-way ANOVA followed by Tukey’s posthoc test. Means with diﬀerent letters are signiﬁcantly diﬀerent (P < 0.05).

line with previous reports. 35−37,39 Ex4 administration
produced anorexia in shrews at all measured time points
(Figure 6D), while 1 had no impact on feeding. 22 treatment
suppressed food intake similar to Ex4 at 6, 24, and 48 h. The
anorectic eﬀect of Ex4 treatment was paralleled by a
signiﬁcant reduction in body weight at 24 h (p < 0.05),
which was not observed following treatment with 1 or 22
(Figure 6E).

To test whether 22 treatment retained the non-emetic
properties of the lead conjugate 1, indicative of an altered
pharmacodynamic proﬁle, despite its comparable potency and
GLP-1R binding aﬃnity compared to 1, and comparable to
nEx4, we compared the emetogenic properties of 1, 22, and
native Ex4 in shrews. Ex4 induced profound emesis in the
majority of the shrews tested (Figure 6F). Indeed, 80% of the
animals exhibited emesis upon administration of native Ex4
within minutes after injection (29 ± 16 min). In line with a
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were analyzed for mass using a Shimadzu LCMS-8040. 1H NMR and
13
C NMR spectra were acquired on a Bruker NMR spectrometer
(Avance 400 MHz) in D2O at a D1 of 3 for all compounds. EAS was
collected on a Varian Cary 50bio UV−visible spectrophotometer in a
1 mL quartz cuvette with baseline correction. CD spectra were
recorded with a Jasco J-715 circular dichroism spectropolarimeter in
40 μM H2O in a 0.1 cm quart cuvette. Data was analyzed and ﬁt
using GraphPad Prism 8.0. We established a new clone of HEK293
cells designated here as HEK293-GLP-1R-H188-C20. This clone was
obtained by G418 antibiotic resistance selection after cotransfection
of cells with the human GLP-1R and the cAMP FRET reporter
H188. Cells were grown in a Memmert Incubator I (Schwabach,
Germany) at 37 °C gassed with 5% CO2 at ∼95% humidity. FRET
assays were conducted utilizing a Molecular Devices FlexStation 3
Multi-Mode Microplate Reader. Data was analyzed utilizing
Molecular Devices SoftMax Pro v.5.4.6. Linear regression analyses
were performed utilizing GraphPad Prism 8.
Materials. The following were purchased from Sigma Aldrich:
acetonitrile (Cat # 14851), diethyl ether (Cat # 673811), ethanol
(Cat # 459844), ethyl acetate (Cat # 319902), isopropyl alcohol
(Cat # 34863), methanol (Cat # 34885), n-methyl-2-pyrrolidone
(Cat # 328634), triethylamine (Cat # 8.08352), vitamin B12 (Cat #
V2876), sodium cyanide (Cat # 205222), 1,1′-carbonyl-di-(1,2,4trizole) (Cat # 21863), propargylamine (Cat # P50900), 1-amino-3butyne (Cat # 715190), 4-pentyne-1-amine (Cat # 779407), hex-5yne-1-amine (Cat # COM497512576), bovine serum albumin (Cat #
A7030), Dulbecco’s modiﬁed Eagle medium (Cat # D6429), fetal
bovine serum (Cat # 12303C), G-418 disulfate salt solution (Cat #
G8168), and HEPES (Cat # H0887). The following were purchased
from ThermoFisher Scientiﬁc: penicillin−streptomycin (Cat #
15140122) and trypsin−EDTA (Cat # 25200072). The following
were purchased from Fisher Scientiﬁc: calcium chloride dihydrate
(Cat # BP510), magnesium chloride hexahydrate (Cat # BP214),
potassium chloride (Cat # BP366), and sodium chloride (Cat #
BP358−1). The following were purchased from BroadPharm:
propargyl-PEG2-amine (Cat # BP22519) and propargyl-PEG4amine (Cat # BP22520). The following were purchased from
Enamine: (4-ethynylphenyl)methanamine (Cat # EN300−233648)
and (3-ethynylphenyl)methanamine (Cat # EN300−248722). KrebsRinger Bicarbonate (KRB) buﬀer was prepared as described
previously.68 D-Glucose (Cat # G 5767) and nEx4 (Cat # E7144)
were purchased from Sigma-Aldrich. Ex4 K12-azido and Ex40 K40azido were produced by Genscript (Piscataway, New Jersey, United
States). The rat insulin radioimmunoassay (RIA) kit was purchased
from Millipore Sigma, Burlington, MA Cat no. RI-13 K. The human
GLP-1R plasmid was provided by M. Beinborn, Tufts University
School of Medicine to author G.G.H.62 The H188 plasmid was
provided by K. Jalink, Netherlands Cancer Institute to authors
G.G.H. and R.P.D.63
Methods. Synthesis of Dicyanocobinamide (Cbi) (2). The
synthesis of dicyanocobinamide (Cbi) was performed according to
previously reported methods.59 Brieﬂy, to a 10 mL microwave
reaction vessel containing a magnetic stir bar were added B12
(cyanocobalamin) (303.8 mg, 0.225 mmol) (see Figures S1−S6),
sodium cyanide (NaCN) (36.9 mg, 0.7096 mmol), and 5 mL of
EtOH, and the vessel was sealed. The reaction was heated to 120 °C
for 10 min. Following completion of the microwave reaction, the
remaining solution was transferred and diluted using isopropyl
alcohol (iPrOH). The reaction was puriﬁed utilizing a normal-phase
silica column. The reaction was eluted using 100% methanol
(MeOH). The product eluted as a purple product. The isolated
product was precipitated utilizing diethyl ether (Et2O) and allowed
to dry producing a solid, purple product, 2 (see Figure 2), in 80%
yield (187.4 mg, 0.1795 mmol). Solubility was measured to be 400
mg/mL in distilled water. 2 was puriﬁed by RP-HPLC as described
for method A1, to 98%; tR: 5.2 and 6.7 min; ESI-MS expected m/z =
1042, observed m/z = [M−CN]+1 1016. 1H NMR (400 MHz, D2O):
δ 5.90 (s, 1H), 3.95−3.87 (m, 1H), 3.85 (d, J = 8.4. Hz, 1H), 3.75
(d, J = 10.4 Hz, 1H), 3.41 (m, 1H), 3.36 (s, 5H), 3.30 (m, 2H), 3.25
(d, J = 4.7 Hz, 1H), 3.17 (dd, J = 6.8, 6.9 Hz, 1H), 2.92−2.86 (m,

previous report, treatment with 1 did not cause emesis in any
of the shrews tested.39 Importantly, the number of single
emetic episodes occurring in the 120 min window after drug
administration was also signiﬁcantly reduced after 22
administration compared to Ex4 and did not diﬀer from
vehicle- or 1-treated groups. Only two animals that received
22 experienced emesis with an average latency of 70 ± 29
min. The greater emetic eﬀect observed for 22 over 1 is likely
a consequence of the greater binding and agonism of 22 at the
GLP-1R, an eﬀect that is likely to be mitigated, without loss of
glucoregulation, by use of lower doses of 22 (on-going work).
The diﬀerence in the emetogenic proﬁles of the corrinated
constructs versus native Ex4 is further emphasized by the
graphical visualization of emetic intensity, recurrence, and
latency for each individual animal across time (Figure 6G).

■

CONCLUSIONS
Neuroendocrine associated pharmacological side eﬀects such
as nausea and emesis are often downplayed or dismissed, left
in the shadow of the overriding target, be it glucoregulation,
weight loss, etc. Indeed, the weight loss gleaned from GLP1RAs, for example, has proven to be a beneﬁcial “side eﬀect”
of T2D treatment due to the high comorbidity of T2D with
obesity.64 In many cases, however, such as lean T2D patients,
or patients with comorbidities where nutritional status is
critical (cystic ﬁbrosis, cancer-cachexia, sarcopenia, chronic
obstructive pulmonary disease, etc.), removal of the CNSassociated side eﬀects would be greatly beneﬁcial. Indeed,
GLP-1RAs have proven to be life-altering, and the ability to
expand their use, or increase patient compliance when using,
should not be understated. Herein, we conceived 16 new CbiEx4/Ex40 conjugates with the aim of designing a construct
with equipotent binding and agonism of the GLP-1R to that
of Ex4 with a view of maintaining activity at peripheral GLP1R populations and mitigating such activity in CNS
populations. We were able to successfully design several
constructs with comparable binding and agonism at GLP-1R
as Ex4, with one conjugate, 22 (IC50 11.9 ± 2.5 nM, EC50
20.7 ± 8.3 pM), translated into ex vivo and in vivo studies. 22
increased glucose secretion compared to vehicle controls in a
glucose-dependent insulin secretion assay in rat islets. In an in
vivo IPGTT, 22 provided glucoregulation comparable to Ex4.
Critically, 22 showed a near absence of emesis and mild body
weight lowering actions compared to profound emesis and
body weight loss observed for nEx4.
While corrination is poorly explored, especially as it pertains
to applications that seek to prevent CNS penetration while
maintaining peripheral activity of a target drug, it shows
considerable promise as a platform technology, moving
beyond GLP-1RAs. An additional highlight of Cbi is its
water solubility (400 mg/mL), akin to glucose (450 mg/mL).
Use of Cbi conjugation with drugs with physical properties
not suited to drug development, such as glucagon65−67 for
rescue of hypoglycemia, oﬀers a great scope for exploration.

■

Article

EXPERIMENTAL SECTION

General Considerations. All commercial reagents and anhydrous solvents purchased were used without further puriﬁcation. All
reactions containing air- and/or moisture-sensitive reactants were
performed under argon. Compounds were puriﬁed using a Shimadzu
Prominence HPLC using a C18 column (Eclipse XDB-C18 5 μm,
4.6 × 150 mm). All compounds had purities at, or in excess of, 97%
(as tracked by RP-HPLC; see the Supporting Information). Products
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1H), 2.75−2.73 (m, 2H), 2.65−2.39 (m, 7H), 2.32−2.26 (m, 15H),
2.19−2.08 (m, 5H), 2.03−1.95 (m, 1H), 1.91−1.76 (4H), 1.69 (s,
3H), 1.54 (s, 3H), 1.50 (s, 3H), 1.44 (s, 3H), 1.32 (s, 3H), 1.19 (s,
4H), 1.16 (d, J = 6.4 Hz, 4H). 13C NMR (400 MHz, D2O): 178.6,
178.4, 177.9, 177.5, 177.3, 176.8, 175.1, 175.0, 172.1, 163.4, 162.9,
105.1, 103.1, 91.0, 83.1, 75.0, 66.2, 64.2, 58.8, 56.3, 55.2, 53.2, 49.2,
48.9, 46.8, 46.3, 46.1, 43.7, 42.2, 39.0, 34.9, 32.5, 32.4, 31.9, 31.7,
31.5, 30.5, 26.6, 25.7, 24.9, 23.8, 21.7, 19.4, 18.7, 18.5, 17.4, 16.5,
15.1, 14.8. See Figures S7−S11.
General Procedure for Cobinamide Linker Coupling. To a 5 mL
round bottom ﬂask containing a stir bar were added 2 (15.8 mg,
0.0152 mmol) and 1 mL of NMP, and the solution was allowed to
stir at 40 °C under argon until the starting material was fully
dissolved. To the stirring solution of 2 was added CDT (51.4 mg,
0.313 mmol, ∼20 equiv.), and the solution was allowed to stir for 1 h
at which time one of the 3A−3H (see Figure 2) (19.2 μL, 16.5 mg,
0.300 mmol, ∼20 equiv.) and triethylamine (TEA) (50 μL) were
added. Upon stirring for an additional hour, a second equivalent of
linker (3A−3H) and TEA were added, and the solution was stirred
for 1 h. The reaction was then poured into ethyl acetate (AcOEt)
(50 mL) and centrifuged (5 min, 4000 rpm, RT). The crude solid
was redissolved in a minimal amount of MeOH (∼5 mL) and
precipitated with diethyl ether (Et2O) and centrifuged. The crude
product was redissolved in 1 mL of deionized (DI) H2O and puriﬁed
utilizing RP-HPLC as described below.
HPLC Puriﬁcation Methods. 4−27 were puriﬁed using a
Shimadzu Prominence HPLC using a C18 column (Eclipse XDBC18 5 μm, 4.6 × 150 mm). Two diﬀering puriﬁcation methods were
used: A1, H2O + 0.1% TFA and MeOH from 1% CH3OH/H2O +
0.1% TFA to 90% CH3OH/H2O + 0.1% TFA in 25 min; A2, H2O +
0.1% TFA and CH3CN from 1% CH3CN/H2O + 0.1% TFA to 70%
CH3CN/H2O + 0.1% TFA in 15 min.
Cbi-Propyne (4). 4 was prepared according to the general
procedure described above, combining 2 (16.8 mg, 0.0161 mmol)
with CDT (51.4 mg, 0.3000 mmol) and stirring the solution for 1 h
at which time 3A (19.2 μL, 16.5 mg, 0.300 mmol) and TEA (50 μL)
were added and stirred for 1 h after which point a second equivalent
amount of 3A and TEA were added and allowed to stir for 1 h to
give the target compound, which was puriﬁed using RP-HPLC
method A1 to produce 4 as an orange solid to 97% purity. Yield 43%
(7.8 mg, 0.007 mmol). The product obtained was in the form of two
diﬀerent isomers with the aquo-group located on the alpha and beta
positions (α-cyano-β-aqua- and α-aqua-β-cyano-). tR: 8.8 and 9.5
min; ESI-MS expected m/z = 1115, observed m/z = [M+−H2O]+1:
1096, [M+−H2O + H+]+2: 549. 1H NMR (400 MHz, D2O): δ 6.50
(1H, s, Ar-H, β-aqua isomer) 6.42 (1H, s, Ar-H, α-aqua isomer).
EAS Ext Coeﬀ354 = 14,500 M−1 cm−1. See Figures S18−S22.
Cbi-Butyne (5). 5 was prepared according to the general procedure
described above, combining 2 (20.5 mg, 0.0197 mmol) with CDT
(61.3 mg, 0.3740 mmol) and stirring the solution for 1 h at which
time 3B (32.0 μL, 27.0 mg, 0.391 mmol) and TEA (50 μL) were
added and stirred for 1 h after which point a second equivalent of 3B
and TEA were added and allowed to stir for 1 h to give the target
compound, which was puriﬁed using RP-HPLC method A1 to
produce 5 as an orange solid to 95% purity. Yield 53% (11.4 mg,
0.010 mmol). The product obtained was in the form of two diﬀerent
isomers with the aquo-group located on the alpha and beta positions
(α-cyano-β-aqua- and α-aqua-β-cyano-). tR: 7.4 and 7.9 min; ESI-MS
expected m/z = 1129, observed m/z = [M+−H2O]+1: 1111, [M+−
H2O + H+]+2: 556. 1H NMR (400 MHz, D2O): δ 6.49 (1H, s, Ar-H,
β-aqua isomer) 6.42 (1H, s, Ar-H, α-aqua isomer). EAS Ext Coeﬀ354
= 19,804 M−1 cm−1. See Figures S29−S33.
Cbi-Pentyne (6). 6 was prepared according to the general
procedure described above, combining 2 (17.3 mg, 0.0166 mmol)
with CDT (49.1 mg, 0.299 mmol) and stirring the solution for 1 h at
which time 3C (29.0 μL, 24.9 mg, 0.300 mmol) and TEA (50 μL)
were added and stirred for 1 h after which point a second equivalent
amount of 3C and TEA were added and allowed to stir for 1 h to
give the target compound, which was puriﬁed using RP-HPLC
method A1 to produce 6 as an orange solid to 97% purity. Yield 21%
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(4.0 mg, 0.003 mmol). The product obtained was in the form of two
diﬀerent isomers with the aquo-group located on the alpha and beta
positions (α-cyano-β-aqua- and α-aqua-β-cyano-). tR: 10.4 and 11.0
min; ESI-MS-expected m/z = 1143, observed m/z = [M+−H2O]+1:
1124, [M+−H2O + H+]+2: 563. 1H NMR (400 MHz, D2O): δ 6.50
(1H, s, Ar-H, β-aqua isomer) 6.43 (1H, s, Ar-H, α-aqua isomer).
EAS Ext Coeﬀ354 = 15,001 M−1 cm−1. See Figures S40−S44.
Cbi-Hexyne (7). 7 was prepared according to the general
procedure described above, combining 2 (15.8 mg, 0.0151 mmol)
with CDT (51.6 mg, 0.314 mmol) and stirring the solution for 1 h at
which time 3D (36.5 μL, 29.2 mg, 0.300 mmol) and TEA (50 μL)
were added and stirred for 1 h after which point a second equivalent
amount of 3D and TEA were added and allowed to stir for 1 h to
give the target compound, which was puriﬁed using RP-HPLC
method A1 to produce 7 as an orange solid to 98% purity. Yield 35%
(6.0 mg, 0.005 mmol). The product obtained was in the form of two
diﬀerent isomers with the aquo-group located on the alpha and beta
positions (α-cyano-β-aqua- and α-aqua-β-cyano-). tR: 11.3 and 11.8
min; ESI-MS-expected m/z = 1157, observed m/z = [M+−H2O]+1:
1139, [M+−H2O + H+]+2: 570. 1H NMR (400 MHz, D2O): δ 6.49
(1H, s, Ar-H, β-aqua isomer) 6.42 (1H, s, Ar-H, α-aqua isomer).
EAS Ext Coeﬀ354 = 17,982 M−1 cm−1. See Figures S51−S55.
Cbi-PEG2-Alkyne (8). 8 was prepared according to the general
procedure described above, combining 2 (19.9 mg, 0.0191 mmol)
with CDT (67.1 mg, 0.409 mmol) and stirring the solution for 1 h at
which time 3E (25.1 μL, 25.4 mg, 0.177 mmol) and TEA (50 μL)
were added and stirred for 1 h after which point a second equivalent
amount of 3E and TEA were added and allowed to stir for 1 h to
give the target compound, which was puriﬁed using RP-HPLC
method A1 to produce 8 as an orange solid to 98% purity. Yield 39%
(8.8 mg, 0.007 mmol). The product obtained was in the form of two
diﬀerent isomers with the aquo-group located on the alpha and beta
positions (α-cyano-β-aqua- and α-aqua-β-cyano-). tR: 18.4 and 19.3
min; ESI-MS-expected m/z = 1204, observed m/z = [M+−H2O]+1:
1185, [M+−H2O + H+]+2: 593. 1H NMR (400 MHz, D2O): δ 6.50
(1H, s, Ar-H, β-aqua isomer) 6.43 (1H, s, Ar-H, α-aqua isomer).
EAS Ext Coeﬀ354 = 22,919 M−1 cm−1. See Figures S62−S66.
Cbi-PEG4-Alkyne (9). 9 was prepared according to the general
procedure described above, combining 2 (15.5 mg, 0.0149 mmol)
with CDT (51.3 mg, 0.313 mmol) and stirring the solution for 1 h at
which time 3F (18.8 μL, 19.5 mg, 0.0843 mmol) and TEA (50 μL)
were added and stirred for 1 h after which point a second equivalent
amount of 3F and TEA were added and allowed to stir for 1 h to
give the target compound, which was puriﬁed using RP-HPLC
method A1 to produce 9 as an orange solid to 97% purity. Yield 32%
(6.1 mg, 0.005 mmol). The product obtained was in the form of two
diﬀerent isomers with the aquo-group located on the alpha and beta
positions (α-cyano-β-aqua- and α-aqua-β-cyano-). tR: 20.0 and 21.8
min; ESI-MS-expected m/z = 1292, observed m/z = [M+−H2O]+1:
1273, [M+−H2O + H+]+2: 637. 1H NMR (400 MHz, D2O): δ 6.50
(1H, s, Ar-H, β-aqua isomer) 6.43 (1H, s, Ar-H, α-aqua isomer).
EAS Ext Coeﬀ354 = 19,439 M−1 cm−1. See Figures S73−S77.
Cbi-4EPMA-Alkyne (10). 10 was prepared according to the general
procedure described above, combining 2 (14.9 mg, 0.0143 mmol)
with CDT (50.1 mg, 0.305 mmol) and stirring the solution for 1 h at
which time 3G (23.8 mg, 0.181 mmol) and TEA (50 μL) were
added and stirred for 1 h after which point a second equivalent
amount of 3G and TEA were added and allowed to stir for 1 h to
give the target compound, which was puriﬁed using RP-HPLC
method A1 to produce 10 as an orange solid to 97% purity. Yield
10% (1.5 mg, 0.001 mmol). The product obtained was in the form of
two diﬀerent isomers with the aquo-group located on the alpha and
beta positions (α-cyano-β-aqua- and α-aqua-β-cyano-). tR: 12.4 and
12.8 min; ESI-MS-expected m/z = 1191, observed m/z = [M+−
H2O]+1: 1173. 1H NMR (400 MHz, D2O): δ 6.49 (1H, s, Ar-H, βaqua isomer) 6.43 (1H, s, Ar-H, α-aqua isomer). EAS Ext Coeﬀ354 =
15,886 M−1 cm−1. See Figures S84−S88.
Cbi-3EPMA-Alkyne (11). 11 was prepared according to the general
procedure described above, combining 2 (15.7 mg, 0.0151 mmol)
with CDT (51.1 mg, 0.311 mmol) and stirring the solution for 1 h at
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which time 3H (21.0 μL, 21.2 mg, 0.162 mmol) and TEA (50 μL)
were added and stirred for 1 h after which point a second equivalent
amount of 3H and TEA were added and allowed to stir for 1 h to
give the target compound, which was puriﬁed using RP-HPLC
method A1 to produce 11 as an orange solid to 97% purity. Yield
14% (2.6 mg, 0.002 mmol). The product obtained was in the form of
two diﬀerent isomers with the aquo-group located on the alpha and
beta positions (α-cyano-β-aqua- and α-aqua-β-cyano-). tR: 12.6 and
13.0 min; ESI-MS-expected m/z = 1191, observed m/z = [M+−
H2O]+1: 1172, [M+−H2O + H+]+2: 587. 1H NMR (400 MHz, D2O):
δ 6.49 (1H, s, Ar-H, β-aqua isomer) 6.42 (1H, s, Ar-H, α-aqua
isomer). EAS Ext Coeﬀ354 = 15,669 M−1 cm−1. See Figures S95−S99.
General Procedure for Copper-Mediated Alkyne-Azide. Cycloaddition. To a 5 mL round bottom ﬂask containing a stir bar,
copper(I) iodide (CuI) (3.3 mg, 0.017 mmol) and TBTA (7.0 mg,
0.013 mmol) were added to 1 mL of 4:1 DMF/H2O. The reaction
mixture was allowed to stir at room temperature until a color change
occurred (clear to yellowish brown) (∼15 min). The solution was
treated with azido-exendin-4/40 (2.0 mg, 0.0004 mmol) (see Figures
S12−S17) and the corresponding Cbi-alkynes (4−11) (4.8 mg,
0.004 mmol) and allowed to stir overnight.
Cbi-Pro-Ex4 (12). 12 was prepared according to the general
procedure described above; combining 4 (1.1 mg, 0.001 mmol) with
CuI (4.0 mg, 0.021 mmol), TBTA (7.5 mg, 0.014 mmol), and Ex4
(3.1 mg 0.0007 mmol) gave the target compound, which was puriﬁed
using RP-HPLC method A2 to produce 12 as a red solid to 98%
purity. tR: 11.7 min; ESI-MS-expected m/z = 5327, observed m/z =
[M+−H2O + 2H+]+3: 1771, [M+−H2O + 3H+]+4: 1328. See Figures
S23−S25.
Cbi-But-Ex4 (13). 13 was prepared according to the general
procedure described above; combining 5 (5.7 mg, 0.005 mmol) with
CuI (4.2 mg, 0.022 mmol), TBTA (7.5 mg, 0.014 mmol), and Ex4
(4.2 mg 0.0010 mmol) gave the target compound, which was puriﬁed
using RP-HPLC method A2 to produce 13 as a red solid to 98%
purity. tR: 12.0 min; ESI-MS-expected m/z = 5341, observed m/z =
[M+−H2O + 2H+]+3: 1775, [M+−H2O + 3H++CH3OH]+4: 1364,
[M+−H2O + 3H+]+4: 1332. See Figures S34−S36.
Cbi-Pent-Ex4 (14). 14 was prepared according to the general
procedure described above; combining 6 (4.9 mg, 0.0043 mmol)
with CuI (3.6 mg, 0.019 mmol), TBTA (6.2 mg, 0.012 mmol), and
Ex4 (3.9 mg 0.0009 mmol) gave the target compound, which was
puriﬁed using RP-HPLC method A2 to produce 14 as a red solid to
98% purity. tR: 12.0 min; ESI-MS-expected m/z = 5355, observed m/
z = [M+−H2O + 2H+]+3: 1780, [M+−H2O + 3H+]+4: 1335. See
Figures S45−S47.
Cbi-Hex-Ex4 (15). 15 was prepared according to the general
procedure described above; combining 7 (9.7 mg, 0.0084 mmol)
with CuI (3.5 mg, 0.018 mmol), TBTA (6.6 mg, 0.012 mmol), and
Ex4 (5.3 mg 0.0013 mmol) gave the target compound, which was
puriﬁed using RP-HPLC method A3 to produce 15 as a red solid to
98% purity. tR: 12.0 min; ESI-MS-expected m/z = 5369, observed m/
z = [M+−H2O + 2H+]+3: 1784, [M+−H2O + 3H+]+4: 1339. See
Figures S56−S58.
Cbi-PEG2-Ex4 (16). 16 was prepared according to the general
procedure described above; combining 8 (2.0 mg, 0.0017 mmol)
with CuI (3.6 mg, 0.019 mmol), TBTA (7.1 mg, 0.013 mmol), and
Ex4 (3.0 mg 0.0007 mmol) gave the target compound, which was
puriﬁed using RP-HPLC method A2 to produce 16 as a red solid to
98% purity. tR: 11.7 min; ESI-MS-expected m/z = 5416, observed m/
z = [M+−H2O + 2H+]+3: 1800, [M+−H2O + 3H+]+4: 1350. See
Figures S67−S69.
Cbi-PEG4-Ex4 (17). 17 was prepared according to the general
procedure described above; combining 9 (3.0 mg, 0.0023 mmol)
with CuI (3.4 mg, 0.018 mmol), TBTA (7.3 mg, 0.014 mmol), and
Ex4 (4.1 mg 0.0010 mmol) gave the target compound, which was
puriﬁed using RP-HPLC method A2 to produce 17 as a red solid to
98% purity. tR: 12.3 min; ESI-MS-expected m/z = 5504, observed m/
z = [M+−H2O + 2H+ + CH3CN]+3: 1870, [M+−H2O + 3H+ +
CH3OH]+4: 1404, [M+−H2O + 4H+]+5: 1098. See Figures S79−S80.
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Cbi-4EPMA-Ex4 (18). 18 was prepared according to the general
procedure described above; combining 10 (3.3 mg, 0.0028 mmol)
with CuI (3.6 mg, 0.019 mmol), TBTA (7.2 mg, 0.014 mmol), and
Ex4 (3.0 mg 0.0007 mmol) gave the target compound, which was
puriﬁed using RP-HPLC method A2 to produce 18 as a red solid to
98% purity. tR: 12.2 min; ESI-MS-expected m/z = 5403, observed m/
z = [M+−H2O + 2H+]+3: 1796, [M+−H2O + 3H+]+4: 1347. See
Figures S89−S91.
Cbi-3EPMA-Ex4 (19). 19 was prepared according to the general
procedure described above; combining 11 (3.0 mg, 0.0025 mmol)
with CuI (4.5 mg, 0.024 mmol), TBTA (7.6 mg, 0.014 mmol), and
Ex4 (2.7 mg 0.0006 mmol) gave the target compound, which was
puriﬁed using RP-HPLC method A2 to produce 19 as a red solid to
97% purity. tR: 12.6 min; ESI-MS-expected m/z = 5403, observed m/
z = [M + −H 2 O + 2H + ] + 3 : 1796, [M + −H 2 O + 2H + +
CH3OH]+3:1379, [M+−H2O + 3H+]+4: 1347. See Figures S100−
S102.
Cbi-Pro-Ex40 (20). 20 was prepared according to the general
procedure described above; combining 4 (3.0 mg, 0.0027 mmol)
with CuI (3.6 mg, 0.019 mmol), TBTA (7.0 mg, 0.013 mmol), and
Ex40 (3.0 mg 0.0007 mmol) gave the target compound, which was
puriﬁed using RP-HPLC method A2 to produce 20 as a red solid to
97% purity. tR: 11.8 min; ESI-MS-expected m/z = 5456, observed m/
z = [M+−H2O + 2H+]+3: 1813, [M+−H2O + 3H+]+4: 1360, [M+−
H2O + 4H+]+5: 1088, [M+−H2O + 5H+]+6: 907, [M+−H2O +
6H+]+7: 777. See Figures S26−S28.
Cbi-But-Ex40 (21). 21 was prepared according to the general
procedure described above; combining 5 (3.4 mg, 0.0030 mmol)
with CuI (4.0 mg, 0.021 mmol), TBTA (6.5 mg, 0.012 mmol), and
Ex40 (3.3 mg 0.0007 mmol) gave the target compound, which was
puriﬁed using RP-HPLC method A2 to produce 21 as a red solid to
97% purity. tR: 11.7 min; ESI-MS-expected m/z = 5469, observed m/
z = [M+−H2O + 2H+ + CH3CN]+3: 1859, [M+−H2O + 2H+]+3:
1819, [M+−H2O + 3H+ + CH3OH]+4: 1395, [M+−H2O + 3H+]+4:
1364, [M+−H2O + 4H+]+5: 1091. See Figures S37−S39.
Cbi-Pent-Ex40 (22). 22 was prepared according to the general
procedure described above; combining 6 (4.4 mg, 0.00388 mmol)
with CuI (3.2 mg, 0.017 mmol), TBTA (6.5 mg, 0.012 mmol), and
Ex40 (4.3 mg 0.0010 mmol) gave the target compound, which was
puriﬁed using RP-HPLC method A2 to produce 22 as a red solid to
97% purity. tR: 11.8 min; ESI-MS-expected m/z = 5483, observed m/
z = [M+−H2O + 2H+]+3: 1822, [M+−H2O + 3H+]+4: 1367, [M+−
H2O + 5H+]+6: 912, [M+−H2O + 6H+]+7: 781. See Figures S48−S50.
Cbi-Hex-Ex40 (23). 23 was prepared according to the general
procedure described above; combining 7 (2.1 mg, 0.0018 mmol)
with CuI (3.6 mg, 0.019 mmol), TBTA (7.1 mg, 0.013 mmol), and
Ex40 (2.6 mg 0.0006 mmol) gave the target compound, which was
puriﬁed using RP-HPLC method A2 to produce 23 as a red solid to
97% purity. tR: 11.8 min; ESI-MS-expected m/z = 5497, observed m/
z = [M+−H2O + 2H+]+3: 1827, [M+−H2O + 3H+]+4: 1371, [M+−
H2O + 5H+]+6: 914, [M+−H2O + 6H+]+7: 784, [M+−H2O + 7H+]+8:
685. See Figures S59−S61.
Cbi-PEG2-Ex40 (24). 24 was prepared according to the general
procedure described above; combining 8 (2.0 mg, 0.0017 mmol)
with CuI (4.1 mg, 0.022 mmol), TBTA (7.4 mg, 0.014 mmol), and
Ex40 (4.0 mg 0.0009 mmol) gave the target compound, which was
puriﬁed using RP-HPLC method A2 to produce 24 as a red solid to
97% purity. tR: 11.6 min; ESI-MS-expected m/z = 5544, observed m/
z = [M+−H2O + 2H+ + CH3CN]+3: 1884, [M+−H2O + 3H+ +
CH3OH]+4: 1414, [M+−H2O + 3H+]+4: 1382. See Figures S70−S72.
Cbi-PEG4-Ex40 (25). 25 was prepared according to the general
procedure described above; combining 9 (3.0 mg, 0.0023 mmol)
with CuI (3.3 mg, 0.017 mmol), TBTA (6.8 mg, 0.013 mmol), and
Ex40 (4.1 mg 0.0009 mmol) gave the target compound, which was
puriﬁed using RP-HPLC method A2 to produce 25 as a red solid to
97% purity. tR: 12.0 min; ESI-MS-expected m/z = 5632, observed m/
z = [M+−H2O + 2H+ + CH3CN]+3: 1914, [M+−H2O + 3H+ +
CH3OH]+4: 1436. See Figures S81−S83.
Cbi-4EPMA-Ex40 (26). 26 was prepared according to the general
procedure described above; combining 10 (2.1 mg, 0.0018 mmol)
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Static Measurement of ISR. ISR was determined statically as
described previously.72 Brieﬂy, islets were handpicked into a Petri
dish containing KRB buﬀer supplemented with 0.1% bovine serum
albumin and 3 mM glucose and incubated at 37 °C gassed with 5%
CO2 for 60 min. Subsequently, islets were placed into 96-well plates
containing desired amounts of glucose and agents as indicated
(Figure 5) and incubated for an additional 60 min. At the end of this
period, the supernatant was assayed for insulin by RIA.
In Vivo Study Design in Shrews. Adult male shrews (n = 32,
Suncus murinus) weighing ∼60 g were bred at the University of
Pennsylvania. These animals generated in our lab were originally
derived from a colony maintained at the University of Pittsburgh
Cancer Institute (a Taiwanese strain derived from stock supplied by
the Chinese University of Hong Kong). Shrews were single-housed in
plastic cages (37.3 × 23.4 × 14 cm, Innovive), fed ad libitum with a
mixture of feline (75%, Laboratory Feline Diet 5003, Lab Diet) and
ferret food (25%, High Density Ferret Diet 5LI4, Lab Diet), and had
ad libitum access to tap water except where noted. All animals were
housed under a 12/12 h light/dark cycle in a temperature- and
humidity-controlled environment. Shrews were habituated to single
housing in their home cages and injected IP at least 1 week prior to
experimentation. All experimental injections in shrews were separated
by at least 72 h. Behavioral experiments were conducted in a withinsubjects, Latin square design.
Eﬀects of Ex4, 1, and 22 on Energy Balance in Shrews. We ﬁrst
evaluated in shrews the eﬀects on food intake and body weight of
doses of nEx4, 1, and 22. Food intake was evaluated using our
custom-made feedometers, consisting of a standard plexiglass rodent
housing cage (29 × 19 × 12.7 cm) with mounted food hoppers
resting on a plexiglass cup (to account for spillage). Shrews had ad
libitum access to powdered food through a circular (3 cm diameter)
hole in the cage. Food was removed 1 h prior to the dark onset.
Shortly before the dark onset, shrews (n = 10) received IP injection
of Ex4 (5 nmol/kg), 1 (5 nmol/kg), 22 (5 nmol/kg), or vehicle (1
mL/100 g BW sterile saline). Food intake was manually measured at
6, 24, and 48 h post injection. BW was measured at 0, 24, and 48 h.
Treatments occurred in a within-subject, counter-balanced design
and were at least 3 days apart.
Eﬀects of Ex4, 1, and 22 on Glucoregulation Following an
IPGTT in Shrews. The protocol for performing an IPGTT in shrews
was similar to that previously described.18,51 Brieﬂy; 3 h before the
dark onset, shrews (n = 12) were food- and water-deprived. Two
hours later, baseline BG levels were determined from a small drop of
tail blood and measured using a standard glucometer. nEx4 (5 nmol/
kg), 1 (5 nmol/kg), 22 (5 nmol/kg), or vehicle (1 mL/100 g BW
sterile saline) were then administered IP. BG was measured 30 min
later (t = 0 min), and then each shrew received an IP bolus of
glucose (2 g/kg). Subsequent BG readings were taken at 20, 40, 60,
and 120 min after glucose injection. After the ﬁnal BG reading, food
and water were returned. IPGTT studies were carried out in a
within-subject, counter-balanced design and separated by at least 72
h.
Eﬀects of Ex4, 1, and 22 on Emesis in Shrews. Shrews (n = 10)
were habituated to IP injections and to clear plastic observation
chambers (23.5 × 15.25 × 17.8 cm) for four consecutive days prior
to experimentation. The animals were injected IP with nEx4, 1, 22
(all at 5 nmol/kg), or vehicle, placed in their respective emetic cages,
and then video-recorded (Vixia HF-R62, Canon) for 120 min. All
recordings started within 2 min after drug administration. After 120
min, the animals were returned to their cages. Treatments were
separated by 72 h. Analysis of emetic episodes was performed by an
observer blinded to treatment groups. Emetic episodes were
characterized by strong rhythmic abdominal contractions associated
with either oral expulsion from the gastrointestinal tract (vomiting)
or without the passage of materials (retching). Latency to the ﬁrst
emetic episode, the total number of emetic episodes, and the number
of emetic episodes per minute were recorded.

with CuI (3.0 mg, 0.016 mmol), TBTA (6.7 mg, 0.013 mmol), and
Ex40 (2.3 mg 0.0005 mmol) gave the target compound, which was
puriﬁed using RP-HPLC method A2 to produce 26 as a red solid to
98% purity. tR: 11.9 min; ESI-MS-expected m/z = 5531, observed m/
z = [M+−H2O + 3H+ + CH3OH]+4: 1411, [M+−H2O + 3H+]+4:
1379, [M+−H2O + 4H+]+5: 1104. See Figures S92−S94.
Cbi-3EPMA-Ex4 (27). 27 was prepared according to the general
procedure described above; combining 11 (3.0 mg, 0.0025 mmol)
with CuI (3.4 mg, 0.018 mmol), TBTA (7.0 mg, 0.013 mmol), and
Ex40 (2.0 mg 0.0005 mmol) gave the target compound, which was
puriﬁed using RP-HPLC method A2 to produce 27 as a red solid to
97% purity. tR: 11.9 min; ESI-MS-expected m/z = 5531, observed m/
z = [M+−H2O + 2H+ + CH3CN]+3: 1880, [M+−H2O + 2H+]+3:
1838, [M+−H2O + 3H+ + CH3OH]+4: 1410, [M+−H2O + 3H+]+4:
1379, [M+−H2O + 4H+]+5: 1103. See Figures S103−S105.
Circular Dichroism (CD) Measurements. All CD spectra were
recorded in three independent runs in 100 μL of H2O with a ﬁnal
concentration of 40 μM using a Jasco J-715 circular dichroism
spectropolarimeter at 25 °C in a 0.1 cm path-length cuvette. The
spectra were recorded from 250 to 200 nm and averaged over 6 scans
with a resolution of 1.0 nm, a band width of 1.0 nm, and a response
time of 4 s. The mean residue ellipticity was plotted versus
wavelength using Prism GraphPad 8.
Statement on Biological Evaluations. All Cbi-peptide conjugates
were at or above 97% purity as conﬁrmed by RP-HPLC (see the
ﬁgures in the Supporting Information) prior to use in in vitro, in islet,
or in in vivo experiments.
All in vitro and islet experiments were conducted at least in
triplicate independent runs, aside from the binding experiments,
which were in duplicate independent runs. In vivo data was analyzed
with repeated-measurements one-way or two-way ANOVA followed
by Tukey’s posthoc test.
Agonism (EC50) at the Human GLP-1R for 12−27. Agonism at
the GLP-1R was monitored utilizing HEK-293 cells stably transfected
with both the human GLP-1R and H188 cAMP FRET reporter
cultured in DMEM with 15% FBS, 1% pen/strep, and 250 μg/mL
geneticin/G-418. Cells were placed in a 96-well plate in suspension
at 200 μL of standard extracellular saline with 11 mM glucose and
0.1% BSA at ∼60,000 cells/well. Peptides and conjugates were
injected to each well at 5× the required concentration. Agonism was
determined through an increase in the 485/535 nm FRET ratio,
indicative of an increase in the cAMP level through binding to the
H188 cAMP FRET reporter.
Agonism (EC50) at the Rat GLP-1R. Ex4, Ex40, and 22 were
screened as previously described.69
Competitive Binding Assay (IC50) at Human GLP-1R for 12−27.
IC50 values were measured in CHO-K1 cells at the human GLP-1R
by Euroscreen Fast (Gosselies, Belgium) using their proprietary
Taglite ﬂuorescence competitive binding assay (Cat No.
FAST0154B). The agonist tracer was GLP-1red at 4 nM with
reference competitor nEx-4. Conjugates were assayed in duplicate
independent runs at nine concentrations per run ranging from 1 pM
to 1 μM (Figure S110).
Statement on Animal Experiments. All procedures conducted in
rats were approved by the Institutional Care and Use Committee of
the University of Washington and conducted in compliance with the
U.S. federal law and institutional guidelines, which are congruent
with the NIH guide for the Care and Use of Laboratory Animals.
All procedures conducted in shrews were approved by the
Institutional Care and Use Committee of the University of
Pennsylvania and conducted in compliance with the U.S. federal
law and institutional guidelines, which are congruent with the NIH
guide for the Care and Use of Laboratory Animals.
Rat Islet Isolation and Culture. Islets were harvested from
Sprague−Dawley rats (approximately 250 g; Envigo/Harlan)
anesthetized by intraperitoneal injection of pentobarbital sodium
(150 mg/kg rat). Islets were prepared and puriﬁed as described.70,71
Islets were then cultured for 18 h at 37 °C, gassed with 5% CO2 in
an incubator in an RPMI medium supplemented with 10% heatinactivated fetal bovine serum (Invitrogen).
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SUMMARY

Glucagon-like peptide-1 receptor (GLP-1R) agonists used to treat type 2 diabetes mellitus often produce
nausea, vomiting, and in some patients, undesired anorexia. Notably, these behavioral effects are caused
by direct central GLP-1R activation. Herein, we describe the creation of a GLP-1R agonist conjugate with
modified brain penetrance that enhances GLP-1R-mediated glycemic control without inducing vomiting. Covalent attachment of the GLP-1R agonist exendin-4 (Ex4) to dicyanocobinamide (Cbi), a corrin ring containing
precursor of vitamin B12, produces a ‘‘corrinated’’ Ex4 construct (Cbi-Ex4). Data collected in the musk shrew
(Suncus murinus), an emetic mammal, reveal beneficial effects of Cbi-Ex4 relative to Ex4, as evidenced by
improvements in glycemic responses in glucose tolerance tests and a profound reduction of emetic events.
Our findings highlight the potential for clinical use of Cbi-Ex4 for millions of patients seeking improved glycemic control without common side effects (e.g., emesis) characteristic of current GLP-1 therapeutics.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) management involves lifelong
pharmaceutical interventions (Drucker et al., 2011; Sadry and
Drucker, 2013), including those based on glucagon-like peptide-1 (GLP-1), an incretin hormone produced in the intestine
and brainstem (Hayes et al., 2014; Holst, 2007). Existing US
Food and Drug Administration (FDA)-approved GLP-1 receptor
(GLP-1R) agonists enhance postprandial insulin secretion and
reduce food intake (Hayes et al., 2014; Hayes and Schmidt,
2016; Kanoski et al., 2016). While the latter is attractive when
considering GLP-1R agonists for obesity treatment, the hypophagic effects of all known GLP-1R agonists are accompanied
by nausea and vomiting, which affects 20%–50% of patients
and leads to discontinuation of drug treatment in 6%–10%
and reduced dose tolerance in another 15% of patients (Bergenstal et al., 2010; Buse et al., 2004; DeFronzo et al., 2005;
John et al., 2007; Kendall et al., 2005). Evidence-based medical
reports are now clear that nausea and emesis are the principal
side effects of existing GLP-1 therapeutics (Bettge et al.,
2017). Even with common approaches to mitigate side effects
such as slow-dose escalation or titration, a recent report from
GlaxoSmithKline concluded that patients reported GI-related is-

sues that ‘‘made me feel sick’’ (64.4%) and ‘‘made me throw up’’
(45.4%) as their major reasons for treatment discontinuation (Sikirica et al., 2017). Importantly, such adverse gastrointestinal
events of GLP-1R agonists are persistent in the profile of current
second-generation GLP-1R-based drugs such as dulaglutide,
semaglutide, and albiglutide (Ahrén et al., 2018; Pratley et al.,
2018; Wysham et al., 2014). Importantly, for some diabetic patients with comorbidities such as cancer, cystic fibrosis, HIV,
or general disease-cachexia, any further weight loss and malaise
are unacceptable side effects that necessitate the creation of a
new class of GLP-1 therapeutic.
There is convincing evidence that a significant portion of the
increase in glucose-stimulated insulin secretion following administration of current exogenous GLP-1R ligands is mediated by
direct activation of GLP-1R expressed on pancreatic b-cells
(for review, see Drucker, 2006; Hayes et al., 2010, 2014; Kanoski
et al., 2016), mimicking the paracrine effects of pancreaticderived GLP-1 that may not occur with endogenous L-cellderived GLP-1(Chambers et al., 2017; Lamont et al., 2012; Smith
et al., 2014). In contrast, GLP-1Rs expressed in the central nervous system (CNS), in particular those in the hindbrain (Alhadeff
et al., 2016; Hayes et al., 2011), mediate the food intake- and
body weight-suppressive effects of GLP-1R agonists, such as

Cell Reports 31, 107768, June 16, 2020 ª 2020 The Author(s). 1
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

ll

Article

OPEN ACCESS

Figure 1. Covalent Conjugation of Ex4 to Cbi Retains GLP-1R Agonism In Vitro and Displays Improved Half-Life In Vivo
(A) Synthetic scheme for Cbi-Ex4 synthesis: 1-amino-3-butyne was coupled to Cbi utilizing carbonyl ditriazole (CDT), priming the Cbi for conjugation to Ex4. Ex4
was covalently bound to the Cbi-alkyne via copper-catalyzed alkyne-azide cycloaddition.
(B) RP-HPLC of Cbi-Ex4 showing purity of R 97% and liquid chromatography-mass spectrometry (LC-MS) showing 1,339 [M+4H]4+ and 1,071 [M+5H]5+,
consistent with the conjugate.
(C) Dose-dependent Cbi-Ex4 agonism at the human GLP-1 receptor, as monitored in FRET assays using the cAMP biosensor H188 expressed in HEK293 cells.
EC50 value for Cbi-Ex4 was determined to be 200 ± 0.09 pM (mean ± SEM) (Chepurny et al., 2019).
(D) Pharmacokinetic profile of two equimolar doses (25 nmol/kg and 50 nmol/kg) of Ex4 and Cbi-Ex4. Data expressed as mean ± SEM.
Full PK parameters are given in Table S2.

liraglutide and exenatide (synthetic Ex4) (Kanoski et al., 2011;
Mietlicki-Baase et al., 2013; Secher et al., 2014; Sisley et al.,
2014). This CNS site-of-action, and not a vagally mediated effect, is also responsible for mediating the illness-like behaviors
(e.g., nausea, conditioned taste avoidance, emesis) of systemically delivered GLP-1R agonists (Kanoski et al., 2012). Thus,
from a therapeutic standpoint aimed at normalizing the chronic
hyperglycemia of diabetic patients, designing a GLP-1R agonist
that does not penetrate readily into the CNS (or at least the hindbrain), but retains enhanced pharmacological action on b-cells,
would theoretically provide an improved tool for glycemic control
without eliciting unwanted nausea/malaise.
Taking advantage of the highly controlled transport and trafficking of vitamin B12 (B12) that occurs in mammalian physiology, together with bioconjugate technology involving peptide-based conjugation to B12 and B12 fragments, Ex4 was
covalently attached to dicyanocobinamide (Cbi), a corrin-ringcontaining precursor of B12, to create the compound Cbi-Ex4
(Figure 1A). The theoretical advantage of this construct was
3-fold. First, there is no known biological function of Cbi in humans and Cbi does not affect intact B12 physiology (Green
et al., 2017). Second, Cbi is highly water soluble and the uptake
of Cbi-Ex4 through the blood brain barrier and into the CNS
would putatively be extremely low (Green et al., 2017). Indeed,
evidence collected postmortem from human brain and liver
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clearly demonstrated negligible amounts of B12 (11.3 pmol/g)
and an 10-fold lower relative concentration of corrinoid-type
analogs (1.3 pmol/g; including cobinamide) in the brain, with
the liver being the main site of concentration for both B12 and
corrinoid analogs (total >600 pmol/g) (Kanazawa and Herbert,
1983). These first two advantages of Cbi-Ex4 provide support
for the third and most important hypothesized benefit—namely
that Cbi-Ex4 should theoretically be a GLP-1R agonist that retains a peripheral site of action when systemically administered,
providing a pancreatic-mediated mechanism for Cbi-Ex4 to
improve hyperglycemia, without producing any CNS-mediated
illness-like behaviors.
Cbi has been identified in humans (Hardlei and Nexo, 2009),
but has no influence on normal B12 homeostasis (Green et al.,
2017) since it is not recognized by the B12 blood transporting
protein transcobalamin (TC), critical for blood-brain barrier penetrance and cell entry via the CD320 receptor (Green et al., 2017).
Instead, Cbi is recognized in blood only by the B12 binding protein haptocorrin (HC). The function of circulating HC is unknown
and no known specific receptor for the Cbi-HC complex has
been identified (Furger et al., 2012). Indeed, congenital defects
in plasma HC are asymptomatic, suggesting that HC and Cbi
are not physiologically relevant in humans (Rosenblatt et al.,
2001). Further, the plasma-binding capacity of HC for molecular
forms of B12, including Cbi, in humans is very limited (reference
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interval 90–270 pM; Gimsing and Nexø, 1989). Thus, using Cbi (in
a conjugate process we coin here ‘‘corrination’’) as a pharmacodynamic/pharmacokinetic modifier of a target peptide pharmaceutical, we have created an ‘‘inert’’ carrier in terms of affecting
B12 homeostasis, but one that would have the advantage of putatively reducing/avoiding CNS permeability/localization while
improving the general proteolytic survival and/or reduce clearance of the bound peptide. Unfortunately, rodents do not represent ideal models to test Cbi-Ex4 as (1) they lack the separate HC
and TC proteins as found in human blood (Kuda-Wedagedara
et al., 2017) and (2) they lack the emetic reflex (Horn et al.,
2013). The musk shrew (Suncus murinus) was therefore chosen
as the model system to evaluate the in vivo efficacy and tolerability of Cbi-Ex4, as shrews are capable of emesis (Ueno et al.,
1987) and were believed, through bioinformatics, to have the
same B12 binding profile in blood as humans (vide infra). Importantly, in the context of modeling the GLP-1 system, the shrew
also shows hypoglycemia, anorexia, and emetic sensitivity to existing GLP-1R agonists (Chan et al., 2011; Chan et al., 2013).
RESULTS AND DISCUSSION
Covalent Conjugation of Ex4 to Cbi Retains GLP-1R
Agonism In Vitro
Here, we present a method, with validation, for corrination of Ex4
with the Cbi compound dicyanocobinamide to produce a GLP1R agonist, namely, Cbi-Ex4 (Figures 1A and 1B), with an half
maximal effective concentration (EC50) of 200 pM in fluorescence resonance energy transfer (FRET) assays that monitor
levels of cAMP in HEK-239 cells stably transfected with the human GLP-1R (Figure 1C). The conjugate is linked between the
K12 residue of Ex4 and the terminal f-branch of Cbi. These two
positions were previously reported by us (Mietlicki-Baase
et al., 2018) and others (Równicki et al., 2017; Wierzba et al.,
2019) to support high-efficiency conjugation. While no spacer
optimization was conducted, we utilized a spacer length that
was already established by us to yield a high-potency B12-Ex4
conjugate (Clardy-James et al., 2013).
Cbi-Ex4 Binds to Shrew HC and Displays Improved HalfLife In Vivo
Initially, we confirmed the presence of both HC and TC in shrew
blood by performing radio-57Co-B12 binding assays and serum
B12 protein isolation and identification (see Table S1). In addition
to confirming the presence of HC (and separately TC, the profile
found in humans, but not rodents [Hygum et al., 2011]), we
showed that the total blood B12 binding in S. murinus was
12 nM, of which 4.5 nM was due to apo-HC. We also demonstrate that, as hypothesized, only HC (Ka 0.45 nM Cbi-Ex4 versus
0.036 nM for Cbi), not TC (Ka for Cbi-Ex4 > 0.2 mM), binds CbiEx4, and that such binding to HC was 10-fold lower in affinity
than for Cbi alone (see Figure S1).
Cbi-Ex4 exhibited reduced plasma clearance (as evidenced
by the area under the curve [AUC] and elimination constants)
relative to native Ex4 (Figure 1D; Table S2). This finding is likely
due, at least in part, to improved stability of the conjugate to proteolytic activity, as we have demonstrated previously for fullvitamin-B12 conjugates (Bonaccorso et al., 2015), and/or
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reduced renal clearance, both major routes of Ex4 clearance
in vivo (Copley et al., 2006; Simonsen et al., 2006). ELISA-based
pharmacokinetic studies demonstrated that Cbi-Ex4 had a
reduced rate of elimination as evidenced by the elimination constants (Ke) of 0.034 h1 for Cbi-Ex4 versus 0.047 h1 for Ex4, and
reduced clearance (0.0044 L/h for Cbi-Ex4 versus 0.0056 L/h for
Ex4) with no significant difference in volume of distribution between either drug (see Table S2). Overall, Cbi-Ex4 provided
greater drug exposure over time, as evidenced by the greater
AUC0-360 (2.82 mg*h/L for Ex4 versus 4.55 mg*h/L for CbiEx4), all above the values reported for the 50 nmol/kg dose (Figure 1D; Table S2). We noted also that the Cmax values for both the
25 nmol/Kg and 50 nmol/Kg doses of Cbi-Ex4 were 17.25 and
30.96 nmol/L (4- to 7-fold greater than the maximum apo-HC
levels measured and recorded above), suggesting that the effects of corrination are due to the Cbi itself, and are not primarily
dependent on binding to HC (the only known binder of Cbi)
in vivo. At this point it is interesting to note that Herbert and Herzlich (1983) first suggested that HC may play a role in removing
corrinoids from the human brain, an idea supported by subsequent work by Hansen et al. (1985), who showed HC was found
in human CSF (CSF-HC) at concentrations ranging from 10 to 41
pmol/L (median 21 pmol/L; Hansen et al., 1985) with plasma/
CSF ratios suggesting such HC was produced in the CNS
directly. Overall, the results described herein then may be a
consequence of naturally less penetrance of Cbi-Ex4 due to
the presence of the highly polar Cbi group, a lack of facilitated
transport into the brain for Cbi-Ex4, and/or binding by CSF-HC
and subsequent removal or deactivation of Cbi-Ex4 in the
CNS. In regard to the latter point, we subsequently assayed
HC-Cbi-Ex4 at the GLP-1R and noted an EC50 of 3 nM,
essentially rendering a physiologically irrelevant construct (see
Figure S2).
Cbi-Ex4 Enhances Glucose Clearance but Does Not
Affect Feeding Behavior
Glucose-stimulated insulin secretion following administration of a
GLP-1 analog is mediated principally by activation of GLP-1Rs
expressed on pancreatic b-cells (Chambers et al., 2017; Lamont
et al., 2012; Smith et al., 2014). Therefore, as a proof of concept,
we first tested whether Cbi-Ex4 retains its in vivo ability to reduce
blood glucose following an intraperitoneal (i.p.) glucose tolerance
test (IPGTT) across different doses compared to equimolar doses
of native Ex4. We observed that shrews treated with Cbi-Ex4 and
native Ex4 display improved glucose clearance following i.p.
glucose administration compared to vehicle injections (Figures
2A–2C). Furthermore, the plasma glucose clearing rate of CbiEx4 did not differ from the relative equimolar dose of native Ex4
following acute administration, which is indicative of a retained
glucoregulatory potency (Figures 2B–2D and S3).
Based on these observations, we then further hypothesized
that Cbi-Ex4 may also retain a plasma glucose-lowering action
for a longer duration compared to native Ex4. Therefore, a ‘‘delayed’’ IPGTT was performed, in which an i.p. glucose bolus
was administered 360 min after drug administration to determine
whether a longer time window exists for Cbi-Ex4 to facilitate
glucose clearance relative to native Ex4. Results show a significant suppression in plasma glucose concentrations 6 h following
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Figure 2. Cbi-Ex4 Enhances Glucose Clearance but Does Not Affect Feeding Behavior
(A) Ex4 (1.25, 5, and 50 nmol/kg, i.p.; i.e., 5, 20, and 200 mg/kg; respectively) dose-dependently suppressed blood glucose (BG) levels following glucose
administration (2 g/kg, i.p.). Saline versus 5 nmol/kg Ex4: **p < 0.01, ***p < 0.001; saline versus 50 nmol/kg Ex4: ###p < 0.001; saline versus 1.25 nmol/kg Ex4:
xxp < 0.01; 1.25 nmol/kg Ex4 versus 50 nmol/kg Ex4: @@@p < 0.001; 1.25 nmol/kg Ex4 versus 5 nmol/kg Ex4: Fp < 0.05, FFp < 0.01, FFFp < 0.001.
(B) Area under the curve (AUC) from 0 (i.e., post-glucose bolus) to 120 min after Ex4.
(C) In an IPGTT Cbi-Ex4 dose-dependently reduced BG levels comparably to equimolar doses of Ex4. Saline versus 5-nmol/kg Cbi-Ex4: **p < 0.01, ***p < 0.001;
saline versus 50 nmol/kg Cbi-Ex4: ###p < 0.001; saline versus 1.25 nmol/kg Cbi-Ex4: xp < 0.05; 1.25 nmol/kg Cbi-Ex4 versus 50 nmol/kg Cbi-Ex4: @@@ p < 0.001.
(D) AUC from 0 to 120 min following Cbi-Ex4.
(E) In a delayed glucose load IPGTT, Ex4, Cbi-Ex4 (5 nmol/kg) or vehicle were injected 6 h before glucose load. While Ex4-treatment was no longer effective in
reducing BG levels, Cbi-Ex4 retained its BG lowering properties; saline versus Cbi-Ex4: **p < 0.01, ***p < 0.001; Ex4 versus Cbi-Ex4: xxp < 0.01), xxxp < 0.001.
(F and G) AUC analyses from 0 to 60 min and 0 to 120 min, respectively. Cbi-Ex4-treated animals had lower AUC 0-120 compared to Ex4-treated animals and a
lower AUC 0–60 compared to Ex4-treated animals and controls.
(H and I) Ex4 dose-dependently induced anorexia leading to weight loss.
(J and K) Equimolar doses of Cbi-Ex4 had no effect on food intake or body weight. All data expressed as mean ± SEM.
Data in (A), (B), (E), and (H)–(K) were analyzed with repeated-measurements two-way ANOVA followed by Tukey’s post hoc test. Data in (B), (D), (F), and (G) were
analyzed with repeated-measurements one-way ANOVA followed by Tukey’s post hoc test. Means with different letters are significantly different (p < 0.05).

Cbi-Ex4 administration in an IPGTT, with no effect on plasma
glucose tolerance being observed after a 6h time delay of native
Ex4 administration (Figures 2E–2G).
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Direct activation of GLP-1R expressed in various nuclei of the
CNS (including, but not limited to those of the hypothalamus and
dorsal vagal complex [DVC]), contributes to the body weight and
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food intake suppressive effects of exogenously administered
first-generation GLP-1R agonists (Kanoski et al., 2011; Mietlicki-Baase et al., 2018; Secher et al., 2014; Sisley et al.,
2014). Indeed, both liraglutide and Ex4 penetrate into the
CNS and activate GLP-1R-expressing nuclei to induce hypophagia and body weight loss (Chambers et al., 2017; Kanoski
et al., 2011; Mietlicki-Baase et al., 2018). In line with previous
reports (Chan et al., 2013), systemic administration of native
Ex4 produced a strong hypophagic response in the shrew,
leading to body-weight loss in a dose-dependent fashion (Figures 2H–2I). This effect is due in part to the ability of native Ex4
to significantly increase the latency of the shrew to initiate
feeding compared to vehicle injections (Figure S3). In contrast,
Cbi-Ex4 did not significantly affect 24 h food intake or latency
to eat, suggesting a lack of neural activation within the CNS
(Figures 2J–2K).
Reduced caloric intake and body weight may be viewed as
positive therapeutic outcomes in many T2DM patients prescribed existing GLP-1-based therapeutics (i.e., in those patients with accompanying obesity); however, there is a substantial number of T2DM patients that require glycemic control
without weight loss. Indeed, in the Western world, 5%–15% of
the patients diagnosed with T2DM have a body mass index
(BMI) of 25 or lower (Centers for Disease Control and Prevention,
2004; George et al., 2015; Hartmann et al., 2017). The prevalence
of T2DM in lean subjects seems to be even higher in some Asiatic
countries and among American ethnic minorities (Coleman et al.,
2014; Mohan et al., 1997). In addition, there are also diabetic patients suffering from life-threatening diseases or medical treatments including, but not limited to cystic fibrosis (Moheet and
Moran, 2017), cancer (Gallo et al., 2018), HIV (Noubissi et al.,
2018), chronic heart failure (Nasir and Aguilar, 2012), or COPD
(Gläser et al., 2015). Indeed, the prevalence of T2DM in COPD
patients is 20% with an incidence for COPD of 10% in the
overall diabetic population (Caughey et al., 2010; Kerr et al.,
2007; Mannino et al., 2008). Further, depending on the tumor
type, between 8% and 18% of the cancer patients at the time
of diagnosis also suffer from T2DM (Gallo et al., 2018; van de
Poll-Franse et al., 2007), and 30%–40% of hospitalized heartfailure patients are diabetic (Echouffo-Tcheugui et al., 2016).
This subgroup of T2DM patients is already at increased risk for
cachexia, nausea/malaise, and unintended weight loss (von
Haehling et al., 2016; von Haehling and Anker, 2014). In these
T2DM patients, as well as overweight/obese T2DM patients
that cannot effectively tolerate the nausea/emesis of existing
GLP-1-based therapeutics, the data provided here support the
hypothesis that the Cbi-Ex4 construct can improve glycemic
control without producing anorexia and drug-treatment-induced
malaise.
Emetic Episodes Are Significantly Reduced Following
Cbi-Ex4 Treatment Compared to Native Ex4, Indicative
of Improved Tolerance
The most common side effects of all existing FDA-approved
GLP-1R agonists are nausea, vomiting, and malaise, with
approximately 20%–50% of T2DM patients that had been prescribed GLP-1-based medication, experiencing nausea and/or
vomiting (Bergenstal et al., 2010; Buse et al., 2004; DeFronzo
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et al., 2005; John et al., 2007; Kendall et al., 2005). These adverse
events are surprisingly under-investigated, as they limit the widespread use, efficacy, and potential ubiquitous utility of existing
GLP-1R agonists for treating metabolic disease. Notably, GLP1-mediated malaise is not caused by GLP-1-mediated vagal
afferent signaling, but is rather promoted by direct central
GLP-1R activation (Kanoski et al., 2012), primarily in the brainstem. We therefore hypothesized that the conjugation of Cbi to
Ex4 would modify CNS penetrance of Ex4, due to the B12-selective transport system involving TC binding (and the receptor
CD320), a system that does not specifically support Cbi binding/transport in general (Mietlicki-Baase et al., 2018), and specifically not in the case of Cbi-Ex4 as measured herein (see Table
S1 and Figure S1).
Ex4 dose-dependently induced emesis with the majority of the
shrews experiencing emesis after 5- and 50-nmol/kg Ex4 dosing
(Figure 3A). Indeed, 29% of the animals exhibited emesis upon
administration of the lowest dose of native Ex4, 79% with the intermediate one, and 93% with the highest dose tested. All doses
of native Ex4 triggered emesis within minutes after administration (1.25 nmol/kg Ex4: 21 ± 15; 5 nmol/kg Ex4: 10 ± 5 min;
50 nmol/kg: 12 ± 5 min, Figure 3B). In contrast to the profound
emesis observed after Ex4, both the prevalence and the number
of emetic episodes following equimolar injections of Cbi-Ex4
were significantly reduced (5 nmol/kg Ex4 versus Cbi-Ex4: p =
0.005, 50 nmol/kg Ex4 versus Cbi-Ex4: p = 0.0003; Figure 3C).
Only one shrew experienced emesis after 1.25 nmol/kg CbiEx4 (i.e., 7%), 28% after 5 nmol/kg Cbi-Ex4, and 64% after
50 nmol/kg Cbi-Ex4. In animals that displayed emesis after
Cbi-Ex4 treatment, the latency was similar to native Ex4 (Figure 3D). However, the severity and occurrence of the emetic episodes was less severe, as represented by the heatmaps of Ex4
and Cbi-Ex4 depicting emetic intensity and latency for each individual animal across time (Figures 3E, 3F, and S4). These differences are particularly striking at the 5 nmol/kg dose of Cbi-Ex4,
which shows a virtual absence of emetic events with the concurrence of strong glycemic effects (see also Figures S3 and S4).
Thus, the conjugation of Ex4 to Cbi renders a GLP-1R agonist
that, at pharmacological doses, retains glucoregulatory ability
without CNS-mediated emesis.
Further support for this hypothesis is found by the near
absence of c-Fos protein immunofluorescence (i.e., neuronal
activation) in the DVC by Cbi-Ex4 compared to the robust
c-Fos activation by native Ex4 (Figure 3G). The DVC is a set of
brainstem nuclei (comprised of the nucleus tractus solitarius
[NTS], area postrema [AP], and dorsal motor nucleus of the vagus) implicated in regulation of food intake and the processing
of aversive stimuli and emetic events (Grill and Hayes, 2012; Hesketh, 2008; Horn, 2014; Miller and Leslie, 1994). Figures 3G and
3H show that systemic native Ex4 induces robust c-Fos expression in both the NTS and AP, whereas an equimolar dose of CbiEx4 did not significantly induce greater c-Fos expression
compared to vehicle injections.
Despite Not Affecting Feeding Behavior, Albiglutide
Triggers Profound Emesis
Finally, as an additional reference control, we performed a
set of studies investigating the emetogenic, anorectic, and
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Figure 3. Emetic Episodes Are Significantly Reduced Following Cbi-Ex4 Treatment Compared to Native Ex4, Indicative of Improved
Tolerance
(A) Ex4 (1.25, 5, and 50 nmol/kg) induced emesis during 120 min after injection in a dose-related fashion. The number of animals exhibiting emesis, expressed as a
fraction of the total number of animal tested, is indicated above each treatment group.
(B) Latency to the first emetic episode of shrews that exhibited emesis after Ex4 treatment.
(C) Number of shrews experiencing emesis following Cbi-Ex4 (1.25, 5, and 50 nmol/kg) during 120 min after injection. The ratio of animals exhibiting emesis is
indicated above each treatment group.
(D) Latency to the first emetic episode of shrews that experienced emesis after Cbi-Ex4 treatment.
(E and F) Heatmaps showing latency, number, and intensity of emesis following Ex4 and Cbi-Ex4 dosing for each individual animal across time.
(G) Representative immunofluorescent images showing c-Fos-positive across different NTS plane levels (0, 250, and 400 mm rostral to the obex) and in the medial
part of the AP, 3 h after Ex4 (5 nmol/kg), Cbi-Ex4 (5 nmol/kg), or saline i.p. injection.
(H) Quantification of c-Fos positive neurons in the rostral, medial, and caudal NTS and medial AP. Peripheral Ex4 administration significantly increased the
number of c-Fos immunoreactive cells in the AP/NTS of shrews 3 h after injection. The number of c-Fos positive cells in the AP/NTS was significantly lower in CbiEx4-treated animals.
All data expressed as mean ± SEM. Means with different letters are significantly different (p < 0.05). Data in (A) and (C) were analyzed with repeated-measurements one-way ANOVA followed by Tukey’s post hoc test. Data in (H) with one-way ANOVA followed by Tukey’s post hoc test. Scale bar, 100 mm (G).
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Figure 4. Albiglutide Does Not Cause
Anorexia or Body Weight Loss but It Induces
Profound Emesis in the Shrew
(A) Number of shrews experiencing emesis and the
number of single emetic episodes following albiglutide (0.5 and 5 mg/kg) for 120 min after injection.
(B) Latency to the first emetic episode of shrews
that exhibited emesis after albiglutide treatment.
(C) Heatmap showing latency, number, and intensity of emesis for each animal across time.
(D) Food intake at 6, 24, 48, and 72 h post treatment.
(E) Body-weight change at 24, 48, and 72 h after
albiglutide or saline treatment. All data expressed
as mean ± SEM.
Data in (A) and (B) were analyzed with repeatedmeasurements one-way ANOVA followed by Tukey’s post hoc test. Data in (C) and (D) were
analyzed with repeated-measurements two-way
ANOVA followed by Tukey’s post hoc test.

body-weight-lowering properties of the long-acting GLP-1
analog albiglutide in our shrew model. This GLP-1-based
‘‘macromolecule,’’ consisting of a modified GLP-1 dimer fused
to recombinant human albumin, was hypothesized to display
minimal brain penetrance due to its size and provide an extended
half-life of several days in humans (Rosenstock et al., 2009).
Compared to short acting GLP-1 analogs (e.g., Ex4), albiglutide
was reported to show reduced incidence of adverse effects (i.e.,
nausea and vomiting) and with attenuated body-weight-suppressing effects in humans, making it the hoped-for, pre-clinical
gold standard for T2DM lean patients (Bettge et al., 2017; Dar
€ller et al.,
et al., 2015; Leiter et al., 2016; Madsbad, 2016; Mu
2019; Prasad-Reddy and Isaacs, 2015; Pratley et al., 2014;
Rosenstock et al., 2009).
In line with the reduced anorectic effects of albiglutide previously observed in rodents and humans (Baggio et al., 2004; Pratley et al., 2014), and similarly to Cbi-Ex4, albiglutide at two doses
(0.5 and 5 mg/kg) did not cause anorexia and body-weight loss
(Figures 4A and 4B) in shrews. Our results demonstrate, however, that both doses of albiglutide induced profound emesis in
the majority of shrews tested, albeit with a different temporal
profile of emetic responses. The first emetic episode following albiglutide administration occurs within minutes after administration (Figures 4C–4E). This is in direct contrast to comparable
doses of Cbi-Ex4 (5 and 0.5 mg/kg of albiglutide correspond to
68 and 6.8 nmol/kg, respectively). While c-Fos following albiglutide treatment was not evaluated in the current study, previous
work in rodents demonstrates neuronal activation in nuclei expressing GLP-1Rs, including the AP/NTS following albiglutide
systemic delivery (Baggio et al., 2004). Collectively, these data

and previous reports suggest that
although the whole-brain penetrance
may be reduced using a GLP-1R macromolecule agonist like albiglutide, there
are still parts of the brain (e.g., AP/NTS)
that provide an access point for
albiglutide to drive significant adverse effects. Altogether, these results further strengthen the potential
future clinical utility that Cbi-Ex4 could have on treating T2DM
at doses that do not produce emesis.
Limitations of Study
In summary, by exploiting a biosynthetic precursor of B12
found naturally in humans, but that is inert in the normal physiology of the vitamin, we generated a potent and metabolically
stable GLP-1 receptor agonist via corrination, with enhanced
and prolonged peripheral glucoregulatory actions at doses
that do not affect feeding and, astonishingly, is virtually devoid
of emetic responses. Chronic animal studies as well as clinical
trials are required to fully elucidate the long-term efficacy and
tolerability of Cbi-Ex4. Given the high prevalence of obesity/
overweight among T2DM patients, the lack of major effects
on feeding and body weight could be considered a negative
outcome of the corrination technology. For these patients,
‘‘classic’’ GLP-1R analogs, if well tolerated, may be most favorable as weight loss contributes to improved overall health.
Nevertheless, our data highlight the incredible potential of corrination, exemplified herein with the development of Cbi-Ex4,
as a treatment that would be most beneficial in treating lean
T2DM patients, T2DM patients suffering from other comorbidities associated with an anorectic/cachectic state (cancer,
COPD, and cystic fibrosis), and T2DM patients seeking glycemic control without emesis.
T2DM and cancer anorexia-cachexia syndrome show similarities in metabolic alterations (Chevalier and Farsijani, 2014; Porporato, 2016). Insulin resistance and reduced glucose tolerance
in cancer patients are well-known phenomena. As early as the
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1920s, glucose intolerance became a recognized metabolic
alteration observed in cancer patients (Petruzzelli and Wagner,
2016). Data from tumor-bearing rodents, partially recapitulating
the human clinical state, showed some beneficial effects of
Ex4 treatment in attenuating muscle atrophy and in counteracting cancer-induced-insulin-signaling dysregulation (Honors and
Kinzig, 2014). However, the CNS-mediated anorectic and emetic
effects induced by native Ex4 represents a substantive limitation
for possible applications in humans. Cbi-Ex4 could therefore
represent an interesting and new GLP-1R-based approach for
future investigations into the treatment of cancer-induced insulin
resistance.
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5003, Lab Diet) and mink food (25%, High Density Ferret Diet 5LI4, Lab Diet) and had ad libitum access to tap water except where
noted.
Shrews were habituated to single housing in their home cage and IP injections at least 1 wk prior to experimentation. All animals
were naive to any experimental drug and test prior to the beginning of the experiment. All experimental injections were separated by
at least 72h. For most in vivo experiments, injections were administered using a within-subjects, Latin square design. The exceptions
were the pharmacokinetic and the immunohistochemical studies, which were conducted in a between-subjects design. All procedures were approved by the Institutional Care and Use Committee of the University of Pennsylvania.
METHOD DETAILS
Drugs
CN2Cbi was purchased from Sigma-Aldrich. K12-azido modified Ex4 was produced by NeoScientific (Cambridge, USA). Cbi-conjugated exendin-4 (Cbi-Ex4) was synthesized, characterized and screened as described below. For all in vivo studies Cbi-Ex4,
Ex4 (Bachem), and albiglutide (AdooQ Bioscience, Cat. No. A16823) were dissolved in 0.9% saline. In all studies, except in the pharmacokinetic study, Ex4 (1.25, 5 and 50 nmol/kg; i.e., 5, 20 and 200 mg/kg; respectively), Cbi-Ex4 (equimolar dose to Ex4), and albiglutide (0.5 and 5 mg/kg) were administered intraperitoneally (IP). For the pharmacokinetic study, Ex4 (25 and 50 nmol/kg) and CbiEx4 (equimolar doses to Ex4) were infused intravenously (IV) (see details below).

Cell Reports 31, 107768, June 16, 2020 e2

ll
OPEN ACCESS

Article

Cbi-alkyne synthesis and purification
(CN)2Cbi (0.077 mmol; 80 mg; 1 equiv.) and CDT (1,10 -carbonyl-di-(1,2,4-triazole); 1.535 mmol; 252 mg, 20 equiv.) were dissolved in
dry N-Methyl-2-pyrrolidone (NMP, 2.5 mL) at 40 C under an argon atmosphere. The resulting solution was stirred for 30 min at 40 C
(full conversion of Cbi to Cbi-CDT adduct was achieved over this time (as established by RP-HPLC). Subsequently, the aminoalkyne
(NH2-C2-alkyne, 126 mL, 20 equiv.) and triethylamine (TEA, 20 mL) were added under an argon atmosphere. The resulting solution was
stirred at 40 C for 1h. After this time the conversion (monitored by RP-HPLC) was not complete, thus another portion of the aminoalkyne (126 mL, 20 equiv.) and TEA (20 mL) were added and the mixture was stirred for an additional hour at 40 C. The reaction mixture
was subsequently poured into ethyl acetate (50 mL), and centrifuged (the residue being transferred with a minimal amount of MeOH
into ethyl acetate). After complete precipitation, the solid was dissolved in 2 mL of MeOH and precipitated with diethyl ether (50 mL).
The crude solid was dissolved in water and purified via preparative HPLC (see supplementary details for full synthetic details and
characterization).
Cbi-Ex4 synthesis and purification
To a 5mL round bottom flask containing a stir bar, copper (I) iodide (Cu(I)I) (3.3 mg, 0.017 mmol), and tris[(1-benzyl-1H-1,2,3-triazol-4yl)methyl]amine (TBTA) (7.0 mg, 0.013 mmol) was added to 500 mL of 4:1 DMF:H2O. The reaction mixture was allowed to stir at room
temperature until a color change occurred (clear to yellowish brown) (15 min). The solution was treated with K12-azido-exendin-4
(2.0 mg, 0.0004 mmol) and Cbi-alkyne (4.8 mg, 0.004 mmol) and allowed to stir overnight (Figure 1A). The product was purified using
Shimadzu Prominence HPLC using a C18 column (Eclipse XDB-C18 5 mm, 4.6 3 150 mm) with H2O + 0.1% TFA and acetonitrle. tR
(RP-HPLC, from 1% CH3CN/H2O + 0.1% to TFA to 70% % CH3CN/H2O + 0.1% to TFA in 15 min): 11.2 min. ESI-MS shows the expected m/z 5354, observed m/z = 1339 [M+4H]+4, 1071 [M+5H]+5(Figure 1B).
Shrew serum total B12, total apo-TC and apo-HC binding capacities
Pool of shrew serum from two animals (1 and 2) as: 3 3 150 ml animal 1 + 2 mixed, 3 3 150 ml animal 1 only, 3 3 150 ml animal 2 only
were assayed as previously described (Gimsing and Nexø, 1989). Briefly, total B12 was measured using serum diluted 1:5 with 0.9%
NaCl on the automatic platform Advia Centaur CP Immunoassay system. Unsaturated B12 binding capacity was measured on serum
diluted 1:10 employing coated charcoal to separate free and bound 57Co-B12 (KemEnTec) to separate TC and HC. A sample saturated with 57Co-B12 was run on a Superdex 200 HR 10/30 column (GE Healthcare Europe) using a Dionex ICS-3000 chromatograph (Dionex Corporation), eluted at a flow rate of 400 mL/min for approx. 70 min employing a Tris buffer (0.1 mol/L) (Sigma Aldrich), 1
mol/L NaCl (Merck), 0.5 g/L bovine albumin (Sigma Aldrich), 0.2 g/L sodium-azide (Merck), pH 8.0. The eluted fractions were counted
in a Wizard Automatic Gamma Counter to monitor the elution of 57Co-B12. Molecular mass markers Blue Dextran (Sigma Aldrich) and
22
Na (GE Healthcare Europe) were used for determination of void volume (Vo), and total volume (Vt).
HC and TC binding of Cbi-Ex4 and Ex4
HC and TC binding assays were conducted as previously reported (Stupperich and Nexø, 1991). In brief, typically 50 pmol 57Co-B12
(KemEnTec) was mixed with Cbi-Ex4 and the binding protein (HC or TC) was added in a concentration between 25-40 pmol/l. The
total incubation volume was 0.375 ml, with 0.1 M sodium phosphate and 0.1% human albumin (Sigma-Aldrich), pH 8. The mixture
was equilibrated at 4 C for 20 h. Free versus protein bound corrinoids (cyanocobalamin versus Cbi-Ex4) were separated by precipitating with hemoglobin-coated charcoal previously prepared by mixing equal volumes of a 5% aqueous suspension of activated
charcoal (Sigma-Aldrich) with a 0.5% aqueous solution of bovine hemoglobin (Sigma-Aldrichk). Protein-bound [57Co-B12] was
then measured in a multichannel counter (Merlsgaard, DK).
In vitro GLP-1 binding assay
Agonism at the GLP-1R of Ex4 and Cbi-Ex4, was monitored using HEK293 cells stably transfected with the human GLP-1 receptor.
The cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 10% FBS, 1% pen/strep and 250 mg/mL geneticin/g-418.
HEK293 cells stably transfected with GLP-1R were seeded at 8.5x105 cells/mL in 12 mL in DMEM in a 100 mm x 20 mm sterile
tissue culture dish (TCD). Within 24h of seeding the TCD is 80% confluent and infected with the H188 adenovirus, the most sensitive
cAMP FRET reporter (Klarenbeek et al., 2015), and incubated for 20h prior to screening. Cells, now infected with the H188 adenovirus, were grown to > 95% confluency at which time they were removed from cultured media and placed in 96-well clear-bottom
assay plate (Costar 3904, Corning, NY) in 200 mL/well of a standard extracellular saline (SES) solution supplemented with 11 mM
glucose and 0.1% BSA. Real-time kinetic FRET assays were performed using a FlexStation 3 Multi-Mode Microplate Reader. Assays
were performed at 25 C, over 400 s with subsequent stimulant injections of Ex4 and Cbi-Ex4 concentrations ranging from 3 pM to
1 nM (see Figure 1C, inset) at 100 s, with emission measurements every 6 s. To determine agonism, an increase in 485/535 nm FRET
ratio was monitored indicating increase of cAMP concentration through cAMP binding to an exchange protein directly activate by
cAMP (EPAC) (Klarenbeek et al., 2015).
Jugular catheter surgery and pharmacokinetic profile of Ex4 and Cbi-Ex4 in shrews
Shrews (n = 15) were deeply anesthetized with a cocktail of ketamine, (180 mg/kg; Butler Schein), xylazine (5.4 mg/kg; Anased), and
acepromazine (1.28 mg/kg; Butler Schein). Homemade silicone catheters (9 cm-long, 3Fr, ID 0.56 mm, OD 1 mm, cat. Sku SIL-3-25,
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SAI Infusion Technologies) were pre-filled with bacteriostatic saline 5 IU/mL heparin solution (Butler Schein). A 3 cm-long incision in
the interscapular region and a 2 cm-long incision from the right mandible toward the shoulder were made without cutting any underlying tissue. A subcutaneous route was cleared between the incision sites and the catheter was threaded over the shoudler of the
animal through the cleared path and fixed to a round mesh back-mount that was implanted subcutaneously between the shoulder
blades. The tissue underlying the ventral neck incision was gently dissected using forceps to expose the right jugular vein. The
exposed jugular vein was stretched and tied off toward the surface of the incision and using a flat spatula. Using microsurgical scissors a partial perpendicular incision was made and microsurgical forceps were used to insert the catheter through the incision and
gently inserted 1 cm (a small silicone ball of sealant glue attached to catheter used as stop guide) into the vein. Cannua placement and
patency were verified by drawing up vein blood with a syringe attached to the catheter before the cathether was sealed with metal
obturator. The catheter was secured to the vein by tying two sutures (4-0, silk) around the catheter above and below the silicone ball.
Sutures were tied together and acyrlic glue was placed over the insertion point to secure the catheter in place. Incisions were closed
with simple interrupted sutures (4-0, silk) and all animals received 2 mL of warm saline and analgesic (Meloxicam, 5mg/kg, IP, Boehringer Ingelheim). To prevent infection and maintain patency, catheters were flushed daily with 0.05 mL of the antibiotic Timentin
(0.93 mg/mL; Fisher) dissolved in heparinized saline solution (5 IU/mL), except for the testing days in which the catheters were flushed
with heparinized saline only 30 min prior drug administration.
Three hours before dark onset, shrews were briefly anesthetized with isoflurane (Henry Schein Animal Health) and 50 mL of blood
were collected from their tail into a heparin container (t = 10). Immediately after, each shrew received a bolus IV infusion of either Ex4
(100 and 200 mg/kg [i.e., 25, 50 nmol/kg; respectively]), or equimolar doses Cbi-Ex4. Subsequent blood collection occurred at 5, 45,
90, 135, 180, 270 and 360 min post IV infusion. Plasma was obtained by spinning blood at 6000 g for 6 min and subsequently stored at
80 C. Concentrations of Ex4 and Cbi-Ex4 were measured using a commercial kit purchased from Phoenix Pharmaceuticals
(Exendin-4 (Heloderma suspectum) EK-070-94). The ELISA was performed according to the manufacturer’s protocol with the exception of shrew blood serum that had been dosed with Cbi-Ex4. A Cbi-Ex4 standard curve was generated by matching concentrations
provided by the manufacturer’s standards.
Dose-response effects of Cbi-Ex4 and native Ex4 on glycemic control
The protocol for performing an intraperitoneal glucose tolerance test (IPGTT) in shrews was similar to that previously used in rodents
(Mietlicki-Baase et al., 2018). Two hours before dark onset, shrews were food- and water- deprived. Three hours later, baseline blood
glucose levels were determined from a small drop of tail blood and measured using a standard glucometer (AccuCheck). Immediately
following, each shrew (n = 10) received IP injection of Ex4 (1.25, 5 or 50 nmol/kg) or vehicle (1 mL/100 g BW sterile saline). BG was
measured 30 minutes later (t = 0 min), then each shrew received an IP bolus of glucose (2 g/kg). Subsequent BG readings were taken
at 20, 40, 60 and 120 min after glucose injection. After the final BG reading, food and water were returned. IPGTT studies were carried
out in a within-subject, counter-balanced design and separated by 7 days. In another cohort of animals (n = 11), the same paradigm
was applied but each shrew received IP injection of Cbi-Ex4 (1.25, 5 or 50 nmol/kg) or vehicle instead.
Direct comparison of pharmacological doses of Cbi-Ex4 and Ex4 on glucoregulation during a standard and a delayed
IPGTT
In shrews (n = 14) a standard IPGTT was performed as described above. In this experiment each shrew received IP injection of Ex4
(5 nmol/kg), Cbi-Ex4 (5 nmol/kg) or vehicle in a within-subject, counter-balanced design. Each treatment was separated by 72h.
For the delayed glucose load IPGTT, food (6h pre-IPGTT) and water (4h prior to testing) were removed in a separate cohort of animals (n = 13). A baseline BG reading (t = 360 min) was performed immediately followed by an IP injection of Ex4 (5 nmol/kg), CbiEx4 (5 nmol/kg) or vehicle. BG was measured 3h (t = 120 min), 5.30h (t = 30 min) and 6h (t = 0 min) later and each shrew received IP
injection of glucose (2 g/kg). Subsequent BG readings were taken at 20, 40, 60 and 120 min after glucose injection. After the final BG
reading, food and water were returned. Each IPGTT round was 72h apart.
Dose-response effects of Ex4 and Cbi-Ex4 on energy balance
We first evaluated in two separate group of shrews the effects on food intake and body weight of different doses of native Ex4 and
Cbi-Ex4; respectively. Food was removed one hour prior to dark onset. Shortly before dark onset the first group of shrews (n = 9)
received IP injection of Ex4 (1.25, 5 or 50 nmol/kg), or vehicle. In a second group of shrews (n = 10), IP injections of Cbi-Ex4
(1.25, 5 or 50 nmol/kg) or vehicle were performed. Shrews had ad libitum access to powdered food through a circular (3 cm diameter)
hole in the cage. Food intake was evaluated using our custom-made feedometers, consisting of a standard plexiglass rodent housing
cage (29 3 19 3 12.7 cm) with mounted food hoppers resting on a plexiglass cup (to account for spillage). Food intake was manually
measured at 6, 24 and 48h post injection. Body weight was taken at 0, 24 and 48h. Treatments occurred in a within-subject, counterbalanced design and were 7 days apart.
Direct comparison of pharmacological doses of Cbi-Ex4 and Ex4 on energy balance
We then compare the effects of Ex4 (5 nmol/kg), Cbi-Ex4 (5 nmol/kg) or vehicle in the same animals (n = 8) using in a within-subject,
counter-balanced design. Food was removed one hour prior to dark onset. In this experiment, food intake was evaluated using our
custom-made automated feedometers, in which the food hoppers were attached to a load-cell. The amount of powdered food
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consumed was measured every 10 s to the nearest 0.1 g (Arduino 1.8.8). Data obtained from the feedometer were processed and
converted by computer software (Processing 3.4 and Microsoft Excel) to determine food ingestion every 10 s. Total food intake
curves were cumulated for 3, 6 and 24h. Latency to eat (defined as time required before the onset of a meal exceeding 0.25 g)
was also measured and analyzed. Treatments occurred 72h apart.
Emetogenic properties of Ex4 and Cbi-Ex4
Shrews (n = 14) were habituated to IP injections and to clear plastic observation chambers (23.5 3 15.25 3 17.8 cm) for two consecutive days prior to experimentation. The animals were injected IP with Ex4 (1.25, 5 or 50 nmol/kg), or vehicle, then video-recorded
(Vixia HF-R62, Canon) for 120 minutes. After 120 min, the animals were returned to their cages. In a second group of shrews (n =
14), IP injections of Cbi-Ex4 (1.25, 5 or 50 nmol/kg) or vehicle were performed. Treatments were separated by 7 days. Analysis of
emetic episodes were measured by an observer blinded to treatment groups. Emetic episodes were characterized by strong rhythmic abdominal contractions associated with either oral expulsion from the gastrointestinal tract (i.e., vomiting) or without the passage
of materials (i.e., retching). Latency to the first emetic episode, total number of emetic episodes and number of emetic episodes per
minute were quantified.
Direct comparison of pharmacological doses of Cbi-Ex4 and Ex4 on emesis
Shrews (n = 8) were habituated to the experimental conditions as described above. The animals were injected IP with Ex4 (5 nmol/kg),
Cbi-Ex4 (5 nmol/kg) or vehicle, then video-recorded (Vixia HF-R62, Canon) for 120 minutes. After 120 min, the animals were returned
to their cages. Treatments were separated by 72 h. Analysis of emetic episodes were measured by an observer blinded to treatment
groups. Emetic episodes as well as emetic bouts (defined as series of one or more emetic episodes that occurred within one minute
from each other) were evaluated. Latency to the first emetic episode, total number of emetic episodes, number of emetic episodes
per minute and total emetic bouts were also quantified.
Assessment of neuronal activation in the DVC following Ex4, Cbi-Ex4 or saline treatments
Body weight-matched shrews (n = 13) received IP injection of Ex4 (5 nmol/kg, n = 3), Cbi-Ex4 (5 nmol/kg, n = 6) or vehicle (n = 4) just
prior to dark onset. Food was removed to avoid feeding-related changes in c-Fos expression between groups. Three hours later,
shrews were deeply anesthetized with IP triple cocktail of ketamine, xylazine and acepromazine (180 mg/kg, 5.4 mg/kg and
1.28 mg/kg; respectively) and transcardially perfused with 0.1M PBS (Boston Bioproducts), followed by 4% PFA (in 0.1M PBS,
pH 7.4, Boston Bioproducts). Brains were removed and post fixed in 4% PFA for 48h and then stored in 25% sucrose for two
days. Brains were subsequently frozen in cold hexane and stored at 20 C until further processing. Thirty micrometer-thick frozen
coronal sections containing the DVC were cut in a cryomicrotome (CM3050S, Leica Microsystem), collected and stored in cryoprotectant (30% sucrose, 30% ethylene glycol, 1% polyvinyl-pyrrolidone-40, in 0.1M PBS) at 20 C until further processing. IHC was
conducted according to previously described procedure (Alhadeff et al., 2015). Briefly, free-floating sections were washed with 0.1M
PBS (3x8min), incubated in 0.1M PBS containing 0.3% Triton X-100 (PBST) and 5% normal donkey serum (NDS) for 1h, followed by
an overnight incubation with rabbit anti-Fos antibody (1:1000 in PBST; s2250; Cell Signaling,). After washing (3x8min) with 0.1M PBS
sections were incubated with the secondary antibody donkey anti-rabbit Alexa Fluor 488 (1:500 in 5% NDS PBST; Jackson Immuno
Research Laboratories,) for 2h at room temperature. After final washing (3x8min in 0.1M PBS) the sections were mounted onto glass
slides (Superfrost Plus, VWR) and coverslipped with Fluorogel (Electron Microscopy Sciences). c-Fos positive neurons spanning the
DVC were visualized (20x; Nikon 80i, NIS Elements AR 3.0) and quantified (FIJI software) using fluorescence microscopy. A total of 4
DVC sections per animal were used to quantify the number of c-Fos labeled cells in the AP and NTS at the level of the obex, caudal
medial DVC (200 and 250 mm rostral to the obex, and medial DVC (400 mm rostral to the obex), similarly as previously described (De
Jonghe and Horn, 2009) by an experimenter blinded to the treatment.
Emetogenic properties of albiglutide
Shrews (n = 15) were habituated to the experimental conditions (see above). The animals were injected IP with albiglutide (0.5 or 5 mg/
kg) or vehicle, and video-recorded for 120 minutes. Treatments were carried out in a within-subject, counter-balanced design and
separated by 7 days. Latency to the first emetic episode, total number of emetic episodes, number of emetic episodes per minute
and total emetic bouts were quantified.
Effects of albiglutide on energy balance
The effects of albiglutide on food intake and body weight were analyzed similarly as described above. Shrews (n = 10) were injected
with albiglutide (0.5 or 5 mg/kg) or vehicle. Food intake was measured manually at 6, 24 and 48h post injection. Body weight was
taken at 0, 24, 48, and 72h. Treatments occurred in a within-subject, counter-balanced design and were 7 days apart.
QUANTIFICATION AND STATISTICAL ANALYSIS
All data were expressed as mean ± SEM. For behavioral studies, data were analyzed by a repeated-measures One-Way ANOVA or
Two-Way ANOVA, followed by Tukey’s post hoc test. For all statistical tests, a p value less than 0.05 was considered significant.

e5 Cell Reports 31, 107768, June 16, 2020

Article

ll
OPEN ACCESS

Information on replicates and significance is reported in the figure legends. In the pharmacokinetic study, area under curves (AUCs)
were calculated from 10 to 360 or 1440 min using the trapezoidal method, and analyzed using One-Way ANOVA followed by Tukey’s post hoc test. BG levels were analyzed using Repeated-measurements Two-Way ANOVA followed by Tukey’s post hoc test.
AUCs were calculated from 0 to 60 and 0 to 120 min; respectively, using the trapezoidal method. Resulting AUCs were analyzed using
Repeated-measurements One-Way ANOVA followed by Tukey’s post hoc test. Total number of emetic episodes and emetic bouts
were analyzed using Repeated-measurements One-Way ANOVA followed by Tukey’s post hoc test. Student’s t test was used to
analyzed emetic episodes between two equimolar doses. Comparisons between different proportions of shrews experiencing
emesis under the different treatment conditions (i.e., occurrence) were made using the Fisher’s exact test. Data obtained from the
feedometer were analyzed with Repeated-measurements One-Way ANOVA followed by Tukey’s post hoc test. For IHC, statistical
comparisons were performed using One-way ANOVA followed by Tukey’s post hoc test. All data were analyzed using Prism
GraphPad 8.

Cell Reports 31, 107768, June 16, 2020 e6

Received: 20 February 2020

Revised: 1 May 2020

Accepted: 12 May 2020

DOI: 10.1111/dom.14089

ORIGINAL ARTICLE

A second-generation glucagon-like peptide-1 receptor
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peptide-1 receptor (GLP-1R) agonist exendin-4 (Ex4) that shows reduced
penetrance into the central nervous system while maintaining peripheral
glucoregulatory function.
Methods: We evaluated whether a vitamin B12 conjugate of Ex4 (B12-Ex4)
improves glucose tolerance without inducing anorexia in Goto-Kakizaki
(GK) rats, a lean type 2 diabetes model of an understudied but medically
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compromised population of patients requiring the glucoregulatory effects of
GLP-1R agonists without anorexia. We also utilized the musk shrew (Suncus
murinus), a mammalian model capable of emesis, to test B12-Ex4 on glycaemic
profile, feeding and emesis.
Results: In both models, native Ex4 and B12-Ex4 equivalently blunted the rise in
blood glucose levels during a glucose tolerance test. In both GK rats and shrews,
acute Ex4 administration decreased food intake, leading to weight loss; by contrast,
equimolar administration of B12-Ex4 had no effect on feeding and body weight.
There was a near absence of emesis in shrews given systemic B12-Ex4, in contrast to
reliable emesis produced by Ex4. When administered centrally, both B12-Ex4 and
Ex4 induced similar potency of emesis, suggesting that brain penetrance of B12-Ex4
is required for induction of emesis.
Conclusions: These findings highlight the potential therapeutic value of B12-Ex4
as a novel treatment for type 2 diabetes devoid of weight loss and with reduced
adverse effects and better tolerance, but similar glucoregulation to current
GLP-1R agonists.
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We report both the preservation of hypoglycaemic responses
and superior tolerance of B12-Ex4 over native Ex4 in musk shrews

Nausea and vomiting are omnipresent side effects of human diseases

and the GK rat. B12-Ex4 shows substantially decreased effects on

and pharmacotherapies that have spawned significant drug discovery

emesis compared with the native drug, while maintaining an incretin

efforts to combat their many causes.1 Glucagon-like peptide-1 recep-

profile of glucoregulatory effects with no change in energy balance

tor (GLP-1R)-based therapies for the treatment of type 2 diabetes

in shrews. These data support the potential clinical utility of

2

(T2D), such as Exendin-4 (Ex4) and liraglutide, are no exception, caus-

B12-Ex4 in lean patients, where anorexia and weight loss are unde-

ing nausea and vomiting in 25% to 50% of patients prescribed these

sirable outcomes of T2D management and/or where dose scheduling

drugs.3–7

of GLP-1R agonists is of major concern for patient compliance

We have recently reported that a vitamin B12 conjugate of Ex4
(hereafter called ‘B12-Ex4’)

8,9

shows retention of glucoregulation com-

because of considerations of extensive episodes of nausea and
vomiting.

parable with native Ex4 without producing Ex4-associated anorexia
and conditioned taste avoidance in lean, healthy rats. Furthermore,
B12-Ex4 co-localized with insulin-containing β-cells within the pan-

2

METHODS

|

creas, while brain penetrance of fluorescently tagged B12-Ex4 was not
detected within the hypothalamus, nor the area postrema (AP), nor the

2.1

|

Drugs

nucleus tractus solitarius (NTS) of the hindbrain. These results corroborated that the incretin action on the pancreas10–12 and hypoglycaemic

B12-Ex4 was synthesized, characterized and screened as previously

effects of Ex4 remained intact when bound to B12, while central sites

described.8 For all systemic administrations, B12-Ex4 and Ex4

of Ex4 action controlling energy homeostasis and nausea/malaise

(Bachem, USA) were dissolved in 0.9% saline and administered intra-

(e.g. the brainstem AP and NTS, as well as hypothalamic nuclei)13–15

peritoneally (IP). B12-Ex4 and Ex4 were dissolved in artificial cerebro-

were putatively not agonized following B12-Ex4 treatment. The

spinal

B12-Ex4 construct may be of considerable clinical utility given the

Liraglutide (Sigma-Aldrich) was dissolved in PBS and injected

potential for retained glycaemic control in combination with improved

IP. Fluorophore-labelled B12-Ex4 (Cy5-B12-Ex4) was synthetized as

tolerability and associated patient compliance through a mechanism of

previously described.9

fluid

(aCSF)

for

intracerebroventricular

(ICV)

delivery.

action that simultaneously limits central nervous system (CNS) penetrance and retains peripheral (i.e. pancreatic) pharmacodynamics.
Weight loss is considered desirable for the majority of patients with

2.2

|

Animals

T2D considered overweight or obese, as they may benefit from improvements in insulin signalling and overall health with concomitant adipose
16,17

tissue loss.

Experimentally naive adult male shrews (n = 81) weighing 70-80 g

However, patients with T2D who also suffer from co-

used in this study were offspring from a colony maintained at the Uni-

morbidities associated with cachexia (e.g. cancer,18 cystic fibrosis,19

versity of Pittsburgh Cancer Institute (a Taiwanese strain derived from

HIV,20 chronic obstructive pulmonary disease21 and sarcopenia22), would

stock supplied by the Chinese University of Hong Kong). At

also benefit from use of the front-line treatments for T2D in the form of

2 months of age, the animals were moved to the University of Penn-

GLP1-R agonists, without affecting their body weight. In addition, 10%

sylvania, where all studies presented here were conducted.

of patients with T2D, such as those potentially with polygenic/inherited

Shrews were single-housed in plastic cages (37.3 × 23.4 × 14 cm,

T2D, are not overweight/obese,23 and weight loss below normal weight

Innovive), fed ad libitum with a mixture of feline (75%, Laboratory

status is undesirable. To this end, given our previous work in healthy,

Feline Diet 5003, Lab Diet) and ferret food (25%, High Density Ferret

lean rats, where we showed comparable glycaemic control without

Diet 5LI4, Lab Diet) and had ad libitum access to tap water except

anorexia/weight loss following acute B12-Ex4 treatment compared with

where noted. Experimentally naive adult male GK rats (n = 21, Taconic)

native Ex4, we employ the use of the Goto-Kakizaki (GK) rat, a model of

weighing 350 g upon arrival were individually housed in hanging wire

spontaneous insulin resistance and T2D.24 These animals develop T2D

mesh cages. Rats were fed ad libitum with a chow diet (NIH-31 M Diet,

25

early in life and maintain a lean phenotype (see Ostenson and Efendic

Taconic) and had ad libitum access to tap water, except where noted.

for a discussion/review), making this strain ideal to model T2D without

All animals were housed under a 12-hour/12-hour light/dark cycle in a

concomitant obesity.

temperature- and humidity-controlled environment. All procedures

The musk shrew (Suncus murinus) is a well-established model of
26

emesis

27

and feeding behaviour

and is suitable for examination of

were approved by the Institutional Care and Use Committee of the
University of Pennsylvania.

the GLP-1 system as this species exhibits glucoregulatory, hypophagic
and emetic responsivity following administration of current Food and
Drug Administration-approved GLP-1R agonists.14,15 Here, we

2.3

|

In vivo study design

employ behavioural, immunohistochemical and pharmacological analyses to examine the effects of B12-Ex4 versus Ex4 administration on

Shrews and GK rats were habituated to single housing in their home

glycaemic control, emesis and feeding behaviour in shrews.

cages and IP injections at least 1 week prior to experimentation. All
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experimental injections in shrews were separated by at least 72 hours.

chosen as the route of glucose administration because of the

Experimental testing in GK rats was conducted every 7 days. In vivo

emetogenic properties of Ex4, which could produce expulsion of glu-

experiments used a within-subjects, Latin-square design, except for

cose delivered to the gastrointestinal tract and confound interpreta-

immunohistochemical studies, which were conducted between

tion of results because of the potential variability of intestinal glucose

subjects.

absorption.
To evaluate the effects of Ex4 and B12-Ex4 on baseline BG without subsequent glucose administration, Ex4, B12-Ex4 or vehicle was

2.4

|

Stereotaxic surgery in shrews

administered in a separate cohort of animals (n = 5). Shrews were
food- and water-deprived as described above. Four hours later

The surgical procedure was similar to that previously described.14

(t = −30 minutes), baseline BG levels were determined, and each

Shrews (n = 8) were deeply anaesthetized with a triple cocktail of

shrew received an IP injection of 5 nmol/kg Ex4, 5 nmol/kg B12-Ex4

KAX

Supply],

or vehicle (1 mL/100 g BW sterile saline). BG was measured

acepromazine [1.28 mg/kg; Butler Animal Health Supply] and xylazine

30 minutes later (t = 0 minutes), followed by an IP saline injection

[5.4 mg/kg; Anased]) and placed into a stereotaxic frame equipped

(1 mL/100 g BW). Subsequent BG readings were taken at 20, 40,

with custom-made ear bars (Kopf Instruments). An incision was made,

60 and 120 minutes after glucose injection. After the final BG reading,

the temporalis muscles on either side of the sagittal crest were dis-

food and water were returned.

(ketamine

[180 mg/kg;

Butler

Animal

Health

placed, and the area was cleaned of connective tissue. A hole was
made according to the following coordinates: 8.2 mm rostral to
lambda and 0.9 mm lateral to the midline. A 26-gauge stainless steel
guide cannula (C315G/SPC, PlasticOne) was lowered 1.2 mm below

2.6 | Effects of Ex4 and B12-Ex4 on energy
balance in shrews

the surface of the dura (2 mm above the lateral ventricle) and
cemented to the skull using two screws. After surgery, animals

Shrews (n = 14) were adapted to powdered food for 5 days and habit-

received 2 mL of warm saline and analgesia (Meloxicam, 5 mg/kg, IP,

uated to IP injections for 2 days prior to experimentation. In one

Boehringer Ingelheim). Shrews were allowed 7 days of recovery

cohort (n = 8), shortly before dark onset, shrews received an IP injec-

before the beginning of the experiment. During drug administration,

tion of 5 nmol/kg Ex4, 5 nmol/kg B12-Ex4 or vehicle. In another sub-

the guide cannula was fitted with a 33-gauge injection cannula

group of animals (n = 6), 50 nmol/kg Ex4 (i.e. 200 μg/kg), 50 nmol/

(C315I/SPC, PlasticOne) that extended 2 mm beyond the tip of the

kg B12-Ex4 or vehicle was injected. Food intake was evaluated using

guide cannula. At the end of the experiments, 1 μL of Evans Blue dye

our custom-made automated feedometers,28 which consisted of a

was injected ICV following termination of the animals with IP KAX.

standard plexiglass rodent housing cage (29 × 19 × 12.7 cm) with

Brains were immediately removed and frozen in cold hexane on dry

mounted food hoppers resting on a plexiglass cup (to account for spill-

ice. Coronal sections were performed to confirm the site of injection.

age) attached to a load-cell. Shrews had ad libitum access to powdered

Only those animals with blue staining in the ventricles were included

food through a circular (3 cm diameter) hole in the cage. Food weights

in the analysis.

were measured every 10 seconds to the nearest 0.1 g (Arduino 1.8.8).
Data obtained from the feedometer were processed and converted by
computer software (Processing 3.4 and Microsoft Excel) to determine

2.5 | Effects of Ex4 and B12-Ex4 on glycaemic
control in shrews

food ingestion each 10 seconds. Total food intake curves were cumulated for 3, 6 and 24 hours.

The protocol for performing an intraperitoneal glucose tolerance test
(IPGTT) in shrews was similar to that previously used in mice.9 One
hour before dark onset, shrews (n = 13) were food- and water-

2.7 | Emetogenic properties of systemic Ex4 and
B12-Ex4

deprived. Four hours later (t = −30 minutes), baseline blood glucose
(BG) levels were determined from a small drop of tail blood and mea-

Shrews (n = 24) were habituated to IP injections and to clear plastic

sured using a standard glucometer (AccuCheck). Immediately follow-

observation chambers (23.5 × 15.25 × 17.8 cm) for 2 consecutive

ing this blood sample, each shrew received an IP injection of 5 nmol/

days prior to experimentation. In one group (n = 16), the animals

kg Ex4 (i.e. 20 μg/kg), 5 nmol/kg B12-Ex4 or vehicle (sterile saline,

were injected IP with 5 nmol/kg Ex4, 5 nmol/kg B12-Ex4 or vehi-

1 mL/100 g body weight). BG was measured 30 minutes later

cle, then video-recorded (Vixia HF-R62, Canon) for 90 minutes; the

(t = 0 minutes), then each shrew received an IP bolus of glucose (2 g/

camera was positioned at a slight angle above the chamber. After

kg). Subsequent BG readings were taken at 20, 40, 60 and

90 minutes, the animals were returned to their cages. In a second

120 minutes after glucose injection. After the final BG reading, food

cohort (n = 8), the animals received supra-pharmacological doses of

and water were returned. The dose selection of Ex4 was based on the

50 nmol/kg Ex4, B12-Ex4 or vehicle, and were then video-recorded

literature and pilot experiments showing reliable BG suppression fol-

as described. Analysis of emetic episodes was carried out by an

lowing glucose challenge in shrews.15 Intraperitoneal delivery was

observer blinded to treatment groups. Emetic episodes were

1732

characterized by strong rhythmic abdominal contractions associated with either oral expulsion from the gastrointestinal tract

BORNER ET AL.

2.8 | Emetogenic properties of centrally
administered Ex4 and B12-Ex4

(i.e. vomiting) or without the passage of materials (i.e. retching
movements). An emetic bout was defined as a series of one or more

Lateral ventricle cannulated shrews (n = 8) were habituated to obser-

emetic episodes that occurred within 1 minute of each other.

vation chambers for 2 days prior to experimentation, as in peripheral

Latency to the first emetic episode, total number of emetic epi-

administration experiments. Ex4 (0.24 nmol, i.e. 1 μg), 0.24 nmol

sodes and the number of emetic episodes per minute, as well as

B12-Ex4 or vehicle (aCSF) was infused ICV (total volume 1 μL).

emetic bouts, were calculated.

Shrews

were

then

video-recorded

for

120 minutes.

After

F I G U R E 1 Systemically delivered
B12-Ex4 enhances glucose clearance
during an intraperitoneal glucose tolerance
test (IPGTT) and co-localizes with insulin in
pancreatic β-cells in shrews. (A) In an
IPGTT, Ex4 (5 nmol/kg, i.e. 20 μg/kg) and
B12-Ex4 (5 nmol/kg) showed a similar
potency in suppressing blood glucose
(BG) levels after intraperitoneal (IP) glucose
administration (2 g/kg, IP) compared with
saline; saline versus B12-Ex4: *** P < .001;
saline versus Ex4: ### P < .001. (B) Area
under the curve (AUC) analysis from
0 (i.e. postglucose bolus) to 120 minutes;
B12-Ex4 and Ex4 similarly reduced AUCs
compared with saline. (C, D) To investigate
the effects of B12-Ex4 and Ex4 on baseline
glucose homeostasis, the same doses of
Ex4, B12-Ex4 or saline were administered
without subsequent glucose administration.
Ex4 and B12-Ex4 treatments were no
longer effective in reducing BG levels and
had no effect on AUC. (E) Systemically
injected fluorophore-labelled B12-Ex4
(Cy5-B12-Ex4, 5 nmol/kg) co-localized with
insulin in shrew pancreatic tissue
supporting the hypothesis that B12-Ex4
acts at the pancreas to improve glycaemic
control. All data are expressed as
mean ± SEM. Data in (A) and (C) were
analysed with repeated measurements
two-way ANOVA followed by Tukey's post
hoc test. Data in (B) and (D) were analysed
with repeated measurements one-way
ANOVA followed by Tukey's post hoc test.
Means with different letters are
significantly different (P < .05). In (A, B),
n = 13, within subject; in (C-D), n = 5,
within subject
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120 minutes, the animals were returned to their cages. Each treat-

hexane and stored at −20 C until further processing. Thirty

ment was 72 hours apart. Analysis of emetic episodes was performed

micrometre-thick frozen coronal sections containing the dorsal vagal

as described above.

complex (DVC) were cut in a cryomicrotome (CM3050S, Leica
Microsystem), then collected and stored in cryoprotectant (30%
sucrose, 30% ethylene glycol, 1% polyvinyl-pyrrolidone-40, in PBS)

2.9 | Assessment of neuronal activation in the
dorsal vagal complex following Ex4, B12-Ex4 or saline
treatments in shrews

at −20 C until further processing. Immunohistochemistry was conducted according to a previously described procedure.29 Briefly,
free-floating sections were washed with PBS (3 × 8 minutes), incubated in PBS containing 0.3% Triton X-100 (PBST) and 5% normal

Body weight-matched shrews (n = 13) received an IP injection of

donkey serum (NDS) for 1 hour, followed by an overnight incuba-

5 nmol/kg Ex4, 5 nmol/kg B12-Ex4 or vehicle, just prior to dark onset.

tion with rabbit anti-Fos antibody (1:1000 in PBST; s2250; Cell Sig-

Food was removed to avoid feeding-related changes in c-Fos expres-

naling). After washing (3 × 8 minutes) with PBS, sections were

sion between groups. Three hours later, shrews were deeply

incubated with the secondary antibody donkey anti-rabbit Alexa

anaesthetized with an IP triple cocktail of KAX and transcardially per-

Fluor 555 (1:500 in 5% NDS PBST; Jackson Immuno Research Lab-

fused with phosphate buffered saline (PBS, 0.1 M, pH 7.4; Boston

oratories) for 2 hours at room temperature. After final washing

Bioproducts), followed by 4% paraformaldehyde (PFA) in PBS. Brains

(3 × 8 minutes in 0.1 M PBS) the sections were mounted onto glass

were removed and postfixed in 4% PFA for 48 hours and then stored

slides (Superfrost Plus, VWR) and coverslipped with Fluorogel

in 30% sucrose for 2 days. Brains were subsequently frozen in cold

(Electron Microscopy Sciences). A total of three DVC sections per

F I G U R E 2 Pharmacological and supra-pharmacological doses of B12-Ex4 do not affect feeding and body weight in shrews. (A, B) Ex4
(5 nmol/kg) suppressed feeding at 3, 6, 12 and 24 hours, whereas equimolar doses of B12-Ex4 had no effect on food intake. (C) Ex4-induced
anorexia was accompanied by body weight loss. No significant changes in body weight were observed after B12-Ex4 administration compared
with controls. (D, E) Ex4 (50 nmol/kg, i.e. 200 μg/kg) suppressed eating at all measured time points. By strict contrast, supra-pharmacological
equimolar doses of B12-Ex4 did not show any effects. (F) While severe body weight loss occurred following supra-pharmacological doses of Ex4,
no significant changes occurred in the B12-Ex4–treated animals. All data are expressed as mean ± SEM. Data were analysed with repeated
measurements one-way ANOVA followed by Tukey's post hoc test. Means with different letters are significantly different (P < .05). In (A-C),
n = 8, within subject; in (D-F), n = 6, within subject
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animal were used to quantify the number of c-Fos–labelled cells in
the AP and NTS of the DVC (200-250 μm rostral to the obex). c-

2.10 | Evaluation of B12-Ex4 presence/penetrance
in the pancreas

Fos–positive neurons were visualized and quantified manually in a
blind fashion using fluorescence microscopy (20x; Nikon 80i, NIS

Shrews (n = 4) received an IP injection of 5 nmol/kg Cy5-B12-Ex4 and

Elements AR 3.0).

were transcardially perfused 3 hours later as described above.

FIGURE 3

Legend on next page.
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Pancreases were immediately dissected. Thirty micrometre-thick fro-

measures two-way ANOVA followed by Tukey's post hoc test. Each

zen sagittal sections were processed via immunohistochemistry for

area under the curve (AUC) was calculated from 0 to 120 minutes

0

insulin and coverslipped with 4 ,6-diamidino-2-phenylindole mounting

using the trapezoidal method. The resulting AUCs were analysed

medium as previously described.9 Sections were visualized with con-

using a repeated measures one-way ANOVA followed by Tukey's post

focal microscopy (Leica SP5 X) using the 488 and 594 laser lines with

hoc test. The total numbers of emetic episodes and emetic bouts were

10x and 20x objectives. All images were collected sequentially to

analysed using a repeated measures one-way ANOVA followed by

avoid contamination of signals from other fluorophores.

Tukey's post hoc test. Data obtained from the feedometer were
analysed with repeated measures one-way ANOVA followed by
Tukey's post hoc test. For the immunohistological study, statistical

2.11 | Effects of B12-Ex4, Ex4 and liraglutide on
glycaemic control, insulin profile and energy balance in
GK rats

comparisons were performed using a one-way ANOVA followed by

GK rats (n = 21) were adapted to insertion of a gavage for 1 week

3

Tukey's post hoc test.

|

RE SU LT S

before the beginning of the experiment. On the test day, animals were
food deprived 2 hours before dark onset and, just after onset of the
dark phase, water was also removed from the cage. Three hours later,
a small drop of blood was collected from the tail tip and analysed for

3.1 | Study 1: systemically delivered B12-Ex4
enhances glucose clearance relative to Ex4 and colocalizes with insulin in pancreatic β-cells in the shrew

BG level using a standard glucometer (AccuCheck). Immediately after
this baseline BG reading (t = −60 minutes), each rat received an IP

We first tested whether B12-Ex4 reduces BG following an IPGTT in

injection of 5 nmol/kg Ex4, 5 nmol/kg B12-Ex4, liraglutide (100 μg/

shrews. We observed that shrews treated with equimolar B12-Ex4

kg) or vehicle (1 mL/kg sterile saline). Doses of drugs were selected

and native Ex4 display similar improvements in glucose clearance fol-

9,30,31

based on previous reports

and pilot studies conducted in GK

lowing glucose load compared with saline controls (Treatment × Time
= 5.522; P < .0001, Figure 1A). Post hoc analyses

rats. BG was measured 60 minutes later (t = 0 minutes) and each rat

interaction F[10,

received an oral gavage of glucose (1 g/kg). Subsequent BG readings

showed that both compounds significantly suppressed BG at

were taken at 20, 40, 60, 120 and 180 minutes after glucose gavage.

20, 40 and 60 minutes after glucose administration compared with

After the final BG reading, food and water were returned.

saline treatment (all P < .001). Furthermore, the AUC for B12-Ex4 did

140]

not differ from native Ex4 following glucose administration
(Treatment effect F

2.12

|

Statistical analyses

(2, 28)

= 7.218; P < .003, Cbi-Ex4 vs. Ex4; P > .05,

Figure 1B). Additionally, we administered Ex4, B12-Ex4 or saline without subsequent glucose injection and observed that both Ex4 and

All data were expressed as mean ± SEM. For behavioural studies, data

B12-Ex4 did not produce basal BG change (Treatment × Time interac-

were analysed by a repeated measures one- or two-way ANOVA,

tion F[10, 60] = 0.1682; P > .05) or impact the glucose AUC (Treatment

followed by Tukey's post hoc tests. For all statistical tests, a P-value

effect F

of less than 0.05 was considered significant. Data were analysed using

B12-Ex4 is taken up by insulin-producing cells in the pancreas, shrews

Prism GraphPad 8.0. BG levels measured during the oral glucose toler-

were injected IP with a fluorescently labelled version of B12-Ex4

ance tests (OGTTs) and IPGTTs were analysed using a repeated

(Cy5-B12-Ex4, 5 nmol/kg) and sacrificed 3 hours after delivery.

(2, 8)

= 1.652; P > .05, Figure 1C,D). To assess whether

F I G U R E 3 Emesis in shrews is significantly reduced following B12-Ex4 treatment compared with native Ex4, denoting improved tolerance
across different doses. (A) The percentage of shrews experiencing emesis was significantly different between Ex4 (5 nmol/kg) and equimolar
B12-Ex4 (*** P < .001). None of the animals experienced emesis following saline administration (data not shown). (B) The number of single emetic
episodes following Ex4 (5 nmol/kg), equimolar B12-Ex4 or saline systemic administration was recorded for 90 minutes. Ex4 induced robust
emetic responses that were not observed after B12-Ex4 or saline injections. (C) The number of emetic bouts was also lower after B12-Ex4
treatment compared with Ex4 and it did not differ from saline controls. (D) Latency to the first emetic episode in Ex4 animals that exhibited
emesis. (E) Heatmap showing the emetic latency and intensity, as well as the number of emetic episodes induced by Ex4 or B12-Ex4 for each
animal across time. A similar experiment was conducted with supra-pharmacological doses of Ex4 and B12-Ex4. Astonishingly, no emesis
occurred after B12-Ex4 administration. (F) The percentage of shrews experiencing emesis was completely reversed between Ex4 (50 nmol/kg,
i.e. 200 μg/kg) and equimolar B12-Ex4 (*** P < .001). No animal experienced emesis following saline injection (data not shown). (G, H) The
number of emetic episodes and bouts following Ex4 (50 nmol/kg), equimolar B12-Ex4 or saline administration was analysed over 90 minutes.
Also, at this dosage Ex4 induced robust emetic responses. (I) Latency to the first emetic episode in Ex4 shrews that exhibited emesis. (J) Heatmap
showing the emetic latency and intensity, as well as the number of emetic episodes for each animal across time. All data are expressed as
mean ± SEM. Data in (A, F) were analysed with Fisher's exact test. Data in (B, C, G, H) were analysed with repeated measurements one-way
ANOVA followed by Tukey's post hoc test. In (A-C), n = 16, within-subject; in (F-H), n = 8, within subject. Means with different letters are
significantly different (P < .05)
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Results show that upon systemic administration, Cy5-B12-Ex4 co-

interaction F

localized with insulin in pancreatic β-cells (Figure 1E).

weight loss 24 hours after injection (all P < .05, Treatment effect
F (2,

14)

(6,

42)

= 4.097; P < .003, Figure 2A,B) and body

= 6.9; P < .01, Figure 2C). By contrast, no significant effects

on food intake (all P > .05, Figure 2A,B) or body weight (P > .05,

3.2 | Study 2: B12-Ex4 does not alter food intake
or body weight, contrary to administration of Ex4,
which does reduce food intake and leads to body
weight loss in the shrew

Figure 2C) were observed following B12-Ex4 treatment. In a
second experiment, shrews were injected IP with a suprapharmacological dose of Ex4 (50 nmol/kg, i.e. 200 μg/kg),
B12-Ex4 (50 nmol/kg) or saline. Ex4 induced anorexia at all
measured time points (all P < .05, Treatment × Time interaction

Shrews received an IP injection of Ex4 (5 nmol/kg), B12-Ex4

F

(5 nmol/kg) or saline, to test whether B12-Ex4 administration alters

loss (P < .05, Treatment effect F (2, 10) = 12.94; P < .002, Figure 2F).

food intake or body weight in this species. In line with previous

By contrast, administration of equimolar doses of B12-Ex4 did not

reports,14 systemic administration of Ex4 produced hypophagia in

induce hypophagia (Figure 2D,E) or body weight loss compared

shrews at all measured time points (all P < .05, Treatment × Time

with saline-treated animals (Figure 2F).

(6, 30)

= 6.894; P < .001, Figure 2D,E), and 24 hours body weight

F I G U R E 4 Systemic administered B12-Ex4 does not activate the area postrema (AP) or the nucleus tractus solitarius (NTS) in shrews but it
causes emesis when administered centrally. (A) Representative immunostainings of the AP/NTS region showing the c-Fos response following
saline (n = 4), Ex4 (5 nmol/kg, n = 4) and equimolar B12-Ex4 (n = 5) systemic treatment. (B) Peripheral Ex4 administration significantly increased
the number of c-Fos immunoreactive (IR) cells in the AP/NTS of shrews 3 hours after injection. The number of c-Fos–positive cells in the AP/NTS
was significantly lower in B12-Ex4–treated animals and it did not differ from saline-treated shrews. (C) Ex4 (0.24 nmol, i.e. 1 μg), equimolar
B12-Ex4 or vehicle was infused into the lateral ventricle. The percentage of shrews showing emesis was similar between Ex4 and B12-Ex.4. (D, E)
The number of single emetic episodes or bouts following Ex4, B12-Ex4 or saline was recorded for 120 minutes. Both Ex4 and B12-Ex4 induced
comparable emetic responses, while none of the animals experienced emesis following vehicle delivery (data not shown). (F) Latency to the first
emetic episode in Ex4- and B12-Ex4–treated animals that exhibited emesis did not differ. Data in (B) were analysed with one-way ANOVA
followed by Tukey post hoc test. Means with different letters are significantly different from each other (P < .05). In (C) the analysis was
performed with Fisher's exact test. Data in (D-F) were analysed with Student t-test (n = 8, within subject). Values are expressed as mean ± SEM.
Scale bar 100 μm
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3.3 | Study 3: B12-Ex4 treatment produces only
slight emesis compared with the potent emetic effects
of Ex4

3.4 | Study 4: systemically administered B12-Ex4
does not induce c-Fos in the AP or the NTS, while
central administration of B12-Ex4 and Ex4 similarly
produce emesis

Ex4 (5 nmol/kg) induced emesis in the majority of the shrews tested
(Figure 3A). By contrast, only one shrew experienced emesis after

Ex4, but not B12-Ex4, induced c-Fos immunofluorescence compared

equimolar B12-Ex4 administration (P < .001). The number of single

with saline-treated controls within the NTS (Treatment effect F

emetic episodes (Treatment effect F

= 28.82; P < .0001) and AP (Treatment effect F

(2,

30)

= 9.368; P < .002,

Figure 3B) and emetic bouts (Treatment effect F

(2, 10)

(2, 10)

= 6.62; P < .02,

= 20.5;

Figure 4A,B). ICV administration of Ex4 (0.24 nmol) and B12-Ex4

P < .0001, Figure 3C) in the 90 minutes window after drug administra-

(0.24 nmol) induced emesis with similar emetogenic profiles. We

tion were also significantly reduced after B12-Ex4 compared with Ex4

observed no difference in the percentage of shrews experiencing

and did not differ from the control condition. Ex4 triggered emesis

emesis following central B12-Ex4 or Ex4 administration (Figure 4C).

with an average latency of 19 ± 5 minutes (Figure 3D). A heatmap

Furthermore, the number of single emetic episodes (Figure 4D), the

representation of the Ex4 and B12-Ex4 effects on emetic intensity

number of emetic bouts (Figure 4E), as well as the latency to the first

and latency for each individual animal across time can be seen in

emetic response (Figure 4F), were not statistically different between

Figure 3E.

B12-Ex4 and Ex4. ICV administration of aCSF did not induce any

(2, 30)

Next, we tested supra-pharmacological doses of Ex4 and

emesis in shrews (data not shown).

B12-Ex4 and observed that Ex4 induced profound emesis,
reflected by both the number and severity of emetic episodes, in
100% (i.e. 8/8, P < .001) of the shrews tested, while an equimolar
dose of B12-Ex4 did not induce emesis in shrews (Treatment
effect on single emetic episodes F

(2, 14)

Treatment effect on emetic bouts F

= 15.39; P < .0003, and

(2, 14)

3.5 | Study 5: B12-Ex4 enhances glucose clearance
during an OGTT without inducing anorexia and body
weight loss in the GK rat

= 20.4; P < .0001,

Figure 3G,H). The average latency to first emetic episode induced

We tested the effects of Ex4, B12-Ex4 and liraglutide on oral glucose

by Ex4 was 52 ± 8 minutes (Figure 3I). The emetic profiles of each

tolerance, food intake and body weight in GK rats. Similar to the

animal following B12-Ex4 or Ex4 administration are represented

effects of liraglutide (100 μg/kg), B12-Ex4 reduced the glucose level

in Figure 3J.

following an OGTT compared with saline at 20 and 40 minutes after

F I G U R E 5 B12-Ex4 enhances glucose clearance during an oral glucose tolerance test (OGTT) without inducing anorexia and body weight loss
in the Goto-Kakizaki lean diabetic rat model. (A) In an OGTT, liraglutide (100 μg/kg, i.e. 26.6 nmol/kg) and 5 nmol/kg B12-Ex4 suppressed blood
glucose levels after intraperitoneal (IP) glucose administration (1 g/kg, PO) compared with 5 nmol/kg Ex4 (i.e. 20 μg/kg) and saline. * saline
versus others; #: Ex4 versus others; $: liraglutide versus others. *, #, $: P < .05; **, ##, $$: P < .01; ***, ###, $$$: P < .001. (B) Liraglutide and Ex4
induced a strong anorectic effect, which was not observed after B12-Ex4 treatment. (C) Hypophagia was accompanied by body weight loss in
liraglutide- and Ex4-treated animals, while no significant body weight change was observed following B12-Ex4. Data were analysed with repeated
measure two-way ANOVA (A) or one-way ANOVA (B, C) followed by Tukey post hoc test; n = 21, within subject. All data are expressed as
mean ± SEM. Means with different letters are significantly different from each other (P < .05)
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glucose load, and to native Ex4 (5 nmol/kg) at 120 and 180 minutes

Indeed, alternative therapies approved for the treatment of T2D

after glucose load (all P < .01, Treatment × Time interaction

(e.g. dipeptidyl peptidase-4 inhibitors, metformin and sodium-glucose

F[18,

= 11.92; P < .0001, Figure 5A). However, while both

co-transporter-2 inhibitors) do not achieve the same overall positive

liraglutide and native Ex4 suppressed 24 hours food intake leading to

outcome on glucose handling compared with GLP-1R agonists. Impor-

24 hours body weight loss (all P < .05), no hypoghagic or body weight

tantly, these alternative strategies also lead to modest but significant

suppressive effects were observed after B12-Ex4 administration in

body weight reductions.36,37

360]

this lean diabetic model (Treatment effect on food F(3,

60)

= 95.41;

Preventing access to CNS GLP-1Rs is the probable explanation

P < .0001, and Treatment effect on body weight F(3,

60)

= 28.21;

for the lack of B12-Ex4–induced emesis in the shrew. Our
immunohistological evidence supports this notion as we observed

P < .0001, Figure 5B,C).

sparse c-Fos activation following systemic B12-Ex4 administration in
the AP and NTS, two hindbrain nuclei known to mediate feeding

4

|

behaviour and emesis,13,38–41 while native Ex4 produced robust acti-

DISCUSSION

vation of these nuclei. To provide functional evidence that B12 conjuExisting GLP-1-based pharmacotherapies are excellent glucoregu-

gation itself does not impact the emetic nature of Ex4, we centrally

latory drugs for treating hyperglycaemia in the majority of patients

administered B12-Ex4 directly into the lateral ventricle of the shrew,

with T2D despite reported nausea and vomiting. These phenomena,

which produced a comparable emetic profile with that of native Ex4

however, are gaining notoriety as overlooked major side effects in

(e.g. the number of emetic episodes, latency to vomit, and the propor-

many patients, which reduce patient compliance and make current

tion of treated animals experiencing emesis). These data suggest that

GLP-1R agonists ‘suboptimal’.

3–7,32,33

Designing and testing second-

when centrally delivered, and thus bypassing the blood–brain barrier,

generation GLP-1-based drugs aimed at improving patient tolerance

B12-Ex4 is a stimulus that can produce an emetic profile consistent

while preserving or enhancing glucoregulatory control therefore

with Ex4 alone.

provides clear clinical value. Here, we report that a B12-Ex4 conjugate

To speculate how conjugation to B12 reduces CNS penetrance of

previously shown to exert comparable glycaemic control with limited

Ex4, increased polarity may be an important variable rather than the

anorexia and nausea-like effects compared with native Ex4 in rats9

increased molecular size alone, given that GLP-1R agonists with

produced comparable glycaemic control, and better tolerance, in an

greater molecular masses, such as liraglutide, have been shown to

emetic mammalian species and in a lean polygenetic rat model

penetrate into the hindbrain and to stimulate direct GLP-1R activa-

of T2D.

tion.30,42,43 It is also possible that the binding of B12-Ex4 to the B12

In line with previous reports in lean, non-diabetic rats and

carrier proteins transcobalamin (TC) or haptocorrin (HC) in serum, pre-

shrews,9,14,30,31 both native Ex4 doses (5 and 50 nmol/kg) tested here

viously confirmed for this construct,9 further reduces brain pene-

induced anorexia and body weight loss over 24 hours in shrews. By

trance because its size (now >60 KDa) either actively transports the

contrast, no such effects occurred after B12-Ex4 treatments, even at

conjugate to systemic targets (via TC), maintains the conjugate in

supra-pharmacological doses (i.e. 50 nmol/kg). The lack of short-term

serum (via HC), or protects the conjugate from proteolytic degrada-

effects on feeding was unexpected given reports of a role of vagal

tion (via TC or HC),8 as is typical for dietary B12 alone.44 As noted,

afferent signalling in the mediation of the early-phase anorexia

however, the shrew has both TC and HC, unlike rodents, which have

34,35

induced by both GLP-1 and native Ex4 in rats.

Our previous

only TC. In comparison with studies performed for B12-Ex4 in

report also observed this effect in lean, healthy rats treated with the

rodents,9 we see comparable pharmacodynamics (in terms of illness

9

highest dose of B12-Ex4. This incongruency, however, could be

behaviours and glucoregulation), suggesting that the presence of both

explained by broad species differences in metabolism between rats

TC and HC is not specifically necessary for the conjugate. It may be

and shrews, rather than by the direct action of the drug.

that the benefits of conjugation lie solely with the B12 molecule itself,

Furthermore, B12-Ex4 administration resulted in a near complete

or simply through the effects of binding to any B12 binding protein in

absence of emesis compared with potent emetic effects of Ex4 in the

terms of protection and/or mitigation of hindbrain access. Our data

shrew. In fact, we observed that 10-fold the threshold concentration

suggest that it is the unique structure of B12-Ex4, rather than simply

necessary for glucoregulation did not cause emesis with B12-Ex4,

mass, which drives its unique pharmacodynamic profile and underlying

while all animals tested with this dose of Ex4 experienced emesis.

properties.

Together, these findings show that it is possible to both physiologi-

Pancreatic β-cells expressing the GLP-1R represent the probable

cally and pharmacologically separate the emetic potential of GLP-1R

cellular substrate mediating the hypoglycaemic effects of B12-Ex4 in

agonists like Ex4 from their glucoregulatory role, and that a wide

shrews. Our proof of concept (via microscopy) shows that a fluores-

range of B12-Ex4 doses produce limited anorectic or emetic side

cently tagged B12-Ex4 conjugate (Cy5-B12-Ex4) co-localizes with

effects. These data suggest that a B12-Ex4 conjugate could improve

insulin in the shrew pancreatic β-cells. By employing fluorescently

T2D medication adherence compared with existing GLP-1 mimetic

tagged Ex4 in combination with Cy5-B12-Ex4, further investigations

drugs. This is particularly relevant given the pleiotropic nature of

are warranted to examine the binding specificity of B12-Ex4 in the

GLP-1, with a myriad of effects, mainly beneficial, which render

pancreas. Nevertheless, the current data support our previous work in

GLP-1 analogues as one of the best current treatments for T2D.

rodents9 and strengthen the notion that the incretin effect occurring
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after GLP-1 analogue administration is mediated by direct activation
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support our hypothesis that limiting or blocking Ex4 entry into the
brain dramatically reduces the side effects of the Ex4 drug
(i.e. prevents anorexia and emesis), while maintaining the glucoregulatory efficacy of the compound. The overall outcomes of
this work highlight the translational potential of B12-Ex4–based
pharmacotherapies for use in lean T2D patients where weight loss
is an undesirable outcome, although chronic studies are needed to
elucidate the efficacy, tolerability and pharmacodynamics of
B12-Ex4 in long-term treatment. Albeit small, there is the possibility that B12-Ex4 chronic exposure would interfere with normal
B12 physiology, potentially reducing the amount of dietary B12
available in the body.51 Further, while we do not predict
tachyphylaxis, the extent to which the observed positive effects
will be maintained requires future empirical testing. Nonetheless,
the current data underlie the potential use of B12-Ex4 for patients
with T2D who either do not tolerate current GLP-1 agonists or suffer from co-morbidities associated with an anorectic/cachectic
state, for which the body weight-suppressing effects of a standard
GLP-1R agonist are an unwanted side effect, with the loss of nausea/emesis an additional benefit.
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Abstract
Previous studies identify a role for hypothalamic glia in energy balance regulation; however, a narrow hypothalamic
focus provides an incomplete understanding of how glia throughout the brain respond to and regulate energy
homeostasis. We examined the responses of glia in the dorsal vagal complex (DVC) to the adipokine leptin and high
fat diet-induced obesity. DVC astrocytes functionally express the leptin receptor; in vivo pharmacological studies
suggest that DVC astrocytes partly mediate the anorectic effects of leptin in lean but not diet-induced obese rats. Ex
vivo calcium imaging indicated that these changes were related to a lower proportion of leptin-responsive cells in the
DVC of obese versus lean animals. Finally, we investigated DVC microglia and astroglia responses to leptin and energy
balance dysregulation in vivo: obesity decreased DVC astrogliosis, whereas the absence of leptin signaling in Zucker
rats was associated with extensive astrogliosis in the DVC and decreased hypothalamic micro- and astrogliosis. These
data uncover a novel functional heterogeneity of astrocytes in different brain nuclei of relevance to leptin signaling
and energy balance regulation.

Introduction
The development of efﬁcacious weight management
therapies to treat obesity requires a broader understanding of the underlying biological basis of obesity.
Current knowledge regarding the neural circuitry that
regulates energy balance is limited, due in part to an
incomplete characterization of the participation of nonneuronal cells such as glia. There are four known types of
glia cells found within the central nervous system (CNS);
astrocytes, oligodendrocytes, microglia, and ependymal
cells. These glia cells represent an important potential
target for the treatment of obesity and obesity-related
disorders. Astrocytes are the most abundant glia cell type
in the mammalian CNS1. Rather than acting as passive
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supporters of neuronal function, modern neuroscience
widely acknowledges the dependence of neurons on
astrocytes for synaptic efﬁciency and neuronal excitability
(reviewed in ref. 2). Astrocytes participate in numerous
CNS functions including assisting in the transport of
circulating factors across the blood-brain barrier3,4, regulation of synaptic glutamate levels5 and the release of
gliotransmitters6 that participate in neurotransmission
(reviewed in ref. 2). Despite our growing appreciation of
this bidirectional communication between astrocytes and
neurons7, the speciﬁc, and likely heterogeneous, role of
astrocytes in energy balance regulation is understudied.
To date, much of our knowledge about the roles of glia
in the control of food intake and body weight regulation
comes from seminal work in the hypothalamus. Indeed,
hypothalamic astrocytes detect and transport nutrients8–10,
aid in the development and plasticity of metabolic circuitry11,12 and respond to an array of neuropeptides and
metabolic hormones such as the adipokine hormone
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leptin13–15. Some research hypothesizes that, as the resident immunocompetent cells of the brain16, microglia
partially drive obesity-associated “neuroinﬂammation”.
This hypothesis is supported by the observed association
between the activation and proliferation of glia cells
(deﬁned as gliosis) in the hypothalamus and obesityinduced hypothalamic inﬂammatory cytokines (often
overstated as “neuroinﬂammation”)17–20. Moreover, in
rats susceptible to diet-induced obesity, there is signiﬁcant
hypothalamic inﬂammation21 and glia-mediated synaptic
reorganization favoring orexigenic signaling22. Several
studies further ascribe obesity-associated inﬂammation in
the hypothalamus to alternations in leptin signaling at its
cognate receptor (LepR). Indeed, leptin-deﬁcient Ob/Ob
mice exhibit profound hypothalamic gliosis when maintained on a high-fat diet23,24. The interactions of high-fat
diet, leptin signaling, and neuroinﬂammation described in
the medial hypothalamus and its relevance to energy
balance regulation are largely uninvestigated in other key
nuclei. Given that the neural control of energy balance is
not restricted to the hypothalamic subnuclei, but rather is
distributed throughout the brain25,26, an investigation of
the role of glia in extra-hypothalamic nuclei governing
energy balance may provide insight into the central dysregulation of diet-induced obesity, as well as the relationship between leptin and astrogliosis.
Looking beyond the hypothalamus, the dorsal vagal
complex (DVC) of the caudal brainstem represents
another CNS node in the detection, integration, and
processing of numerous metabolic and endocrine signals,
including leptin27–29. The DVC is comprised of the
nucleus tractus solitarius (NTS), area postrema (AP), and
dorsal motor nucleus of the vagus. Leptin receptor signaling in the DVC suppresses food intake and most
notably potentiates the intake suppressive effects of
within-meal gastrointestinally derived satiation signals
(e.g., gastric distension and cholecystokinin)28,30–34.
Despite a clear role for the DVC in energy homeostasis,
very few studies characterize the speciﬁc cellular phenotypes that express LepR in the DVC. Evidence of LepR
expression on NTS astrocytes35 led to the current
hypothesis investigated here, that DVC glia are a prime
cellular target for central leptin signaling. We investigated
the expression of LepR on astrocytes in the DVC and
assessed the role of DVC astrocytes in mediating the
anorectic effects of leptin. Moreover, we examine the
inﬂuence of obesity and perturbations in leptin signaling
on the glia landscape in both the DVC and hypothalamus.

Materials and methods
Animals

Male Sprague Dawley rats (250–265 g, Charles River
(UPenn) or Envigo (PBRC)) were maintained on either
standard chow (Purina Rodent Chow 5001; Ralston
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Purina Company, St. Louis, Missouri) or a 60% high-fat
diet (HFD; Rodent Diet D12492; Research Diets, New
Brunswick, New Jersey) with ad libitum access to tap
water. Zucker diabetic fatty rats (ZDF; Charles River) were
maintained on a standard chow diet. Animals were singlehoused in hanging wire cages in a temperature- and
humidity-controlled environment on a reverse 12h:12h
light-dark cycle. All behavioral experiments were carried
out in a counter-balanced, within-subjects design, no
randomization required. All experimental procedures
were conducted with the approval of the University of
Pennsylvania and Pennington Biomedical Research Center Institutional Animal Care and Use Committees.
Stereotaxic surgeries

Rats were anesthetized with an intramuscular injection of
ketamine (90 mg/kg; Butler Schein), xylazine (2.7 mg/kg;
Midwest Veterinary Supply), and acepromazine (0.64 mg/
kg; Midwest Veterinary Supply). Using stereotaxic surgery,
rats were implanted with an indwelling cannula (26-gauge;
Plastics One) directed at the 4th cerebroventricle (4V;
coordinates: on midline, 2.5 mm anterior to the occipital
suture and 7.2 mm ventral to the skull36. Postoperative
analgesia (2 mg/kg meloxicam) was administered subcutaneously for 2 days, and animals were allowed to recover
for one week. Proper placement and cannula patency were
veriﬁed before behavioral testing via 5-thio-D-glucose
(210 μg)-induced hyperglycemia as previously described37;
only animals that passed veriﬁcation were tested.
Synthesis and administration of Cy5-labeled leptin

Recombinant mouse leptin (2.0 mg; NHPP) was dissolved in 500 μL of 50 mM phosphate buffer (pH 7.4) and
gently rocked in non-stick Eppendorf tubes (Thermo
Scientiﬁc, Cat no. 3451). A quantity of 0.2 mg sulfocyanine 5 NHS ester (Lumiprobe, Cat no. 23320) was
dissolved in 50 μL DMSO and then added to the predissolved leptin in 10-μL aliquots over 1 h. The reaction
was stirred at ambient temperature overnight then puriﬁed using a Shimadzu Prominence HPLC with a C18
column (Eclipse XDB-C18 5μm, 4.6 x 150 mm) and a
gradient of [1% CH3CN/H2O + 0.1% to TFA] to [70%
CH3CN/H2O + 0.1% to TFA] over 15 min. The product
was obtained with a ~TR of 10 min at 98% purity, lyophilized, and stored at –20 °C. Electronic absorption
spectra were obtained on a Varian Cary 50 Bio spectrophotometer in a 2 mL quartz cuvette between
500–800 nm in aqueous acetonitrile. An absorption
maximum was identiﬁed at 651 nm. Fluorescence spectra
were obtained on an Agilent Cary Eclipse Fluorescence
Spectrophotometer in a 2 mL cuvette between
500–800 nm in aqueous acetonitrile. The instrument was
used in ﬂuorescence mode with the excitation slit at 5 nm
and emission slit at 5 nm. Excitation occurred at 651 nm
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with an emission maximum at 669 nm. SDS-PAGE was
performed using an Invitrogen Mini-cell GEL Surelock
Cell Module with 12% tris-glycine gel in SDS running
buffer. Protein masses were identiﬁed using the Precision
Plus Protein Kaleidoscope pre-stained protein standard
(BioRad, Cat no. 1610375) (Supplementary Fig. 1). A
standard chow-fed male rat with an indwelling 4V cannula received a single icv injection of 4.5 ng (3 μL at
1.5 ng/mL) ﬂuorescently labeled leptin (Cy5-Lep) dissolved in 0.1 M PBS, pH 7.4. An hour later, the rat was
anesthetized, transcardially perfused, and harvested for
brain removal and IHC processing as described below.
Images acquired with Leica SP5 X confocal microscope
using 63x oil-immersion objective with 405, 488, 647 laser
lines. Image z-stacks were collected with a step size of
1μm and processed using Imaris 8.1.2 software (Bitplane).
Fluorescent in situ hybridization of astrocytic LepR

For veriﬁcation of the leptin receptor on rat DVC
astrocytes, a single animal (n = 1) was anesthetized for
rapid removal of the brain and ﬂash frozen in isopentane
over dry ice. The brain was sectioned on a cryostat at
18 μm thickness, slide mounted, and stored at −80 °C.
Fluorescent in situ hybridization (FISH) was performed
using the RNAscope Multiplex Fluorescent Reagent kit v2
(Cat no. 323100; ACDBio, Hayward, CA) per manufacturer instructions. Detection was carried out using
probes designed by ACDBio for LepR mRNA (Rn-LepRC1, Cat no. 415951), the astrocyte-speciﬁc marker
Aldh1L1 (Rn-Aldh1L1-C2, Cat no. 459821-C2), and the
neuronal marker RbFox3 (Rn-RbFox3-C3, Cat no.
436351-C3). Following a series of ampliﬁcation steps,
sections were mounted with DAPI-containing mounting
media (Fluorogel; Fischer Scientiﬁc). Sections were
visualized with a Leica SP5 X confocal microscope with a
40x objective. Image z-stacks were collected with a step
size of 1 μm. Collected z-stack images were processed
using Imaris 8.1.2 software (Bitplane).
Live cell Ca+2 imaging of neurons and astrocytes in NTS
slice preparations

Male Sprague Dawley rats (290–420 g; chow n = 4, HFD
n = 3) were deeply anesthetized with urethane (1.5 g/kg,
intraperitoneal; ethyl carbamate, Sigma; this anesthetic
was selected because it readily washes out of ex vivo slices38) and placed in a stereotaxic frame. Using aseptic
technique, 4 unilateral injections (40 nL each) of 0.4%
Cal520 (AAT Bioquest), 0.3% sulforhodamine 101 (SR101;
Sigma Chemical) and 10% pluronic-DMSO (F-127, Invitrogen) in normal Krebs solution were administered into
the medial NTS. After 60 min, rats were decapitated, and
the brainstem was quickly harvested. Pre-labeled brainstems were cut into 300-μm coronal sections using a
vibrating microtome (Leica VT1200) and submerged in
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cold (~4 °C) carboxygenated (95% O2; 5% CO2) cutting
solution. NTS slices were placed in normal Krebs’ solution and bubbled with 95% O2/5% CO2 at a constant
temperature of 29 °C. Sections were allowed equilibrate
for 1 h prior to imaging39.
Live cell calcium imaging of pre-labeled neurons and
astrocytes was performed as previously described39–41.
Cal-520/SR101 pre-labeled slices were transferred to a
custom imaging chamber42. Immunohistochemical conﬁrmation of SR101 speciﬁcity to astrocytes in the DVC
was previously reported43. The recording chamber was
continuously perfused at a rate of 2.5 mL/min with normal Krebs’ (or containing 100ng/mL leptin) solution at a
constant temperature of 33 °C. Hindbrain slices were
viewed with a Zeiss Axioskop 2 ﬁxed stage microscope
equipped with normal epiﬂuorescence optics, a Yokogawa
CSU21 laser confocal scan head, and a Hamamatsu
ORCA-ER camera. Pre-labeled cells of interest were
selected visually with epiﬂuorescence optics and subsequently confocal images were captured with the ORCAER camera at the rate of 1 frame per second.
Once in the recording chamber, hindbrain slices were
perfused with normal Krebs’ solution for a minimum of
10 min. Dual exposure images (i.e., 488 nm and 591 nm)
were collected just prior to each experimental trial in
order to conﬁrm the cell types being recorded. All slices
were then challenged with a cocktail of 100 μM ATP and
500 μM glutamate to determine which cells in the ﬁeld
were viable39,44. Viability was deﬁned as a minimum
increase in ﬂuorescence of 7% in response to the ATP/
glutamate challenge45. Next, slices were exposed to Krebs’
solution plus 100 ng/mL leptin for 30 s. Changes in
intracellular calcium concentrations in response to leptin
stimuli within Cal-520 pre-labeled NST astrocytes and
neurons were recorded simultaneously using the 488-nm
laser line to excite the Cal-520. Increases in intracellular
calcium concentrations were identiﬁed as an increase in
ﬂuorescence and interpreted to represent increased cellular activity. During experimental trials, time-lapse images of mixed ﬁelds of NTS astrocytes and neurons were
monitored for responses to the leptin challenge. Timelapse laser confocal images of changes in intracellular
calcium levels of both astrocytes and neurons were captured with the ORCA-ER at a rate of 1 frame per second.
Behavioral experiments

Rats were maintained on either standard chow (n = 10)
or a high-fat diet for 2 weeks (n = 7). All animals were
implanted with a cannula directed at the 4th ventricle
(4V) to allow for intracerebroventricular (icv) administration. The recovery period was 1 week, during which
time placement of the cannula was veriﬁed with a
hyperglycemic response to 5-TG46,47. Food hoppers were
removed, and animals were weighed approximately 1 h
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before dark onset. Thirty min before dark onset, animals
received 4V icv vehicle (0.1 M PBS) or 50 nmol ﬂuorocitrate pretreatment (Sigma Aldrich40,48–50) followed by
vehicle (0.1 M NaHCO3) or 5 μg/mL leptin (NHPP51).
Fluorocitrate is a well-established pharmacologic agent
used to transiently inhibit the Kreb’s cycle in an astrocytespeciﬁc manner48,50,52–54. The selected dose of 50nmol
ﬂuorocitrate is established to be astrocyte-speciﬁc40,48. At
dark onset, food hoppers were replaced and cumulative
food intake was recorded at 1, 3, 6, and 24 h. Body weights
were recorded at 0 and 24 h after injection. Experimental
injections were separated by a 72 h washout period.
Immunohistochemical analysis of gliosis

Rats were placed on either a standard chow (n = 6) or a
high-fat diet (n = 6) for 8 weeks. Food intake and body
weights were recorded every 48 h. After the 8-week period, anesthetized animals were transcardially perfused
with 0.1 M sodium phosphate buffer (PBS; pH 7.4) followed by 4% paraformaldehyde (4% PFA) in 0.1 M PBS,
pH 7.4. Brains were removed and stored in 4% PFA
overnight at 4 °C, then transferred to a 20% sucrose
solution in 0.1 M PBS. Brains were ﬂash frozen in hexane
over dry ice. Subsequently, the DVC and hypothalamus
were sectioned coronally at 30 μm. Free-ﬂoating serial
sections were processed for immunohistochemical
detection of glia ﬁbrillary acidic protein (GFAP; astrocyte
activation marker18,55) and ionized calcium binding
adaptor molecule 1 (Iba1; microglia marker56) as follows.
Sections were washed 3 times for 5 min each in 0.1 M
PBS, incubated in 10 mM sodium citrate buffer solution
(Sigma Aldrich) for 30 min at 90 °C, then washed an
additional 3 times in 0.1 M PBS containing 0.2% Triton-X
(Sigma Aldrich). Next, sections were incubated in 5%
normal donkey serum (NDS; Jackson ImmunoResearch)
and 0.2% Triton-X in 0.1 M PBS for 1 h at RT, then
incubated overnight at 4 °C in an antibody mixture of
1:1000 chicken anti-GFAP (Millipore, Cat no. AB5541)
and 1:500 rabbit anti-Iba1 (Wako; Cat no. 019-19741) in
blocking buffer. Following wash steps, sections were
incubated for 2 h in secondary antibody mixture of 1:500
donkey anti-chicken Alexa 594 (Jackson ImmunoResearch) and 1:500 donkey anti-rabbit Alexa 488 (Jackson
ImmunoResearch). Sections were mounted to Superfrost
Plus slides (Fisher Scientiﬁc) with Fluorogel DAPIcontaining mounting media (Fischer Scientiﬁc). Images
were acquired using a Keyence BZ-X800 ﬂuorescent
microscope under a 20x or 40x objective as 1-μm z-stack
images. Z-stack images were compressed using standard
full focus and background subtraction. During image
capture and analysis, investigator was blinded regarding
corresponding diet cohort. Quantiﬁcation was done using
FIJI software. The integrated density of GFAP immunoreactivity was determined after default thresholding of
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images57. Microglia density was determined using the
MorphoLibJ plugin58.
Statistics

All data are represented as the mean ± standard error of
the mean. Power analysis was conducted prior to carrying
out experiments using an alpha of 0.05 and 80% power.
Comparisons in qPCR studies were made using a 1-way
analysis of variance (ANOVA) with Dunnet post hoc tests.
For live calcium imaging, signiﬁcance was determined by
one-way ANOVA with Bonferroni t-tests. Comparisons of
percentage of responsive cells were performed using
Fisher’s exact test. For behavioral comparisons of food
intake and body weight, we applied a repeated measure 3or 2-way ANOVA, respectively, with Neuman-Keuls post
hoc analyses. Statistical signiﬁcance was set at p < 0.05.
Statistical outliers were identiﬁed using the ROUT
method (Q = 0.5%) and excluded from analysis.

Results
DVC astrocytes express the leptin receptor

The expression of the leptin receptor on hypothalamic
astrocytes is well established in rats and mice14,15,35,59. To
complement, we performed immunohistochemistry to
conﬁrm LepR expression on DVC astrocytes in the rat.
Following 4th intracerebroventricle (4V) injection of
ﬂuorescently labeled leptin (4.5 ng Cy5-Lep), we observed
co-localization with DVC astrocytes (GFAP; green;
Fig. 1a), predominately at the subpostrema, the border of
the AP and NTS. The presence of LepR expression on rat
DVC astrocytes was detected by FISH using RNA-scope.
LepR mRNA expression (yellow) was observed on both
neurons (magenta) and astrocytes (cyan) within the
subpostrema and medial NTS (Fig. 1b; Supplementary
Video 1).
High fat diet-induced obesity reduces the percentage of
both DVC astrocytes and neurons showing leptin-induced
Ca+2 signaling in ex vivo brainstem slice preparations

To better characterize the role of DVC astrocytes in
energy homeostasis, we next investigated leptin-induced
intracellular Ca+2 responses in DVC neurons and astrocytes in ex vivo brainstem slice preparations (Fig. 2). In
addition, we examined whether leptin-induced responses
were altered by dietary status and obesity (i.e., comparison
of Ca+2 signaling in the DVC of lean rats maintained on a
standard chow or obese rats maintained on a 60% high-fat
diet). Imaging experiments on the pre-labeled hindbrain
slices from chow-maintained rats (n = 4) yielded 61 viable
neurons and 35 viable astrocytes; high fat diet-maintained
rats (n = 3) yielded 37 viable neurons and 24 viable
astrocytes.
Both neurons and astrocytes from lean animals produced live cell Ca+2 ﬂux (i.e., increases in cytoplasmic
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Fig. 1 Immunohistochemical and FISH validation of leptin binding and LEP-R expression on DVC astrocytes. a Immunohistochemical
visualization of Cy5-Lep (4V icv 4.5 ng; red) colocalized to DVC astrocytes (GFAP; green), DAPI in blue; 63x image (inset: 2x optical zoom). b FISH
visualization of the lateral NTS (at the level of the AP) of LEP-Rb (yellow) expression on DVC astrocytes (ALDH1L1; cyan) and neurons (RbFox3;
magenta). Counterstain with DAPI (blue); 40x image (inset: 3.4x optical zoom with gaussian ﬁlter). See Supplementary Video 1 for 3D rotational image
of area outlined by the dotted box.

Fig. 2 Leptin-induced Ca+2 ﬂux in DVC neurons and astrocytes vary by dietary status. Live cell calcium recordings in DVC brain slices in
astrocytes and neurons simultaneously. a Cells prelabeled with Cal520 (calcium sensitive dye; taken up by both neurons and astrocytes) encircled in
green. b Cells prelabeled with SR101 (astrocyte-speciﬁc dye) are identiﬁed as astrocytes and encircled in red. c Yellow localization conﬁrms that the
calcium-sensitive dye is localized within astrocytes and distinguishable from neurons (green circle). d Total ﬁeld of view (showing both neurons and
astrocytes) at “rest” (i.e., baseline) and the same ﬁeld of view shown in e at period of peak response leptin perfusion (see Supplementary Video 2 and
3). f Response to leptin perfusion of individual astrocyte marked by red arrow in g Response to leptin perfusion of individual neuron marked by green
arrow in panel. Changes in ﬂuorescence were measured in brain slices prepared from lean rats (n = 4) and rats exposed to a high-fat diet (n = 3)
following bath leptin exposure (100ng/mL). h Magnitude of the leptin response was attenuated in neurons but not astrocytes of obese compared to
lean animals. Obese animals had lower proportions of leptin-responsive (i) neurons and (j) astrocytes compared to lean animals. Changes in
magnitude are represented as the mean ± standard error of the mean and were analyzed with a 2-way ANOVA and Bonferroni post hoc tests; *p <
0.05. Percentages of leptin-responsive cells were analyzed using Fisher’s exact test; *p < 0.05. See Supplementary Video 2 and Supplementary Video 3.
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Fig. 3 DVC astrocytes partly mediate the anorectic effects of leptin in lean but not obese rats. Changes in cumulative food intake (a, c) and 24h body weight (b, d) were recorded following 4V icv pretreatment with 50 nmol ﬂuorocitrate and subsequent treatment with 5 μg/mL leptin in rats
maintained on either standard chow (n = 10; a, b) or a high-fat diet (n = 7; c, d). Data were analyzed using a 3-way (a, c) or 2-way (b, d) repeated
measures ANOVA. Lowercase letters indicate signiﬁcant differences (p < 0.05) within each time point (a, c) for food intake and at 24 h (b, d) for body
weight according to Neuman-Keuls post hoc analyses.

Ca+2) in response to bath application of 100ng/mL leptin
(Fig. 2h). High-fat diet maintenance attenuated DVC
neuron Ca+2 response without affecting astrocyte
responses (F3,62 = 4.072; p = 0.01). Further, animals
exposed to a high-fat diet had a signiﬁcant reduction in
the percentage of leptin-responsive neurons and astrocytes compared to lean animals (Fig. 2i, j). In astrocytes,
this suggests a potential alteration in functional expression of LepR rather than changes in leptin responsiveness
at the cellular level. Representative videos show a mixed
neuro-astrocytic ﬁeld of live calcium imaging following
leptin administration in chow (Supplementary Video 2)
and HFD (Supplementary Video 3) maintained rats.
DVC astrocytes partly mediate the anorectic effects of
leptin in lean but not obese rats

A well-established pharmacologic approach was used to
assess the contribution of DVC astrocytes in mediating
the intake and body weight suppressive effects of leptin.
Food intake (Fig. 3a, c) and consequent body weight

change (Fig. 3b, d) were measured in rats following 4V
administration of 50 nmol ﬂuorocitrate, an astrocytespeciﬁc Krebs cycle inhibitor48,52–54, and 5 μg/mL leptin51. At the time of experimental treatment, animals fed a
high-fat diet weighed signiﬁcantly more than chowmaintained animals (Supplementary Fig. 2). While there
appears to be a slight trend, ﬂuorocitrate treatment alone
did not signiﬁcantly affect food intake or body weight
change in either group. In lean rats, pretreatment with
ﬂuorocitrate modestly attenuated the food intake inhibitory effects of leptin on 24-h food intake (ﬂuorocitrate ×
leptin interaction: F1,9 = 7.678, p = 0.022; ﬂuorocitrate x
leptin x time interaction: F3,27 = 2.677; p = 0.067; Fig. 3a)
and body weight gain (ﬂuorocitrate x leptin interaction:
F1,9 = 11.19; p = 0.009; Fig. 3b). Conversely, leptin
administration in early onset obese rats exerted a modest
hypophagic effect at 24hr (ﬂuorocitrate × leptin interaction: F1,6 = 21.61; p = 0.009; F3,18 = 0.899, p = 0.46; Fig.
3c) and did not alter 24h body weight change (ﬂuorocitrate × leptin interaction: F1,6 = 1.348, p = 0.29; Fig. 3d).
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Fig. 4 A high-fat diet alters gliosis in the brainstem but not the hypothalamus. Astrogliosis and microglial inﬁltration determined by the degree
of GFAP immunoreactivity (a–e) and density of Iba1 positive cells (f–j), respectively. HFD signiﬁcantly decreased GFAP immunoreactivity but did not
affect microglial density. Diet had no inﬂuence on the glial landscape of the arcuate nucleus. Representative images (20x) of the DVC of lean (k) and
obese rats (l) and of the hypothalamus of lean (m) and obese rats (n). Images were quantiﬁed in ImageJ and analyzed using unpaired t-tests; *p <
0.05, **p < 0.01, ***p < 0.001 compared to the lean group (n = 6 per group). AP, area postrema; NTS, nucleus tractus solitarius; sub-AP, sub-area
postrema; cc, central canal; 3V, third ventricle.

Maintenance on a high-fat diet decreases DVC astrocyte
activation

Maintenance on a high-fat diet is associated with
increased glia activation and proliferation in the hypothalamus17,18,23, such that the degree of astrogliosis may
predict metabolic outcomes60. Given the observation that
a high-fat diet was associated with fewer leptinresponsive neurons and astrocytes in the DVC (Fig. 2)
and an attenuated hindbrain leptin response in vivo
(Fig. 3), we next investigated maladaptive changes in the
neuro-glia landscape of the DVC in response to obesity
and, within the same rats, compared these changes to
those observed in the arcuate nucleus of the hypothalamus. Rats that were fed either standard chow or a highfat diet for eight weeks were sacriﬁced for immunohistochemical analysis of astrocyte activation (measured by
GFAP integrated density18,55) and microglia inﬁltration
(measured by density of Iba1+ cells56) in the whole DVC
and individual nuclei including the AP, sub-AP, NTS, as
well as the arcuate nucleus of the hypothalamus. Rats fed

a high-fat diet had signiﬁcantly lower GFAP integrated
density in the entire DVC (Fig. 4a) as well as in all distinct
nuclei of the DVC (Fig. 4b–d) compared to animals fed
standard chow. There was no effect of diet on microglia
density in the DVC (Fig. 4f–i). There was no detectable
effect of a high-fat diet on gliosis within the arcuate
nucleus (Fig. 4e, j).
Loss of LepR signaling promotes astrogliosis in the DVC

Zucker diabetic fatty rats (ZDF) have a mutation within
the leptin receptor that prevents downstream signaling
following leptin binding61,62. This form of leptin receptor
deﬁciency results in obesity, hyperphagia, and hyperglycemia (Supplementary Fig. 3). Obesity due to deﬁcient
leptin receptor signaling in these ZDF rats was associated
with signiﬁcantly higher astrogliosis in the DVC
(Fig. 5a–d) but a marked reduction in density of GFAPpositive cells in the arcuate nucleus compared to wildtype control rats (Fig. 5e). Microglia density was
signiﬁcantly lower in the arcuate nucleus of ZDF rats
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Fig. 5 Zucker diabetic fatty rats (ZDF) exhibit heightened astrogliosis in the DVC and attenuated gliosis in the arcuate nucleus compared
to wild type (WT) rats. Astrogliosis was determined by quantifying the integrated density of GFAP immunoreactivity within distinct regions of the
DVC. ZDF rats had signiﬁcantly higher GFAP integrated density in the DVC (a), AP (b), sub-AP(c), and NTS (d) compared to WT rats. There was no
difference in microglial density in the DVC between ZDF and WT rats (f–i). Conversely, there was a signiﬁcant reduction in both GFAP integrated
density (e) and microglial density (j) in the arcuate nucleus of ZDF vs. WT rats. Representative images at 20x magniﬁcation of WT (k) and ZDF (l) dorsal
vagal complex and 40x magniﬁcation of WT (m) and ZDF (n) arcuate nucleus. Images were quantiﬁed in ImageJ and analyzed using unpaired t-tests;
*p < 0.05, **p < 0.01 compared to the WT group (n = 5 per genotype). AP, area postrema; NTS, nucleus tractus solitarius; sub-AP, sub-area postrema;
cc, central canal; 3V, third ventricle; Arc, arcuate nucleus.

compared to wild-type rats (Fig. 5j). In contrast, no
alteration in microglia density was observed in the DVC of
ZDF rats compared to control rats (Fig. 5f–i).
The neurobiological control of energy balance involves
a vast, interconnected network of neuronal crosstalk that
continually senses and responds to an organism’s metabolic status25,26. Recent work has highlighted a role of glia
in energy balance, but our limited knowledge regarding
glia-neuron interplay in brain regions beyond the arcuate
hypothalamus necessitates further exploration48. Here, we
examined the contribution of caudal brainstem DVC
astrocytes to the effects of leptin on food intake, as well as
the effects of diet on glia cell density and activation in the
DVC. Similar to previous characterizations of hypothalamic astrocytes13,14,63, an important main ﬁnding of our
research was the discovery that DVC astrocytes are an
additional site for leptin receptor expression and activation. The IHC and in situ observations combined with
ex vivo live cell recordings of astrocytes demonstrate

functional LepR receptors on rodent DVC astrocytes.
Astrocyte-speciﬁc inhibition revealed a functionally relevant role of hindbrain astrocytes in mediating the effects
of leptin administered into the 4th ventricle. The current
data also points to the DVC astrocytes as a site of leptin
dysfunction in obesity. Calcium imaging revealed that
animals fed a high-fat diet also exhibited a reduction in
the proportion of leptin-responsive neurons and astrocytes in the DVC compared to lean animals. Exposure to a
high-fat diet elicited the selective reduction of astrogliosis
in the DVC, in contrast with previous studies of the
hypothalamus17–19, and no effect on arcuate hypothalamic astrocytes. Further, the absence of leptin signaling
in Zucker diabetic fatty rats was associated with enhanced
astrogliosis in the DVC and decreased hypothalamic
astrogliosis. These data in no way suggest that the DVC
astrocytes are the only cellular substrate for leptin signaling or obesity-induced leptin resistance. Instead, our
data highlight the DVC as a critical and overlooked CNS
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cellular site-of-action that may be targeted for restoring
leptin signaling in obesity.
The role of hypothalamic astrocyte LepR signaling in
energy homeostasis is well established in previous studies:
knockdown of LepR in the hypothalamus leads to
alterations in neural circuitry and attenuates leptininduced anorexia in mice15,14,64. Yet, the signiﬁcance of
astrocytic LepR expression in the DVC is unknown. For
this reason, we performed a series of pharmacologic
experiments to estimate the involvement of the DVC
astrocytes in the effects of leptin on food intake. We
observed effects of 4V leptin on overnight food intake and
subsequent weight gain in lean animals and further found
that these effects were modestly attenuated by pretreatment with 4V ﬂuorocitrate, an astrocyte-speciﬁc inhibitor
of cellular respiration48,50,52,53. Albeit not signiﬁcant,
there appeared to be a slight inhibitory trend of ﬂuorocitrate alone on food intake. As astrocytes and neurons
comprise the tripartite synapse in which surrounding glia
cells form intimate association with pre- and postsynaptic membranes7,65,66, it is plausible that a transient
non-speciﬁc inhibition of astrocytes with ﬂuorocitrate
potentially elicits a modulation of vagal-NTS signaling to
transiently decrease food intake. Interestingly, the
attenuating effect of 4V ﬂuorocitrate was absent in rats
fed a high-fat diet. As the duration of HFD exposure does
not correspond with a full manifestation of leptin resistance67,68, these data indicate a surprising, albeit limited
role for hindbrain astrocytes in leptin responsiveness in
obesity, and moreover, suggest that a loss of leptin
responsiveness in hindbrain astrocytes represents part of
the maladaptive neuroregulatory response to obesity in
rodents. This idea is consistent with numerous reports
describing a causal association between HFD and hypothalamic leptin resistance11,17–19,21. Our calcium imaging
results support this statement, in which exposure to a
high-fat diet signiﬁcantly reduced the proportion of
leptin-responsive astrocytes and neurons and decreased
the magnitude of neuronal (but not astrocytic) responses
to leptin in the DVC. While we speculate this may be a
result of maladaptive changes to LepR functional
expression, one cannot rule out the potential for alternative LepR signaling cascades within astrocytes. Indeed,
Yasumoto et al. provide evidence of preference toward
leptin- mediated increases in extracellular receptor kinase
(ERK) expression as opposed to the classical increase in
phosphorylation of STAT369. Therefore, in order to
provide mechanistic insight into leptin action on astrocytes and the effect of diet on astrocytic LepR signaling is
required.
Astrocytes serve as the predominant regulator of
synaptic glutamate (reviewed in ref. 70) Given that vagal
afferent transmission of all satiation signaling from the GI
tract is glutamatergic, it is intriguing to consider what
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effect leptin-astrocyte signaling would have on modulating vagal-to-NTS glutamatergic signaling. Leptin administration into the lateral ventricle results in a signiﬁcant
decrease in astrocyte speciﬁc glutamate transporters,
GLT1 and GLAST, in the hypothalamus63. Thus, in the
lean state, the well documented ability of DVC leptin
signaling to suppress food intake via enhancement of GIderived satiation signals31,71–73, may actually involve a
leptin-mediated astrocyte speciﬁc suppression in astrocyte glutamate re-uptake transporters and subsequent
augmentation of vagal glutamatergic transmission. A
logical extension of this hypothesis would therefore follow
that in the HFD-induced obese state, leptin’s ability to
downregulate these astrocyte glutamate transporters
would be blunted, consistent with our observed decrease
in astrocyte Ca++ responsivity to leptin in HFD NTS slice
preparations. It is clear that further investigations are
warranted to assess the evolving role of DVC astrocytes in
mediating leptin signaling and modulation of vagal-toNTS glutamatergic transmission.
Another major ﬁnding of the current data, when considered in the context of pre-existing literature on the
hypothalamus, was the remarkable divergence in the
responses of DVC and hypothalamic glia cells to obesity.
Since microglia serve as the resident immunocompetent
cells of the central nervous system74 and previously
shown to be responsive to high fat diet and obesity, we
measured the effects of HFD and absence of leptin signaling on microglia density. Exposure to a high fat
diet alone did not result in changes to microglia density in
either the DVC or hypothalamus. Future characterization
of microglia state, i.e., resting vs. activated, is required to
determine whether diet and/or leptin increase the number
of activated microglia.
Taken together, these ﬁndings support the hypothesis
that DVC astrocytes contribute to energy balance regulation
and constitute a component of the maladaptive changes
that occur in response to diet-induced obesity. Moreover,
our results suggest that astrocytes in the DVC may be
particularly susceptible to the loss of leptin signaling.
Finally, we performed an in-detail characterization of
gliosis in the DVC and hypothalamus of the same rats in
order to better characterize the interplay of DVC astrogliosis and leptin signaling in response to a high-fat diet.
Our observation that ﬂuorocitrate attenuated leptin
responses in lean but not obese animals indicated the
possibility of corresponding astrocytic changes at the level
of the brainstem. To test this hypothesis, we quantiﬁed
gliosis (astrocytic and microglia) in speciﬁc areas of the
DVC and hypothalamus in lean rats, rats exposed to a
high-fat diet, and ZDF rats. Both HFD-induced obesity
and ZDF rats serve as models of obesity; both are
hyperphagic, hyperglycemic and increased adiposity. The
Zucker diabetic fatty rat (ZDF) is an inbred sub-strain of
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the obese Zucker fatty rat, with a missense mutation in
the LepR gene resulting in non-functional leptin signaling62. ZDF rats exhibiting early hyperglycemia, especially
when maintained on a high fat diet. The HFD-induced
obese model serves more clinical relevance as most forms
of human obesity are due to polygenic alterations and
environmental factors. Chronic exposure to a HFD not
only results in an obese phenotype but is accompanied by
the gradual development of leptin resistance. Studies in
both humans and rodents revealed that at the level of the
hypothalamus there is signiﬁcant gliosis as a result of HFD
exposure. Utilization of these two models begins to disentangle driving forces of obesity-induced gliosis and in
turn, how gliosis contributes to the development and
maintenance of obesity. Apart from the ﬁnding of an
overall decrease in GFAP (but not Iba1) density in the
DVC nuclei of animals exposed to a high-fat vs. standard
diet, we did not observe any diet-induced changes in
gliosis in the arcuate nucleus of the hypothalamus, a key
target of leptin in energy homeostasis25,26. Our result is
inconsistent with previous rodent (often murine) studies
describing an association between a high-fat diet,
increased gliosis in the hypothalamus, and the etiological
development of obesity17–19. One possible explanation for
this discrepancy is that the vast majority of these aforementioned studies were carried out in mice and therefore
the HFD-induced gliosis, or lack of, may be speciesdependent. Collectively, published studies reveal that
gliosis occurs dynamically across time and does not persist throughout the entire duration of HFD exposure17,19,22,75,76. Future time-course analyses are required
to fully assess HFD-induced gliosis in the hypothalamus
and DVC. Nonetheless, we also observed that ZDF rats
maintained on a standard diet exhibited an increase in
astrogliosis in the DVC in tandem with attenuated
microgliosis in the arcuate nucleus of the hypothalamus.
These collective ﬁndings, although in stark contrast to
previous literature, uncover a novel divergence in the
leptin responses and function of glia between the DVC
and hypothalamus. Whereas leptin appears to act on glia
to enhance neurotransmission in the hypothalamus, leptin
action in the DVC may serve to decrease neuronal output
in a manner that facilitates the appetite suppressant
activity of leptin. In the absence or complete dysregulation of LepR signaling, the excitatory output from the
hypothalamus and inhibition of output from the DVC are
lost, resulting in a loss of leptin-associated inhibitory
control of food intake and weight gain.
The present study had several limitations. One caveat is
that HFD-induced obese rats are hyperglycemic but not
diabetic, whereas the ZDF animals display a full type II
diabetic phenotype, raising the possibility that hyperglycemia and insulin resistance may contribute to the observed
effect on astrocytes. Our immunohistochemical analyses of
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gliosis does not provide a reﬁned characterization of the
effects of diet on glia cells. Future analyses on the dietinduced effects on gliogenesis, morphological changes to
glia processes, glia activation, and associations with neuronal synapses are required. Second, we relied on historic
literature examining the hypothalamic leptin-astrocyte
interplay11,13–15. It is entirely possible that each of the
previous reports may have some speciﬁc detailed methodological limitations in the IHC quantiﬁcations performed.
Regardless of these limitations, the current data strongly
suggest that the ﬁeld would beneﬁt from broadening our
understanding of divergent astrocyte responses in different brain nuclei to obesity and alterations in leptin signaling if we are to understand fully the role that astrocytes
are playing in energy balance regulation.
In conclusion, LepR is functionally expressed on
astrocytes of the DVC and exert a different functional role
in the DVC than it does in the hypothalamus. Unlike
hypothalamic astrocytes, DVC astrocytes may be particularly vulnerable to the absence of leptin signaling.
Future efforts should focus on elucidation of the neural
pathways supported by the divergent functional roles of
DVC vs. hypothalamic glia, as well as examine the contribution of leptin-astrocyte signaling in other CNS nuclei
of relevance to energy balance control. Collectively, current ﬁndings uncover a novel role for DVC astrocytes in
mediating the actions of leptin.
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PEPTIDE LIGANDS OF THE GDNF FAMILY RECEPTOR A-LIKE (GFRAL)
RECEPTOR
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims priority under 35 U.S.C. § 1 19(e) to U.S. Provisional
Patent Application No. 62/801,391, filed February 5, 2019, which is incorporated herein by
reference in its entirety.
BACKGROUND OF THE INVENTION
Long-term weight management and regulation of normal ingestive behavior in
patients suffering from chronic diseases are serious problems without sufficient therapeutic
treatments. Cachexia, nausea and chronic emesis from chemotherapy, cancer, chronic
diseases and morning sickness are all difficult to manage and can be extremely debilitating
and can compromise an individual’s quality-of-life. Nausea and emesis can also set the upper
tolerable dose of a therapeutic due to patient intolerance, thus potentially limiting drug
efficacy. Accordingly, there is a need for an approach that can modulate the anorectic /
nausea / emesis response to cancer, metabolic diseases and therapeutic treatments of various
diseases. There is also a need for treatments for diseases or conditions that result in unhealthy

increases or decreases in body weight, including but not limited to obesity and anorexia
nervosa. As energy balance regulation also includes autonomic control of sympathetic and
parasympathetic neural functions that affect various physiological responses, it is conceivable
that systems regulating the aversive aspects of illness behavior can also be targeted in
contrast to influence motivated and maladaptive motivated behaviors, such as substance
abuse. To this end, given the need for treatments for sexual dysfunction there is a possibility

to target a biological system that can also influence sexual behaviors and actions.
The present invention addresses the aforementioned unmet needs.

SUMMARY OF THE INVENTION
In one aspect, the invention provides an engineered peptide comprising any one of the
amino acid sequences of SEQ ID NOs: 1-10.
In another aspect, the invention provides a polynucleotide encoding the engineered
peptide of the invention.

In yet another aspect the invention provides a pharmaceutical composition comprising

the engineered peptide of the invention.
In yet another aspect, the invention provides a method of treating a disease or a

condition in a subject in need thereof, composing the step of administering the engineered
peptide of the invention to the subject.
In yet another aspect, the invention provides a method of promoting weight gain in a

subject in need thereof by administering the engineered peptide of the invention to the
subject.

In yet another aspect, the invention provides a method of promoting weight loss in a

subject in need thereof by administenng the engineered peptide of the invention to the
subject.

In certain embodiments, at least one of the amino acids of the peptide is a modified
amino acid.
In certain embodiments, the engineered peptide is an antagonist of a GDNF family

receptor alpha-like (GFRAL) receptor.
In certain embodiments, the amino acid sequence of the engineered peptide comprises
SEQ ID NO: 5 .

In certain embodiments, the engineered peptide is an agonist of a GFRAL receptor.
In certain embodiments, the amino acid sequence of the engineered peptide comprises
SEQ ID NO:

1.

In certain embodiments, the engineered peptide is linked to a vitamin B12 compound,

a lipid or a fluorophore. In certain embodiments, the vitamin B12 compound, the lipid, or the
fluorophore is linked to the peptide directly or via a linker. In certain embodiments, the
vitamin B12 compound, the lipid, or the fluorophore is directly linked to any amino acid of
the peptide. In certain embodiments, the vitamin B12 compound, the lipid or the fluorophore
is directly linked to any modified amino acid of the peptide. In certain embodiments, the

engineered peptide further comprises a metal ion bound to the peptide.
In certain embodiments, the metal ion is a Zn 2+ ion or a Ca + ion.

In certain embodiments, the disease or the condition is nausea, emesis, cachexia,
unintentional weight loss, loss of appetite, pica, anorexia or illness-like behaviors.
In certain embodiments, the disease or the condition is obesity or body weight

regulation.
In certain embodiments, the disease or the condition is sexual dysfunction.

In certain embodiments, the engineered peptide is administered in a dosage of 1

pmole/kg to 100 mmoles/kg.
In certain embodiments, the engineered peptide is administered acutely or chronically

over the course of multiple hours or days.

BRIEF DESCRIPTION OF THE DRAWINGS

The following detailed description of selected embodiments of the invention will be
better understood when read in conjunction with the appended drawings. For the purpose of
illustrating the invention, selected embodiments are shown in the drawings. It should be
understood, however, that the invention is not limited to the precise arrangements and
instrumentalities of the embodiments shown in the drawings.
FIG. 1 illustrates the peptide GFANT05. The sequence shown is that of GFANT05,

wherein the GFANT05 peptide of SEQ ID NO: 5 has a wild-type lysine (K) in position K2.
FIG. 2A shows the method of production GFANT05 peptide conjugated with palmitic

acid, wherein the GFANT05 peptide of SEQ ID NO: 5 has a modified lysine (K azido) in

position K2. The GFANT05 peptide is linked to 16:0 PE at the K2 residue.
FIG. 2B shows the results of electrospray mass spectrometry on the GFANT05

conjugated synthesis product.
FIG. 3A shows a 1H NMR structure of GFANT05, which reveals a broad spread of

peaks consistent with a folded state for this peptide. FIG. 3B displays the 2D spectra COSY
NMR structure of the GFANT05 peptide. FIG. 3C shows the 2D spectra TOCSY N R
structure of the GFANT05 peptide. Both FIGs. 3B and 3C suggest that the structure of
GFANT05 contains at least one alpha helix.
FIG. 4 shows the results of an ELISA binding assay measuring the affinity of

Recombinant human GDF-15 rhGDF

) for its receptor.

FIG. 5A is a graph of a food intake study performed to evaluate the efficacy of

unconjugated GFANT05 peptide (TK*EELIHAHADPMVLIQKTDTGV SLQTYD; SEQ ID
NO: 5, wherein K* is K azido) to reduce nausea. FIG. 5B shows a graph of a kaolin intake

study performed to evaluate the efficacy of unconjugated GFANT05 peptide in reducing

nausea.
FIG. 6 is a graph confirming GFRAL receptor antagonist binding to the GFRAL

receptor. A Cy5-conjugate of GFRAL receptor antagonist was synthesized and exposed to the
human GFRAL receptor in vitro and tracked for binding using an anti-Cy5 antibody.

FIG. 7 is a graph confirming Zinc binding to GFRAL receptor antagonist at the

HAHAD region (residues H7-P12) as observed by chemical shifts in 2D NMR.
FIG. 8 is a graph illustrating the results from in vitro PK study of GFRAL receptor

antagonist in rat microsomes. The half-life was calculated to be: 104.43 min. Reaction
velocity (V) was calculated to be 511uL/lmg. Intrinsic clearance (Cl-int) was determined to
be 339 uL/min/mg protein.
FIG. 9 is an image showing GFANT05 peptide technology co-localizing with the

GFRAL receptor in the brainstem (a major source of illness behaviors in disease and/or
disease treatments). This technology provides a new route to treat cachexia and
chemotherapy induced nausea/vomiting by uniquely blocking the GDF15-GFRAL signaling
in the brainstem

DETAILED DESCRIPTION
Definitions
Unless defined otherw se all technical and scientific terms used herein have the same
meaning as commonly understood by one of ordinary skill in the art to which the invention
pertains. Although any methods and materials similar or equivalent to those described herein
can be used in the practice for testing of the present invention, the preferred materials and
methods are described herein. In describing and claiming the present invention, the
following terminology will be used.
It is also to be understood that the terminology used herein is for the purpose of

describing particular embodiments only and is not intended to be limiting.
The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at
least one) of the grammatical object of the article. By way of example, “an element” means
one element or more than one element.

“About” as used herein when referring to a measurable value such as an amount, a
temporal duration, and the like, is meant to encompass variations of ±20% or ±10%, more
preferably ±5%, even more preferably ±1%, and still more preferably ±0.1% from the
specified value, as such vanations are appropriate to perform the disclosed methods.
As used herein, the term conservative sequence modifications” is intended to refer to amino

acid modifications that do not significantly affect or alter the binding characteristics of the
peptide containing the amino acid sequence. Such conservative modifications include amino
acid substitutions, additions and deletions and use of similar structured non-canonical ammo
acids or D-isomers of any of the canonical amino acids and/or non-canonical amino acids.

Modifications can be introduced into a peptide of the invention by standard techniques
known in the art, such as solid-phase peptide synthesis, site-directed mutagenesis and PCRmediated mutagenesis. Conservative ammo acid substitutions are ones in which the amino
acid residue is replaced with an amino acid residue having a similar side chain. Families of
amino acid residues having similar side chains have been defined in the art. These families
include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains
(e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine,

glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g.,
alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side
chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine,
phenylalanine, tryptophan, histidine).Non-canonical examples include azido-lysine, methylalanine.

A “disease” is a state of health of a subject wherein the subject cannot maintain
homeostasis, and wherein if the disease is not ameliorated then the subject’s health continues
to deteriorate. In contrast, a “disorder” in a subject is a state of health in which the subject is
able to maintain homeostasis, but in which the subject’s state of health is less favorable than
it would be in the absence of the disorder. Left untreated, a disorder does not necessarily
cause a further decrease in the subject’s state of health.
“Effective amount” or “therapeutically effective amount” are used interchangeably
herein, and refer to an amount of a compound, formulation, material, or composition, as
described herein effective to achieve a particular biological result or provides a therapeutic or
prophylactic benefit. Such results may include, but are not limited to, anti-tumor activity as
determined by any means suitable in the art.
“Encoding” refers to the inherent property of specific sequences of nucleotides in a
polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of
other polymers and macromolecules in biological processes having either a defined sequence
of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the
biological properties resulting therefrom. Thus, a gene encodes a protein if transcription and
translation of mRNA corresponding to that gene produces the protein in a cell or other
biological system. Both the coding strand, the nucleotide sequence of which is identical to
the mRNA sequence and is usually provided in sequence listings, and the non-coding strand,
used as the template for transcription of a gene or cDNA, can be referred to as encoding the
protein or other product of that gene or cDNA.

As used herein “endogenous” refers to any material from or produced inside an

organism, cell, tissue or system.
As used herein, the term “exogenous” refers to any material introduced from or

produced outside an organism, cell, tissue or system.
The term “expression” as used herein is defined as the transcription and/or translation
of a particular nucleotide sequence driven by its promoter.
“Expression vector” refers to a vector comprising a recombinant polynucleotide
comprising expression control sequences operatively linked to a nucleotide sequence to be
expressed. An expression vector comprises sufficient cis-acting elements for expression;

other elements for expression can be supplied by the host cell or in an in vitro expression
system. Expression vectors include all those known in the art, such as cosmids, plasmids

(e.g, naked or contained in liposomes) and viruses (e.g, sendai viruses, lentivimses,
retrovimses, adenoviruses, and adeno-associated vimses) that incorporate the recombinant
polynucleotide.
“Homologous” as used herein, refers to the subunit sequence identity between two
polymeric molecules, e.g., between two nucleic acid molecules, such as, two DNA molecules
or two RNA molecules, or between two polypeptide molecules. When a subunit position in

both of the two molecules is occupied by the same monomeric subunit; e.g, if a position in
each of two DNA molecules is occupied by adenine, then they are homologous at that
position. The homology between two sequences is a direct function of the number of

matching or homologous positions; e.g, if half (e.g, five positions in a polymer ten subunits
in length) of the positions in two sequences are homologous, the two sequences are 50%
homologous; if 90% of the positions (e.g, 9 of 10), are matched or homologous, the two
sequences are 90% homologous.
“Humanized” forms of non-human (e.g., murine) antibodies are chimeric
immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab ,
F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal
sequence derived from non-human immunoglobulin. For the most part, humanized
antibodies are human immunoglobulins (recipient antibody) in which residues from a
complementary-determining region (CDR) of the recipient are replaced by residues from a
CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired
specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of
the human immunoglobulin are replaced by corresponding non-human residues.
Furthermore, humanized antibodies can comprise residues which are found neither in the

recipient antibody nor in the imported CDR or framework sequences. These modifications
are made to further refine and optimize antibody performance. In general, the humanized
antibody will comprise substantially all of at least one, and typically two, variable domains,
in which all or substantially all of the CDR regions correspond to those of a non-human
immunoglobulin and all or substantially all of the FR regions are those of a human
immunoglobulin sequence. The humanized antibody optimally also will comprise at least a
portion of an immunoglobulin constant region (Fc), typically that of a human
immunoglobulin. For further details, see Jones et al, Nature, 321: 522-525, 1986;
Reichmann et al., Nature, 332: 323-329, 1988; Presta, Curr. Op. Struct. Biol., 2 : 593-596,
1992.

“Fully human” refers to an immunoglobulin, such as an antibody, where the whole
molecule is of human origin or consists of an amino acid sequence identical to a human form
of the antibody.
“Identity” as used herein refers to the subunit sequence identity between two
polymeric molecules particularly between two amino acid molecules, such as, between two
polypeptide molecules. When two amino acid sequences have the same residues at the same
positions; e.g, if a position in each of two polypeptide molecules is occupied by an Arginine,
then they are identical at that position. The identity or extent to which two amino acid
sequences have the same residues at the same positions in an alignment is often expressed as
a percentage. The identity between two amino acid sequences is a direct function of the
number of matching or identical positions; e.g., if half (e.g, five positions in a polymer ten
amino acids in length) of the positions in two sequences are identical, the two sequences are
50% identical; if 90% of the positions (e.g, 9 of 10), are matched or identical, the two amino
acids sequences are 90% identical.
The term “immune response” as used herein is defined as a cellular response to an
antigen that occurs when lymphocytes identify antigenic molecules as foreign and induce the
formation of antibodies and/or activate lymphocytes to remove the antigen.
As used herein, an “instructional material” includes a publication, a recording, a

diagram, or any other medium of expression which can be used to communicate the
usefulness of the compositions and methods of the invention. The instructional material of
the kit of the invention may, for example, be affixed to a container which contains the nucleic
acid, peptide, and/or composition of the invention or be shipped together with a container

which contains the nucleic acid, peptide, and/or composition. Alternatively, the instructional

material may be shipped separately from the container with the intention that the instructional
material and the compound be used cooperatively by the recipient.
“Isolated” means altered or removed from the natural state. For example, a nucleic
acid or a peptide naturally present in a living animal is not “isolated,” but the same nucleic
acid or peptide partially or completely separated from the coexisting materials of its natural
state is “isolated.” An isolated nucleic acid or protein can exist in substantially purified form,
or can exist in a non-native environment such as, for example, a host cell.

A “lentivirus” as used herein refers to a genus of the Retroviridae family. Lentiviruses
are unique among the retroviruses in being able to infect non-dividing cells; they can deliver

a significant amount of genetic information into the DNA of the host cell, so they are one of
the most efficient methods of a gene delivery vector. HIV, SIV, and FIV are all examples of
lentiviruses. Vectors derived from lentiviruses offer the means to achieve significant levels of
gene transfer in vivo.
By the term “modified” as used herein, is meant a changed state or structure of a

molecule or cell of the invention. Molecules may be modified in many ways, including
chemically, structurally, and functionally. Cells may be modified through the introduction of
nucleic acids.
By the term “modulating,” as used herein, is meant mediating a detectable increase or

decrease in the level of a response in a subject compared with the level of a response in the
subject in the absence of a treatment or compound, and/or compared with the level of a
response in an otherwise identical but untreated subject. The term encompasses perturbing
and/or affecting a native signal or response thereby mediating a beneficial therapeutic
response in a subject, preferably, a human.
In the context of the present invention, the following abbreviations for the commonly

occurring nucleic acid bases are used. “A” refers to adenosine, “C” refers to cytosine, “G”
refers to guanosine, “T” refers to thymidine, and “U” refers to uridine.
Unless otherwise specified, a “nucleotide sequence encoding an amino acid sequence”
includes all nucleotide sequences that are degenerate versions of each other and that encode
the same amino acid sequence. The phrase nucleotide sequence that encodes a protein or an
RNA may also include introns to the extent that the nucleotide sequence encoding the protein
may in some version contain an intron(s).
The term “operably linked” refers to functional linkage between a regulatory
sequence and a heterologous nucleic acid sequence resulting in expression of the latter. For
example, a first nucleic acid sequence is operably linked with a second nucleic acid sequence

when the first nucleic acid sequence is placed in a functional relationship with the second
nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the
promoter affects the transcription or expression of the coding sequence. Generally, operably
linked DNA sequences are contiguous and, where necessary to join two protein coding
regions, in the same reading frame.
The term ‘‘overexpressed” tumor antigen or “overexpression” of a tumor antigen is
intended to indicate an abnormal level of expression of a tumor antigen in a cell from a
disease area like a solid tumor within a specific tissue or organ of the patient relative to the
level of expression in a normal cell from that tissue or organ. Patients having solid tumors or
a hematological malignancy characterized by overexpression of the tumor antigen can be
determined by standard assays known in the art.
“Parenteral” administration of an immunogenic composition includes, e.g.,
subcutaneous (s.c.), intravenous (i.v.), intramuscular (i.

), or intrastemal injection, or

infusion techniques.
The term “polynucleotide” as used herein is defined as a chain of nucleotides.
Furthermore, nucleic acids are polymers of nucleotides. Thus, nucleic acids and
polynucleotides as used herein are interchangeable. One skilled in the art has the general
knowledge that nucleic acids are polynucleotides, which can be hydrolyzed into the
monomeric “nucleotides.” The monomeric nucleotides can be hydrolyzed into nucleosides.
As used herein polynucleotides include, but are not limited to, all nucleic acid sequences

which are obtained by any means available in the art, including, without limitation,
recombinant means, i.e., the cloning of nucleic acid sequences from a recombinant library or
a cell genome, using ordinary cloning technolog} and PCR™, and the like, and by synthetic
means.

As used herein, the terms “peptide,” “polypeptide,” and “protein” are used
interchangeably, and refer to a compound comprised of amino acid residues covalently linked
by peptide bonds. A protein or peptide must contain at least two amino acids, and no

limitation is placed on the maximum number of amino acids that can comprise a protein’s or
peptide’s sequence. Polypeptides include any peptide or protein comprising two or more
amino acids joined to each other by peptide bonds. As used herein, the term refers to both
short chains, which also commonly are referred to in the art as peptides, oligopeptides and
oligomers, for example, and to longer chains, which generally are referred to in the art as
proteins, of which there are many types. “Polypeptides” include, for example, biologically
active fragments, substantially homologous polypeptides, oligopeptides, homodimers,

heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion
proteins, among others. The polypeptides include natural peptides, recombinant peptides,
synthetic peptides, or a combination thereof.
The term “promoter” as used herein is defined as a DNA sequence recognized by the
synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the
specific transcription of a polynucleotide sequence.
As used herein, the term “promoter/regulatory sequence” means a nucleic acid

sequence which is required for expression of a gene product operably linked to the
promoter/regulatory sequence. In some instances, this sequence may be the core promoter
sequence and in other instances, this sequence may also include an enhancer sequence and
other regulatory elements which are required for expression of the gene product. The
promoter/regulatory sequence may, for example, be one which expresses the gene product in
a tissue specific manner.
A “constitutive” promoter is a nucleotide sequence which, when operably linked with
a polynucleotide which encodes or specifies a gene product, causes the gene product to be
produced in a cell under most or all physiological conditions of the cell.
An “inducible” promoter is a nucleotide sequence which, when operably linked with a
polynucleotide which encodes or specifies a gene product, causes the gene product to be
produced in a cell substantially only when an inducer which corresponds to the promoter is
present in the cell.
A “tissue-specific” promoter is a nucleotide sequence which, when operably linked
with a polynucleotide encodes or specified by a gene, causes the gene product to be produced
in a cell substantially only if the cell is a cell of the tissue type corresponding to the promoter.
A “Sendai virus” refers to a genus of the Paramyxoviridae family. Sendai viruses are
negative, single stranded RNA viruses that do not integrate into the host genome or alter the
genetic information of the host cell Sendai viruses have an exceptionally broad host range
and are not pathogenic to humans. Used as a recombinant viral vector, Sendai viruses are
capable of transient but strong gene expression.
A “signal transduction pathway” refers to the biochemical relationship between a
variety of signal transduction molecules that play a role in the transmission of a signal from
one portion of a cell to another portion of a cell. The phrase “cell surface receptor” includes
molecules and complexes of molecules capable of receiving a signal and transmitting signal
across the plasma membrane of a cell.

The term “subject” is intended to include living organisms in which an immune
response can be elicited (e.g., mammals). A “subject” or “patient,” as used therein, may be a
human or non-human mammal. Non-human mammals include, for example, livestock and
pets, such as ovine, bovine, porcine, canine, feline, and murine mammals. Preferably, the

subject is human.
As used herein, “substantially purified” refers to being essentially free of other

components. For example, a substantially purified polypeptide is a polypeptide which has
been separated from other components with which it is normally associated in its naturally
occurring state.
The term “therapeutic” as used herein means a treatment and/or prophylaxis. A
therapeutic effect is obtained by suppression, remission, or eradication of a disease state.
The term “transfected” or “transformed” or “transduced” as used herein refers to a
process by which exogenous nucleic acid is transferred or introduced into the host cell. A
“transfected” or “transformed” or “transduced” cell is one which has been transfected,
transformed or transduced with exogenous nucleic acid. The cell includes the primary
subject cell and its progeny.
To “treat” a disease as the term is used herein, means to reduce the frequency or
severity of at least one sign or symptom of a disease or disorder experienced by a subject.
The phrase “under transcriptional control” or “operatively linked” as used herein
means that the promoter is in the correct location and orientation in relation to a
polynucleotide to control the initiation of transcription by RNA polymerase and expression of
the polynucleotide.
A “vector” is a composition of matter which comprises an isolated nucleic acid and
which can be used to deliver the isolated nucleic acid to the interior of a cell. Numerous
vectors are known in the art including, but not limited to, linear polynucleotides,
polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses.
Thus, the term “vector” includes an autonomously replicating plasmid or a vims. The term
should also be construed to include non-plasmid and non-viral compounds which facilitate
transfer of nucleic acid into cells, such as, for example, polylysine compounds, liposomes,
and the like. Examples of viral vectors include, but are not limited to, Sendai viral vectors,
adenoviral vectors, adeno-associated virus vectors, retroviral vectors, lentiviral vectors, and
the like.
As used herein, the term "genetic construct" refers to the DNA or RNA molecules that

comprise a nucleotide sequence which encodes protein. The coding sequence includes

initiation and termination signals operably linked to regulatory elements including a promoter
and polyadenylation signal capable of directing expression in the cells of the individual to
whom the nucleic acid molecule is administered.
Ranges: throughout this disclosure, various aspects of the invention can be presented

in a range format. It should be understood that the description in range format is merely for
convenience and brevity and should not be construed as an inflexible limitation on the scope
of the invention. Accordingly, the description of a range should be considered to have
specifically disclosed all the possible subranges as well as individual numerical values within
that range. For example, description of a range such as from 1 to 6 should be considered to
have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to
4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example,
1, 2,

2.7, 3, 4, 5, 5.3, and 6 . This applies regardless of the breadth of the range.

Description
Peptide Ligands of the GFRAL-RET Receptor
The present invention relates to ligands for the glial cell-derived neurotrophic factor
(GDNF) family receptor α-like (GFRAL)- RET (a receptor tyrosine kinase) receptor complex
and, more specifically, to non-naturally occurring peptides specially designed to encourage or

block the action of the native ligand growth and differentiation factor 15 (GDF15, also
known as Macrophage inhibitory cytokine I (MIC-1). Importantly, the GFRAL-RET receptor
complex is localized in the brainstem, specifically the nuclei of the dorsal vagal complex
(including the area postrema, nucleus tractus solitarius and dorsal motor nucleus of the
vagus). As the area postrema lies outside of the blood brain barrier - this implicates the

GFRAL-RET receptor complex accessible to a peripheral-derived ligand action.
GDF15 is a transforming growth factor- β (TGF- β) superfamily protein. More

specifically, it has been proposed that this protein belongs to the subgroup of glial-cellderived neurotrophic factors (GDNFs). GDNF ligands include glial-cell-derived neurotrophic
factor (GDNF), neurturin (NTN), artemin (ART), and persephm (PSP). These family ligands
signal through GNDF receptor alpha (GFRa^), respectively. Some cross talk occurs between

the GDNF ligands and their receptors, but GDF15 is unable to activate any of the GFRa’s. As
discussed above, GDF15 is the native ligand for GFRAL-RET receptor complex.
The invention comprises the design of a series of non-naturally occurring peptides
that can act as agonists or antagonists of the GFRAL receptor. The peptides that act as
agonists may be used for the control of weight gain, for the control of obesity, or to treat

sexual dysfunction. The peptides that act as antagonists may be used for treating unwanted
anorexia, cachexia or for controlling nausea, emesis, gastrointestinal distress, gastroparesis,
or other illness-like behaviors, including but not limited to the reduction of nausea, e.g.
nausea associated with the use of chemotherapy drugs or nausea associated with cancer,
morning sickness, or chronic illness.
In some embodiments, the peptides may act to control energy balance regulation. In
some embodiments, the peptides regulate energy intake. In further embodiments, the peptides
regulate energy expenditure (e.g. regulation of cardiac rate or locomotive activity). In some
embodiments, the peptides regulate sleep and circadian rhythm.
The peptides may be conjugated to a vitamin B12 compound for preventing brain
penetration, particularly the hypothalamus, and target peripheral sites of action only.
Provided herein are engineered peptides. The amino acid sequences for selected
peptides is shown in Table

1.

Provided is an engineered peptide comprising any one of the ammo acid sequences of
SEQ ID NOs: 1-10. In some embodiments, at least one of the amino acids of the peptide is a

modified amino acid.
In some embodiments, the engineered peptide is an antagonist of a GDNF family
receptor alpha-like (GFRAL) receptor. In further embodiments, the antagonist comprises the
amino acid sequence of SEQ ID NO: 5 . Without wishing to be bound by theory, the GFRALRET receptor antagonist of the invention may be a competitive inhibitor, a non-competitive
inhibitor and/or an allosteric inhibitor.
In some embodiments, the engineered peptide is an agonist of a GFRAF receptor. In
further embodiments, the agonist comprises the amino acid sequence of SEQ ID NO:

1.

In some embodiments, the engineered peptide is linked to a vitamin B12 or precursor
compound, or a polymer, or lipid or a fluorophore. In some embodiments, the vitamin B12
compound is cyanocobalamin, or aquocobalamin, or hydroxocobalamin, or methylcobalamin,
or adenosylcobalamin. In some embodiments, the vitamin B12 precursor compound is
dicyanocobinamide. In some embodiments, the lipid is Capryhc acid (C8), or Capric acid
(CIO), or Laurie acid (C12), or Myristic acid (C14), or Palmitic acid (C16) or Stearic acid

(C18). In some embodiments, the fluorophore is Cy5, or Cy3, or Alexa555, or Alexa488. In

some embodiments, the lipid is 16:0 PE. In further embodiments, the vitamin B12 compound,
the lipid or the fluorophore is linked to the peptide directly or via a linker. In some
embodiments, the linker is propargyl amine, or butargyl amine, or ethylene diamine, or
polyethylene glycol. In yet further embodiments, the vitamin B12 compound, the lipid or the

fluorophore is directly linked to any amino acid of the peptide. In some embodiments, the
vitamin B12 compound, the lipid or the fluorophore is directly linked to any modified amino
acid of the peptide. Also provided is the engineered peptide of any one of the previous
embodiments, further comprising a metal ion bound to the peptide. In some embodiments, the
metal ion is a Zn2+ ion or a Ca2+ ion.
Provided is a polynucleotide encoding the engineered peptide of any one of the
previous embodiments.
Also provided is a pharmaceutical composition comprising the engineered peptide of
any one of the previous embodiments.

Provided is a method of treating a disease in a subject in need thereof, comprising the
step of administering the engineered peptide of any one of the previous embodiments. In
some embodiments, the engineered peptide is an antagonist of a GFRAL-RET receptor. In
some embodiments, the disease/illness treated is nausea, cachexia, pica, loss of appetite or
anorexia nervosa. In further embodiments, the engineered peptide is administered
systemically (e.g. subcutaneous or intravenous) in a dosage of 1 pmole/kg to 100 mmoles/kg,
e.g., 10 pmoles/kg to 90 mmoles/kg, 20 pmoles/kg to 80 mmoles/kg, 30 pmoles/kg to 70

mmoles/kg, 40 pmoles/kg to 60 mmoles/kg, 50 pmoles/kg to 50 mmoles/kg, 60 pmoles/kg to
40 mmoles/kg, 70 pmoles/kg to 30 mmoles/kg, 80 pmoles/kg to 20 mmoles/kg, 90 pmoles/kg

to 10 mmoles/kg, 100 pmoles/kg to 1 mmole/kg. In some embodiments the engineered
peptide is administered acutely from 1 min or chronically over the course multiple hours /
days, up to once per week. In yet further embodiments, the engineered peptide is

administered acutely or chronically over the course of lmin to 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11,
12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or more hours. In yet further embodiments,

the engineered peptide is administered over the course of 1, 2, 3, 4, 5, 6, 7, or more days. In
yet further embodiments, the engineered peptide is administered once per week.
In some embodiments, the engineered peptide is an agonist of a GFRAL-RET
receptor. In some embodiments, the disease or condition is obesity or body weight regulation.
In further embodiments, the engineered peptide is administered in a dosage of 1 pmole/kg to
100 mmoles/kg, e.g., 10 pmoles/kg to 90 mmoles/kg, 20 pmoles/kg to 80 mmoles/kg, 30

pmoles/kg to 70 mmoles/kg, 40 pmoles/kg to 60 mmoles/kg, 50 pmoles/kg to 50 mmoles/kg,
60 pmoles/kg to 40 mmoles/kg, 70 pmoles/kg to 30 mmoles/kg, 80 pmoles/kg to 20

mmoles/kg, 90 pmoles/kg to 10 mmoles/kg, 100 pmoles/kg to 1 mmole/kg. In yet further
embodiments, the engineered peptide is administered systemically (e.g. subcutaneous). In
some embodiments the engineered peptide is administered acutely from 1 min or chronically

over the course multiple hours / days, up to once per week. In yet further embodiments, the
engineered peptide is administered acutely or chronically over the course of 1 min to 1, 2, 3,
4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or more hours. In yet

further embodiments, the engineered peptide is administered over the course of 1, 2, 3, 4, 5,
6, 7, or more days. In yet further embodiments, the engineered peptide is administered once

per week
In some embodiments, the disease is sexual dysfunction. In further embodiments, the
engineered peptide is administered in a dosage from lpmole/kg to lOOmmoles/kg, e.g., 10
pmoles/kg to 90 mmoles/kg, 20 pmoles/kg to 80 mmoles/kg, 30 pmoles/kg to 70 mmoles/kg,
40 pmoles/kg to 60 mmoles/kg, 50 pmoles/kg to 50 mmoles/kg, 60 pmoles/kg to 40

mmoles/kg, 70 pmoles/kg to 30 mmoles/kg, 80 pmoles/kg to 20 mmoles/kg, 90 pmoles/kg to
10 mmoles/kg, 100 pmoles/kg to 1 mmole/kg. In yet further embodiments, the engineered

peptide is administered systemically (e.g. subcutaneous). In some embodiments the
engineered peptide is administered acutely from 1 min or chronically over the course multiple
hours / days, up to once per week. In yet further embodiments, the engineered peptide is
administered acutely or chronically over the course of lmin to 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11,
12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or more hours. In yet further embodiments,

the engineered peptide is administered over the course of 1, 2, 3, 4, 5, 6, 7, or more days. In
yet further embodiments, the engineered peptide is administered once per week
Provided is a method of promoting weight gain in a subject in need thereof,
comprising the step of administering the engineered peptide of any one of the previous
embodiments. In some embodiments, the engineered peptide is an agonist of a GFRAL
receptor administered in a dosage of 1 pmole/kg to 100 mmoles/kg, e.g., 10 pmoles/kg to 90
mmoles/kg, 20 pmoles/kg to 80 mmoles/kg, 30 pmoles/kg to 70 mmoles/kg, 40 pmoles/kg to
60 mmoles/kg, 50 pmoles/kg to 50 mmoles/kg, 60 pmoles/kg to 40 mmoles/kg, 70 pmoles/kg

to 30 mmoles/kg, 80 pmoles/kg to 20 mmoles/kg, 90 pmoles/kg to 10 mmoles/kg, 100
pmoles/kg to 1 mmole/kg. In yet further embodiments, the engineered peptide is administered
systemically (e.g. subcutaneous). In some embodiments the engineered peptide is
administered acutely from 1 min or chronically over the course multiple hours / days, up to
once per week. In yet further embodiments, the engineered peptide is administered acutely or
chronically over the course of lmin to 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22, 23, 24, or more hours. In yet further embodiments, the engineered peptide is

administered over the course of 1, 2, 3, 4, 5, 6, 7, or more days. In yet further embodiments,
the engineered peptide is administered once per week

Provided is a method of promoting weight loss in a subject in need thereof,
comprising the step of administering the engineered peptide of any one of the previous
embodiments. In some embodiments, the engineered peptide is an antagonist of a GFRAL
receptor. In further embodiments, the engineered peptide is administered in a dosage of
dosage of 1 pmole/kg to 100 mmoles/kg, e.g., 10 pmoles/kg to 90 mmoles/kg, 20 pmoles/kg
to 80 mmoles/kg, 30 pmoles/kg to 70 mmoles/kg, 40 pmoles/kg to 60 mmoles/kg, 50
pmoles/kg to 50 mmoles/kg, 60 pmoles/kg to 40 mmoles/kg, 70 pmoles/kg to 30 mmoles/kg,
80 pmoles/kg to 20 mmoles/kg, 90 pmoles/kg to 10 mmoles/kg, 100 pmoles/kg to 1

mmole/kg. In yet further embodiments, the engineered peptide is administered systemically
(i.e. subcutaneous). In some embodiments the engineered peptide is administered acutely

from 1 min or chronically over the course multiple hours / days, up to once per week. In yet
further embodiments, the engineered peptide is administered acutely or chronically over the
course of lmin to 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24, or more hours. In yet further embodiments, the engineered peptide is administered over

the course of 1, 2, 3, 4, 5, 6, 7, or more days. In yet further embodiments, the engineered
peptide is administered once per week
The practice of the present invention employs, unless otherwise indicated,
conventional techniques of molecular biology (including recombinant techniques),
microbiology, cell biology, biochemistry and immunology, which are well within the purview
of the skilled artisan. Such techniques are explained fully in the literature, such as,
“Molecular Cloning: A Laboratory Manual”, fourth edition (Sambrook, 2012);
“Oligonucleotide Synthesis” (Gait, 1984); “Culture of Animal Cells” (Freshney, 2010);
“Methods in Enzymology” “Handbook of Experimental Immunology” (Weir, 1997); “Gene
Transfer Vectors for Mammalian Cells” (Miller and Calos, 1987); “Short Protocols in
Molecular Biology” (Ausubel, 2002); “Polymerase Chain Reaction: Principles, Applications
and Troubleshooting”, (Babar, 2011); “Current Protocols in Immunology” (Coligan, 2002).
These techniques are applicable to the production of the polynucleotides and polypeptides of
the invention, and, as such, may be considered in making and practicing the invention. The
engineered cytokines of the invention were codon optimized so as to enhance their ability to
modulate the immune response in a mammal into which they are introduced. The invention
includes sequences that are homologous to the sequences disclosed herein. Sequence
homology for nucleotides and amino acids may be determined using FASTA, BLAST and
Gapped BLAST (Altschul et ak, Nuc. Acids Res., 1997, 25, 3389, which is incorporated
herein by reference in its entirety) and PAUP* 4.0bl0 software (D. L . Swofford, Sinauer

Associates, Massachusetts). "Percentage of similarity" is calculated using PAUP* 4.0M0
software (D. L . Swofford, Sinauer Associates, Massachusetts). The average similarity of the
consensus sequence is calculated compared to all sequences in the phylogenic tree.
Briefly, the BLAST algorithm, which stands for Basic Local Alignment Search Tool
is suitable for determining sequence similarity (Altschul et al., J . Mol. Biol., 1990, 215, 403-

410, which is incorporated herein by reference in its entirety). Software for performing

BLAST analyses is publicly available through the National Center for Biotechnology
Information. This algorithm involves first identifying high scoring sequence pair (HSPs) by
identifying short words of length W in the query sequence that either match or satisfy some
positive-valued threshold score T when aligned with a word of the same length in a database
sequence. T is referred to as the neighborhood word score threshold (Altschul et al, supra).
These initial neighborhood word hits act as seeds for initiating searches to find HSPs
containing them. The word hits are extended in both directions along each sequence for as far
as the cumulative alignment score can be increased. Extension for the word hits in each

direction are halted when: 1) the cumulative alignment score falls off by the quantity X from
its maximum achieved value; 2) the cumulative score goes to zero or below, due to the
accumulation of one or more negative-scoring residue alignments; or 3) the end of either
sequence is reached. The Blast algorithm parameters W, T and X determine the sensitivity
and speed of the alignment. The Blast program uses as defaults a word length (W) of 11, the
BLOSUM62 scoring matrix (see Henikoff et al, Proc. Natl. Acad. Sci. USA, 1992, 89,
10915-10919, which is incorporated herein by reference in its entirety) alignments (B) of 50,
expectation (E) of 10, M=5, N=4, and a comparison of both strands. The BLAST algorithm
(Karlin et al, Proc. Natl. Acad. Sci. USA, 1993, 90, 5873-5787, which is incorporated herein
by reference in its entirety) and Gapped BLAST perform a statistical analysis of the similarity

between two sequences. One measure of similarity provided by the BLAST algorithm is the
smallest sum probability (P(N)), which provides an indication of the probability by which a
match between two nucleotide sequences would occur by chance. For example, a nucleic acid
is considered similar to another if the smallest sum probability in comparison of the test

nucleic acid to the other nucleic acid is less than about 1, preferably less than about 0.1, more
preferably less than about 0.01, and most preferably less than about 0.001.
When taken up by a cell, the genetic construct(s) may remain present in the cell as a
functioning extrachromosomal molecule and/or integrate into the cell's chromosomal DNA.
DNA may be introduced into cells where it remains as separate genetic material in the form
of a plasmid or plasmids. Alternatively, linear DNA that can integrate into the chromosome

may be introduced into the cell. When introducing DNA into the cell, reagents that promote
DNA integration into chromosomes may be added. DNA sequences that are useful to
promote integration may also be included in the DNA molecule. Alternatively, RNA may be
administered to the cell. It is also contemplated to provide the genetic construct as a linear
minichromosome including a centromere, telomeres and an origin of replication. Gene
constructs may remain part of the genetic material in attenuated live microorganisms or
recombinant microbial vectors which live in cells. Gene constructs may be part of genomes
of recombinant viral vaccines where the genetic material either integrates into the
chromosome of the cell or remains extrachromosomal. Genetic constructs include regulatory
elements necessary for gene expression of a nucleic acid molecule. The elements include: a
promoter, an initiation codon, a stop codon, and a polyadenylation signal. In addition,
enhancers are often required for gene expression of the sequence that encodes the peptide. It
is necessary that these elements be operable linked to the sequence that encodes the desired

proteins and that the regulatory elements are operably in the individual to whom they are
administered.
Initiation codons and stop codon are generally considered to be part of a nucleotide
sequence that encodes the desired protein. However, it is necessary that these elements are
functional in the individual to whom the gene construct is administered. The initiation and
termination codons must be in frame with the coding sequence.
Promoters and polyadenylation signals used must be functional within the cells of the
individual.
Examples of promoters useful to practice the present invention, especially in the
production of a genetic vaccine for humans, include but are not limited to promoters from
Simian Virus 40 (SV40), Mouse Mammary Tumor Virus (MMTV) promoter, Human
Immunodeficiency Virus (MV) such as the BIV Long Terminal Repeat (LTR) promoter,
Moloney virus, ALV, Cytomegalovirus (CMV) such as the CMV immediate early promoter,
Epstein Barr Virus (EBV), Rous Sarcoma Virus (RSV) as well as promoters from human
genes such as human Actin, human Myosin, human Hemoglobin, human muscle creatine and
human metalothionein.
Examples of polyadenylation signals useful to practice the present invention,
especially in the production of a genetic vaccine for humans, include but are not limited to
SV40 polyadenylation signals and LTR polyadenylation signals. In particular, the SV40

polyadenylation signal that is in pCEP4 plasmid (Invitrogen, San Diego Calif.), referred to as
the SV40 polyadenylation signal, is used.

In addition to the regulatory elements required for DNA expression, other elements
may also be included in the DNA molecule. Such additional elements include enhancers. The
enhancer may be selected from the group including but not limited to: human Actin, human
Myosin, human Hemoglobin, human muscle creatine and viral enhancers such as those from
CMV, RSV and EBV.
Genetic constructs can be provided with mammalian origin of replication in order to
maintain the construct extrachromosomally and produce multiple copies of the construct in
the cell. Plasmids pVAXl, pCEP4 and pREP4 from Invitrogen (San Diego, Calif.) contain
the Epstein Barr virus origin of replication and nuclear antigen EBNA-1 coding region which
produces high copy episomal replication without integration. In order to maximize peptide
production, regulatory sequences may be selected which are well suited for gene expression
in the cells the constmct is administered into. Moreover, codons may be selected which are
most efficiently transcribed in the cell. One having ordinary skill in the art can produce DNA
constructs that are functional in the cells. In some embodiments for which protein is used,
i.e., the engineered peptides of the invention, for example, one having ordinary skill in the art
can, using well known techniques, produce and isolate peptides of the invention using well
know n techniques. In some embodiments for which protein is used, for example, one having

ordinary skill in the art can, using well known techniques, inserts DNA molecules that encode
a protein of the invention into a commercially available expression vector for use in wellknown expression systems. For example, the commercially available plasmid pSE420
(Invitrogen, San Diego, Calif.) may be used for production of protein in E . coli. The
commercially available plasmid pYES2 (Invitrogen, San Diego, Calif.) may, for example, be
used for production in S . cerevisiae strains of yeast. The commercially available
MAXBAC.TM. complete baculovirus expression system (Invitrogen, San Diego, Calif.) may,
for example, be used for production in insect cells. The commercially available plasmid
pcDNA I or pcDNA3 (Invitrogen, San Diego, Calif.) may, for example, be used for
production in mammalian cells such as Chinese Hamster Ovary cells. One having ordinary
skill in the art can use these commercial expression vectors and systems or others to produce

protein by routine techniques and readily available starting materials. (See e.g., Sambrook et
a , Molecular Cloning, Third Ed. Cold Spring Harbor Press (2001) which is incorporated

herein by reference.) Thus, the desired peptides can be prepared in both prokaryotic and
eukaryotic systems, resulting in a spectrum of processed forms of the peptide.
One having ordinary skill in the art may use other commercially available expression
vectors and systems or produce vectors using well known methods and readily available

starting matenals. Expression systems containing the requisite control sequences, such as
promoters and polyadenylation signals, and preferably enhancers are readily available and
know n in the art for a vanety of hosts. See e.g., Sambrook et ak, Molecular Cloning Third
Ed. Cold Spring Harbor Press (2001). Genetic constructs include the protein coding sequence

operably linked to a promoter that is functional in the cell line into which the constructs are
transfected. Examples of constitutive promoters include promoters from cytomegalovirus or
SV40. Examples of inducible promoters include mouse mammary leukemia virus or

metallothionein promoters. Those having ordinary skill in the art can readily produce genetic
constructs useful for transfecting with cells with DNA that encodes protein of the invention
from readily available starting materials. The expression vector including the DNA that
encodes the peptide is used to transform the compatible host which is then cultured and
maintained under conditions wherein expression of the foreign DNA takes place.
The protein produced is recovered from the culture, either by lysing the cells or from
the culture medium as appropriate and known to those in the art. One having ordinary skill in
the art can, using well known techniques, isolate peptide that is produced using such
expression systems. The methods of purifying protein from natural sources using antibodies
which specifically bind to a specific peptide as described above may be equally applied to
purifying peptide produced by recombinant DNA methodology.
In addition to producing peptides by recombinant techniques, automated peptide
synthesizers may also be employed to produce isolated, essentially pure peptide. Such
techniques are well known to those having ordinary skill in the art and are useful if
derivatives which have substitutions not provided for in DNA-encoded protein production.
The polynucleotides encoding the engineered peptides of the invention may be
delivered using any of several well-known technologies including DNA injection (also
referred to as DNA vaccination), recombinant vectors such as recombinant adenovims,
recombinant adenovirus associated vims and recombinant vaccinia vims.
Routes of administration include, but are not limited to, intramuscular, intranasally,
intraperitoneal, intradermal, subcutaneous, intravenous, intraarterially, intraocularly and oral
as well as topically, transdermally, by inhalation or suppository or to mucosal tissue such as

by lavage to vaginal, rectal, urethral, buccal and sublingual tissue. Preferred routes of

administration include intramuscular, intraperitoneal, intradermal and subcutaneous injection.
Genetic constmcts may be administered by means including, but not limited to,
electroporation methods and devices, traditional syringes, needleless injection devices, or
"microprojectile bombardment gone guns".

Pharmaceutical Compositions and Dosing Regimens
Administration of the compositions of the invention is typically parenteral, by
subcutaneous, intravenous, intramuscular, or intraperitoneal injection, or by infusion or by
any other acceptable systemic method. In a preferred embodiment, administration is by

subcutaneous injection. In another preferred embodiment, administration is by intravenous
infusion, which may typically take place over a time course of about 1 to 5 hours. In addition,
there are a variety of oral delivery methods for administration of therapeutic peptides, and
these can be applied to the therapeutic peptides of this invention.
Often, treatment dosages are titrated upward from a low level to optimize safety and
efficacy. Generally, daily dosages will fall within a range of about 0.01 to 20 mg peptide per
kilogram of body weight. Typically, the dosage range will be from about 0.1 to 5 mg peptide
per kilogram of body weight. Various modifications or derivatives of the peptides, such as
addition of polyethylene glycol chains (PEGylation), lipidation or linkage to a vitamin B12
compound, may be made to influence their pharmacokinetic and/or pharmacodynamic
properties.
To administer the peptide by other than parenteral administration, it may be necessary
to coat the peptide with, or co-administer the peptide with, a material to prevent its
inactivation. For example, peptide may be administered in an incomplete adjuvant, co¬
administered with enzyme inhibitors or in liposomes. Enzyme inhibitors include pancreatic
trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol. Liposomes include waterin-oil-in- water CGF emulsions as well as conventional liposomes (Strejan el al, 1984, J .

Neuroimmunol. 7:27).
Although the compositions of the invention can be administered in simple solution,
they are more ty pically used in combination with other materials such as carriers, preferably
pharmaceutically acceptable carriers. Useful pharmaceutically acceptable carriers can be any
compatible, non-toxic substance suitable for delivering the compositions of the invention to a
patient. Sterile water, alcohol, fats, waxes, and inert solids may be included in a carrier.

Pharmaceutically acceptable adjuvants (buffering agents, dispersing agents) may also be
incorporated into the pharmaceutical composition. Generally, compositions useful for
parenteral administration of such dmgs are well known; e.g., Remington's Pharmaceutical

Science , 17th Ed. (Mack Publishing Company, Easton, Pa., 1990). Alternatively,
compositions of the invention may be introduced into a patient's body by implantable dmg
delivery systems (Urquhart el al. 1984. Ann. Rev. Pharmacol. Toxicol. 24:199).

Therapeutic formulations may be administered in many conventional dosage
formulations. Formulations typically comprise at least one active ingredient, together with
one or more pharmaceutically acceptable carriers. Formulations may include those suitable
for oral, rectal, nasal, or parenteral (including subcutaneous, intramuscular, intravenous and
intradermal) administration.
The formulations may conveniently be presented in unit dosage form and may be
prepared by any methods well known in the art of pharmacy. See, e.g., Gilman el al. (eds.)
(1990), The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and

Remington's Pharmaceutical Sciences, supra, Easton, Pa.; Avis et al. (eds.) (1993)
Pharmaceutical Dosage Forms: Parenteral Medications, Dekker, N.Y.; Lieberman et al.
(eds.) (1990) Pharmaceutical Dosage Forms: Tablets, Dekker, N.Y.; and Lieberman et al.
(eds.) (1990), Pharmaceutical Dosage Forms: Disperse Systems, Dekker, N.Y.
The pharmaceutical compositions according to the present invention are formulated
according to the mode of administration to be used. In cases where pharmaceutical
compositions are injectable pharmaceutical compositions, they are sterile, pyrogen free and
particulate free. An isotonic formulation is preferably used. Generally, additives for
isotonicity can include sodium chloride, dextrose, mannitol, sorbitol and lactose. In some
cases, isotonic solutions such as phosphate buffered saline are preferred. Stabilizers include

gelatin and albumin. In some embodiments, a vasoconstriction agent is added to the
formulation.
In additional embodiments, the present invention contemplates administration of the
peptides by gene therapy methods, e.g., administration of an isolated nucleic acid encoding a
peptide of interest. The peptides of the present invention have been well-characterized, both
as to the nucleic acid sequences encoding the peptides and the resultant amino acid sequences

of the peptides. Engineering of such isolated nucleic acids by recombinant DNA methods is
well within the ability of one skilled in the art. Codon optimization, for purposes of
maximizing recombinant protein yields in particular cell backgrounds, is also well within the
ability of one skilled in the art. Administration of an isolated nucleic acid encoding the fusion
protein is encompassed by the expression “administering a therapeutically effective amount
of a fusion protein of the invention.” Gene therapy methods are well known in the art. See,

e.g., WO96/07321 which discloses the use of gene therapy methods to generate intracellular
antibodies. Gene therapy methods have also been successfully demonstrated in human
patients. See, e.g., Baumgartner etal, 1998, Circulation 97: 12, 1114-1123, and more
recently, Fatham, 2007, “A gene therapy approach to treatment of autoimmune diseases,”

Immun. Res. 18:15-26; and U.S. Pat. No. 7.378,089, both incorporated herein by reference.

See also Bainbndge et al, 2008, “Effect of gene therapy on visual function in Leber's
congenital Amaurosis,” N Engl Med 358:2231-2239; and Maguire etal, 2008, “Safety and
efficacy of gene transfer for Leber's congenital Amaurosis,” N Engl JMed 358:2240-8.
There are two major approaches for introducing a nucleic acid encoding the peptide
(optionally contained in a vector) into a patient’s cells: in vivo and ex vivo. For in vivo
delivery, the nucleic acid is injected directly into the patient, usually at the site where the
peptide is required. For ex vivo treatment, the patient's cells are removed, the nucleic acid is
introduced into these isolated cells and the modified cells are administered to the patient
either directly or, for example, encapsulated within porous membranes which are implanted
into the patient (see, e.g.. U.S. Pat. Nos. 4,892,538 and 5,283,187). There are a variety of
techniques available for introducing nucleic acids into viable cells. The techniques vary
depending upon whether the nucleic acid is transferred into cultured cells in vitro, or in vivo
in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into
mammalian cells in vitro include the use of liposomes, electroporation, microinjection, cell
fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. Commonly used
vectors for ex vivo delivery of the gene are retroviral and lentiviral vectors.
Preferred in vivo nucleic acid transfer techniques include transfection with viral
vectors such as adenovirus, Herpes simplex I virus, adeno-associated virus), lipid-based
systems (useful lipids for lipid-mediated transfer of the gene are DOTMA, DOPE and DCChol, for example), naked DNA, and transposon-based expression systems. For review of the

currently known gene marking and gene therapy protocols see Anderson et al., Science
256:808-813 (1992). See also WO 93/25673 and the references cited therein.
“Gene therapy” includes both conventional gene therapy where a lasting effect is
achieved by a single treatment, and the administration of gene therapeutic agents, which
involves the one time or repeated administration of a therapeutically effective DNA or
mRNA. Oligonucleotides can be modified to enhance their uptake, e.g. by substituting their
negatively charged phosphodiester groups by uncharged groups. Peptides of the present
invention can be delivered using gene therapy methods, for example locally in tumor beds,
intrathecally, or systemically (e.g., via vectors that selectively target specific tissue types, for
example, tissue-specific adeno-associated viral vectors). In some embodiments, primary cells
(such as lymphocytes or stem cells) from the individual can be transfected ex vivo with a
gene encoding any of the fusion proteins of the present invention, and then returning the
transfected cells to the individual's body.

“Treating” or “treatment” refers to therapeutic treatment, wherein the object is to
prevent or slow down (lessen) the targeted pathologic condition or disorder. A subject is
successfully “treated” if: after receiving a therapeutic amount of a peptide of the invention
according to the methods of the present invention, the subject shows observable and/or
measurable reduction in or absence of one or more signs and symptoms of the particular
disease. Reduction of the signs or symptoms of a disease may also be felt by the patient.

Treatment can achieve a complete response, defined as disappearance of all signs of cancer,
or a partial response, wherein the size of the tumor is decreased, preferably by more than
50%, more preferably by 75%. A patient is also considered treated if the patient experiences a

stabilization of disease. These parameters for assessing successful treatment and
improvement in the disease are readily measurable by routine procedures familiar to a
physician of appropriate skill in the art.

Design of peptides

Table 1

*Lysines marked with an asterisk (K*) may be wildtype (K) or azido (K(Ns)), or otherwise
modified
In some embodiments, at least one of the amino acids of the peptide is a modified

amino acid. In some embodiments, the peptide wherein at least one of its amino acids is a
modified amino acid is an agonist of a GFRAL receptor. In further embodiments, the peptide
wherein at least one of its amino acids is a modified amino acid is an antagonist of a GFRAL
receptor.
The practice of the invention is illustrated by the following non-limiting examples.
The invention should not be construed to be limited solely to the compositions and methods

described herein, but should be construed to include other compositions and methods as well.
One of skill in the art will know that other compositions and methods are available to perform

the procedures described herein.
The practice of the present invention employs, unless otherwise indicated,
conventional techniques of molecular biology (including recombinant techniques),
microbiology, cell biology, biochemistry and immunology, which are well within the purview
of the skilled artisan. Such techniques are explained fully in the literature, such as,
“Molecular Cloning: A Laboratory Manual”, fourth edition (Sambrook, 2012);
“Oligonucleotide Synthesis” (Gait, 1984); “Culture of Animal Cells” (Freshney, 2010);
“Methods in Enzymology” “Handbook of Experimental Immunology” (Weir, 1997); “Gene
Transfer Vectors for Mammalian Cells” (Miller and Calos, 1987); “Short Protocols in
Molecular Biology” (Ausubel, 2002); “Polymerase Chain Reaction: Principles, Applications
and Troubleshooting”, (Babar, 2011); “Current Protocols in Immunology” (Coligan, 2002).
These techniques are applicable to the production of the polynucleotides and polypeptides of
the invention, and, as such, may be considered in making and practicing the invention.
Particularly useful techniques for particular embodiments will be discussed in the sections
that follow.

EXPERIMENTAL EXAMPLES
The invention is further described in detail by reference to the following experimental
examples. These examples are provided for the purposes of illustration only and are not
intended to be limiting unless otherwise specified. Thus, the invention should in no way be
construed as being limited to the following examples, but rather, should be construed to
encompass any and all variations which become evident as a result of the teaching provided
herein.

Without further description, it is believed that one of ordinary skill in the art can,
using the preceding description and the following illustrating examples, make and utilize the
compounds of the present invention and practice the claimed methods. The following
working examples therefore specifically point out the preferred embodiments of the present
invention, and are not to be construed as limiting in any way the remainder of the disclosure.

Example 1-Peptide Design and Conjugation of GFANT05 with or without Palmitic Acid.
Putative agonistic and antagonistic peptide ligands of the GFRAL receptor were
predicted using in silico analysis of known peptide ligands that bind across the GDF family

(Table 1). In some of the peptides of Table 1 (GFANT05-GFANT10), addition of a metal
(e.g Ca

+

or Zn +) binding motif (HAHAD) was introduced to incorporate possible secondary

structure changes to the peptide and/or to facilitate interaction with the receptor. In some
embodiments, the peptides have additional residues from human GDF15 known to interact
with the GFRAL receptor. In addition, specific residues were modified in order to help
increase noncovalent interactions and modify hydrophilicity of the peptide, as suggested by
modeling
Five peptides from Table 1 (GFANT01-GFANT05, SEQ. ID NOs 1-5, wherein the
K* in each peptide is Lysine(N 3)) were synthesized. The peptides are capable of being

conjugated to a lipid. GFANT05 was incubated with palmitic acid overnight at room
temperature to produce GFANT conjugated to palmitic acid (FIG. 2 A). The resulting
molecule was subjected to electrospray mass spectrometry to confirm proper production of
the GFANT05 product.
1H NMR analysis of the GFANT05 peptide alone revealed a broad spectrum of peaks

consistent with a folded state (FIG. 3A). Further 2D NMR analysis revealed that the
GFANT05 peptide consisted of at least one alpha helix (FIG. 3B-3C).

Example 2-ELISA Assay
To validate binding of the synthesized peptides to the GFRAL receptor, an ELISA
assay was developed to determine the binding affinity of the peptides for their receptor. The
primary antibody (Abeam ab206414) was diluted to 1 µg/mL. The secondary antibody was
diluted by placing 5 pL into 10 mL assay buffer. GDF15 was run at concentrations of 100
ng/mL to 0.005 ng/mL. The recombinant human GFRa-like His-tag receptor (R&D 9647GR-050) was added to the Pierce™ nickel coated plate (ThermoFisher Scientific 15442) at
0.1 pg/mL in a total volume of 100 pL. The KD was determined to be 1.03 ng/mL, consistent

with published values, thus demonstrating that the ELISA is functional (FIG. 4A). These data
reveal a novel ELISA assay that can be utilized to test the ability of the artificial peptides to
bind GFRAL.

Example 3-Nausea / Malaise (i.e. illness-like behaviors) Studies in Rats
Five potential ligands (GFANT01-GFANT05, SEQ. ID NOs: 1-5, wherein the K* in
each peptide is Lysine(N )) were synthesized. The effects of each of the novel ligands were
tested for their ability to alter nausea in rats over the course of 24 hours. Although

GFANT01-GFANT05 were tested, only GFANT05 was found to have a significant effect on
nausea / illness-like behaviors in rats. Animals were given either MIC-1 (30 pmol), the
endogenous ligand of GFRAL that suppresses appetites, GFANT05 (300 pmol), or a
combination of both and their food intake was monitored for up to 24 hrs (FIG. 5A). While
there was little difference in food consumption between control and treated groups early, at
24 hrs post-administration, animals given GFANT05 alone ate the same amount of food as
untreated control animals. Further, the addition of GFANT05 to shrew that also received
MIC-1 did not increase overall food consumption over MIC-1 (FIG. 5A). In addition, kaolin

intake, a reliable measure of nausea in rats, was reduced in animals receiving GFANT05
compared to vehicle alone and that of a known nausea-inducing compound (MIC-1) (FIG.
5B). Taken together, these data suggest that GFANT05 is an antagonistic compound that

promotes food consumption and decreases nausea in animals. Analysis of emetic episodes
were measured by an observer blinded to treatment groups.

Example 4-Ejaculation Studies in Rats
Administration of GFANT01 to rats was found to result in spontaneous ejaculation in
male rats. MIC-1 was found to have the same effect on male rats. Rats were video recorded
for 3h and the number of spontaneous ejaculations were analyzed by an observer blinded to
treatment groups. Without wishing to be bound by theory, GFANT01 may be an agonist of
the GFRAL receptor.

Other Embodiments
The recitation of a listing of elements in any definition of a variable herein includes

definitions of that variable as any single element or combination (or subcombination) of
listed elements. The recitation of an embodiment herein includes that embodiment as any

single embodiment or in combination with any other embodiment or portions thereof.

The disclosures of each and every patent, patent application, and publication cited

herein are hereby incorporated herein by reference in their entirety. While this invention has
been disclosed with reference to specific embodiments, it is apparent that other embodiments

and variations of this invention may be devised by others skilled in the art without departing

from the true spirit and scope of the invention. The appended claims are intended to be
construed to include all such embodiments and equivalent variations.

CLAIMS
What is claimed is:
1.

An engineered peptide comprising any one of the amino acid sequences of SEQ ID
NOs: 1-10.

2.

The engineered peptide of claim 1, wherein at least one of the amino acids of the
peptide is a modified amino acid.

3.

The engineered peptide of claim 1, wherein the engineered peptide is an antagonist of
a GDNF family receptor alpha-like (GFRAL) receptor.

4.

The engineered peptide of claim 3, wherein the amino acid sequence of the
engineered peptide comprises the amino acid sequence of SEQ ID NO: 5 .

5.

The engineered peptide of claim 1, wherein the engineered peptide is an agonist of a
GFRAL receptor.

6.

The engineered peptide of claim 5, wherein the amino acid sequence of the
engineered peptide comprises the amino acid sequence of SEQ ID NO:

7.

1.

The engineered peptide of claim 1, wherein the engineered peptide is linked to a
vitamin B12 compound, a lipid or a fluorophore.

8.

The engineered peptide of claim 7, wherein the vitamin B12 compound, the lipid, or
the fluorophore is linked to the peptide directly or via a linker.

9.

The engineered peptide of claim 8, wherein the vitamin B12 compound, the lipid, or
the fluorophore is directly linked to any amino acid of the peptide.

10.

The engineered peptide of claim 8, wherein the vitamin B12 compound, the lipid or
the fluorophore is directly linked to any modified amino acid of the peptide.

11.

The engineered peptide of any one of claims 1-10, further comprising a metal ion
bound to the peptide.

12.

The engineered peptide of claim 11, wherein the metal ion is a Zn2+ ion or a Ca2+ ion.

13.

A polynucleotide encoding the engineered peptide of any one of claims 1-12.

14.

A pharmaceutical composition comprising the engineered peptide of any one of
claims 1-12.

15.

A method of treating a disease or a condition in a subject in need thereof, the method
comprising administering the engineered peptide of claim 3 to the subject.

16.

The method of claim 15, wherein the disease or the condition is nausea, emesis,
cachexia, unintentional weight loss, loss of appetite, pica, anorexia or illness-like
behaviors.

17.

The method of claim 15, wherein the engineered peptide is administered in a dosage
of 1 pmole/kgto 100 mmoles/kg.

18.

The method of claim 15, wherein the engineered peptide is administered acutely or
chronically over the course multiple hours or days.

19.

A method of treating a disease or a condition in a subject in need thereof, comprising
administering the engineered peptide of claim 5 to the subject.

20.

The method of claim 19, wherein the disease or the condition is obesity or body
weight regulation.

2 1.

The method of claim 20, wherein the engineered peptide is administered in a dosage
of 1 pmole/kgto 100 mmoles/kg.

22.

The method of claim 20, wherein the engineered peptide is administered acutely or
chronically over the course multiple hours or days.

23.

The method of claim 19, wherein the disease or the condition is sexual dysfunction.

24.

The method of claim 23, wherein the engineered peptide is administered in a dosage
of 1 pmole/kgto 100 mmoles/kg.

25.

The method of claim 23, wherein the engineered peptide is administered acutely or
chronically over the course multiple hours or days.

26.

A method of promoting weight gain in a subj ect in need thereof, the method
comprising administering the engineered peptide of claim 3 to the subject.

27.

The method of claim 26, wherein the engineered peptide is administered in a dosage
of 1 pmole/kgto 100 mmoles/kg.

28.

The method of claim 26, wherein the engineered peptide is administered acutely or
chronically over the course multiple hours or days.

29.

A method of promoting weight loss in a subj ect in need thereof, comprising
administering the engineered peptide of claim 5 to the subject.

30.

The method of claim 29, wherein the engineered peptide is administered in a dosage
of 1 pmole/kgto 100 mmoles/kg.

31.

The method of claim 29, wherein the engineered peptide is administered acutely or
chronically over the course of multiple hours or days.
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